

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF TRIAMTERENE

(CAS NO. 396-01-0)

IN F344/N RATS AND B6C3F, MICE

(FEED STUDIES)

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
National Institutes of Health

FOREWORD

The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation.

The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease.

The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The prechronic and chronic studies were conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice Regulations, and all aspects of the chronic studies were subjected to retrospective quality assurance audits before being presented for public review.

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection *per se* is not an indicator of a chemical's carcinogenic potential.

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge while supplies last from NTP Central Data Management, NIEHS, P.O. Box 12233, MD A0-01, Research Triangle Park, NC 27709 (919-541-1371).

NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF TRIAMTERENE

(CAS NO. 396-01-0)

IN F344/N RATS AND B6C3F, MICE

(FEED STUDIES)

NATIONAL TOXICOLOGY PROGRAM
P.O. Box 12233
Research Triangle Park, NC 27709

December 1993

NTP TR 420

NIH Publication No. 94-3151

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
National Institutes of Health

CONTRIBUTORS

National Toxicology Program

Evaluated and interpreted results and reported findings

C.J. Alden, Ph.D.

G.A. Boorman, D.V.M., Ph.D.

D.A. Bridge, B.S.

W.W. Carlton, D.V.M., Ph.D., Purdue University

J.K. Dunnick, Ph.D.

S.L. Eustis, D.V.M., Ph.D.

T.J. Goehl, Ph.D.

R.A. Griesemer, D.V.M., Ph.D.

J.R. Hailey, D.V.M.

J.K. Haseman, Ph.D.

M.P. Jokinen, D.V.M.

G.N. Rao, D.V.M., Ph.D.

D.B. Walters, Ph.D.

K.L. Witt, M.S., Oak Ridge Associated Universities

International Research and Development Corporation

Conducted 15-day and 13-week studies, evaluated pathology findings

D.E. Johnson, Ph.D., Principal Investigator

D.C. Jessup, Ph.D.

D. Rajasekaran, M.V.Sc.

Battelle Columbus Division

Conducted 2-year studies, evaluated pathology findings

A.C. Peters, D.V.M., Principal Investigator

M.R. Heitmancik, Ph.D.

L.E. Mezza, D.V.M.

M.J. Ryan, D.V.M., Ph.D.

Experimental Pathology Laboratories, Inc.

Provided pathology quality assurance

J.F. Hardisty, D.V.M., Principal Investigator K. Yoshitomi, D.V.M., Ph.D.

Integrated Laboratory Systems

Prepared quality assurance audits

J.C. Bhandari, D.V.M., Ph.D., Principal Investigator

NTP Pathology Working Group

Evaluated slides, prepared pathology report on rats (14 August 1990)

M.A. Stedham, D.V.M., M.S., Chair Pathology Associates Incorporated

J.F. Hardisty, D.V.M.

Experimental Pathology Laboratories, Inc.

M.P. Jokinen, D.V.M.

National Toxicology Program

A.W. Macklin, D.V.M., Ph.D.

Burroughs Wellcome Research Laboratories

M.M. McDonald, D.V.M., Ph.D.

National Toxicology Program

D. Meuten, D.V.M., Ph.D.

North Carolina State University

A. Pinter, M.D., Ph.D.

National Institute of Hygiene, Hungary

Evaluated slides, prepared pathology report on mice (25 September 1990)

P.K. Hildebrandt, D.V.M., Chair PATHCO

J. Everitt, D.V.M.

Chemical Industry Institute of Toxicology

J.R. Hailey, D.V.M.

National Toxicology Program

J.D. Ibanes, D.V.M. (observer) North Carolina State University

M.P. Jokinen, D.V.M.

National Toxicology Program

M.M. McDonald, D.V.M., Ph.D.

National Toxicology Program

A. Pinter, M.D., Ph.D.

National Institute of Hygiene, Hungary

K. Yoshitomi, D.V.M., Ph.D.

Experimental Pathology Laboratories, Inc.

Biotechnical Services, Inc.

Prepared Technical Report

D.D. Lambright, Ph.D., Principal Investigator

G.F. Corley, D.V.M.

M.C. Hirrel, Ph.D.

K.D. Mencer, B.A.

CONTENTS

ABSTRACT		4
EXPLANATION	OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY	10
TECHNICAL R	EPORTS REVIEW SUBCOMMITTEE	11
SUMMARY OF	TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS	12
INTRODUCTIO	N	13
MATERIALS A	ND METHODS	17
RESULTS		27
DISCUSSION A	AND CONCLUSIONS	61
REFERENCES	••••••	67
Appendix A	Summary of Lesions in Male Rats in the 2-Year Feed Study of Triamterene	73
Appendix B	Summary of Lesions in Female Rats in the 2-Year Feed Study of Triamterene	117
Appendix C	Summary of Lesions in Male Mice in the 2-Year Feed Studies of Triamterene	159
Appendix D	Summary of Lesions in Female Mice in the 2-Year Feed Studies of Triamterene	229
Appendix E	Genetic Toxicology	299
Appendix F	Organ Weights and Organ-Weight-to-Body-Weight Ratios	307
Appendix G	Hematology, Clinical Chemistry, and Urinalysis Results	321
Appendix H	Chemical Characterization and Dose Formulation Studies	337
Appendix I	Feed and Compound Consumption in the 2-Year Feed Studies	351
Appendix J	Ingredients, Nutrient Composition, and Contaminant Levels in NIH-07 Rat and Mouse Ration	359
Appendix K	Sentinel Animal Program	365

ABSTRACT

TRIAMTERENE

CAS No. 396-01-0

Chemical Formula: C₁₂H₁₁N₇ Molecular Weight: 253.26

Synonyms: 6-Phenyl-2,4,7-pteridinetriamine; 6-phenyl-2,4,7-triaminopteridine; 2,4,7-triamino-6-phenypteridine; ademin; pterofen; pterophane; NSC-77625; SKF 8542

Trade names: Dyrenium, Dyazide, Dyren, Dytac, Jatropur, Maxzide, Noridyl, Triteren, Teriam, Urocaudal

Triamterene is a potassium-sparing diuretic used in the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and other diseases in which edema may occur. Toxicity and carcinogenicity studies were conducted by administering triamterene (greater than 99% pure) in feed to groups of male and female F344/N rats and B6C3F₁ mice for 15 days, 13 weeks, or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium and Chinese hamster ovary cells.

15-Day Studies: Groups of five male and five female rats were fed diets containing 0, 1,000, 3,000, 10,000, 30,000, or 60,000 ppm triamterene. The diets containing 10,000 ppm or more were unpalatable, and feed consumption by the 3,000 ppm groups was reduced. Rats exposed to 1,000 or 3,000 ppm triamterene received approximate doses of 80 or 60 mg/kg body weight per day (males) or 70 or 50 mg/kg per day (females). One male rat and two female rats receiving 3,000 ppm died during the second week of the study. The final mean body weights of 3,000 ppm male and female rats were significantly lower than those of controls. Rats in the 3,000 ppm groups had

renal tubule regeneration and cytoplasmic vacuolization of the zona glomerulosa of the adrenal gland.

Groups of five male and five female mice were fed diets containing 0, 300, 1,000, 3,000, 10,000, or 30,000 ppm triamterene, but the diets containing 10,000 or 30,000 ppm were unpalatable. All mice receiving 3,000 ppm died by day 6. Mice exposed to 300 or 1,000 ppm triamterene received approximate doses of 40 or 155 mg/kg body weight per day (males) or 45 or 170 mg/kg body weight per day (females). The final mean body weights of mice in the 300 and 1,000 ppm groups were similar to those of the controls. Renal tubule degeneration and necrosis were observed in the kidney of 3,000 ppm mice.

13-Week Studies: Groups of 10 male and 10 female rats were fed diets containing 0, 150, 300, 600, 1,200, or 2,400 ppm triamterene. All rats receiving 2,400 ppm died before the end of the study; all other rats survived to the end of the study. Rats exposed to 150, 300, 600, or 1,200 ppm triamterene received approximate doses of 10, 20, 40, or 70 mg/kg body weight per day (males) or 10, 20, 40, or 80 mg/kg per day (females). Body weight gains and final mean

body weights of rats in the 1,200 ppm groups were significantly lower than those of controls. There were no biologically significant differences in hematologic, clinical chemistry, or urinalysis parameters among exposed and control rats. Calculi were observed in the renal pelvis of four male rats in the 1,200 ppm group. Chemical-related lesions were observed in the kidney and adrenal gland of rats in the 1,200 and 2,400 ppm groups. These consisted of degeneration and regeneration of the renal tubule epithelium and cytoplasmic vacuolization of cells of the zona glomerulosa of the adrenal cortex. Depletion of hematopoietic cells from the bone marrow and of lymphocytes from the spleen and thymus of rats in the 2,400 ppm groups may have been related to debilitation and reduced feed consumption rather than chemical exposure.

Groups of 10 male and 10 female mice were fed diets containing 0, 100, 200, 400, 800, or 1,600 ppm triamterene. All mice receiving 1,600 ppm, one 800 ppm female, one 200 ppm male, and four 100 ppm males died before the end of the study. Mice exposed to 100, 200, 400, or 800 ppm triamterene received approximate doses of 15, 25, 50, or 90 mg/kg body weight per day (males) or 15, 25, 50, or 115 mg/kg per day (females). The body weight gain and final mean body weight of male mice receiving 800 ppm were significantly lower than those of the controls. The total leukocyte and lymphocyte counts of males receiving 800 ppm and of females receiving 100, 400, or 800 ppm were significantly lower than those of controls. No other differences in hematologic, clinical chemistry, or urinalysis parameters were considered to be biologically significant. Necrosis of lymphocytes was observed in the lymph node, spleen, and thymus of mice in the 800 and 1,600 ppm groups.

2-Year Studies: The doses selected for the 2-year studies were based on lower body weights, mortality, and chemical-related lesions observed in exposed animals during the 13-week studies. Groups of 70 male and 70 female rats were fed diets containing 0, 150, 300, or 600 ppm triamterene and groups of 70 male and 70 female mice were fed diets containing 0, 100, 200, or 400 ppm. Ten animals from each group were included for interim evaluations at 3 and 15 months. Because of a dosing error involving the high-dose mice at week 40, a second study was conducted with groups of 60 male and 60 female mice fed diets containing 0 or 400 ppm triamterene.

In the 2-year studies, rats exposed to 150, 300, or 600 ppm triamterene received approximately 5, 10, or 25 mg/kg body weight per day (males) and 5, 15, or 30 mg/kg (females) and mice exposed to 100, 200, or 400 ppm received approximately 10, 25, or 45 mg/kg (males) and 15, 30, or 60 mg/kg (females) per day.

3-Month and 15-Month Interim Evaluations in the 2-Year Studies: There were no biologically significant differences in hematologic, clinical chemistry, or urinalysis parameters between exposed and control rats or mice at the 3- or 15-month interim evaluations. At necropsy, the mean body weights of exposed rats and mice were similar to those of the controls. There were no chemical-related lesions in exposed rats at 3 months or in exposed mice at 3 or 15 months. At the 15-month evaluation, basophilic, clear cell, and mixed cell foci of the liver occurred in exposed male rats. No chemical-related lesions were observed in female rats at 15 months.

Survival, Body Weights, Clinical Findings, and Feed Consumption in the 2-Year Studies: Survival of exposed rats was similar to that of controls (males: 0 ppm, 25/47; 150 ppm, 25/50; 300 ppm, 19/50; 600 ppm, 27/50; females: 29/50, 34/50, 34/50, 29/50). The mean body weights of 600 ppm rats were consistently lower than, but within 5% of, those of controls after week 49. Feed consumption by male and female rats was similar among exposed and control groups throughout the studies. There were no clinical findings of toxicity.

Survival of 400 ppm male mice in the first study was lower than that of controls because of the dosing accident at week 40. Survival of 100 and 200 ppm male mice and of all exposed groups of female mice in the first study and of exposed males and females in the second study was similar to controls (males: first study, 0 ppm, 47/50; 100 ppm, 45/50; 200 ppm, 46/50; 400 ppm, 46/60; second study, 0 ppm, 43/50; 400 ppm, 39/50; females: first study, 38/50; 43/50; 43/50; 43/60; second study, 40/50; 38/51). Mean body weights of exposed mice were similar to those of controls throughout the first study with one exception; in the week following the dosing error, the mean body weight of 400 ppm males was 16% lower than that of controls. In the second study, mean body weights of 400 ppm mice were slightly lower than those of controls during the final 8 weeks. Feed consumption by exposed mice was similar to that by controls

throughout the studies. There were no clinical findings of toxicity in exposed mice.

Neoplasms and Nonneoplastic Lesions in the 2-Year Studies: The incidences of mixed cell foci and focal hyperplasia of the liver were significantly increased in 300 and 600 ppm male rats, and the incidences of clear cell and mixed cell foci were significantly increased in 300 and 600 ppm female rats. Hepatocellular adenomas occurred in all groups of exposed male rats, but none occurred in controls; the incidence of hepatocellular adenoma in the 150 ppm males was significantly higher than that of controls (0 ppm, 0/50; 150 ppm, 6/50; 300 ppm, 4/50; 600 ppm, 3/49). Hepatocellular adenomas were observed in two 600 ppm female rats, but not in the lower exposure groups or in controls. No hepatocellular carcinomas were seen in exposed or control rats.

The incidences of nephropathy in exposed rats were similar to those of controls, but the average severity of the lesion was marginally increased in male rats receiving 300 ppm and in female rats receiving 600 ppm (males: 47/50, 2.4; 49/50, 2.7; 50/50, 3.0; 49/50, 2.8; females: 38/50, 1.1; 45/50, 1.2; 45/50, 1.3; 45/50, 1.4).

Although in the first study the incidences of hepatocellular adenoma in exposed male mice were similar to that of controls, the incidences of multiple adenomas were greater in the exposed groups, and the incidence of hepatocellular carcinoma in the 400 ppm group was marginally greater (hepatocellular adenoma: 0 ppm, 17/50; 100 ppm, 22/50; 200 ppm, 19/50; 400 ppm, 20/60; hepatocellular carcinoma: 5/50; 7/50; 3/50; 13/60). In the second study, the incidence of hepatocellular adenoma in the 400 ppm males was significantly higher than that of controls (hepatocellular adenoma: 0 ppm, 21/50; 400 ppm, 36/50; hepatocellular carcinoma: 9/50; 11/50).

The incidences of hepatocellular adenoma in exposed female mice in the first and second studies were significantly greater than those of controls (hepatocellular adenoma, first study: 10/50; 22/50; 23/50; 36/60; second study: 7/50; 28/51). The incidences of multiple adenoma were also increased in the exposed groups. Although the incidences of hepatocellular carcinoma were similar among exposed and control female mice in the first study, the incidence of hepatocellular carcinoma in the 400 ppm females in the second study was marginally greater

than that of controls (hepatocellular carcinoma, first study: 4/50; 4/50; 3/50; 8/60; second study: 5/50; 11/50). In both studies, hepatocellular foci (basophilic, eosinophilic, clear cell, or mixed cell) also occurred more frequently in exposed female mice than in controls.

The incidences of thyroid gland follicular cell hyperplasia in the 200 and 400 ppm males and in all exposed groups of females were significantly greater than those of controls in the first study. These findings were confirmed in the second study (follicular cell hyperplasia: males, first study, 3/50, 8/50, 16/50, 20/60; second study, 0/50, 16/50; females, first study, 4/49, 17/49, 18/50, 28/60; second study, 9/50, 32/51). The incidences of follicular cell neoplasms were similar among exposed and control mice in both studies.

The incidences (28/50, 36/50, 43/50, 49/60) and average severity (0.56, 0.80, 1.00, 1.07) of nephropathy were marginally higher in exposed female mice than in controls in the first study. In the second study, the differences in incidence (15/50, 21/50) and severity (0.38, 0.55) were not as great. It is uncertain if these increases were related to the ingestion of triamterene. The incidences and severity of nephropathy were similar among exposed and control male mice in both studies.

Genetic Toxicology: Triamterene was not mutagenic in Salmonella typhimurium strains TA98, TA100, TA1535, or TA1537 with or without exogenous metabolic activation (S9). It did not induce chromosomal aberrations in Chinese hamster ovary cells, with or without S9. Positive results were obtained for induction of sister chromatid exchanges in Chinese hamster ovary cells with and without S9.

Conclusions: Under the conditions of these 2-year feed studies, there was equivocal evidence of carcinogenic activity* of triamterene in male F344/N rats based on a marginal increase in the incidence of hepatocellular adenoma. There was no evidence of carcinogenic activity of triamterene in female F344/N rats administered 150, 300, or 600 ppm. There was some evidence of carcinogenic activity of triamterene in male B6C3F₁ mice based on a marginal increase in the incidence of hepatocellular carcinoma in the first study and a significantly increased incidence of hepatocellular adenoma in the second study. There was some evidence of carcinogenic activity of

triamterene in female $B6C3F_1$ mice based on significantly increased incidences of hepatocellular adenoma and of adenoma and carcinoma (combined).

Exposure to triamterene was associated with an increased incidence of hepatocellular foci, primarily

mixed cell type, and an increase in the severity of nephropathy in female rats. In mice, exposure to triamterene was associated with an increased incidence of hepatocellular foci in females and an increased incidence of thyroid gland follicular cell hyperplasia in males and females.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 10. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 12.

Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Triamterene

Variable	Male F344/N Rats	Female F344/N Rats	
Doses	0, 150, 300, or 600 ppm in feed (approximately 5, 10, or 25 mg/kg body weight)	0, 150, 300, or 600 ppm in feed (approximately 5, 15, or 30 mg/kg body weight)	
Body weights	Exposed groups similar to controls	600 ppm group lower than controls	
2-Year survival rates	25/47, 25/50, 19/50, 27/50	29/50, 34/50, 34/50, 29/50	
Nonneoplastic effects	Liver: hyperplasia (0/50, 3/50, 5/50, 10/49); eosinophilic foci (2/50, 3/50, 2/50, 8/49); mixed cell foci (0/50, 6/50, 8/50, 12/49)	Liver: clear cell foci (3/50, 3/50, 4/50, 9/50); mixed cell foci (2/50, 2/50, 8/50, 13/50); Kidney: nephropathy (38/50, 45/50, 45/50, 45/50); severity grades (1.1, 1.2, 1.3, 1.4)	
Neoplastic effects	None	None	
Uncertain findings	Liver: adenoma (0/50, 6/50, 4/50, 3/49); Kidney: nephropathy severity (2.4, 2.7, 3.0, 2.8)	None	
Level of evidence of carcinogenic activity	Equivocal evidence	No evidence	

Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Triamterene (continued)

Variable	Male Bo	6C3F, Mice	Female Bo	C3F, Mice	
	First Study	Second Study	First Study	Second Study	
Doses	0, 100, 200, or 400 ppm in feed (approximately 10, 25, or 50 mg/kg body weight)	0 or 400 ppm (approximately 40 mg/kg body weight)	0, 100, 200, or 400 ppm in feed (approximately 15, 30, or 60 mg/kg body weight)	0 or 400 ppm (approximately 60 mg/kg body weight)	
Body weights	High-dose group lower than controls	Exposed group similar to controls	Exposed groups similar to controls	Exposed group similar to controls	
2-Year survival rates	47/50, 45/50, 46/50, 46/60	43/50, 39/50	38/50, 43/50, 43/50, 43/60	40/50, 38/51	
Nonneoplastic effects	Thyroid gland: follicular cell hyperplasia (3/50, 8/50, 16/50, 20/60)	Thyroid gland: follicular cell hyperplasia (0/50, 16/50)	Liver: basophilic cell foci (1/50, 6/50, 6/50, 6/50, 11/60); clear cell foci (0/50, 1/50, 4/50, 3/60); all foci (8/50, 16/50, 24/50, 19/60)	Liver: basophilic cell foci (0/50, 5/51); clear cell foci (0/50, 4/51); all foci (10/50 20/51)	
		·	Thyroid gland: follicular cell hyperplasia (4/49, 17/49, 18/50, 28/60)	Thyroid gland: follicular cell hyperplasia (9/50, 32/51)	
Neoplastic effects	Liver: hepatocellular carcinoma (5/50, 7/50, 3/50, 13/60); hepatocellular adenoma or carcinoma (20/50, 26/50, 19/50, 29/60)	Liver: hepatocellular adenoma (21/50, 36/50); hepatocellular adenoma or carcinoma (25/50, 38/50)	Liver: hepatocellular adenoma (10/50, 22/50, 23/50, 36/60); hepatocellular adenoma or carcinoma (13/50, 26/50, 25/50, 37/60)	Liver: hepatocellular adenoma (7/50, 28/51); hepatocellular adenoma or carcinoma (10/50, 31/51)	
Uncertain findings	None	None	None	None	
Level of evidence of carcinogenic activity	Some	e evidence	Some	evidence	
Genetic toxicology Salmonella typhimurium Sister chromatid exchan Chinese hamster ov Chromosomal aberratio Chinese hamster ov	ges ary cells in vitro: Posi ns	ative with and without S9 metative with and without S9 metations	polic activation		

EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence, including animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results (clear evidence and some evidence); one category for uncertain findings (equivocal evidence); one category for no observable effects (no evidence); and one category for experiments that cannot be evaluated because of major flaws (inadequate study). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Report series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following five categories is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to potency or mechanism.

- Clear evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a dose-related
 (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- Some evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a chemically related
 increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than
 that required for clear evidence.
- Equivocal evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related.
- No evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms.
- Inadequate study of carcinogenic activity is demonstrated by studies that, because of major qualitative or quantitative limitations, cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. Such consideration should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- · adequacy of the experimental design and conduct;
- · occurrence of common versus uncommon neoplasia;
- · progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic to neoplastic lesions;
- some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to assume that benign neoplasms of those types have the potential to become malignant;
- combining benign and malignant tumor incidence known or thought to represent stages of progression in the same organ or tissue;
- · latency in tumor induction;
- multiplicity in site-specific neoplasia;
- · metastases;
- supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- · presence or absence of dose relationships;
- · statistical significance of the observed tumor increase;
- · concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- survival-adjusted analyses and false positive or false negative concerns;
- · structure-activity correlations; and
- · in some cases, genetic toxicology.

NATIONAL TOXICOLOGY PROGRAM BOARD OF SCIENTIFIC COUNSELORS TECHNICAL REPORTS REVIEW SUBCOMMITTEE

The members of the Technical Reports Review Subcommittee who evaluated the draft NTP Technical Report on triamterene on November 21, 1991, are listed below. Subcommittee members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, subcommittee members have five major responsibilities in reviewing NTP studies:

- o to ascertain that all relevant literature data have been adequately cited and interpreted,
- · to determine if the design and conditions of the NTP studies were appropriate,
- · to ensure that the Technical Report presents the experimental results and conclusions fully and clearly,
- o to judge the significance of the experimental results by scientific criteria, and
- · to assess the evaluation of the evidence of carcinogenic activity and other observed toxic responses.

Curtis D. Klaassen, Ph.D., Chair Department of Pharmacology and Toxicology University of Kansas Medical Center Kansas City, KS

Paul T. Bailey, Ph.D. Toxicology Division Mobil Oil Corporation Princeton, NJ

Louis S. Beliczky, M.S., M.P.H.
Department of Industrial Hygiene
United Rubber Workers International Union
Akron, OH

Gary P. Carlson, Ph.D., Principal Reviewer Department of Pharmacology and Toxicology Purdue University West Lafayette, IN

Kowetha A. Davidson, Ph.D., Principal Reviewer Health and Safety Research Division Oak Ridge National Laboratory Oak Ridge, TN

Harold Davis, D.V.M., Ph.D.* School of Aerospace Medicine Brooks Air Force Base, TX

Robert H. Garman, D.V.M. Consultants in Veterinary Pathology Murrysville, PA Jay I. Goodman, Ph.D.

Department of Pharmacology and Toxicology
Michigan State University
East Lansing, MI

David W. Hayden, D.V.M., Ph.D., Principal Reviewer Department of Veterinary Pathobiology College of Veterinary Medicine University of Minnesota St. Paul, MN

Daniel S. Longnecker, M.D.*

Department of Pathology

Dartmouth Medical School,

Lebanon, NH

Barbara McKnight, Ph.D. Department of Biostatistics University of Washington Seattle, WA

Ellen K. Silbergeld, Ph.D.*
University of Maryland Medical School
Baltimore, MD

Matthew van Zwieten, D.V.M., Ph.D.
Department of Safety Assessment
Merck, Sharp & Dohme Research Laboratories
West Point, PA

Lauren Zeise, Ph.D.
California Department of Health Services/RCHAS
Berkeley, CA

^{*} Did not attend

SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS

On November 21, 1991, the draft Technical Report on the toxicology and carcinogenesis studies of triamterene received public review by the National Toxicology Program Board of Scientific Counselors Technical Reports Review Subcommittee. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, NC.

Dr. J.K. Dunnick, NIEHS, introduced the toxicology and carcinogenesis studies of triamterene by discussing the chemical's use and the rationale for study, describing the experimental design, reporting on survival and body weight effects, and commenting on compound-related neoplasms and nonneoplastic lesions in rats and mice.

The proposed conclusions were equivocal evidence of carcinogenic activity of triamterene in male F344/N rats; no evidence of carcinogenic activity in female F344/N rats; some evidence of carcinogenic activity in male B6C3F₁ mice; and some evidence of carcinogenic activity in female B6C3F₁ mice.

Dr. Carlson, a principal reviewer, agreed with the proposed conclusions. He suggested more relevant toxicology data on triamterene should be added to the introduction, mainly to help focus on possible target organs such as the liver and kidneys. Dr. Dunnick noted that many of the toxicity studies performed in industry had not been reported in the literature.

Dr. Davidson, the second principal reviewer, agreed with the proposed conclusions. Her agreement for the conclusions in male mice was based primarily on the results from the second study. She suggested that combined incidences of hepatocellular adenoma and carcinoma be added to the statement for both studies in male mice. She stated that the dosing error in the high-dose mice in the 2-year study was a concern.

Dr. Dunnick said the staff considered that both studies supported the conclusion of *some evidence* in male mice.

Dr. Hayden, the third principal reviewer, agreed with the proposed conclusions. He said there should be some discussion of thyroid lesions in exposed male mice since they are statistically significant and doserelated. Dr. Dunnick said severity grades would be added to the table and more discussion of thyroid follicular cell hyperplasia in treated mice would be included.

Dr. Goodman commented that since triamterene had been on the market for 30 years, more information could be included about human toxicity, placing it in context with the rodent toxicity data (p. 64). Dr. Hayden and Dr. McKnight suggested that rats in the 2-year studies might have tolerated higher doses because mean body weights of exposed rats were within 5% of controls and terminal survival rates for control and 2-year survival rates of exposed groups were similar (see p. 62 for dosing rationale).

Dr. Carlson moved that the Technical Report on triamterene be accepted with the revisions discussed and with the conclusions as written for male F344/N rats, equivocal evidence of carcinogenic activity, for female F344/N rats, no evidence of carcinogenic activity, and for male and female B6C3F₁ mice, some evidence of carcinogenic activity. Dr. Bailey seconded the motion. Dr. Goodman offered an amendment that the conclusion in male mice be changed to equivocal evidence of carcinogenic activity. amendment was tabled for lack of a second. Dr. Davidson offered an amendment that adenoma and carcinoma (combined) be added to the conclusion statement for male mice. The amendment was tabled for lack of a second. Dr. Carlson's motion was then accepted by eight yes votes to one no vote (Dr. Goodman) with one abstention (Dr. van Zwieten).

INTRODUCTION

$$\begin{array}{c|c} H_2N & N & N & NH_2 \\ \hline \\ N & NH_2 & \end{array}$$

TRIAMTERENE

CAS No. 396-01-0

Chemical Formula: C₁₂H₁₁N₇ Molecular Weight: 253.26

Synonyms: 6-Phenyl-2,4,7-pteridinetriamine; 6-phenyl-2,4,7-triaminopteridine; 2,4,7-triamino-6-phenypteridine; ademin; pterofen; pterophane; NSC-77625; SKF 8542

Trade names: Dyrenium, Dyazide, Dyren, Dytac, Jatropur, Maxzide, Noridyl, Triteren, Teriam, Urocaudal

PHYSICAL AND CHEMICAL PROPERTIES

Triamterene is a yellow, odorless, crystalline powder with a melting point of 316° C. It is practically insoluble in water and slightly soluble in alcohol (*Merck Index*, 1983). Triamterene was first synthesized by Spickett and Timmis (1954) by a reaction of 4-amino-5-nitrosopyrimidine with phenylacetonitrile.

USE AND PRODUCTION

Triamterene has been used since 1961 as a potassium-sparing diuretic in the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome, as well as in the treatment of other diseases in which edema may occur. Diuresis usually occurs within 2 to 4 hours after drug administration and diminishes in approximately 7 to 9 hours. The usual initial adult oral dose of triamterene is 100 mg twice daily, and maintenance therapy is 100 mg once daily. Although triamterene is not usually administered to children, the recommended dose is 4 mg/kg daily or 115 mg/m² (body surface area) daily. The maximum therapeutic dose of triamterene is 5 mg/kg daily. Because of its low water solubility, triamterene is administered orally and is not available for parenteral administration (Laragh et al., 1961; Weinstock and Wiebelhaus, 1963; Weiner, 1990; Physicians' Desk Reference, 1991). In a 1990 survey, Dyazide, which contains triamterene, was the sixth most frequently prescribed drug in the United States (American Druggist, 1991). Information on the number of prescriptions written per year for triamterene was not available in the literature.

Although triamterene (Dyrenium) is effective alone, it is used frequently in combination therapy with other diuretics (e.g., hydrochlorothiazide) that act at different sites in the nephron. Products containing both triamterene and hydrochlorothiazide are Dyazide (50 mg triamterene and 25 mg hydrochlorothiazide) and Maxzide (75 mg triamterene and 50 mg hydrochlorothiazide) (Hollenberg and Bannon, 1986; Sica and Gehr, 1989).

PHARMACOLOGY AND TOXICITY

Diuretics are designed to increase urine flow, and triamterene acts as a diuretic agent at the distal tubule in the nephron by increasing sodium excretion by 2% to 3%. While triamterene increases the excretion of sodium, it decreases excretion of potassium. Triamterene is usually used in combination

with the thiazides, which increase potassium excretion, to block kaliuresis (Greenberg, 1986).

Laragh et al. (1961) originally suggested that the basis of diuretic action of triamterene was aldosterone antagonism. However, Baba et al. (1962a,b) reported that triamterene directly affects the renal tubule cells. Others have suggested that triamterene regulates the activity of renal plasma membrane Na-K-ATPase, an enzyme considered to be a biochemical vehicle for the active transport of sodium across the cell membrane (Ožegović et al., 1979). Triamterene primarily affects the distal tubule, where it inhibits sodium reabsorption and potassium excretion. Although it acts as an aldosterone antagonist, triamterene functions in adrenalectomized animals and in patients in which aldosterone has been chemically blocked (Nielsen and Lassen, 1963; Cohen, 1966). Analysis of urine samples collected from rats at two sites along the distal tubule (at the beginning and end of the distal tubule) demonstrated an inhibition of potassium secretion and an increase in sodium excretion in the distal tubule after triamterene treatment (Lacy et al., 1980; Lant, 1985).

In humans, the most frequent side effect from triamterene therapy is electrolyte imbalance, mainly hyperkalemia. Hyperkalemia, because it can lead to cardiac arrhythmia, is the most serious toxic effect of overexposure (Weiner, 1990). Triamterene is a pteridine that is structurally similar to folic acid and other inhibitors of dihydrofolate reductase (e.g., methotrexate) and is a weak inhibitor of dihydrofolate reductase. Increased blood urea nitrogen concentrations have occurred during therapy and serum creatinine levels may be increased. Other side effects reported include nausea, vomiting, diarrhea, and gastrointestinal disturbances. Hemolytic anemia has been reported in patients treated with triamterene (Takahashi and Tsukada, 1979). Schiffl and Schollmeyer (1985) reported that with appropriate management, patients could be treated with triamterene and hydrochlorothiazide for 71 months with minimal side effects.

Triamterene administration has been associated with lithiasis, and it is estimated that the incidence of triamterene-induced kidney stones in Dyazide users is about 1 in 1,500. The kidney stones of Dyazide users consisted of triamterene, calcium oxalate monohydrate and dihydrate, uric acid, and protein (Sörgel et al., 1985a,b; 1986).

When triamterene was administered by gavage to CD-1 male mice for 5 consecutive days, at doses of 5 to 300 mg/kg, renal cortical tubule dilation and basophilia occurred at doses of 50 mg/kg and greater (Manson et al., 1986). These alterations were accompanied by an increase in blood urea nitrogen and creatinine levels. Also in this study, male mice treated for 5 days with triamterene at doses of 5 to 100 mg/kg were mated to untreated female mice. There were no adverse effects on mating or fertility and no evidence of induced dominant lethal mutations. Fischer rats given daily doses of 30 to 45 mg/kg triamterene for 3 weeks had renal damage characterized by degenerative changes of the renal cortical and medullary tubules (Ožegović et al., 1981). Histological alterations were most severe in the proximal convoluted tubules and consisted of vacuolar degeneration with a loss of periodic acid-Schiff-staining of the brush border. In the medullary tubules, a few hyaline casts occurred. These renal lesions were not seen at doses of 3.6 to 15 mg/kg, which more closely approximate the dose levels used in humans.

The oral LD₅₀ is 285 mg/kg for mice and 400 mg/kg for rats (RTECS, 1991). No 2-year rodent toxicity or carcinogenicity studies of triamterene were found in the literature.

METABOLISM

In humans triamterene is rapidly absorbed from the gastrointestinal tract. The plasma half-life of triamterene after oral administration is 1.5 to 2 hours. Peak plasma concentrations of 50 to 280 ng/mL are achieved within 2 to 4 hours following oral administration of a single 100 or 200 mg dose. The major metabolite of triamterene in humans is the hydroxy-triamterene sulfuric acid ester, which is excreted in the bile as well as in the urine. The oral bioavailability of triamterene is estimated to be 50% to 80% (Pruitt et al., 1977; Hasegawa et al., 1982; Gilfrich et al., 1983; Mutschler et al., 1983; Loew et al., 1984; Sörgel et al., 1986).

In patients with liver disease, the pharmacokinetics of triamterene may be markedly altered, and in older patients, the elimination of triamterene may be impaired (Mutschler et al., 1983; Williams et al., 1986). After an oral dose of 50 mg, the mean peak concentration of triamterene in older patients was 84 ng/mL compared with 41 ng/mL in younger

patients. Villeneuve et al. (1984) reported that when patients with cirrhosis were administered triamterene orally, the apparent clearance of the drug was reduced 92%. Dao and Villeneuve (1988) reported that after an oral dose of 200 mg, the mean plasma concentration in normal patients was 45 ng/mL for triamterene and 967 ng/mL for hydroxytriamterene sulfate, while in patients with cirrhosis, the mean concentration increased to 586 ng/mL for triamterene but was reduced to 747 ng/mL for hydroxytriamterene sulfate.

After intravenous administration of 1 to 4 mg/kg of ¹⁴C-triamterene to Sprague-Dawley rats, the drug was recovered in the kidney, liver, heart, lungs, and skeletal muscle, but there was little accumulation of the radioactivity in the brain, testes, or fat. The plasma half-life of triamterene was estimated to be 2.7 hours (Kau and Rama Sastry, 1977). Sprague-Dawley rats receiving a subcutaneous dose of ¹⁴C-triamterene (2 mg/kg), 45% and 50% of the total radioactivity was excreted in the urine and feces, respectively, during the 72 hours following treatment. Triamterene accounted for 72% to 79% of the radioactivity recovered in the urine and feces. The major metabolites found in the urine were free p-hydroxytriamterene (10% to 15%) and its sulfuric acid ester conjugate (1% to 5%). When the bile duct was ligated, metabolites were not found in either the urine or feces, suggesting that the liver is a major metabolic site (Kau et al., 1975). Leilich et al. (1980) demonstrated that the hydroxytriamterene sulfuric acid ester has a diuretic effect in rats.

GENETIC TOXICITY

Triamterene is not a bacterial mutagen. It did not inhibit growth in *Bacillus subtilis* due to DNA damage (Kawachi et al., 1980) and did not induce gene mutations in *Salmonella typhimurium* with or without S9 activation (Kawachi et al., 1980; Ishidate et al., 1981; Mortelmans et al., 1986). Triamterene

was also negative in the silkworm gene mutation assay (Kawachi et al., 1980). However, results of in vitro tests in mammalian cells indicated a capability to induce chromosomal damage in some cell types. In the absence of S9, triamterene induced chromosomal aberrations (Kawachi et al., 1980; Ishidate et al., 1981), sister chromatid exchanges (Kawachi et al., 1980; Sasaki et al., 1980), and micronuclei (Sasaki et al., 1980) in Chinese hamster lung cells. However, in human embryo cell cultures, triamterene induced sister chromatid exchanges without S9 (Kawachi et al., 1980; Sasaki et al., 1980), but did not induce chromosomal aberrations (Sasaki et al., 1980) or micronuclei (Kawachi et al., 1980). Few data are available for evaluation of the genetic toxicity of triamterene in vivo, and the data that do exist contrast with the positive results observed for induction of chromosomal effects in mammalian cells in vitro. In vivo, triamterene was negative in tests for induction of chromosomal aberrations in bone marrow cells and dominant lethal mutations in germ cells of CD-1 male mice (Manson et al., 1986). In the chromosomal aberrations test, a maximum dose of 250 mg/kg was administered by intraperitoneal injection and cells were sampled from 6 to 24 hours after treatment; in the dominant lethal test, triamterene was administered daily by gavage for 5 consecutive days at a maximum dose of 100 mg/kg. In male rats, triamterene did not induce chromosomal aberrations in bone marrow cells (Kawachi et al., 1980) or unscheduled DNA synthesis in hepatocytes (Mirsalis et al., 1983).

STUDY RATIONALE

Triamterene was selected for toxicity and carcinogenicity testing in F344/N rats and B6C3F₁ mice because of its widespread use as a diuretic agent and the lack of data on the potential effects of long-term exposure. The oral route of administration was chosen because this is the route of exposure in humans.

MATERIALS AND METHODS

PROCUREMENT AND

CHARACTERIZATION OF TRIAMTERENE

Triamterene, manufactured by Secifarma (Milan, Italy), was obtained from Gyma Laboratories of America (Garden City, NJ). One lot (84/1) was used during the 15-day, 13-week, and 2-year studies. The identity and purity analyses were performed by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO). Details of the analyses are presented in Appendix H.

The study chemical, a yellow microcrystalline solid, was identified as triamterene by infrared, ultraviolet/visible, and nuclear magnetic resonance spectroscopy (Figures H1 and H2). Purity was found to be greater than 99% by elemental analysis, Karl Fischer water analysis, potentiometric titration of the amine functional group, thin-layer chromatography, and high-performance liquid chromatography (HPLC). No impurities were detected by HPLC with a peak area greater than or equal to 0.1% of the major peak area. Lot 84/1 met the United States Pharmacopeia requirements for purity.

Stability studies were performed by the analytical chemistry laboratory using HPLC. The chemical was found to be stable in bulk form when stored protected from light for 2 weeks at temperatures up to 60° C. The stability of the bulk chemical was monitored periodically at the study laboratory using titration of the amine group and HPLC and no degradation of the study chemical was detected. To ensure stability, the bulk chemical was stored at 5° C or lower in the dark during the 15-day, 13-week, and 2-year studies.

Preparation and Analysis of Dose Formulations

The dose formulations were prepared by mixing triamterene with a small amount of feed to form a premix. The premix and additional feed were layered into a blender and mixed. Dose formulations were prepared weekly for the 15-day studies and every

2 weeks for the 13-week and 2-year studies. Homogeneity and stability studies were conducted by the analytical chemistry laboratory on the dosed feed preparations. Dose formulations in feed were homogeneous and stable for up to 2 weeks when stored at 5° C and protected from light. Details of the preparation and analyses of the dose formulations are presented in Appendix H.

The dose formulations were analyzed once at the beginning of the 15-day studies by the study laboratory and were within 10% of the target concentrations (Table H2). During the 13-week studies, the dose formulations were analyzed at the beginning and midpoint of the studies; all rat and 15 of 17 mouse formulations were within 10% of the target concentrations (Table H3). During the 2-year studies, the dose formulations were analyzed at least once every 8 weeks (Table H4). All dose formulations were within 10% of the target concentrations, except dose formulations prepared in week 40 for rats receiving 600 ppm and for mice receiving 400 ppm. Rats in the 600 ppm group received 0 ppm for approximately 1% of the dosing duration, which was considered to have no effect on the results. Mice in the 400 ppm group received approximately 1,600 ppm, which caused 16 deaths. Survivors of the dosing accident were returned to the appropriate dose formulation (first study), and a second set of 2-year studies was started with exposure levels of 0 and 400 ppm. Throughout the second study, the 400 ppm formulation was within 10% of the target concentration. Periodic analyses of the dose formulations of triamterene were performed by the study laboratory and the analytical chemistry laboratory with either an HPLC or ultraviolet spectroscopy method. Results of the analyses performed by the analytical chemistry laboratory indicated good agreement with the results of the study laboratory (Table H5).

15-DAY STUDIES

Male and female F344/N rats and B6C3F₁ mice were obtained from Charles River Breeding Laboratories

(Portage, MI). Rats were observed for 14 days and mice were observed for 15 days before being assigned to groups. The rats were 42 to 49 days old and the mice were 50 to 65 days old when the studies began.

Groups of five male and five female rats were fed diets containing 0, 1,000, 3,000, 10,000, 30,000, or 60,000 ppm triamterene for up to 14 days, and groups of five male and five female mice were fed diets containing 0, 300, 1,000, 3,000, 10,000, or 30,000 ppm triamterene for up to 14 days. After 14 days on a dosed diet, surviving animals were fed an untreated diet for 1 day. Animals were housed five per cage. Water and feed were available *ad libitum*. Details of study design, animal maintenance, and method of sacrifice are described in Table 1.

Animals were weighed at the beginning of the studies and on days 8 and 15. Animals were observed twice daily, except on weekends. Feed consumption was measured weekly. Complete necropsy was performed on all animals 16 days after exposure began.

Organs weighed at the end of the studies included the brain, heart, right kidney, liver, lungs, right testis, and thymus. Complete histopathologic examinations were performed on rats fed 3,000 ppm and on mice fed 1,000 and 3,000 ppm. Selected tissues from rats fed 0 and 1,000 ppm were examined. Tissues examined microscopically are listed in Table 1.

13-WEEK STUDIES

These studies were conducted to evaluate the cumulative toxic effects of repeated exposure to triamterene. Male and female F344/N rats and B6C3F₁ mice were obtained from the Charles River Breeding Laboratories (Portage, MI). Rats were observed for 13 days and mice were observed for 16 days before being assigned to groups. The rats were 41 to 48 days old and the mice were 57 to 68 days old when the studies began.

Groups of 10 male and 10 female rats were fed a diet containing 0, 150, 300, 600, 1,200, or 2,400 ppm triamterene for 13 weeks. Groups of 10 male and 10 female mice were fed diets of 0, 100, 200, 400, 800, or 1,600 ppm for 13 weeks. Rats and mice were housed five per cage. Feed and water were available ad libitum. Details of study design, animal maintenance, and method of sacrifice are described in Table 1.

Animals were observed twice daily. Individual animal weights were recorded initially, once weekly, and at the end of the studies. Feed consumption was measured weekly. Organs weighed at the end of the studies included the brain, heart, right kidney, liver, lungs, right testis, and thymus. Blood for hematology and clinical chemistry was collected from the orbital sinus plexus of rats and mice, which were fasted for approximately 20 hours prior to blood sample collection. Urine for urinalysis was collected during this 20-hour fasting period from animals housed in metabolism cages. Clinical pathology parameters were evaluated at 13 weeks from blood and urine collected from rats fed 0, 150, 600, and 1,200 ppm and from mice fed 0, 100, 400, and 800 ppm. Complete histopathologic examinations were performed on all animals killed moribund or that died before the end of the studies, on all rats fed 0 or 2,400 ppm, and all mice fed 0 or 1,600 ppm. Selected tissues from animals in the other exposure groups were examined. The tissues routinely examined microscopically are listed in Table 1. The health of the rats was monitored during the studies according to the protocols of the NTP Sentinel Animal Program (Appendix K).

2-YEAR STUDIES

Study Design

Groups of 70 male and 70 female rats were fed diets containing 0, 150, 300, or 600 ppm triamterene for 104 weeks. Ten rats per group were designated for interim evaluation at 3 and 15 months. Groups of 70 male and 70 female mice were fed diets containing 0, 100, 200, or 400 ppm triamterene for 104 weeks. As a result of a dose formulation error at week 40, high-dose mice received diets containing 1,600 ppm for 7 days, which resulted in the death of 16 animals. Ten mice per group were designated for interim evaluation at 3 and 15 months, but because of the dosing error the 15-month interim evaluation was not conducted for mice at 400 ppm. Because of the uncertain effect of the overdose on mice, a second study was begun with 60 male and 60 female mice fed 0 and 400 ppm triamterene for 103 weeks, and 10 mice per group were designated for interim evaluation at 15 months. The organs weighed at the 3- and 15-month interim evaluation were the brain, kidney, and liver. Blood for hematology and clinical chemistry was collected from the retroorbital sinus of rats and mice at the 3- and 15-month evaluations. Urine for urinalysis was collected overnight from animals

housed in metabolism cages before the 3- and 15-month evaluations. The tissues routinely examined microscopically are listed in Table 1.

Source and Specification of Animals

The male and female F344/N rats and B6C3F, mice used in the 2-year studies were obtained from Frederick Cancer Research Facility (Frederick, MD). Rats were 28 days old when received by the study laboratory and were quarantined for 13 days. Mice were 28 days old when received by the study laboratory; the quarantine period was 12 days for the first study and 13 days for the second study. During quarantine, the animals were observed daily. To assess the health status of the animals before the start of the studies, five male and five female rats and five male and five female mice in the first study, and five male and four female mice in the second study were killed and examined for evidence of disease and parasite infection. The rats were 41 days old and the mice were 40 or 41 days old when the studies began. The health of the animals was monitored during the studies according to the protocols of the NTP Sentinel Animal Program (Appendix K).

Animal Maintenance

Rats were housed five per cage; mice were housed individually. Feed and water were available ad libitum. Feed consumption was measured once every 4 weeks. Cages were rotated clockwise on the racks every 2 weeks and cage racks were rotated clockwise to a new location in the animal room every 2 weeks. Further details of animal maintenance are given in Table 1.

Clinical Examinations and Pathology

All animals were observed twice daily. Body weights and clinical findings were recorded weekly for the first 13 weeks and then once every 4 weeks until the end of the studies. All animals were necropsied. At necropsy, all organs and tissues were examined for gross lesions.

Complete histopathologic examinations were performed on all animals that died or were killed moribund before the end of the studies, all animals that reached study termination, all rats from the 0 and 600 ppm groups at the 3- and 15-month interim evaluations, all mice from the 0 and 400 ppm groups in the first study at the 3-month interim evaluation, and all mice from the 0 and 200 ppm groups in the first study and from the 0 and 400 ppm

groups in the second study at the 15-month interim evaluation. Selected tissues were examined from rats and mice in other groups at the 3- and 15-month interim evaluations. Tissues examined microscopically are listed in Table 1. At necropsy all organs and tissues were fixed and preserved in phosphate-buffered neutral formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for microscopic examination. Nonneoplastic lesions were rated using a four-step grading system of minimal, mild, moderate, and marked.

Pathology evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the Toxicology Data Management System. The microscopic slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet-tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assessment laboratory. The individual animal records and pathology tables were compared for accuracy, slides and tissue counts were verified, and histotechnique was evaluated. A quality assessment pathologist reviewed the liver of male and female rats, the pituitary gland of female rats, the liver, pituitary gland, and thyroid gland of male and female mice, the ovary and uterus of female mice in both study groups, and the harderian gland of male and female mice in the second study for accuracy and consistency of lesion diagnosis.

The quality assessment report and slides were submitted to the NTP Pathology Working Group (PWG) chair, who reviewed selected tissues for which there was disagreement in diagnosis between the laboratory and the quality assessment pathologist. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnosis between the laboratory and quality assessment pathologist, or lesions of general interest were presented by the chair to the PWG for review. The PWG included the quality assessment pathologist and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without knowledge of exposure level or previously rendered diagnoses. When the consensus opinion of the PWG differed from that of the laboratory pathologist, the diagnosis was changed to reflect the PWG consensus. Details of these review procedures have been described by Maronpot and Boorman (1982) and Boorman et al. (1985). For later analyses of pathology data, the diagnosed lesions for each tissue type were evaluated separately or combined according to the guidelines of McConnell et al. (1986).

Statistical Methods

Survival Analyses

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals were censored from the survival analyses at the time they were found dead from other than natural causes. Animals dying from natural causes were not censored. Statistical analyses for a possible dose-related effect on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.

Calculation of Incidence

The incidence of neoplasms or nonneoplastic lesions is given as the number of animals bearing such lesions at a specific anatomic site and the number of animals with that site examined microscopically. In most instances, the denominators include only those animals for which the site was examined histologically. However, when macroscopic examination was required to detect lesions (e.g., skin or mammary gland neoplasms) before histologic sampling or when lesions (e.g., mononuclear cell leukemia) had multiple potential sites of occurrence, the denominators consist of the number of animals on which a necropsy was performed.

Analysis of Neoplasm Incidence

The majority of neoplasms in these studies were considered to be incidental to the cause of death or not rapidly lethal. Thus, the primary statistical method used was a logistic regression analysis, which assumed that the diagnosed neoplasms were discovered as the result of death from an unrelated cause and thus did not affect the risk of death. In this approach, neoplasm prevalence was modeled as a logistic function of chemical exposure and time. Both linear and quadratic terms in time were incorporated initially, and the quadratic term was eliminated if it did not significantly enhance the fit of the model. The control and exposed groups were compared on the basis of the likelihood score test for the regression coefficient of dose. This method of adjusting for intercurrent mortality is the prevalence analysis of Dinse and Lagakos (1983), further described and illustrated by Dinse and Haseman

(1986). When neoplasms are incidental, this comparison of the time-specific neoplasm prevalences also provides a comparison of the time-specific neoplasm incidences (McKnight and Crowley, 1984).

In addition to logistic regression, alternative methods of statistical analysis were used, and the results of these tests are summarized in the appendixes. These include the life table test (Cox, 1972; Tarone, 1975), which is appropriate for rapidly lethal neoplasms, the Fisher exact test and the Cochran-Armitage trend test (Armitage, 1971; Gart et al., 1979), procedures based on the overall proportion of neoplasm-bearing Tests of significance include pairwise comparisons of each exposed group with controls and a test for an overall dose-response trend. Continuitycorrected tests were used in the analysis of neoplasm incidence, and reported P values are one sided. The procedures described above were also used to evaluate selected nonneoplastic lesions. For further discussion of these methods, refer to Haseman (1984).

Historical Control Data

Although the concurrent control group is always the first and most appropriate control group used for evaluation, there are certain instances in which historical control data can be helpful in the overall assessment of neoplasm incidence. Consequently, neoplasm incidences from the NTP historical control database (Haseman et al., 1984, 1985) are included in the NTP reports for neoplasms appearing to show compound-related effects.

Analysis of Continuous Variables

Two approaches were employed to assess the significance of pairwise comparisons between exposed and control groups in the analysis of continuous variables. Organ and body weight data, which have approximately normal distributions, were analyzed using the parametric multiple comparison procedures of Williams (1971, 1972) and Dunnett (1955). Hematology, clinical chemistry, and urinalysis data, which typically have skewed distributions, were analyzed using the multiple comparison methods of Shirley (1977) or Dunn (1964). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of dose-response trends and to determine whether a trend-sensitive test (Williams' test) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-response trend (Dunnett's test). Average nephropathy severity values for the 2-year studies were analyzed for significance using the Mann-Whitney U test (Hollander and Wolfe, 1973).

Quality Assurance Methods

The 13-week and 2-year studies were conducted in compliance with FDA Good Laboratory Practice Regulations (21 CFR, Part 58). In addition, as records from the 2-year studies were submitted to the NTP Archives, they were audited retrospectively by an independent quality assurance contractor. Separate audits covering completeness and accuracy of the pathology data, pathology specimens, final pathology tables, and preliminary draft of this NTP Technical Report were conducted. Audit procedures and findings are presented in the reports filed at the

NIEHS. The audit findings were reviewed and assessed by NTP staff and had been resolved or were otherwise addressed during the preparation of this Technical Report.

GENETIC TOXICOLOGY

Triamterene was tested for induction of gene mutations in Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 with preincubation in the presence and in the absence of Aroclor 1254-induced male Sprague-Dawley rat or Syrian hamster liver S9. The induction of sister chromatid exchanges and chromosomal aberrations was tested using Chinese hamster ovary cells with and without S9 activation.

TABLE 1
Experimental Design and Materials and Methods in the Feed Studies of Triamterene

15-Day Studies	13-Week Studies	2-Year Studies
Study Laboratory		
International Research and	International Research and	Battelle Columbus Division
Development Corp. (Mattawan, MI)	Development Corp. (Mattawan, MI)	(Columbus, OH)
Strain and Species		
Rats: F344/N	Rats: F344/N	Rats: F344/N
Mice: B6C3F ₁	Mice: B6C3F ₁	Mice: B6C3F ₁
Animal Source		
Charles River Breeding Laboratories	Charles River Breeding Laboratories	Frederick Cancer Research Facility
(Portage, MI)	(Portage, MI)	(Frederick, MD)
Fime Held Before Study		
Rats: 14 days	Rats: 13 days	Rats: 13 days
Mice: 15 days	Mice: 16 days	Mice: First study, 12 days; Second study, 13 days
Age When Placed on Study		
Rats: 42-49 days	Rats: 41-48 days	Rats: 41 days
Mice: 50-65 days	Mice: 57-68 days	Mice: First study, 40 days; Second study, 41 days
Date of First Dose		
Rats: 4 May 1982	Rats: 13 September 1982	Rats: 10 September 1984
Mice: 5 May 1982	Mice: 16 September 1982	Mice: First study, 17 September 1984; Second study, 26 August 1985
Date of Last Dose		
Rats: 17 May 1982	Rats: 14 December 1982	Rats: 1 September 1986
Mice: 19 May 1982	Mice: 15 December 1982	Mice: First study,
•		9 September 1986;
		Second study, 17 August 1987
Duration of Dosing		
14 days	13 weeks	104 weeks
Average Age at Necropsy		
Rats: 8-9 weeks	Rats: 19-20 weeks	Rats: 3-month interim evaluation,
Mice: 7-8 weeks	Mice: 22-23 weeks	19 weeks; 15-month interim evaluation, 71 weeks; terminal, 111 weeks
		Mice: First study, 3-month interim evaluation, 19 weeks; 15-month interim evaluation, 71 weeks (excep for 400 ppm group); terminal,
		110 weeks Second study, 15-month interim evaluation, 72 weeks; terminal, 110 weeks

TABLE 1
Experimental Design and Materials and Methods in the Feed Studies of Triamterene (continued)

15-Day Studies	13-Week Studies	2-Year Studies
Necropsy Dates		
Rats: 19 May 1982 Mice: 20 May 1982	Rats: 13-14 December 1982 Mice: 16-17 December 1982	Rats: 3-month interim evaluation, 11-14 December 1984; 15-month interim evaluation, 9 December 1985; terminal, 8-10 September 1986 Mice: First study, 3-month interim evaluation, 18-21 December 1984; 15-month interim evaluation, 16-17 December 1985; terminal, 15-16 and 18-19 September 1986; Second study, 15-month interim evaluation, 1 December 1986; terminal, 24-25 August 1987
Size of Study Groups		
5 males and 5 females	10 males and 10 females	Rats: 70 males and 70 females Mice: First study, 70 males and 70 females; Second study, 60 males and 60 females
Animals per Cage		
Rats: 5 Mice: 5	Rats: 5	Rats: 5
Mice: 5	Mice: 5	Mice: 1
Method of Animal Distribution		
Animals were weighed and randomized into dose groups using a pseudorandom number generator.	Same as 15-day studies	Animals were weighed and randomized into exposure groups by partitioning algorithm using the Xybion® Pathology/Toxicology Data System
Method of Animal Identification		
Rats: Ear tag	Rats: Ear tag	Rats: Toe mark
Mice: Toe clip	Mice: Toe clip	Mice: Toe mark
Diet		
NIH-07 Rat and Mouse Open Formula, mash diet (Zeigler Bros., Inc., Gardners, PA), available ad libitum, feeders exchanged weekly	Same as 15-day studies	NIH-07 Rat and Mouse Open Formula, meal diet (Zeigler Bros., Inc., Gardners, PA), available ad libitum, feeders exchanged weekly
Water Well water from Village of Mattawan,	Same as 15-day studies	City of Columbus, OH, municipal
MI, and IRDC wells. Available ad libitum using an Edstrom Industries automatic watering system		water supply, available ad libitum using an Edstrom Industries automatic watering system (Waterford, WI)
(Waterford, WI)		
Cages		
Polycarbonate, solid bottoms (Hazleton	Same as 15-day studies; changed	Same as 15-day studies. Cages were
System, Inc., Aberdeen, MD, and Lab Products, Inc., Maywood, NJ); changed twice weekly	biweekly. Cages rotated within exposure groups on racks	changed weekly (mice) or twice weekly (rats). Cages were rotated clockwise on the racks every 2 weeks.

TABLE 1
Experimental Design and Materials and Methods in the Feed Studies of Triamterene (continued)

15-Day Studies	13-Week Studies	2-Year Studies
Racks		
Stainless steel, (Unifab Corporation, Kalamazoo, MI, and Wahmann Manufacturing Co., Timonium, MD); changed once every 2 weeks	Same as 15-day studies, changed once every 2 weeks and racks rotated in the animal room once every 2 weeks	Same as 15-day studies. Cage racks were changed and rotated clockwise to a new location in the animal room once every 2 weeks
Bedding BetaChips®, heat-treated hardwood	Same as 15-day studies	BetaChips®, heat-treated hardwood
chips (Northeastern Products Corp., Warrensburg, NY), changed twice weekly	came as 13 day studies	chips (Northeastern Products Corp., Warrensburg, NY), changed weekly (mice) or twice weekly (rats)
Cage Filters		
Reemay spun-bonded polyester fiber filters (Snow Filtration, Cincinnati, OH), changed once every 2 weeks	Same as 15-day studies	Dupont 2024, spun-bonded polyester fiber filters (Snow Filtration, Cincinnati, OH), changed once every 2 weeks
Animal Room Environment		
Average temperature: 24° C Relative humidity: 47% Fluorescent light: 12 hours/day Room air flow: minimum of 10 changes/hour	Average temperature: 22° C Relative humidity: 50% Fluorescent light: 12 hours/day Room air flow: minimum of 10 changes/hour	Rats: Temperature: 20°-26° C Relative humidity: 31%-73% Fluorescent light: 12 hours/day Room air flow: minimum of 15 changes/hour Mice (first study): Temperature: 20°-26° C Relative humidity: 20%-66% Fluorescent light: 12 hours/day Room air flow: minimum of 10 changes/hour Mice (second study): Temperature: 20°-24° C Relative humidity: 28%-66% Fluorescent light: 12 hours/day Room air flow: minimum of 10 changes/hour
Doses		
Rats: 0, 1,000, or 3,000, 10,000, 30,000, or 60,000 ppm in feed Mice: 0, 300, 1,000, 3,000, 10,000, or 30,000 ppm in feed	Rats: 0, 150, 300, 600, 1,200, or 2,400 ppm in feed Mice: 0, 100, 200, 400, 800, or 1,600 ppm in feed	Rats: 0, 150, 300, or 600 ppm in feed Mice: First study, 0, 100, 200, or 400 ppm in feed; Second study, 0 or 400 ppm in feed
Type and Frequency of Observation Observed twice/day; body weight initially, on day 8, and on day 15; feed consumption measured daily and recorded weekly; clinical findings were noted daily	Observed twice/day; body weight once/week until the end of the studies; feed consumption measured daily and recorded weekly; clinical observation once weekly.	Observed twice/day; body weights once/week for the first 13 weeks, then once/month until the end of the study; feed consumption measured approximately every 4 weeks; clinical findings noted at body weight determinations.

TABLE 1
Experimental Design and Materials and Methods in the Feed Studies of Triamterene (continued)

15-Day Studies	13-Week Studies	2-Year Studies
Method of Sacrifice Carbon dioxide asphyxiation	Same as 15-day studies	Same as 15-day studies
Necropsy Necropsy performed on all animals. Organs weighed on animals surviving to the end of the studies were brain, heart, right kidney, liver, lungs, right testis, and thymus.	Same as 15-day studies	Necropsy performed on all animals. Organs weighed at 3-month and 15-month interim evaluations were brain, kidney, and liver.
Histopathology Complete histopathologic examinations were performed on rats in the 3,000 ppm groups and on mice in the 1,000 and 3,000 ppm groups. Tissues examined microscopically included adrenal gland, bone (including marrow), brain, epididymis, esophagus, gallbladder (mice only), gross lesions, heart, kidney, large intestine, liver, lung, mammary gland, mesenteric lymph node, nose, ovary, pancreas, parathyroid gland, pituitary gland, prostate gland, salivary gland, small intestine, spinal cord, spleen, stomach, testis, thymus, thyroid gland, tissue masses, trachea, urinary bladder, and uterus. Selected tissues examined from rats fed 0 or 1,000 ppm were: bone and bone marrow, kidney, mammary gland, adrenal gland, and gross lesions.	Complete histopathologic examinations were performed on all rats in the 0, 1,200, and 2,400 ppm groups, on all mice in the 0, 800, and 1,600 ppm groups and all animals that died prior to study termination. Tissues routinely examined microscopically were the same as those included in the 15-day studies. Adrenal gland, kidney, and gross lesions were examined from rats in the 150, 300, and 600 ppm groups. Thymus and gross lesions were examined from mice in the 100, 200, and 400 ppm groups.	Complete histopathologic examinations were performed on all rats and all mic (from both first and second studies) that died or were killed moribund prio to the end of the studies or survived to study termination. At the 3- and 15-month interim evaluations, complet histopathologic examinations were performed on all rats from the 0 and 600 ppm groups; in the 150 and 300 ppm groups only gross lesions were examined at the 3-month evaluation while gross lesions, hearts in males, and kidneys in females were examined at the 15-month evaluation. At the 3-month interim evaluation of mice (conducted in first study only) complete histopathologic examinations were performed on all mice in the 0 and 400 ppm groups and only gross lesions were examined in the other groups. At the 15-month interim evaluation, complete histopathologic examinations were performed on all mice from the 0 and 200 ppm groups in the first study and on the 0 and 400 ppm groups in the second study, kidneys and gross lesions were examined from 100 ppm groups in the first study. Tissues routinely examined microscopically included adrenal gland bone (including marrow), brain, clitora gland (rats only), epididymis, esophagus, gallbladder (mice only), gross lesions, heart, kidney, large intestine, liver, lung, mammary gland, mandibular lymph node, mesenteric lymph node, nose, ovary, pancreas, parathyroid gland

TABLE 1
Experimental Design and Materials and Methods in the Feed Studies of Triamterene (continued)

15-Day Studies	13-Week Studies	2-Year Studies
Histopathology		
		(continued) pituitary gland, preputial gland (rats only), prostate gland, salivary gland, skin, small intestine, spleen, stomach, testis, thymus, thyroid gland, tissue masses, trachea, urinary bladder, and uterus.
Clinical Pathology		
None	Blood and urine were collected from rats in the 0, 150, 600, and 1,200 ppm groups and from mice in the 0, 100, 400, and 800 ppm groups. Hematology: hematocrit, hemoglobin, erythrocyte count, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, total and differential leukocyte counts Clinical chemistry: creatinine, calcium, chloride, potassium, phosphorus, and sodium Urinalysis: specific gravity and volume	Clinical pathology studies were made at 3- and 15- month interim evaluations. Blood collected from the retroorbital sinus following methoxyflurane anesthesia and urine collected overnight in metabolism cages. Hematology: hematocrit, hemoglobin, erythrocyte count, mean cell volume, mean cell hemoglobin, concentration, total and differential leukocyte counts, platelets reticulocytes Clinical chemistry: bilirubin, urea nitrogen, pH, bicarbonate, creatinine, calcium, chloride, potassium, phosphorus, and sodium. Urinalysis: specific gravity and volume

RESULTS

RATS 15-DAY STUDY

The diets containing triamterene at levels of 10,000 ppm or more were unpalatable. Reduced palatability of the diet containing 3,000 ppm was also evident and the feed consumption by rats in these groups was less than that by controls (Table 2). Rats exposed to 1,000 or 3,000 ppm received approximate triamterene doses of 80 or 60 mg/kg per day (males) or 70 or 50 mg/kg per day (females). One male and two females receiving 3,000 ppm died on day 14 or 15. The deaths of these rats were likely due primarily to malnutrition associated with the reduced feed consumption, although physiological and pathological renal effects associated with triamterene may have contributed to their deaths. There were no clinical findings attributed to triamterene.

The final mean body weights of males and females in the 3,000 ppm group were 52% and 42% lower than controls (Table 2). The absolute organ weights of rats receiving 3,000 ppm were lower than those of the controls primarily as a result of the reduced feed consumption and lower body weights observed in these groups (Table F1).

Microscopic examination of the kidneys of all males and three females receiving 3,000 ppm revealed one or a few scattered individual tubules with basophilic epithelial cells containing vesicular nuclei. The nuclear and cytoplasmic features of the epithelium in the affected renal tubules were characteristic of epithelial regeneration following tubule damage. Cellular debris was observed in the lumens of a few scattered tubules in males but not in females. Cytoplasmic vacuolization of cells of the zona glomerulosa

TABLE 2 Survival, Mean Body Weights, and Feed Consumption of Rats in the 15-Day Feed Study of Triamterene

		Mea	an Body Weight ^b	(g)	Final Weight	Feed		
Concentration (ppm)	Survival ^a	Initial	Initial Final Change		Relative to Controls (%)	Consumption ^c Week 1 Week		
Male								
0	5/5	187 ± 5	243 ± 4	56 ± 2		18.1	15.3	
1,000	5/5	186 ± 7	237 ± 7	51 ± 2	97	16.7	16.6	
3,000	4/5 ^d	187 ± 7	117 ± 5**	$-74 \pm 6**$	48	4.2	1.8	
10,000	0/5 ^d	184 ± 5	_	-	-	_	_	
30,000	0/5 ^d	183 ± 7	_	_	_	_	_	
60,000	0/5 ^d	186 ± 7	-	-		-	-	
Female								
0	5/5	136 ± 3	159 ± 4	24 ± 2		12.0	11.6	
1,000	5/5	135 ± 4	157 ± 3	23 ± 1	99	9.1	11.3	
3,000	3/5 ^d	136 ± 5	92 ± 10**	$-44 \pm 5**$	58	2.4	1.6	
10,000	0/5 ^d	134 ± 4	-	~	_	_	_	
30,000	0/5 ^d	135 ± 3	_	-	_	_	_	
60,000	0/5 ^d	135 ± 5	_	-	_	_	_	

^{**} Significantly different (P≤0.01) from the control group by Williams' or Dunnett's test

Number of animals surviving/number initially in group. Animals were given dosed feed for 14 days followed by 1 day of undosed feed.

Weights and weight changes are given as mean ± standard error. Subsequent calculations are based on animals surviving to the end of the study. No data were calculated for groups with 100% mortality.

Grams of feed consumed per animal per day

d All deaths occurred between days 11 and 15

was observed in the adrenal gland of all males and one female receiving 3,000 ppm. The bone marrow of rats receiving 3,000 ppm contained fewer hematopoietic cells than that of controls, presumably due to the reduced feed consumption and lower body weights.

Because of the poor palatability of diets containing triamterene at levels of 3,000 ppm or more and the chemical-related kidney and adrenal gland lesions observed in the 3,000 ppm groups in the 15-day feed study, the high dose selected for the 13-week study in rats was 2,400 ppm.

13-WEEK STUDY

All rats in the 2,400 ppm group died during the first 4 weeks, apparently as a result of reduced feed consumption (Table 3) as well as the nephrotoxic

effects of triamterene. All rats receiving 1,200 ppm or less survived to the end of the study. Clinical findings of toxicity observed only in rats in the 2,400 ppm groups were piloerection and inactivity and, finally, body tremors, ataxia, bradypnea, and prostration. These findings commonly accompany debilitation as a result of reduced feed consumption and toxicity and may not be the result of specific, chemical-related morphological or functional alterations. During the first 4 weeks of the study, feed consumption by rats in the 2,400 ppm group was markedly lower than that by controls. It is uncertain if the reduced feed consumption was related to decreased palatability of the diet or to anorexia resulting from toxicity. Feed consumption by rats receiving 1,200 ppm or less was similar to that by controls. Rats exposed to 150, 300, 600, or 1,200 ppm triamterene received approximate doses of 10, 20, 40, or 70 mg/kg per day (males) or 10, 20, 40, or 80 mg/kg per day (females).

TABLE 3
Survival, Mean Body Weights, and Feed Consumption of Rats in the 13-Week Feed Study of Triamterene

		Mea	an Body Weight ^b	(g)	Final Weight	Feed		
Concentration (ppm)	Survival ^a	Initial	Final	Change	Relative to Controls (%)		mption ^c Week 13	
Male								
0	10/10	164 ± 3	390 ± 8	226 ± 8		18.8	16.1	
150	10/10	163 ± 4	383 ± 11	220 ± 7	98	19.3	16.4	
300	10/10	163 ± 6	382 ± 9	219 ± 6	98	19.6	15.0	
600	10/10	163 ± 4	375 ± 7	213 ± 7	96	18.6	15.3	
1,200	10/10	164 ± 4	$338 \pm 6**$	174 ± 4**	87	15.6	14.9	
2,400	0/10 ^d	158 ± 4	_	-	· -	-	-	
Female								
0	10/10	121 ± 3	218 ± 3	97 ± 5	•	12.8	8.3	
150	10/10	121 ± 2	214 ± 2	92 ± 2	98	11.9	10.0	
300	10/10	120 ± 3	209 ± 4	89 ± 2	96	11.5	9.9	
600	10/10	120 ± 3	210 ± 3	90 ± 1	96	11.9	9.8	
1,200	10/10	117 ± 3	$192 \pm 2**$	75 ± 3**	88	10.4	9.4	
2,400	0/10 ^e	119 ± 3	-	-	_	_	_	

^{**} Significantly different (P≤0.01) from the control group by Williams' or Dunnett's test

^a Number of animals surviving/number initially in group

Weights and weight changes are given as mean ± standard error. Subsequent calculations are based on animals surviving to the end of the study. No data were calculated for groups with 100% mortality.

^c Grams of feed consumed per animal per day

d Week of death: 3, 3, 3, 4, 4, 4, 4, 4, 4

e Week of death: 2, 2, 3, 3, 3, 3, 4, 4, 4, 4

There were slight differences in the mean values of several hematologic, clinical chemistry, or urinalysis parameters in rats receiving 1,200 ppm (Table G1). These were not considered biologically significant and were not clearly related to the administration of triamterene.

The final mean body weights and body weight gains of rats in the 1,200 ppm groups were 13% and 23% lower than those of controls for males and 12% and 23% lower for females. At 1,200 ppm, the absolute weights of brain and kidney in males and of brain, heart, kidney, lungs, and thymus in females were significantly lower than those of controls (Table F2). Since the relative organ-weight-to-body-weight ratios were not significantly affected, the absolute organ weight changes were attributed to reduced body weight and not to organ toxicity.

At necropsy, minute, sand-like calculi were observed in the renal pelvis of four male rats receiving 1,200 ppm triamterene; none were observed in the kidney of females in the 1,200 ppm group or in males or females of any other group. Chemical-related microscopic lesions were observed in the kidney and adrenal gland (Table 4). Mild regeneration of the renal tubule epithelium was observed in all males and most females in the 2,400 ppm groups. The lesions were often most extensive in the outer stripe of the outer medulla and extended into the inner regions of the cortex. Although the straight portions of the renal tubules were most often affected, there were also segmental areas involving the full thickness of the cortex. The epithelium of the affected renal

tubules was more basophilic than normal with slightly enlarged, vesicular nuclei. A few necrotic cells and mitotic figures were also observed and, infrequently, tubule lumens contained cellular debris or hyaline (protein) casts. The kidney lesions in the 1,200 ppm groups were less severe and involved fewer tubules. Minimal renal tubule regeneration involving a few scattered individual tubules was observed in most male rats in the lower dose groups and controls and was typical of spontaneous nephropathy.

Cytoplasmic vacuolization of cells of the zona glomerulosa was observed in the adrenal glands of nearly all male rats, but the severity of this lesion was greater in rats receiving 2,400 ppm (Table 4). In females, both the incidence and severity of cytoplasmic vacuolization were greater in the 2,400 ppm group than in the controls. Bone marrow hypocellularity and lymphoid depletion in the spleen and thymus of rats receiving 2,400 ppm may have been the result of emaciation and debilitation rather than direct chemical toxicity.

Dose selection rationale: Dietary concentrations of triamterene selected for the 2-year feed study in rats were 0, 150, 300, and 600 ppm. Exposure levels of 1,200 ppm were considered too great for the 2-year study, primarily because of the kidney lesions observed in 1,200 ppm rats in the 13-week study. Spontaneous renal disease occurrs in aging rats, particularly males, and is a major contributing cause of death. This age-related disease, in combination with renal toxicity related to triamterene ingestion may have reduced life-span, and thus negatively affected the sensitivity to detect carcinogenic effects.

TABLE 4 Incidences of Treatment-Related Lesions in Rats in the 13-Week Feed Study of Triamterene

	0 p	pm	150	ppm	300 ppm		600 ppm		1,200 ppm		2,400 ppm	
Male												
n ·	10		10		10		10		10		10	
Kidney												
Tubule degeneration	0		0		0		0		8**	$(1.3)^{b}$	10**	(3.1)
Tubule dilatation	0		0		0		0		8**	(1.3)	0	` ,
Cast	0		0		0		0		4*	(2.0)	5*	(1.0)
Tubule regeneration	8	(1.1)	6	(1.0)	5	(1.0)	6	(1.0)	10	(1.8)	9	(1.7)
Calculi ^a	0	(1.1)	0	(1.0)	0	(1.0)	0	(1.0)	4	(1.0)	Ó	(1.7)
Adrenal gland, cortex												
Vacuolar change	9	(1.0)	9	(1.0)	10	(1.0)	7	(1.0)	2	(1.0)	10	(2.6)
Bone marrow												
Hypocellularity	0		_c		-		-		0		10**	(3.2)
Spleen												
Lymphoid depletion	0		-		-		-		0		8**	(1.6)
Thymus												
Lymphoid depletion	0		-		-		-		0		8**	(3.4)
Female	. •											
n	10		10		10		10		10		9	
Kidney												
Tubule degeneration	0		0		0		0		3	(1.7)	8**	$(3.0)^{d}$
Tubule dilatation	0		0		0		1	(1.0)	3	(1.3)	2	(1.0)
Cast	0		0		0		0	()	2	(1.0)	0	()
Tubule regeneration	o		0		0		1	(1.0)	5*	(1.2)	5*	(2.2)
Adrenal gland, cortex												•
Vacuolar change	0		0		1	(1.0)	0		2	(1.0)	8**	(1.9)
Bone marrow												
Hypocellularity	0		-		-		-		0		9**	(3.2)
Spleen												
Lymphoid depletion	0		-		-		-		0		6**	(2.3)
Thymus									_			
Lymphoid depletion	0		_		_		_		0		7**	(3.3)

^{*} Significantly different (P≤0.05) from the control group by the Fisher exact test

a Calculi were observed by macroscopic examination at necropsy; all other lesions were observed by microscopic examination.
b Average severity grade for affected animals: 1=minimal; 2=mild; 3=moderate; 4=marked

^c Not examined microscopically at this exposure level

2-YEAR STUDY

3-Month Interim Evaluation

There were no biologically significant differences in hematologic, clinical chemistry, or urinalysis parameters between exposed and control rats (Table G2). At necropsy the mean body weights of 150 and 300 ppm male rats and of 300 and 600 ppm female rats were slightly lower than those of controls (Table F3). The body weight decrement of the 150 and 300 ppm males was not considered to be chemical related because the mean body weight of the 600 ppm group was similar to controls. The absolute kidney weights of 300 and 600 ppm females and the absolute and relative kidney weights of 150 ppm males were slightly lower than those of controls, apparently because of the lower body weights of these groups (Table G2). No chemical-related gross or microscopic lesions were observed in rats after exposure to triamterene for 3 months.

15-Month Interim Evaluation

There were no biologically significant differences in hematologic, clinical chemistry, or urinalysis parameters between exposed and control rats (Table G3). At necropsy, the mean body weights of exposed rats were within 5% of the controls. Differences in absolute or relative organ weights between some exposed groups and controls were associated with

slight differences in mean body weight and were not considered chemical related (Table F4). Basophilic, clear cell, and mixed cell foci occurred in the liver of exposed male rats, but not in controls (Table A5). No liver neoplasms were observed in rats at 15 months.

Body Weights, Feed Consumption, and Clinical Findings

The mean body weights of 600 ppm rats were consistently lower than, but within 5% of, those of controls after week 49 of the studies (Tables 5 and 6, Figure 1). After week 90 the decrement in mean body weight between 600 ppm males and controls diminished. Feed consumption by exposed male and female rats was similar to that by controls throughout the study. Dietary levels of 150, 300, or 600 ppm resulted in average daily consumption levels of 5, 10, or 25 mg/kg (males) and 5, 15, or 30 mg/kg (females) (Tables 11 and 12). No chemical-related clinical findings of toxicity were observed.

Survival

Estimates of 2-year survival probabilities for male and female rats are presented in Table 7 and in the Kaplan-Meier survival curves in Figure 2. Survival of exposed male and female rats was similar to the controls.

TABLE 5
Mean Body Weights and Survival of Male Rats in the 2-Year Feed Study of Triamterene


Week	0 ppm		150 ppm			300 ppm			600 ppm			
on	Av. Wt.	No. of	Av. Wt.		No. of	Av. Wt.			Av. Wt.	Wt. (% of		
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	
1	136	70	133	98	70	132	97	70	132	97	70	
2	182	70	178	97	70	174	96	70	176	97	70	
3	219	70	215	98	70	211	96	70	211	96	70	
4	241	70	237	99	70	234	97	70	231	96	70	
5	263	70	263	100	70	254	97	70	255	97	70	
6	279	70	279	100	70	270	97	70	275	99	70	
7	290	70	292	101	70	283	98	70	287	99	70	
8	303	70	302	100	70	292	96	70	291	96	70	
9	316	70	317	100	70	308	98	70	305	97	70	
10	328	70	330	100	70	325	99	70	324	99	70	
11	333	70	333	100	70	330	99	70	330	99	70	
12	350	70	349	100	70	347	99	70	347	99	70	
13	356	67	358	100	70	355	100	70	355	100	70	
17 ^a	379	57	384	101	60	378	100	60	374	99	60	
21	396	57	399	101	60	391	99	60	390	99	60	
25	414	57	415	100	60	409	99	60	408	99	60	
29	425	57	426	100	60	417	98	60	418	98	60	
33	444	57	445	100	60	441	99	60	434	98	60	
37	451	57	457	101	60	448	99	60	439	97	60	
42	455	57	458	101	60	453	100	60	447	98	60	
45	465	57	467	101	60	460	99	60	449	97	60	
49	479	56	483	101	59	470	98	60	458	96	60	
53	482	56	481	100	58	472	98	60	459	95	59	
57	481	56	488	102	58	478	99	60	466	97	59	
61	485	56	488	101	58	476	98	60	467	96	59	
65	484	56	491	101	58	477	99	60	466	96	59	
69 ^a	489	45	493	101	48	483	99	50	470	96	49	
73	490	43	489	100	48	480	98	50	463	95	49	
77	488	41	486	100	48	473	97	49	466	96	46	
81	487	40	489	100	46	477	98	46	466	96	44	
85	482	39	482	100	46	473	98	45	459	95	43	
89	471	38	467	99	41	462	98	43	455	97	41	
93	454	37	449	99	39	447	98	40	446	98	39	
97	435	33	439	101	34	421	97	34	426	98	36	
101	420	31	415	99	31	405	96	24	401	95	30	
104	382	27	418	109	25	391	102	20	393	103	27	
Mean for	weeks											
1-13	277		276	100		270	97		271	98		
14-52	434		437	101		430	99		424	98		
53-104	466		470	101		458	98		450	97		

a Interim evaluations occurred during weeks 13 and 65.

TABLE 6
Mean Body Weights and Survival of Female Rats in the 2-Year Feed Study of Triamterene

Week	0	0 ppm		150 ppm			300 ppm			600 ppm		
on	Av. Wt.	No. of	Av. Wt.		No. of	Av. Wt.	Wt. (% of		Av. Wt.	Wt. (% of		
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)		Survivors	
1	108	70	107	100	70	107	100	70	106	98	70	
2	131	70	129	99	70	129	98	70	127	97	70	
3	146	70	145	99	70	144	99	70	141	97	70	
4	155	70	154	99	70	151	98	70	150	97	70	
5	164	70	162	99	70	160	98	70	159	97	70	
6	170	70	168	99	70	169	99	70	167	98	70	
7	178	70	176	99	70	177	99	70	175	98	70	
8	181	70	180	100	70	179	99	70	178	99	70	
9	188	70	186	99	70	183	98	70	184	98	70	
10	190	70	189	100	70	190	100	70	187	99	70	
11	191	70	190	99	70	192	101	70	189	99	70	
12	197	70	196	100	70	196	100	70	193	98	70	
13	200	70	199	99	70	199	100	70	192	96	70	
17 ^a	206	60	204	99	60	207	100	60	203	99	60	
21	211	60	210	100	60	211	100	60	208	99	60	
25	214	60	212	99	60	214	100	60	212	99	60	
29	221	60	219	99	60	221	100	60	217	98	60	
33	229	60	227	99	60	230	100	60	224	98	60	
37	241	60	237	99	60	240	100	60	235	97	60	
41	246	60	244	99	60	241	98	60	241	98	60	
45	252	60	248	98	60	250	99	60	245	97	60	
49	262	60	258	99	60	262	100	60	252	96	60	
53	276	60	273	99	60	272	99	60	264	96	60	
57	284	60	283	100	60	286	101	57	274	97	60	
61	290	60	287	99	60	290	100	57	279	96	60	
65	298	60	295	99	60	297	100	57	284	96	60	
69 ^a	304	49	301	99	49	303	99	47	290	95	49	
73	314	49	310	99	49	313	100	47	297	95	49	
77	319	48	316	99	48	315	99	47	301	94	47	
81	327	47	324	99	48	321	98	47	307	94	45	
85	335	45	327	98	48	326	97	47	309	92	44	
89	344	44	333	97	45	323	94	47	305	89	44	
93	343	44	331	97	44	331	97	44	312	91	40	
97	339	41	332	98	42	324	96	42	309	91	37	
101	337	37	336	100	39	332	99	37	318	94	33	
104	333	30	337	101	34	332	100	34	317	95	29	
Mean for	weeks											
1-13	169		168	99		167	99		165	98		
14-52	231		229	99		231	100		226	98		
53-101	317		313	99		312	98		298	94		
_				-								

^a Interim evaluations occurred during weeks 13 and 65.






FIGURE 1 Growth Curves for Male and Female Rats Administered Triamterene in Feed for 2 Years

TABLE 7
Survival of Rats in the 2-Year Feed Study of Triamterene


	0 ppm	150 ppm	300 ppm	600 ppm
Male				
Animals initially in study	70	70	70	70
3-Month interim evaluation ^a	10	· 10	10	10
15-Month interim evaluation ^a	10	10	10	10
Accidental deaths ^a	3	0	. 0	0
Moribund	18	20	18	17
Natural deaths	. 4	5	13	. 6
Animals surviving to study termination	25	25	19	27
Percent probability of survival at end of study ^b	53	50	38	54
Mean survival days ^c	535	563	567	565
Survival analysis ^d	P=1.000N	P=0.901	P=0.287	P=1.000N
Female				
Animals initially in study	70	70	70 .	70
3-Month interim evaluation ^a	10	10	10	10
15-Month interim evaluation ^a	10	10	10	10
Moribund	17	11	12	18
Natural deaths	4	5	4	3
Animals surviving to study termination	29	34	34	29
Percent probability of survival at end of study	58	68	69	58
Mean survival days	576	581	575	570
Survival analysis	P=0.722	P=0.383N	P=0.455N	P=0.985

a Censored from survival analyses

Mean of all deaths (uncensored, censored, terminal sacrifice)

b Kaplan-Meier determinations

^d The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed columns. A negative trend or lower mortality in an exposure group is indicated by N.






FIGURE 2
Kaplan-Meier Survival Curves for Male and Female Rats
Administered Triamterene in Feed for 2 Years

Pathology and Statistical Analyses of Results
Statistically significant or biologically noteworthy changes in the incidences of neoplasms or nonneoplastic lesions in the liver, kidney, and uterus are described below. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendixes A for male rats and B for female rats.

Liver: The incidence of mixed cell foci occurred with a significant positive trend in male and female rats, and the incidences in the 300 and 600 ppm groups were significantly greater than those of the controls by pairwise comparisons (Table 8). Moreover, the incidences of eosinophilic foci in males and clear cell foci in females were marginally greater in the 600 ppm groups. In contrast, the incidence of basophilic foci in 300 ppm males was significantly less than that of controls.

Lesions classified as hyperplasia were also increased in exposed male rats. All males in the 150 and 300 ppm groups with hyperplasia and half the males in the 600 ppm group with hyperplasia also had mononuclear cell leukemia. The Pathology Working Group believed that hyperplasia in some of these rats may have represented a regenerative response to the hepatocellular degeneration associated with the mononuclear cell leukemia. However, there was no obvious hepatocellular degeneration in the remaining (leukemia-free) 600 ppm rats with hyperplasia.

Hepatocellular adenomas occurred at low incidence in all groups of exposed male rats but not in control males (Table 8). The incidence of hepatocellular adenoma in the 150 ppm group, but not those of the 300 or 600 ppm groups, was significantly greater than that of concurrent controls and exceeded the range for historical controls from recent NTP feed studies (Table A4). Hepatocellular adenomas were seen in only two females in the 600 ppm group, none were seen in the controls or in the 150 or 300 ppm groups, and the incidences were within the historical control range (Table B4). No hepatocellular carcinomas were observed in exposed or control rats.

Foci (basophilic, eosinophilic, clear cell, or mixed cell) were generally the size of one or two hepatic lobules and consisted of cells with either basophilic, eosinophilic, or clear-staining cytoplasm, or a mixture of cells with these staining properties. These staining properties are determined by the relative amounts of the various cytoplasmic constituents, particularly ribosomes or polyribosomes, which are responsible for the basophilia; proteins, which are responsible for the eosinophilia; and glycogen or lipids, which are responsible for the clear or vacuolated appearance. The lobular architecture of the foci was normal or minimally altered and there was no compression of adjacent parenchyma. Lesions classified as hyperplasia were similar to the various foci but were generally larger, often several lobules or more in size. The hepatocellular adenomas observed in exposed male rats were generally similar to foci but were larger and more circumscribed with distinct borders and some compression of the adjacent normal parenchyma. There was some alteration in growth pattern with subsequent distortion or loss of lobular architecture. The hepatocytes were generally arranged in plates one or two cell layers thick and had basophilic, eosinophilic, or clear cytoplasm similar to the foci. The hepatocytes were well differentiated with no cytologic atypia.

TABLE 8
Incidences of Liver Lesions in Rats in the 2-Year Feed Study of Triamterene^a

	0 ppm	150 ppm	300 ppm	600 ppm
Male	· ·			
				•
Hyperplasia	0/50 (0%)	3/50 (6%)	5/50 (10%)*	10/49 (20%)**
Basophilic focus	16/50 (32%)	10/50 (20%)	3/50 (6%)**	19/49 (39%)
Clear cell focus	4/50 (8%)	5/50 (10%)	4/50 (8%)	7/49 (14%)
Eosinophilic focus	2/50 (4%)	3/50 (6%)	2/50 (4%)	8/49 (16%)
Mixed cell focus	0/50 (0%)	6/50 (12%)*	8/50 (16%)**	12/49 (24%)**
Hepatocellular Adenomab		•		
Overall rates	0/50 (0%)	6/50 (12%)	4/50 (8%)	3/49 (6%)
Adjusted rates ^c	0.0%	20.9%	15.6%	9.3%
Terminal rates ^d	0/25 (0%)	4/25 (16%)	2/19 (11%)	2/27 (7%)
First incidence (days)	_f ` ` ´	610	668	508
Logistic regression tests ^e	P=0.355	P = 0.021	P=0.069	P = 0.108
			•	
Female				•
Hyperplasia	1/50 (2%)	3/50 (6%)	3/50 (6%)	2/50 (4%)
Basophilic focus	37/50 (74%)	36/50 (72%)	34/50 (68%)	34/50 (68%)
Clear cell focus	3/50 (6%)	3/50 (6%)	4/50 (8%)	9/50 (18%)*
Eosinophilic focus	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Mixed cell focus	2/50 (4%)	2/50 (4%)	8/50 (16%)*	13/50 (26%)**
Hepatocellular Adenomag	**	·		
Overall rates	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
Adjusted rates	0.0%	0.0%	0.0%	6.9%
Terminal rates	0/29 (0%)	0/34 (0%)	0/34 (0%)	2/29 (7%)
First incidence (days)		_ ` ` `		729 (T)
Logistic regression tests	P=0.052		and the second s	P=0.246

^{*} Significantly different (P≤0.05) from the control group by logistic regression test

^{**} P≤0.01

^a Number of animals with lesion/number of animals examined microscopically

b 2-Year historical incidence for untreated control groups in NTP feed studies (mean ± standard deviation): 19/799 (2.4% ± 2.9%); range 0%-8%

c Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

d Observed incidence at terminal kill

e Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between that controls and that exposure group. The logistic regression test regards these lesions as nonfatal.

Not applicable; no neoplasms in animal group

^g 2-Year historical incidence: $3/800 (0.4\% \pm 1.5\%)$; range 0%-6%

Nephropathy occurred in nearly all male rats and most female rats, but the average severity of this disease was marginally greater in exposed male and female rats (Table 9). Because of the marginal and subtle nature of these findings, the histologic sections of kidney were reevaluated in a "blind" procedure. The findings were generally confirmed by the "blind" reevaluation. In the first evaluation of male rats, the group average severity grade of nephropathy of the 300 ppm group was significantly greater than that of the controls. Since the average severity of nephropathy in the 600 ppm group in the first evaluation and that of all groups in the blind evaluation were not significantly greater than controls, it is uncertain if the marginal increase was chemical related. In contrast, the average severity of nephropathy in 600 ppm female rats in both the first and blind evaluations was significantly greater than controls. Therefore, the slight increase in severity in 600 ppm female rats was considered to be related to the ingestion of triamterene.

Nephropathy was characterized by glomerulosclerosis, degeneration and regeneration of the renal tubule epithelium, thickening of the renal tubule basement membrane, dilatation of renal tubule lumens with the formation of hyaline and granular casts, interstitial fibrosis, and chronic inflammation. The severity of nephropathy was graded as minimal, mild, moderate, or marked depending on the extent of the disease and approximate amount of renal parenchyma affected (minimal, 5%-25% of the renal tubules; mild, 25%-50%; moderate, 50%-75%; marked, >75%).

Uterus: Two 600 ppm females had uterine leiomyomas (Table B1). Smooth muscle neoplasms are relatively uncommon in female F344/N rats (NTP historical controls: 6/800, 0.1%; range 0%-2%).

TABLE 9
Incidences and Severity of Nephropathy in Rats in the 2-Year Feed Study of Triamterene^a

Dose	0 p	pm	150	ppm	300 1	ppm	600	ppm
Male								
Nephropathy First evaluation Blind evaluation	47/50 48/49	(2.4) ^b (3.0)	49/50 _c	(2.7)	50/50 50/50	(3.0)** (3.2)	49/50 49/50	(2.8) (3.3)
Female								
Nephropathy First evaluation Blind evaluation	38/50 36/50	(1.1) (0.9)	45/50 -	(1.2)	45/50 42/50	(1.3) (1.2)	45/50 49/50	(1.4)* (1.6)**

^{*} Significantly different (P≤0.05) from the control group by the Mann-Whitney U test

^{**} P≤0.01

Number of animals with lesion/number of animals examined microscopically

Group average severity grade for all animals: 0=none; 1=minimal; 2=mild; 3=moderate; 4=marked

^c The 150 ppm groups were not evaluated in the blind microscopic examination.

MICE 15-DAY STUDY

The diets containing triamterene at levels of 10,000 or 30,000 ppm were unpalatable, and feed consumption by mice in the 3,000 ppm groups was substantially less than that by controls. Mice exposed to 300 or 1,000 ppm triamterene received approximate doses of 40 or 155 mg/kg per day (males) or 45 or 170 mg/kg per day (females). All mice receiving 3,000 ppm triamterene died on day 5 or 6; all other mice survived until the end of the study (Table 10). The final mean body weights of mice in the 300 or 1,000 ppm groups were within 5% of controls. The absolute heart weight of females, the relative heart and kidney weights of males and females, and the relative liver weight of females receiving 1,000 ppm were lower than those of controls, whereas the relative liver weight of males in this group was greater than that of controls (Table F5). The significance of these organ weight differences is uncertain. There were no clinical findings attributed to the ingestion of triamterene.

Microscopic examination of the kidney of all 3,000 ppm mice revealed mild to moderate degeneration and necrosis of the epithelium of the convoluted tubules (nephrosis). This lesion did not occur in any animal in the 1,000 ppm groups. Lymphoid depletion in the thymus and spleen was also observed in most mice receiving 3,000 ppm and may have been related to debilitation and stress rather than to a specific cytotoxic effect of the chemical.

Because of the poor palatability of diets containing 3,000 ppm or more triamterene and the nephrosis in the 3,000 ppm groups in the 15-day feed study, the high dose selected for the 13-week feed study was 1,600 ppm.

TABLE 10
Survival, Mean Body Weights, and Feed Consumption of Mice in the 15-Day Feed Study of Triamterene

		Mea	n Body Weight ^b	(g)	Final Weight	Fe	eed
Concentration	Survival ^a	Initial	Final	Change	Relative to Controls	Consu	mption ^c
(ppm)	· .			(%)	Week 1		
Male				······································	:		
0	5/5	22.6 ± 0.6	24.8 ± 0.7	2.2 ± 0.4		3.1	3.4
300	5/5	22.2 ± 0.5	23.8 ± 0.6	1.7 ± 0.5	96	2.8	3.1
1,000	5/5	22.8 ± 0.9	23.8 ± 1.0	1.1 ± 0.5	96	3.2	3.9
3,000	0/5 ^d	22.8 ± 1.0	_	_	_	_	_
10,000	0/5 ^d	22.2 ± 0.9	_	_	- .	,- .	. –
30,000	0/5 ^d	22.1 ± 0.9	-	-	-	- '	-
		•					
Female		,	•		• •		
. 0	5/5	18.8 ± 0.5	20.5 ± 0.6	1.8 ± 0.2		2.7	3.1
300	5/5	18.6 ± 0.6	19.5 ± 0.6	0.9 ± 0.1	95	2.5	3.0
1,000	5/5	18.9 ± 0.4	19.9 ± 0.4	1.0 ± 0.6	97	2.2	4.3
3,000	0/5 ^d	18.6 ± 0.3		·	-	_	_
10,000	0/5 ^d	18.8 ± 0.5	_	_	· _	-	_
30,000	0/5 ^d	19.4 ± 0.4	_	-	<u> </u>	_	_

^a Number of animals surviving/number initially in group

Weights and weight changes are given as mean ± standard error. Subsequent calculations are based on animals surviving to the end of the study. No data were calculated for groups with 100% mortality. Differences from the control group were not significant by Williams' or Dunnett's test.

Grams of feed consumed per animal per day

All deaths occurred between days 4 and 6

13-WEEK STUDY

All mice receiving 1,600 ppm triamterene died by week 2 (Table 11). The deaths of one male mouse in the 200 ppm group during week 7, one female mouse in the 800 ppm group during week 9, and four males in the 100 ppm group during the first week were not clearly related to triamterene exposure. Clinical signs of toxicity observed in the 1,600 ppm groups included emaciation, decreased activity, and piloerection. Feed consumption by mice receiving 1,600 ppm was substantially lower than that by controls during the first week of the study. Feed consumption by the other groups was similar to controls (Table 11). Mice

exposed to 100, 200, 400, or 800 ppm triamterene received approximate doses of 15, 25, 50, or 90 mg/kg per day (males) or 15, 25, 50, or 115 mg/kg per day (females).

The total leukocyte and lymphocyte counts of males receiving 800 ppm and of females receiving 100, 400, or 800 ppm were significantly lower than those of the controls and were considered to be related to the lymphoid depletion observed in the thymus and spleen (Table G4). No other differences in hematologic, clinical chemistry, or urinalysis parameters were considered to be biologically significant.

TABLE 11 Survival, Mean Body Weights, and Feed Consumption of Mice in the 13-Week Feed Study of Triamterene

		Mea	n Body Weight ^b	(g)	Final Weight	F	eed
Concentration (ppm)		Initial	Final	Change	Relative to Controls (%)		mption ^c Week 13
Male							
0	10/10	24.4 ± 0.6	31.6 ± 0.9	7.2 ± 1.4		3.2	3.8
100	6/10 ^d	24.5 ± 0.5	30.2 ± 1.1	5.7 ± 0.9	96	3.5	3.8
200	9/10 ^e	23.7 ± 0.8	30.3 ± 1.0	7.0 ± 0.5	96	3.3	3.6
400	10/10	23.8 ± 0.6	30.0 ± 0.8	6.2 ± 0.5	95	3.4	3.6
800	10/10	24.3 ± 0.5	$27.4 \pm 1.2^{\circ}$	3.1 ± 1.1 *	87	2.9	3.0
1,600	0/10 ^d	24.1 ± 0.9	-		-		-
Female							
0	10/10	19.0 ± 0.4	23.8 ± 0.5	4.8 ± 0.4		2.6	3.1
100	10/10	18.8 ± 0.5	23.7 ± 0.6	4.9 ± 0.2	100	2.7	3.1
200	10/10	18.6 ± 0.3	24.3 ± 0.4	$5.6 \pm 0.4^{\circ}$	102	3.1	3.3
400	10/10	18.9 ± 0.3	23.7 ± 0.3	4.9 ± 0.3	100	2.6	3.2
800	9/10 ^f	18.8 ± 0.4	24.3 ± 0.4	5.5 ± 0.3 *	102	3.1	3.2
1,600	0/10 ^g	19.0 ± 0.2	_	_	_	_	_

^{*} Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

^a Number of animals surviving/number initially in group

b Weights and weight changes are given as mean ± standard error. Subsequent calculations are based on animals surviving to the end of the studies. No data were calculated for groups with 100% mortality.

^c Grams of feed consumed per animal per day

Week of death: all deaths occurred during week 1

e Week of death: 7

f Week of death: 9

Week of death: nine deaths during week 1, one death during week 2

The final mean body weight and body weight gain of male mice receiving 800 ppm were significantly lower than those of the controls (Table 11). The final mean body weight of male mice in the 800 ppm group was 13% lower than that of the controls. In the 800 ppm groups, the absolute and relative thymus weights of male mice and the relative kidney weight of female mice were significantly less than those of the controls (Table F6).

On microscopic examination, lesions were observed in the lymphoid organs of male and female mice (Table 12). Necrosis of lymphocytes in the lymph node, spleen, and thymus was observed primarily in mice in the 800 and 1,600 ppm groups; necrosis in the thymus occurred infrequently in other groups (Table 12). Necrosis was characterized by scattered

individual or small foci of lymphocytes with pyknotic or fragmented nuclei and macrophages filled with cellular debris. Lymphoid depletion characterized by the reduction in thickness of the thymic cortex or periarteriolar lymphocytic sheaths in the spleen was also apparent in a few mice in the 1,600 ppm groups. Whether these lesions were related to debilitation and stress or to the direct cytotoxic effects of triamterene is unknown.

Dose selection rationale: Dietary concentrations of triamterene selected for the 2-year studies in mice were 0, 100, 200, and 400 ppm. Doses of 800 ppm or more were considered too great because of the mortality observed in mice receiving 1,600 ppm and the lesions observed in the 800 and 1,600 ppm groups in the 13-week study.

TABLE 12
Incidences of Treatment-Related Lesions in Mice in the 13-Week Feed Study of Triamterene

	0 ppm	100 ppm	200 ppm	400 ppm	800 ppm	1,600 ppm
n	10	10	10	10	10	10
Male						
Spleen						
Necrosis	0	_a	_	_	$(2.3)^{b}$	4* (1.5)
Lymphoid depletion	0	-	_	_	0 ` ´	2 (2.5)
Thymus						
Necrosis	0	3 (2.7)	1 (1.0)	1 ₁ (2.0)	8** (1.6)	8** (3.0)
Lymphoid depletion	0	0	0	0,	0	2 (3.0)
Lymph node						
Necrosis	0	-	-	-	1 (2.0)	4* (1.5)
Female						
Spleen						
Necrosis	0	_	_	-	5* (1.4)	7** (2.0)
Lymphoid depletion	0	-	-	-	0 '	3 (2.3)
Thymus						
Necrosis	0	2 (2.0)	0	3 (2.0)	1 (1.0)	10** (3.0)
Lymph node						
Necrosis	0	_		_	0	2 (2.0)

^{*} Significantly different (P≤0.05) from the control group by the Fisher exact test

^{**} P<0.01

a Not examined microscopically at this exposure level

b Average severity grade for affected animals: 1=minimal; 2=mild; 3=moderate

2-YEAR STUDIES

3-Month Interim Evaluation

The values of several hematologic and clinical chemistry parameters of 200 or 400 ppm mice varied slightly from those of controls (Table G5). These differences were not considered biologically significant and their relationship to the ingestion of triamterene is uncertain. At necropsy the mean body weights of all groups of exposed mice were similar to those of the controls (Table F7). The absolute kidney and liver weights of male mice in the 400 ppm group were significantly lower than those of the controls, but the relative weights were similar (Table F7). There were no other significant differences in organ weights. No chemical-related lesions were observed during necropsy or microscopic examination.

15-Month Interim Evaluations

Because of an error in preparation of feed for the 400 ppm group in week 40, 12 male and four female mice died. The 15-month interim evaluation, therefore, was conducted only on mice from the 0, 100, and 200 ppm groups. For this reason, a second 2-year feed study was conducted in male and female mice using only control and 400 ppm groups; mice in this study were also evaluated at 15 months.

The values of several hematologic or clinical chemistry parameters in the 200 (first study) and 400 ppm groups (second study) varied slightly from those of controls (Tables G6 and G7). None of these differences were considered biologically significant or chemical related. In 400 ppm females in the second study, the urine volume was significantly greater than controls, and the urine specific gravity was significantly lower. These differences may have been chemical related, although a similar finding was not observed in males.

Mean body weights of exposed mice in both studies were similar to those of controls (Tables F8 and F9). The absolute brain weights of 400 ppm males in the second study were significantly greater than those of controls. Since the relative brain weight was similar to controls, the marginal difference in mean brain weights was not considered chemical related. The incidences of nonneoplastic lesions and neoplasms in exposed mice were similar to those of controls at the 15-month interim evaluations. The occurrence of

liver neoplasms in mice evaluated at 15 months is notable because of the chemical-related increase in hepatocellular adenomas in the core 2-year study. In males in the first study, hepatocellular adenomas were observed in one control, three 100 ppm, and two 200 ppm mice; none were seen in the 400 ppm males (Table C1a). In the second study, an adenoma was observed in a 400 ppm male and none were observed in the controls (Table C1b). No hepatocellular carcinomas were observed in male mice. In female mice in the first study, adenomas were observed in two control, two 100 ppm, and two 200 ppm mice; in the second study a carcinoma was observed in one control female (Tables D1a, D1b).

Body Weights, Feed Consumption, and Clinical Findings

Mean body weights of exposed mice were similar to those of the controls throughout most of the first 2-year study with one notable exception (Tables 13a,b and 14a,b, Figure 3). The mean body weight of 400 ppm males was 16% lower than controls at week 41 following the dosing error during week 40. The decrement in body weight gradually decreased over the next several weeks. The mean body weights of 400 ppm males in the second study (Figure 4) and of females receiving 400 ppm in the first and second studies were slightly lower than controls during the final 8 weeks of the studies. Feed consumption by exposed mice was similar to that by the controls throughout the studies, and approximately 10, 25, or 45 mg/kg (males) and 15, 30, or 60 mg/kg of triamterene per day was ingested by mice fed diets containing 100, 200, or 400 ppm (Tables I3, I4, I5, and I6). There were no clinical findings of toxicity in exposed mice.

Survival

Estimates of 2-year survival probabilities for male and female mice are shown in Table 15 and in the Kaplan-Meier curves in Figures 5 and 6. Survival of 400 ppm males in the first study was significantly lower than that of the controls, primarily because of the dosing error in week 40. Sixteen 400 ppm mice died shortly after the dosing error, and the deaths of 11 males and 3 females were attributed, in part, to renal toxicity. The cause of death for the remaining two mice was undetermined. Survival of exposed mice in the second study was similar to that of the controls.

TABLE 13a
Mean Body Weights and Survival of Male Mice in the 2-Year Feed Study of Triamterene: First Study

Week	0 1	ppm		100 ppm			200 ppn	1		400 ppi	m -
on	Av. Wt.	No. of	Av. Wt.	Wt. (% o		Av. Wt.			Av. Wt.		
Study	(g)	Survivors	(g)	•	Survivors	(g)	-	Survivors	(g)	•	Survivors
•				•			ŕ			ŕ	
	· · · · ·		· · · · · · · · · · · · · · · · · · ·								÷.
1	20.0	70	20.2	101	70	20.1	101	70	20.2	101	70
2	22.2	70	22.6	102	70	22.5	101	70	22.5	101	70
3	23.5	70	23.6	100	70	23.5	100	70	23.5	100	70
4	24.2	70	24.4	101	70	24.5	101	70	24.4	101	70
5	25.4	70	25.2	99	70	25.1	99	70	25.3	100	70
6	26.0	70	26.1	100	70	26.1	100	70	26.2	101	70
7	26.6	70	26.9	101	70	26.8	101	70	26.7	100	70
8	27.8	70	27.7	100	70	27.6	99	70	27.4	99	70
9	28.7	70	28.8	100	70	28.2	98	70	28.3	99	70
10	29.5	70	29.4	100	70	29.4	100	70	29.1	99	70
11	30.4	70	30.0	99	70	30.1	99	70	29.7	98	70
12	30.8	70	30.5	99	70	30.5	99	70	30.0	97	70
13	31.5	70	31.3	99	70	31.4	100	70	30.7	98	70
18 ^a	34.0	60	33.9	100	60	33.7	99	60	33.6	99	60
21	34.4	60	34.8	101	60	34.3	100	60	34.0	99	60
25	34.5	60	35.2	102	60	34.6	100	60	34.7	101	60
29	36.0	60	36.7	102	60	35.9	100	60	35.6	99	60
33	37.9	60	38.4	101	60	37.6	99	60	37.3	98	60
37	38.3	60	39.0	102	60	38.6	101	60	38.5	101	60
41	39.4	60	40.5	103	60	39.4	100	60	32.9	84	49
45	40.7	60	41.0	101	60	40.5	100	60	38.0	93	48
49	41.6	60	41.9	101	60	41.1	99	60	39.3	95	48
53	42.3	60	43.3	102	60	42.3	100	60	40.9	97	48
57	43.1	60	43.8	102	60	42.8	99	60	41.9	97	48
61	43.8	60	44.1	101	60	42.9	98	60	42.5	97	48
65	44.8	60	44.9	100	60	43.6	97	60	43.1	96	48
69 ^a	44.8	50	45.8	102	50	44.4	99	50	44.2	99	48
73	45.2	50	46.2	102	50	45.2	100	50	44.8	99	48
77	45.5	50	46.6	102	49	45.7	100	50	45.5	100	48
81	45.5	50	46.1	101	48	45.2	99	50	44.5	98	48
85	45.7	49	46.2	101	48	45.2	99	50	44.7	98	48
89	44.9	´ 48	46.0	102	46	44.6	99	49	44.3	99	47
93	47.1	48	46.9	100	46	45.5	97	48	44.9	95	47
97	46.6	48	48.3	104	46	45.8	98	48	45.3	97	47
101	46.0	47	46.6	101	45	45.2	98	46	45.0	98	47
104	44.4	47	45.1	102	45	43.8	99	46	43.0	97	46
Mean for	weeks										
1-13	26.7		26.7	100		26.6	100		26.5	99	
14-52	37.4		37.9	101		37.3	100		35.8	96	
53-104	45.0		45.7	102		44.4	99		43.9	98	
				. –							

^a Interim evaluations occurred during week 13 for all exposure groups and during week 65 for 0, 100, and 200 ppm groups.

Table 13b
Mean Body Weights and Survival of Male Mice in the 2-Year Feed Study of Triamterene: Second Study

Week		pm	<u></u>	400 ррг			
om	Av. Wt.	No. of	Av. Wt.	W& (% of	No. of		
Study	(g)	Survivors	(g)	controls)	Survivors		

1	19.9	60	20.0	101	60		
3	22.7	60	22.7	100	60		
4	23.8	60	24.0	101	60		
5	24.8	60	24.6	99	60		
6	26.2	60	26.1	100	60		
7	27.0	60	27.2	101	60		
8	27.6	60	27.9	101	60		
9	28.4	60	28.6	101	60		
10	29.6	60	29.8	101	60		
11	30.0	60	30.2	101	60		
12	31.5	60	31.4	100	60		
13	31.6	60	31.6	100	60		
17	34.4	60	34.3	100	60		
21	36.9	60	36.9	100	60		
25	38.9	60	39.3	101	60		
29	40.8	60	40.9	100	60		
33	42.1	60	42.8	102	60		
37	43.2	60	43.6	101	60		
41	44.0	60	44.3	101	60		
45	44.6	60	45.0	101	60		
49	45.8	60	46.1	101	60		
53	45.8	60	46.0	100	60		
57	45.2	60	45.8	101	60		
61	46.4	60	46.9	101	60		
65	46.2	59	46.1	100	60		
69 ^a	46.7	49	47.0	101	50		
73	47.2	49	48.1	102	49		
77	46.7	49	47.7	102	48		
81	46.5	48	46.9	101	47		
85	47.4	48	47.5	100	47	•	
89	45.9	48	46.0	100	46		
93	45.6	47	44.4	97	45		
97	45.4	47	42.9	95	43		
101	43.4	46	41.4	95	41		
ı for weeks							
_	26.9		27.0	100			
;	41.2		41.5	101			
1	46.0		45.9	100			

^a Interim evaluation occurred during week 65.

TABLE 14a Mean Body Weights and Survival of Female Mice in the 2-Year Feed Study of Triamterene: First Study


Week	0 1	ppm		100 ppm			200 ppm	, . 1		400 ppi	n
on	Av. Wt.	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of		Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g) _.	controls)	Survivors	(g) ,	controls)	Survivors	(g)	controls)	Survivors
1	16.4	70	16.4	100	70	16.5	101	70	16.4	100	70
2	18.6	70	18.6	100	-70	18.6	100	70	18.3	98	70
3	19.8	70	19.7	100	. . 7 0	19.6	99	70	19.6	99	70
4	20.7	69	20.7	100	70	20.6	100	70	20.5	99	70
5	21.7	69	21.5	99	70	21.5	99	70	21.3	98	70
6	22.5	69	22.4	100	70	22.3	., 99	70	22.3	99	70
7	22.9	69	22.9	100	70	22.9	100	70	22.7	99	70
8	24.1	69	. , 24.0	100	.70	23.9	. 99	70	23.9	99 .	70
9	25.0	69	24.8	99	70	24.6	98	70	24.8	99	70
10	25.0	69	24.7	99	70	24.6	. 98	70	24.6	98	70
11	25.7	69	25.6	100	70	25.2	98	· 70 :	25.0	97	70
12	26.3	69	25.9	99	-70	26.0	. 99	70	25.6	97	70
13	26.8	69	26.7	100	70	26.8	100	-70	26.3	98	70
18 ^a	30.3	58	30.1	99	- 60	30.0	99	60	29.7	98	60
21	31.6	58 .	31.0	98	60	31.1	98	60	30.4	96	- 60
25	33.5	58	33.2	99	. 60	33.4	100	60	32.9	98	- 60
29	36.2	58	35.6	98	. 60	35.4	. 98	60	35.2	97	60
33	37.5	58	36.9 .	98	60	37.1	99	60	36.4	97	60
37	39.7	58	39.1	99	59	38.5	97	60	37.6	95	. 60
41	40.6	58	: 40.3	. 99	. 59	39.6	98	60.	30.3	75	56
45	42.3	58	41.9	. 99	. 59	41.2	97	60	38.2	90 -	. 56
49	43.9	- 58	43.6	. 99	. 59	42.7	97	. 60	40.9	. 93	56
53	45.5	57	45.3	100	59	44.4	. 98	60	42.1	93	56
57	46.2	57	46.4	100	59	45.3	98	60	43.3	94	56
61	46.8	57	47.0	100	- 59	46.1	- 99	60	44.1	94	56
65	48.0	56	48.7	102	59	47.5	99	60	45.8	95	56
69 ^a	48.7	46	49.8	102	49	48.3	99	50	46.8	96	56
73	49.8	44	51.3	103	49	49.6	100	. 49	48.0	96	56
77	50.2	43	52.6	105	49	51.0	102	48	49.2	98	55
81	50.6	43	52.1	. 103	.49	50.7	100	47	48.7	96	55
85	50.9	42	52.6	103	48	50,7	100	46	49.0	96	. 53
89	50.3	42	. 52.1	104	48	50.6	101	46	48.1	96	50
93	51.2	42	53.8	. 105	46	51.2	100	46	49.5	97	48
97	51.6	42 ^b	54.2	105	44	50.2	97	44	49.1	95	48 ^b
101	49.4	41 ^b	52.8	107	43	49.3	100	44	46.6	94	44 ^b
104	47.0	38	49.9	106	43	47.4	101	43	44.4	95	43
Mean for	weeks										
1-13	22.7		22.6	100		22.5	99		22.4	99	
14-52	37.3		36.9	99		36.6	98		34.4	92	
53-104	49.0		50.6	103		48.7	99		46.8	96	

Interim evaluations occurred during week 13 for all exposure groups and during week 65 for the 0, 100, and 200 ppm groups. The number of animals weighed for this week is fewer than the number of animals surviving.

TABLE 14b
Mean Body Weights and Survival of Female Mice in the 2-Year Feed Study of Triamterene: Second Study

Week		0 <u>r</u>	pm		400 ррп	n .		
on		Av. Wt.	No. of	Av. WL				
Study		(g)	Survivors	(g)		Survivors	* *	
		· · · · · ·					· · · · · ·	
• '					•			
1	,	16.7	60	16.5	99	60		•
3		19.2	60	19.1	100	60		
4		20.1	60	20.0	100	60		
5		21.0	60	20.8	99	60		
6		22.4	60	22.4	100	60	• :	
7		22.9	60	22.9	100	60		
8		23.4	60	23.7	101	60		
9		23.9	60	23.9	100	60		
10		25.6	60	25.2	98	60		
11		25.9	60	25.5	. 99	60		
12	* .	26.6	60	26.4	99	60		
13		27.2	60	27.0	99	60		
17		30.4	60	30.2	99	60		2
21		32.9	60	32.5	99	60		
25		35:5	60	35.0	99	- 60		
29		37.5	60	37.2	99	60		
33		39.5	60	39.2	99	60		
37		40.0	60	39.2	100	60		
41		42.1	60		98			٠.
45				41.4		60		
43 49	v	43.3	60	42.9	99	60		
49		45.0	60	44.5	99	60		• • • • • • • • • • • • • • • • • • • •
53		45.6	60	44.8	98	60		
57		45.8	60	45.1	99	60		
61		47.7	60	46.9	98	59		
65		47.7	60	47.0	99	59		
69 ^a		48.6	50	47.7	98	50		
73		49.3	49	48.8	99	50		• .
77		49.5	49	48.7	98	50		
81		49.2	46	48.8	99	48		
85		49.9	46	48.8	98	47		•
89		49.5	45	47.8	97	46		٠.
93	•	49.6	44	47.7	96	45		
97		48.7	44	44.2	91	43		
101	•	45.9	42	43.3	94	38		
ean for weeks								
.3		22.9	-	22.8	100			
-52		38.5		38.1	. 99			
101		48.2		46.9	97			

^a Interim evaluation occurred during week 65.







FIGURE 3
Growth Curves for Male and Female Mice Administered
Triamterene in Feed for 2 Years: First Study






FIGURE 4
Growth Curves for Male and Female Mice Administered
Triamterene in Feed for 2 Years: Second Study

TABLE 15
Survival of Mice in the 2-Year Feed Studies of Triamterene

		First S	Study		Secon	nd Study
	0 ppm	100 ppm	200 ppm	400 ppm	0 ppm	400 ppn
Male						
Animals initially in study	70	70	70	70	60	60
-Month interim evaluation ^a	10	10	10	10	0	0
5-Month interim evaluation ^a	10	10	10	0	10	10
Moribund	1	2	2	6	3	4
latural deaths	. 2	3	2	8	4	7
Animals surviving to study termination	47	45	46	46	43 ^b	39
ercent probability of survival at end of study	c 94	90	92	77	86	78
fean survival days ^d	723	715	724	638	674	667
urvival analysis ^e	P=0.004	P=0.685	P=0.997	P = 0.021		P=0.415
					130 2	
			r		A	• •
				er and section	:	
emale				t. 0		
nimals initially in study	70	70	70	70	. 60	60
-Month interim evaluation ^a	10	10	10	10	0	0
5-Month interim evaluation ^a	10	10	10	0	10	9
foribund	8	5	10	10	7	4
latural deaths	4	2	6	7	3	9
nimals surviving to study termination	38	43	43	43	40	38
ercent probability of survival at end of study		86	86	72	80	75
fean survival days	672	709	711	680	667	666
urvival analysis	P=0.361	P=0.285N	P=0.283N	P=0.776		P=0.643


^a Censored from survival analyses

b Includes one animal that died the last day of the study.

^c Kaplan-Meier determinations

d Mean of all deaths (uncensored, censored, terminal sacrifice)

e The result of the life table trend test (Tarone, 1975) is in the control column (first study), and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed columns. A lower mortality in an exposure group is indicated by N.







FIGURE 5
Kaplan-Meier Survival Curves for Male and Female Mice
Administered Triamterene in Feed for 2 Years: First Study






FIGURE 6
Kaplan-Meier Survival Curves for Male and Female Mice
Administered Triamterene in Feed for 2 Years: Second Study

Pathology and Statistical Analyses of Results Statistically significant or biologically noteworthy changes in the incidences of neoplasms or nonneoplastic lesions in the liver, thyroid gland, kidney, harderian gland, and small intestine are described below. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendixes C for male mice and D for female mice.

Liver: The incidences of hepatocellular adenoma in exposed female mice in the first study occurred with a significant positive trend, and the incidences in the exposed groups were significantly greater than that of controls (Table 16a). Moreover, the incidences of multiple hepatocellular adenoma were increased in exposed females (Table D1a). The incidences of hepatocellular carcinoma in exposed and control females in the first study were similar. The overall

incidences of hepatocellular foci (basophilic, eosinophilic, clear cell, or mixed cell) were also increased in exposed female mice. These findings were confirmed in the second study, where incidences of hepatocellular adenoma, multiple adenoma, and foci (any type) were significantly greater than those of controls (Table 16b).

In contrast, the incidences of hepatocellular adenoma in exposed and control males in the first study were similar, but the incidence of hepatocellular carcinoma in the 400 ppm males was marginally greater than that of controls (Table 16a). However, the incidences of multiple hepatocellular adenoma in exposed males were marginally increased (Table C1a). The overall incidences of hepatocellular foci (any type) in exposed and control groups were similar. In the second study, the incidence of hepatocellular adenoma in 400 ppm males was significantly greater than that of controls, as was the incidence of multiple adenoma, but the incidences of hepatocellular carcinoma were similar (Table 16b).

TABLE 16a
Incidences of Liver Lesions in Mice at the 15-Month Interim Evaluations and in the 2-Year Feed Studies of Triamterene: First Study^a

	0 ppm	100 ppm	200 ppm	400 ppm
Male			, 	
15-Month interim evaluation			•	
Basophilic focus	0/10 (0%)	2/3 (67%)	1/10 (10%)	_b
2-Year study			,	
Basophilic focus	6/50 (12%)	4/50 (8%)	10/50 (20%)	5/60 (8%)
Clear cell focus	1/50 (2%)	9/50 (18%)**	4/50 (8%)	11/60 (18%)**
Eosinophilic focus	7/50 (14%)	12/50 (24%)	11/50 (22%)	3/60 (5%)
Focus (any type)	14/50 (28%)	18/50 (36%)	20/50 (40%)	18/60 (30%).
Hepatocellular Adenoma ^c				
15-Month interim evaluation				
Overall rates	1/10 (10%)	3/3 (100%)	2/10 (20%)	-
2-Year study			•	
Overall rates	17/50 (34%)	22/50 (44%)	19/50 (38%)	20/60 (33%)
Adjusted rates ^d	36.2%	48.9%	40.3%	42.6%
Terminal rates ^e	17/47 (36%)	22/45 (49%)	18/46 (39%)	19/46 (41%)
First incidence (days)	729 (T)	729 (T)	617	711
Logistic regression tests ^f	P = 0.391	P=0.154	P=0.417	P=0.314
र र :	•		· .	
(continued)				

TABLE 16a
Incidences of Liver Lesions in Mice at the 15-Month Interim Evaluations and in the 2-Year Feed Studies of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
Male (continued)		<u> </u>		
Hepatocellular Carcinoma ^g				
Overall rates	5/50 (10%)	7/50 (14%)	3/50 (6%)	13/60 (22%)
Adjusted rates	10.6%	14.8%	6.5%	28.3%
Terminal rates	5/47 (11%)	5/45 (11%)	3/46 (7%)	13/46 (28%)
First incidence (days)	729 (T)	557	729 (T)	729 (T)
Logistic regression tests	P=0.022	P=0.448	P=0.368N	P=0.030
lepatocellular Adenoma or Caro	inoma ^h		15 MA 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Overall rates	20/50 (40%)	26/50 (52%)	19/50 (38%)	29/60 (48%)
Adjusted rates	42.6%	55.3%	40.3%	61.7%
Terminal rates	20/47 (43%)	24/45 (53%)	18/46 (39%)	28/46 (61%)
First incidence (days)	729 (T)	557	617	711
Logistic regression tests	P=0.074	P=0.136	P=0.500N	P=0.043
Logistic regression tests	1 - 0.077	* = 0.150	1-0.50014	1 = 0.043
Hepatoblastoma	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/60 (0%)
	tración de la companya de la company		$egin{array}{cccccccccccccccccccccccccccccccccccc$	
Female			A Committee of the Comm	$(\mathbf{x}^{\bullet})^{-1} = (\mathbf{x}^{\bullet})^{\bullet} \cdot (\mathbf{x}^{\bullet})^{\bullet} \cdot (\mathbf{x}^{\bullet})^{\bullet} \cdot (\mathbf{x}^{\bullet})^{\bullet}$
remare	end the set of the		e get the first of the control of	Light of the State of
(FBFa) to a to a		and the second of the second	and the second of the second	1 - 12 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
15-Month interim evaluation		The second secon	and the state of t	and the property of
Basophilic focus	2/10 (20%)	0/2 (0%)	0/10 (0%)	1 / 7 To 1
Eosinophilic focus	0/10 (0%)	0/2 (0%)	1/10 (10%)	· · · · · · · · · · · · · · · · · · ·
2-Year study				
Basophilic focus	1/50 (2%)	6/50 (12%)	6/50 (12%)	11/60 (18%)*
Clear cell focus	0/50 (0%)	1/50 (2%)	4/50 (8%)	3/60 (5%)
Eosinophilic focus	7/50 (14%)	11/50 (22%)	19/50 (38%)*	7/60 (12%)
Mixed focus	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/60 (2%)
Focus (any type)	8/50 (16%)	16/50 (32%)	24/50 (48%)**	19/60 (32%)*
Hepatocellular Adenoma ⁱ			4	
15-Month interim evaluation				•
Overall rates	2/10 (20%)	2/2 (100%)	2/10 (20%)	-
2-Year study				
Overall rates	10/50 (20%)	22/50 (44%)	23/50 (46%)	36/60 (60%)
Adjusted rates	25.6%	51.2%	52.3%	78.1%
Terminal rates	9/38 (24%)	22/43 (51%)	22/43 (51%)	33/43 (77%)
First incidence (days)	723	729 (T)	712	579
Logistic regression tests	P<0.001	P=0.014	P=0.008	P<0.001
Hepatocellular Carcinoma ^j				
Overall rates	4/50 (8%)	4/50 (8%)	3/50 (6%)	8/60 (13%)
Adjusted rates	10.0%	9.3%	7.0%	18.6%
Terminal rates	3/38 (8%)	4/43 (9%)	3/43 (7%)	8/43 (19%)
First incidence (days)	589	729 (T)	729 (T)	729 (T)
inst including (days)		` '	, <i>,</i>	
Logistic regression tests	P=0.159	P = 0.614N	P = 0.472N	P = 0.272

TABLE 16a
Incidences of Liver Lesions in Mice at the 15-Month Interim Evaluations and in the 2-Year Feed Studies of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
Female (continued)				
Hepatocellular Adenoma or Ca	arcinoma ^k			
Overall rates	13/50 (26%)	26/50 (52%)	25/50 (50%)	37/60 (62%)
Adjusted rates	32.3%	60.5%	56.8%	80.3%
Terminal rates	11/38 (29%)	26/43 (60%)	24/43 (56%)	34/43 (79%)
First incidence (days)	589	729 (T)	712	579
Logistic regression tests	P<0.001	P=0.014	P=0.022	P<0.001

- ° Significantly different (P≤0.05) from the control group by the logistic regression test
- °° P≤0.01

(T)Terminal sacrifice

- ^a Number of animals with lesion/number of animals with liver examined microscopically
- Interim evaluation not performed on animals receiving 400 ppm
- c 2-Year historical incidence for untreated control groups in NTP feed studies (mean ± standard deviation): 145/865 (16.8% ± 8.2%); range 4%-38%
- d Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality
- Observed incidence at terminal kill
- Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The logistic regression test regards these lesions as nonfatal. For all tests, a lower incidence in an exposure group is indicated by N.
- g 2-Year historical incidence: 122/865 (14.1% ± 7.2%); range 3%-27%
- ^h 2-Year historical incidence: 249/865 ($28.8\% \pm 10.9\%$); range 17%-58%
- i 2-Year historical incidence: $74/863 (8.6\% \pm 6.5\%)$; range 0%-28%
- ¹ 2-Year historical incidence: $28/863 (3.2\% \pm 2.9\%)$; range 0%-10%
- k 2-Year historical incidence: 98/863 (11.4% ± 7.6%); range 3%-34%

TABLE 16b
Incidences of Liver Lesions in Mice at the 15-Month Interim Evaluations and the second Study and the 2-Year Feed Studies of Triamterene: Second Study and the second Study are second Study are second Study and the second Study are second Study are second Study and the second Study are s

	A Section 1	O ppm erger e	400 ppm	
Male				Section 2
15-Month interim evaluation				The wither are a few office
Basophilic focus	* *	1/9 (11%)	0/10 (0%)	V 20 13 15 15
Clear cell focus		0/9 (0%)	1/10 (10%)	Protection of the Participant
2-Year study			•	James goden)
Basophilic focus	Artist Commence	0/50 (0%)	7/50 (14%)**	the second of th
Clear cell focus	4	8/50 (16%)	4/50 (8%)	www.arty in a service
Eosinophilic focus	,	12/50 (24%)	10/50 (20%)	The state of the state of
Focus (any type)		18/50 (36%)	16/50 (32%)	and the second s
rocus (any type)	e de la companya del companya de la companya del companya de la co	16/30 (30%)	10/30 (3270)	Commence of the second second
Hepatocellular Adenoma ^b				
:				Transit Large Land
45 Balance (to a color con location)		The second section of the second	•	200 3 (39)
15-Month interim evaluation		an	4 4 0 (4 0 00)	15 5 5 5 5 6
Overall rates	1	0/9 (0%)	1/10 (10%)	The state of the s
• T7	<i>.</i>			化二氯苯基苯酚 医大脑囊病炎
2-Year study	19 1 13 to		0.000.000	
Overall rates	•	21/50 (42%)	36/50 (72%)	
Adjusted rates ^c		44.7%	81.7%	一个 网络盐酸镍磷基磺基磺基苯
Terminal rates ^d		17/43 (40%)	31/39 (79%)	•
First incidence (days)		701	522	The grates a contract of the contract
Logistic regression tests ^e	11.0	1. 6 . 1.	P = 0.001	Secret By M.
Hepatocellular Carcinoma ^f				1.7
Overall rates	in the second	9/50 (18%)	11/50 (22%)	मृतिहरूता । अस्ति है। जिल्लामा अस्ति । अस्ति वि
Adjusted rates	· · · · · · · · · · · · · · · · · · ·	19.3%	25.0%	
Terminal rates		6/43 (14%)	7/39 (18%)	
First incidence (days)	14 9,	622	494	
Logistic regression tests	1 to	•	P=0.422	and the second of the second o
Hepatocellular Adenoma or C	arcinoma ^s		1,547,385,34	the expession westwaring fi
Overall rates		25/50 (50%)	38/50 (76%)	and the second
Adjusted rates		52.1%	82.5%	e gradini e e e e gradini
Terminal rates	180	20/43 (47%)	31/39 (79%)	a third is a think
First incidence (days)	*:	622	494	and the second
Logistic regression tests	74 4 J	•	P=0.005	the sign of the state of the st
Hepatoblastoma		·// 0/50 (0%)	1/50 (2%)	and the second of the second of the second of the second
		, ,	, ,	The state of the second section is
(continued)	2° 1°			The second of th

The graph of the first of the control of the contro

THE PART HAS DO

TABLE 16b Incidences of Liver Lesions in Mice at the 15-Month Interim Evaluations and in the 2-Year Feed Studies of Triamterene: Second Study (continued)

	1, j - 80	0 ppm	400 ppm	
Female				. 4
15-Month interim evaluation Basophilic focus Eosinophilic focus	(1/10 (10%) 1/10 (10%)	1/9 (11%) 0/9 (0%)	is that is a special of the second of the se
2-Year study Basophilic focus Clear cell focus Eosinophilic focus Mixed focus Focus (any type)	Congress of Congress Congress of Congress Congress of Congress Congress of Congress Congress of Congress	0/50 (0%) 0/50 (0%) 9/50 (18%) 1/50 (2%) 10/50 (20%)	5/51 (10%)° 4/51 (8%) 16/51 (31%) 0/51 (0%) 20/51 (39%)°	
Hepatocellular Adenomah Overall rates Adjusted rates Terminal rates First incidence (days) Logistic regression tests		7/50 (14%) 17.5% 7/40 (18%) 730 (T)	28/51 (55%) 70.0% 26/38 (68%) 687 P<0.001	
Hepatocellular Carcinomai 15-Month interim evaluation Overall rates		1/10 (10%)	0/9 (0%)	the second of th
2-Year study Overall rates Adjusted rates Terminal rates First incidence (days) Logistic regression tests		5/50 (10%) 12.0% 4/40 (10%) 616	11/51 (22%) 28.0% 10/38 (26%) 676 P=0.082	
Hepatocellular Adenoma or C Overall rates Adjusted rates Terminal rates First incidence (days) Logistic regression tests	Carcinoma ^j	10/50 (20%) 24.2% 9/40 (23%) 616	31/51 (61%) 75.6% 28/38 (74%) 676 P<0.001	

[°] Significantly different (P≤0.05) from the control group by the logistic regression test

(T)Terminal sacrifice

Number of animals with lesion/number of animals with liver examined microscopically

²⁻Year historical incidence for untreated control groups in NTP feed studies (mean ± standard deviation): 145/865 (16.8% ± 8.2%); range 4%-38% Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Observed incidence at terminal kill

Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The logistic regression test regards these lesions as nonfatal.

²⁻Year historical incidence: 122/865 ($14.1\% \pm 7.2\%$); range 3%-27%

g 2-Year historical incidence: 249/865 ($28.8\% \pm 10.9\%$); range 17%-58%

²⁻Year historical incidence: 74/863 (8.6% \pm 6.5%); range 0%-28%

²⁻Year historical incidence: $28/863 (3.2\% \pm 2.9\%)$; range 0%-10%

j 2-Year historical incidence: 98/863 (11.4% \pm 7.6%); range 3%-34%

Thyroid gland: In the first study, chemical-related increases in the incidences of follicular cell hyperplasia occurred, and the incidences were significantly greater than those of the controls in all but the 100 ppm males (Table 17). The incidences in the 400 ppm groups in the second study were also significantly greater than those of the controls. However, the average severity of hyperplasia was similar among exposed and control groups. The incidences of follicular cell adenoma in exposed and control mice were similar in both studies (Tables C1a,b and D1a,b).

Follicular cell hyperplasia was generally minimal to mild in severity. Minimal hyperplasia involved one to several individual follicles, occasionally with slightly dilated lumens, lined by enlarged epithelial cells that formed small projections into the follicular lumen. Mild lesions usually consisted of small clusters of follicles with lumens partially or totally filled by projections of enlarged epithelial cells (Plate 1). The follicular cell neoplasms were generally larger with more distinct borders and compressed or replaced the normal parenchyma.

TABLE 17
Incidences of Thyroid Gland Lesions in Mice in the 2-Year Feed Studies of Triamterene

	0 ppm	100 ppm	200 ppm	400 ppm
First Study		<u></u>		
Male		A	•	•
Follicular cell, hyperplasia	3/50 (1.3) ^a	8/50 (1.4)	16/50** (1.4)	20/60** (1.5)
Female			ender of the second sec	
Follicular cell, hyperplasia	4/49 (2.3)	17/49** (1.4)	18/50** (1.4)	28/60** (1.5)
Second Study			•	
Male		•		
Follicular cell, hyperplasia	0/50			16/50** (1.6)
Female		:	e e e e e e e e e e e e e e e e e e e	
Follicular cell, hyperplasia	9/50 (1.2)			32/51** (1.6)

^{**} Significantly different (P≤0.01) from the control group by the logistic regression test

^a Average severity grade for affected animals: 1 = minimal; 2 = mild; 3 = moderate.

The incidences (control, 28/50; 100 ppm, Kidney: 36/50; 200 ppm, 43/50; 400 ppm, 49/60) and average severity (over all animals) (0.56, 0.80, 1.00, 1.07) of nephropathy in exposed females were greater than in controls in the first study (Table D5a). In the second study, however, the differences in incidences (control, 17/50; 400 ppm, 21/50) and severity (0.38, 0.55) of nephropathy between 400 ppm females and the controls were not as great (Table D5b). Thus, it is uncertain if these marginal changes are related to the ingestion of triamterene. In males, the incidences (first study: 49/50, 48/50, 49/50, 58/60; second study: 45/50, 43/50) and severity (first study: 1.7, 1.7, 1.6, 1.7; second study: 1.06, 1.16) of nephropathy were similar among exposed and control groups (Tables C5a,b).

Nephropathy was characterized by individual or clusters of cortical tubules with basophilic epithelial cells often surrounded by increased amounts of interstitial collagen and accumulations of small numbers of mononuclear inflammatory cells.

Harderian gland: Although the incidences of harderian gland neoplasms (adenoma or carcinoma) were similar among exposed and control male mice in the first study, the incidence of adenoma in the 400 ppm group in the second study was marginally greater than that of controls (first study: 1/50, 1/50, 3/50, 2/50; second study: 1/50, 6/50). No harderian gland adenomas were observed in male mice at the 3- or 15-month interim evaluations. The incidence of adenomas in the 400 ppm males in the second study was within the historical range for control male B6C3F₁ mice in recent NTP 2-year feed studies (48/872, 6%, range, 0%-20%). Hyperplasia occurred at low incidences in the control, 100 ppm, and 200 ppm males of the first study and in the control males of the second study; hyperplasia was not observed in the 400 ppm groups of the first or second study. The increased incidence of harderian gland adenomas in male mice was not considered to be chemical related because 1) it occurred only in the second study, 2) the incidence was within the range of historical controls, and 3) there was no supporting increase in hyperplasia (Tables C5a and C5b).

Small intestine: Adenocarcinomas of the small intestine occurred in two 400 ppm male mice in the first study; none were seen in other exposure groups or in groups in the second study (Tables C1a and C1b). Neoplasms of the small intestine are uncommon in male B6C3F₁ mice and have occurred in 3/872 (0.2%) NTP historical controls with a range of 0%-2%. Because this neoplasm occurred at low incidence in the first study and not in 400 ppm males in the second study, they were not considered to be chemical related.

GENETIC TOXICOLOGY

Triamterene (10-10,000 μ g/plate) was tested at two laboratories for induction of gene mutations in Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 with a preincubation protocol with and without Aroclor 1254-induced male Sprague-Dawley rat or Syrian hamster liver S9: no induction of mutations was observed at either laboratory (Mortelmans et al., 1986; Table E1). In cytogenetic tests with Chinese hamster ovary cells, triamterene induced sister chromatid exchanges with and without Aroclor 1254-induced male Sprague-Dawley rat liver S9 (Table E2). Without S9, doses tested ranged from 0.5 to 40 μ g/mL and 10 μ g/mL was the lowest dose at which a positive response occurred. With S9, doses of 5 to 500 µg/mL were tested and the lowest effective dose was 160 µg/mL. Tests for induction of chromosomal aberrations in Chinese hamster ovary cells were negative, with and without S9 activation (Table E3). With S9, the first trial showed a significant increase in aberrations at the middle dose of 50 μ g/mL, but this response was not repeated in a second trial.

Methods as well as the property of the control of the

And the first of the second of

.




PLATE 1 Thyroid Gland: Follicular cell hyperplasia. Follicles are lined by large cells which have filled much of the lumens of some follicles. Female $B6C3F_1$ mouse given 400 ppm triamterene in the 2-year feed study. $H\&E \times 150$

DISCUSSION AND CONCLUSIONS

Triamterene is a widely used potassium-sparing diuretic which was first synthesized in 1954 and was made commercially available in the 1960's. Toxicology and carcinogenesis studies were conducted in F344/N rats and $B6C3F_1$ mice because there have been no previous long-term studies of this drug in animals.

The dietary admixtures were unpalatable at concentrations of 10,000 ppm or more in the NTP 15-day studies. Reduced feed consumption was also observed with dietary admixtures containing approximately 1,600 ppm (mice) or 2,400 ppm (rats) in the 13-week studies, but it was uncertain to what extent this was associated with palatability of the diet or with anorexia resulting from toxicity.

In the NTP 13-week studies, all rats receiving 2,400 ppm and all mice receiving 1,600 ppm died before the end of the studies. Most of the rats died during the third and fourth weeks, whereas mice died during the first week of the studies. Although renal lesions were observed in most of the rats that died, nutritional deficiencies associated with the reduced feed consumption may also have contributed to their deaths. In contrast to rats, renal lesions were not observed in mice. Moreover, there were no histological lesions in other organs of mice that could account for their deaths. In humans, an increase in serum potassium concentration (hyperkalemia) may result from the overdose of triamterene, resulting in ventricular tachycardia or fibrillation and death (Weiner 1990). Whether hyperkalemia and physiological alterations associated with the diuretic effects of triamterene contributed to the deaths of mice and rats in the 13-week studies was not determined.

In the NTP 13-week study, sand-like calculi were observed at necropsy in the renal pelvis of several male rats receiving 1,200 ppm, which is consistent with reports of abnormal urinary sediments and nephrolithiasis in humans as complications of triamterene therapy or as toxic effects from overdose (Sica and Gehr, 1989). The urine sediments of patients receiving therapeutic doses of triamterene contained pigmented brown casts and hyaline casts with bire-

fringent crystals (Fairley et al., 1986). Furthermore, renal calculi composed of triamterene and its primary metabolites, hydroxytriamterene and hydroxytriamterene sulfate ester, have been observed in patients receiving triamterene (Patel, 1981; Grunberg and Silberg, 1981; Werness et al., 1982; Sörgel et al., 1985a).

Although triamterene and its primary metabolites have been identified in urinary calculi (sometimes as a major constituent), the role of triamterene in the formation of calculi in humans has not been fully clarified. It has been proposed that triamterene may promote the growth of calculi in three different ways. First, the precipitation of triamterene and its metabolites in the urine may result in the formation of concretions composed almost entirely of the drug (Gault et al., 1981). Second, the triamterene crystals may provide a nidus upon which other crystals are deposited, and third, triamterene may increase the size of existing calculi by being adsorbed to the protein matrix common to most renal or urinary calculi (Werness et al., 1982; Sörgel et al., 1985a). The formation of urinary calculi in male F344/N rats receiving triamterene may provide a model for studying this process.

Triamterene therapy also has been associated with transient declines in renal function and, less frequently, acute renal failure in humans. Several different causal mechanisms for these effects have been proposed, including interstitial nephritis from drug-induced hypersensitivity (Bailey et al., 1982; Magil, 1983), intrarenal obstruction due to crystalline deposits in renal tubules and collecting ducts (Farge et al., 1986), and hemodynamic events accompanying the administration of triamterene with nonsteroidal anti-inflammatory agents (Weinberg et al., 1985; Mathews and Baille, 1986). The results of the NTP studies suggest that the intrinsic nephrotoxicity of triamterene or its metabolites may also play a role in these conditions.

Rats receiving 3,000 ppm in the 15-day study and 1,200 or 2,400 ppm in the 13-week study had moderately severe renal lesions involving the outer stripe of

62 Triamterene, NTP TR 420

the outer medulla and, to a lesser extent, cortical tubules or medullary collecting ducts. The epithelium of the straight portions of renal tubules in the outer stripe of the outer medulla exhibited increased cytoplasmic basophilia and enlarged nuclei with occasional cells in mitosis. These cytologic features are consistent with a rapid rate of cell turnover and are usually due to enhanced cell loss or necrosis. Individual necrotic cells were occasionally seen. Segments of convoluted tubules with similar features were also observed in the cortex, and occasionally segmental lesions involving the full thickness of the cortex were seen. Cellular degeneration and necrosis were more prominent features of the lesion in mice receiving 3,000 ppm in the 15-day study than in rats.

The particular segment or segments of the nephron affected is not entirely clear from these studies. The focal, segmental lesions involving the full thickness of the cortex clearly included the P1 and P2 segments of the proximal convoluted tubules. The outer stripe of the outer medulla, which seemed to be the most extensive region affected, contains the descending straight portion of the proximal tubules (P3), the thick ascending limb of the distal tubules, and collecting ducts. Ožegović et al. (1979) reported renal lesions in rats given triamterene. These authors described vacuolar degeneration and loss of PASstaining of the brush border of the proximal convoluted tubule epithelium with focal karyolysis and cytolysis (necrosis) in male Fischer rats given 3 or 4.5 mg triamterene per 100 g body weight.

Necrosis of lymphocytes in the spleen, lymph nodes, and thymus was observed in mice receiving 800 or 1,600 ppm in the 13-week studies, and lymphoid depletion and bone marrow hypocellularity were seen in rats receiving 2,400 ppm. Although similar lesions are commonly associated with debilitation, malnutrition, and stress, there may be an alternative explanation for the lesions in rats and mice receiving triam-The molecular structure of triamterene consists of a pteridine nucleus like the antifolate drugs used in cancer chemotherapy. The antifolate drugs, such as methotrexate, bind to dihydrofolate reductase, an enzyme essential in the synthesis of DNA, and inhibit DNA synthesis and the growth of rapidly dividing cells. Since the bone marrow and lymphoid tissues have a relatively high rate of cell turnover, the lesions in these tissues in the 13-week studies might be related to the antifolate effects of triamterene. Although triamterene has been reported

to be a weak antifolate compound in vitro, it has not exhibited antifolate activity in vivo (Maass et al., 1967; Manson et al., 1986).

The high dose selected for the 2-year study in rats was 600 ppm, one-half the lowest dose at which triamterene-related kidney lesions were observed in the 13-week study and one-fourth the dose at which all rats died in the 13-week study. Dietary concentrations greater than 600 ppm were considered too great, primarily because of the potential for triamterene-related kidney toxicity to exacerbate the spontaneous renal disease of aging rats and shorten their lifespan. At the end of the 2-year study, a slight but statistically significant increase in the severity of nephropathy was observed in high-dose female rats and in male rats receiving 300 ppm. The slight but consistent decrement in body weight between exposed and control rats in the second year of the study was also attributed to triamterene administration.

The high dose selected for the 2-year study in mice was 400 ppm, one-half the dose at which necrosis of lymphocytes was observed in lymph nodes, spleen, and thymus and one-fourth the dose at which all mice died in the 13-week study. Moreover, one female mouse receiving 800 ppm also died and the body weight gain of males in this exposure group was less than 50% of the controls. Thus, a dietary concentration of 800 ppm was considered too great for the 2-year study.

In the 2-year studies, the estimated amount of triamterene consumed was approximately 5, 10, or 25 mg/kg per day for rats fed 150, 300, or 600 ppm, and was approximately 10, 20, or 50 mg/kg per day for mice fed 100, 200, or 400 ppm. In humans, up to 5 mg/kg per day may be used in the treatment of edema from various causes.

In the 2-year rat and mouse studies, there were no drug-related effects on survival at the targeted concentrations, and there were no clinical findings of toxicity. An effect on survival was observed in the high-dose mice that received approximately four times the targeted concentration (approximately 1,600 ppm) of triamterene for 7 days at week 40. Because of the overdosing, 12 male and four female mice died during week 40 of treatment. However, the majority of the mice in the high-dose group survived, unlike the 13-week study in which all the mice fed 1,600 ppm died during the first week of

treatment. Since the older mice may consume less feed on a body weight basis, it is unknown if the apparent greater resistance is related to the amount of triamterene ingested or to some other factor. The surviving high-dose mice were kept in the 2-year study, but because of the uncertainty about what effect this one week of increased exposure would have on the outcome of the study, a second study was conducted with control and 400 ppm male and female mice.

Other than the slight increase in the severity of nephropathy in rats, the principal drug-related effects in rats and mice in the 2-year studies were observed in the liver. The incidences of mixed cell foci occurred with a significant positive trend in male and female rats and the incidences in the mid- and high-dose groups were significantly greater than in controls. Moreover, the incidence of eosinophilic foci in males and clear cell foci in females were marginally increased in the high-dose groups. The incidences of lesions classified as hyperplasia, which were morphologically similar to the various foci, were also increased in exposed male rats.

In hematoxylin and eosin stained sections, hepatocellular foci are typically categorized as basophilic, eosinophilic, clear, vacuolated, or mixed depending on the predominant staining properties of the cytoplasm. These staining properties are determined by the relative amounts of the various cytoplasmic constituents. Therefore, although convenient and necessary for making diagnoses, the descriptive categories of the various foci are not mutually exclusive. Consequently, all phenotypes must be considered when evaluating the biological significance of these lesions.

Hepatocellular foci can also be identified by a variety of histochemical and immunoperoxidase stains for various enzymes. The foci observed in this study and those described in aged rats by other investigators (Ogawa et al., 1981; Ward, 1981) are morphologically and phenotypically similar to the foci induced by potent hepatocarcinogens (Williams, 1989). In shortand medium-term rat liver initiation/promotion carcinogenesis models, the analysis of hepatocellular foci is believed to provide a qualitative and quantitative measurement of a chemical's potential to induce liver cancer (Campbell et al., 1982, 1986; Williams, 1989). Foci are rapidly induced by hepatocarcinogens, and the numbers of induced foci are related

to the dose of the carcinogen (Emmelot and Scherer, 1980). Foci increase in number and size with continued carcinogen exposure or with time after cessation of exposure to certain carcinogens (Rabes and Szymkowiak, 1979; Barbason and Betz, 1981). Furthermore, hepatocellular neoplasms are believed to develop from some foci, even though the number of induced foci far exceeds the number of neoplasms that ultimately develop. The rate of progression of foci to neoplasms has been estimated to be on the order of 1 in 1,000 (Watanabe and Williams, 1978) to 1 in 2,500 (Pitot et al., 1978) for certain carcinogens.

Based on these experimental considerations, the more frequent occurrences of mixed cell foci, eosinophilic foci, and hyperplasia in male rats and mixed cell and clear cell foci in female rats receiving triamterene may reflect early biochemical changes that could lead to the development of hepatocellular neoplasms. However, the incidences of hepatocellular neoplasms in exposed rats at the end of the 2-year study do not convincingly support this hypothesis. No hepatocellular carcinomas were observed in male or female Although the incidence of hepatocellular rats. adenomas in male rats in the 150 ppm group was significantly greater than that of concurrent controls and exceeded the range of historical controls, the incidences in males receiving twice (300 ppm) or four times that amount (600 ppm) of triamterene were not significantly greater than controls. Therefore, the data were considered to provide equivocal evidence of carcinogenic activity in male rats.

Hepatocellular adenomas were observed in two highdose female rats, and none were seen in the lower exposure groups or in controls. While hepatocellular adenomas are relatively uncommon in untreated female rats, an incidence as high as 6% has been observed in a single control group. Therefore, it was concluded that there was no evidence of carcinogenic activity in female rats.

In contrast to rats, the incidences of hepatocellular neoplasms (adenoma or carcinoma) were significantly increased in female mice receiving diets containing 100, 200, or 400 ppm triamterene. The rates observed in the 400 ppm groups in both studies also fall outside the range of recent NTP historical control data. Moreover, the number of females with multiple liver neoplasms or with hepatocellular foci also increased in the exposed groups, providing further evidence that these lesions are related to the

ingestion of triamterene. The increased incidences of hepatocellular neoplasms in exposed female mice were due primarily to the more frequent occurrence of hepatocellular adenomas. Therefore, these findings were considered some evidence of carcinogenic activity rather than clear evidence.

In male mice, there were significant increases in the incidences of hepatocellular neoplasms in the groups receiving 400 ppm. In the first study, this was due primarily to an increased incidence of carcinomas, whereas in the second study it was due to an increased incidence of adenomas. As in females, the number of high-dose males with multiple liver neoplasms was greater than controls. In contrast to female mice, however, the overall incidences of hepatocellular foci were similar in exposed groups of male mice and controls. Because of the consistent finding of increased incidences of hepatocellular neoplasms in both the first and second studies and the increased incidence of multiple adenomas in the treated groups, these findings were considered to be some evidence of carcinogenic activity.

In addition to the treatment-related effects in the liver of exposed mice, there was an increase in the incidence of thyroid follicular cell hyperplasia. The reason for this thyroid effect is unknown.

The mechanism by which triamterene increased the incidences of hepatocellular foci in rats and liver neoplasms in mice is unknown. Liver toxicity is not reported as a common side effect from triamterene treatment in humans, although in older patients metabolism of the drug may be decreased and accumulation of the drug may contribute to liver and kidney disease (Knauf et al., 1983). Results of in vitro genetic toxicity assays show that triamterene is not mutagenic in Salmonella typhimurium, but it does induce chromosomal aberrations, sister chromatid exchanges, and micronuclei formation in Chinese hamster lung cells (Kawachi et al., 1980; Sasaki et al., 1980; Ishidate et al., 1981). On the other hand, triamterene did not induce chromosomal aberrations in bone marrow cells or dominant lethal mutations in germ cells of CD-1 mice (Manson et al., 1986), nor did it induce chromosomal aberrations in bone marrow cells (Kawachi et al., 1980) or unscheduled DNA synthesis in hepatocytes of male rats (Mirsalis et al., 1983).

The NTP has evaluated the results of genetic toxicity tests and carcinogenicity studies of 114 chemicals (Zeiger et al., 1990). In this group of chemicals, positive tests for the induction of chromosomal aberrations or sister chromatid exchanges were less predictive of carcinogenicity than positive tests for the induction of mutations in Salmonella typhimurium. That is, 73% of chemicals inducing chromosomal aberrations and 64% of chemicals inducing sister chromatid exchanges were carcinogenic in rodents, while 89% of the chemicals mutagenic in S. typhimurium were carcinogenic in rodents. Moreover, the specificity of tests for chromosomal aberrations and sister chromatid exchanges was less than tests for mutagenicity in S. typhimurium. The proportion of noncarcinogens that was negative in tests for chromosomal aberrations was 72% while the proportion that was negative in tests for sister chromatid exchanges was 45%, as compared with 91% for While a chemical mutagenic in S. typhimurium. S. typhimurium strongly implicates a mechanism of carcinogenicity involving DNA damage, the significance of tests for the induction of chromosomal aberrations or sister chromatid exchanges is less certain. Further study is necessary to determine how triamterene induces liver neoplasms in mice. In compilations of NCI and NTP rat and mouse carcinogenicity test results, the proportions of chemicals that induced neoplasms only in the liver of mice that were also mutagenic were 20% (Zeiger, 1987) and 39% (Ashby and Tennant, 1991).

CONCLUSIONS

Under the conditions of these 2-year feed studies, there was equivocal evidence of carcinogenic activity* of triamterene in male F344/N rats based on a marginal increase in the incidence of hepatocellular adenoma. There was no evidence of carcinogenic activity of triamterene in female F344/N rats administered 150, 300, or 600 ppm. There was some evidence of carcinogenic activity of triamterene in male B6C3F₁ mice based on a marginal increase in the incidence of hepatocellular carcinoma in the first study and a significantly increased incidence of hepatocellular adenoma in the second study. There was some evidence of carcinogenic activity of triamterene in female B6C3F, mice based on significantly increased incidences of hepatocellular adenoma and of adenoma and carcinoma (combined).

Exposure to triamterene was associated with an increased incidence of hepatocellular foci, primarily mixed cell type, and an increase in the severity of nephropathy in female rats. In mice, exposure to

triamterene was associated with an increased incidence of hepatocellular foci in females and an increased incidence of thyroid gland follicular cell hyperplasia in males and females.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 10. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 12.

REFERENCES

American Druggist (1991). The top 200 Rx drugs of 1990. The drugs dispensed most frequently in U.S. community pharmacies. 203, 56-68.

Armitage, P. (1971). Statistical Methods in Medical Research, pp. 362-365. John Wiley and Sons, New York.

Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity, and mutagenicity for 301 chemicals tested by the U.S. NTP. *Mutat. Res.* 257, 229-306.

Baba, W.I., Tudhope, G.R., and Wilson, G.M. (1962a). Triamterene, a new diuretic drug. I. Studies in normal men and in adrenalectomized rats. *Br. Med. J.* 2, 756-760.

Baba, W.I., Tudhope, G.R., and Wilson, G.M. (1962b). Triamterene, a new diuretic drug. II. Clinical trial in oedematous patients. *Br. Med. J.* 2, 760-764.

Bailey, R.R., Lynn, K.L., Drennan, C.J., and Turner, G.A.L. (1982). Triamterene-induced acute interstitial nephritis. *Lancet* 1, 226.

Barbason, A.H., and Betz, E.H. (1981). Proliferation of preneoplastic lesions after discontinuation of chronic DEN feeding in the development of hepatomas in the rat. *Br. J. Cancer* 44, 561-566.

Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.

Campbell, H.A., Pitot, H.C., Potter, V.R., and Laishes, B.A. (1982). Application of quantitative stereology to the evaluation of enzyme-altered foci in the rat liver. *Cancer Res.* 42, 465-472.

Campbell, H.A., Xu, Y.-D., Hanigan, M.H., and Pitot, H.C. (1986). Application of quantitative stereology to the evaluation of phenotypically heterogeneous enzyme-altered foci in the rat liver. *JNCI* 76, 751-767.

Code of Federal Regulations (CFR) 21, Part 58.

Cohen, A.B. (1966). Hyperkalemic effects of triamterene. Ann. Intern. Med. 65, 521-527.

Cox, D.R. (1972). Regression models and life-tables. J. R. Stat. Soc. B34, 187-220.

Dao, M.T., and Villeneuve, J.-P. (1988). Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis. *Clin. Invest. Med.* 11, 6-9.

Dinse, G.E., and Haseman, J.K. (1986). Logistic regression analysis of incidental-tumor data from animal carcinogenicity experiments. *Fundam. Appl. Toxicol.* 6, 44-52.

Dinse, G.E., and Lagakos, S.W. (1983). Regression analysis of tumour prevalence data. *Appl. Statist.* 32, 236-248.

Dunn, O.J. (1964). Multiple comparisons using rank sums. *Technometrics* 6, 241-252.

Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.

Emmelot, P., and Scherer, E. (1980). The first relevant cell stage in rat liver carcinogenesis. A quantitative approach. *Biochim. Biophys. Acta* 605, 247-304.

Fairley, K.F, Woo, K.T, Birch, D.F, Leaker, B.R, and Ratnaike, S. (1986). Triamterene-induced crystalluria and cylinduria: Clinical and experimental studies. *Clin. Nephrol.* 26, 169-173.

Farge, D., Turner, M.W., Roy, D.R., and Jothy, S. (1986). Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition. *Am. J. Kidney Dis.* **8**, 445-449.

Galloway, S.M, Bloom, A.D., Resnick, M., Margolin, B.H., Nakamura, F., Archer, P., and Zeiger, E. (1985). Development of a standard protocol for *in vitro* cytogenetic testing with Chinese hamster ovary cells: Comparison of results for 22 compounds in two laboratories. *Environ. Mutagen.* 7, 1-51.

Galloway, S.M., Armstrong, M.J., Reuben, C., Colman, S., Brown, B., Cannon, C., Bloom, A.D., Nakamura, F., Ahmed, M., Duk, S., Rimpo, J., Margolin, B.H., Resnick, M.A., Anderson, B., and Zeiger, E. (1987). Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: Evaluations of 108 chemicals. *Environ. Mol. Mutagen.* 10 (Suppl. 10), 1-175.

Gart, J.J., Chu, K.C., and Tarone, R.E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. *J. Natl. Cancer Inst.* **62**, 957-974.

Gault, M.H, Snedden, W., Taor, R.E., Churchill, D.N., and Ahmed, M. (1981). Triamterene urolithiasis. *Can. Med. Ass. J.* 124, 1556-1557.

Gilfrich, H.J., Kremer, G., Möhrke, W., Mutschler, E., and Völger, K.-D. (1983). Pharmacokinetics of triamterene after I.V. administration to man: Determination of bioavailability. Eur. J. Clin. Pharmacol. 25, 237-241.

Greenberg, A. (1986). What's new in diuretic therapy. Am. Fam. Physician 33, 200-212.

Grunberg, R.W., and Silberg, S.J. (1981). Triamterene-induced nephrolithiasis. *J. Am. Med. Assoc.* **245**, 2494-2495.

Hasegawa, J., Lin, E.T., Williams, R.L., Sörgel, F., and Benet, L.Z. (1982). Pharmacokinetics of triamterene and its metabolite in man. *J. Pharmacokinet. Biopharm.* 10, 507-523.

Haseman, J.K. (1984). Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies. *Environ. Health Perspect.* **58**, 385-392.

Haseman, J.K., Huff, J., and Boorman, G.A. (1984). Use of historical control data in carcinogenicity studies in rodents. *Toxicol. Pathol.* 12, 126-135.

Haseman, J.K., Huff, J.E., Rao, G.N., Arnold, J.E., Boorman, G.A., and McConnell, E.E. (1985). Neoplasms observed in untreated and corn oil gavage control groups of F344/N rats and (C57BL/6N \times C3H/HeN)F₁ (B6C3F₁) mice. *JNCI* 75, 975-984.

Hollander, M., and Wolfe, D.A. (1973). Nonparametric Statistical Methods, p.p. 120-123. John Wiley and Sons, New York.

Hollenberg, N.K., and Bannon, J.A. (1986). The PACT study: Post-marketing surveillance in 47,465 patients treated with Maxzide (triamterene/hydrochlorothiazide). *Am. J. Med.* 80 (Suppl. 4A), 30-36.

Ishidate, M., Jr., Sofuni, T., and Yoshikawa, K. (1981). Chromosomal aberration tests *in vitro* as a primary screening tool for environmental mutagens and/or carcinogens. *Gann Monogr. Cancer Res.* 27, 95-108.

Jonckheere, A.R. (1954). A distribution-free k-sample test against ordered alternatives. *Biometrika* 41, 133-145.

Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* 53, 457-481.

Kau, S.T., and Rama Sastry, B.V. (1977). Distribution and pharmacokinetics of triamterene in rats. *J. Pharm. Sci.* **66**, 53-56.

Kau, S.T., Rama Sastry, B.V., Alvin, J.D., and Bush, M.T. (1975). Metabolism of triamterene in the rat. *Drug Metab. Dispos.* 3, 345-351.

Kawachi, T., Komatsu, T., Kada, T., Ishidate, M., Sasaki, M., Sugiyama, T., and Tazima, Y. (1980). Results of recent studies on the relevance of various short-term screening tests in Japan. *Appl. Methods Oncol.* 3, 253-267.

Knauf, H., Möhrke, W., and Mutschler, E. (1983). Delayed elimination of triamterene and its active metabolite in chronic renal failure. *Eur. J. Clin. Pharmacol.* 24, 453-456.

Lacy, F.B., Dobyan, D.C., and Jamison, R.L. (1980). Effect of triamterene on the mammalian distal tubule in vivo. Renal Physiol. 2, 36-43.

Lant, A. (1985). Diuretics: Clinical pharmacology and therapeutic use (part II). *Drugs* 29, 162-188.

Laragh, J.H., Reilly, E.B., Stites, T.B., and Angers, M. (1961). Pteridine compound as an inhibitor of aldosterone action in man. *Fed. Proc.* 20, 410. (Abstr.)

Leilich, G., Knauf, H., Mutschler, E., and Völger, K.-D. (1980). Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application. *Arzneimittelforschung* 30, 949-953.

Loew, D., Barkow, D., Schuster, O., and Knoell, H.E. (1984). Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. *Eur. J. Clin. Pharmacol.* 26, 191-195.

Maass, A.R., Wiebelhaus, V.D., Sosnowski, G., Jenkins, B., and Gessner, G. (1967). Effect of triamterene on folic reductase activity and reproduction in the rat. *Toxicol. Appl. Pharmacol.* 10, 413-423.

McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *JNCI* 76, 283-289.

McKnight, B., and Crowley, J. (1984). Tests for differences in tumor incidence based on animal carcinogenesis experiments. *J. Am. Stat. Assoc.* 79, 639-648.

Magil, A.B. (1983). Drug-induced acute interstitial nephritis with granulomas. *Hum. Pathol.* 13, 36-41.

Manson, J.M., Guerriero, F.J., Brown, T., and San Sebastian, J. (1986). Lack of *in vivo* mutagenicity and testicular toxicity of triamterene in mice. *Fundam. Appl. Toxicol.* 7, 533-546.

Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* 10, 71-80.

Mathews, A., and Baille, G. (1986). Acute renal failure and hyperkalemia associated with triamterene and indomethacin. *Vet. Hum. Toxicol.* 28, 224-225.

The Merck Index. (1983). 10th ed. (M. Windholz, Ed.). Merck and Company, Rahway, NJ.

Mirsalis, J., Tyson, K., Beck, J., Loh, F., Steinmetz, K., Contreras, C., Austere, L., Martin, S., and Spalding, J. (1983). Induction of unscheduled DNA synthesis (UDS) in hepatocytes following in vitro and in vivo treatment. Environ. Mutagen. 5, 182. (Abstr.)

Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B., and Zeiger, E. (1986). Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals. Environ. Mutagen. 8 (Suppl. 7), 1-119.

Mutschler, E. Gilfrich, H.J., Knauf, H., Möhrke, W., and Völger, K.-D. (1983). Pharmakokinetik von Triamteren bei Probanden und Patienten mit Leberund Nierenfunktionsstörungen. Klin. Wochenschr. 61, 883-891.

National Cancer Institute (NCI) (1976). Guidelines for Carcinogen Bioassay in Small Rodents. Technical Report Series No. 1. NIH Publication No. 76-801. National Institutes of Health, Bethesda, MD.

National Institutes of Health (NIH) (1978). Open Formula Rat and Mouse Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

Nielsen, O.E., and Lassen, J.B. (1963). Triamterene activity investigated by the stop-flow technique and *in vitro* studies on carbonic anhydrase. *Acta Pharmacol. Toxicol.* 20, 351-356.

Ogawa, K., Onoé, T., and Takeuchi, M. (1981). Spontaneous occurrence of γ-glutamyl transpeptidase-positive hepatocytic foci in 105-week-old Wistar and 72-week-old Fischer 344 male rats. *JNCI* 67, 407-412.

Ožegović, B., Schön, E., and Milković, S. (1979). The effect of triamterene upon the rat kidney plasma membrane Na-K-ATP-ase activity. *Arch. Int. Pharmacodyn.* 241, 16-23.

Ožegović, B., Milković, S., and Rode, B. (1981). Nephrotic changes in the rat induced by overdosage of triamterene. *Arzneimittelforschung* 31, 1257-1260.

Patel, K.M. (1981). Triamterene nephrolithiasis complicating Dyazide therapy. J. Urol. 126, 230.

Physicians' Desk Reference (1991). 44th ed. pp. 1, 183, 2105-2106. Medical Economics Company, Inc., Oradell, NJ.

Pitot, H.C., Barsness, L., Goldsworthy, T., and Kitagawa, T. (1978). Biochemical characterisation of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. *Nature* 271, 456-458.

Pruitt, A.W., Winkel, J.S., and Dayton, P.G. (1977). Variations in the fate of triamterene. *Clin. Pharmacol. Ther.* 21, 610-619.

Rabes, H.M., and Szymkowiak, R. (1979). Cell kinetics of hepatocytes during the preneoplastic period of diethylnitrosamine-induced liver carcinogenesis. *Cancer Res.* 39, 1298-1304.

RTECS, [database online] (1991). Bethesda, MD. National Institute for Occupational Safety and Health; 1971. Updated quarterly. Available from National Library of Medicine, Bethesda, MD.

Sadtler Standard Spectra. IR No. 2800; UV No. 10896. Sadtler Research Laboratories, Philadelphia, PA.

Sasaki, M., Sugimura, K., Yoshida, M.A., and Abe, S. (1980). Cytogenetic effects of 60 chemicals on cultured human and Chinese hamster cells. *La Kromosomo* **20**, 574-584.

Schiffl, H., and Schollmeyer, P. (1985). Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 23, 585-588.

Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* 33, 386-389.

Sica, D.A., and Gehr, T.W.B. (1989). Triamterene and the kidney. *Nephron* 51, 454-461.

Sörgel, F., Ettinger, B., and Benet, L.Z. (1985a). The true composition of kidney stones passed during triamterene therapy. *J. Urol.* 134, 871-873.

Sörgel, F., Hasegawa, J., Lin, E.T., and Williams, R.L. (1985b). Oral triamterene disposition. *Clin. Pharmacol. Ther.* 38, 306-312.

Sörgel, F., Ettinger, B., and Benet, L.Z. (1986). Metabolic fate and solubility of triamterene — Not an explanation for triamterene nephrolithiasis. *J. Pharm. Sci.* 75, 129-132.

Spickett, R.G.W., and Timmis, G.M. (1954). The synthesis of compounds with potential anti-folic acid activity. Part I. 7-Amino- and 7-hydroxy-pteridines. *J. Chem. Soc.*, 2887-2895.

Takahashi, H., and Tsukada, T. (1979). Triamtereneinduced immune haemolytic anaemia with acute intravascular haemolysis and acute renal failure. Scand. J. Haematol. 23, 169-176.

Tarone, R.E. (1975). Tests for trend in life table analysis. *Biometrika* 62, 679-682.

Villeneuve, J.P., Rocheleau, F., and Raymond, G. (1984). Triamterene kinetics and dynamics in cirrhosis. *Clin. Pharmacol.* 35, 831-837.

Ward, J.M. (1981). Morphology of foci of altered hepatocytes and naturally-occurring hepatocellular tumors in F344 rats. *Virchows Arch. A. Pathol. Anat. Histol.* **390**, 339-345.

Watanabe, K., and Williams, G.M. (1978). Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital: Evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions. J. Natl. Cancer Inst. 61, 1311-1314.

Weinberg, M.S., Quigg, R.J., Salant, D.J., and Bernard, D.B. (1985). Anuric renal failure precipitated by indomethacin and triamterene. *Nephron* 40, 216-218.

Weiner, I.M. (1990). Diuretics and other agents employed in the mobilization of edema fluid. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (A.G. Gilman, T.W. Rall, A.S. Nies, and P. Taylor, Eds.), 8th ed., p. 713. Pergamon Press, New York.

Weinstock, J., and Wiebelhaus, V.D. (1963). Diuretic and antihypertensive triaminoarylpteridines. Patent No. 3,081,230, United States Patent Office.

Werness, P.G., Bergert, J.H., and Smith, L.H. (1982). Triamterene urolithiasis: Solubility, pK, effect on crystal formation, and matrix binding of triamterene and its metabolites. *J. Lab. Clin. Med.* 99, 254-262.

Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. *Biometrics* 27, 103-117.

Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. *Biometrics* 28, 519-531.

Williams, G. (1989). The significance of chemically-induced hepatocellular altered foci in rat liver and application to carcinogen detection. *Toxicol. Pathol.* 17, 663-672.

Williams, R.L., Thornhill, M.D., Upton, R.A., Blume, C., Clark, T.S., Lin, E., and Benet, L.Z. (1986). Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: Influence of age and renal function. Clin. Pharmacol. Ther. 40, 226-232

Zeiger, E. (1987). Carcinogenicity of mutagens: Predictive capability of the *Salmonella* mutagenesis assay for rodent carcinogenicity. *Cancer Res.* 47, 1287-1296.

Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four *in vitro* genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. *Environ. Mol. Mutagen.* 16 (Suppl. 18), 1-14.

APPENDIX A SUMMARY OF LESIONS IN MALE RATS IN THE 2-YEAR FEED STUDY OF TRIAMTERENE

TABLE A1	Summary of the Incidence of Neoplasms in Male Rats	
	in the 2-Year Feed Study of Triamterene	75
TABLE A2	Individual Animal Tumor Pathology of Male Rats	
	in the 2-Year Feed Study of Triamterene	80
TABLE A3	Statistical Analysis of Primary Neoplasms in Male Rats	
	in the 2-Year Feed Study of Triamterene	104
TABLE A4	Historical Incidence of Liver Neoplasms in Untreated Male F344/N Rats	107
	in the 2-Year Feed Study of Triamterene	108

TABLE A1
Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene^a

	0 ppm	150 ppm	300 ppm	600 ppm
Disposition Summary				· · · · · · · · · · · · · · · · · · ·
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
15-Month interim evaluation	10	10	10	10
2-Year study				
Early deaths				
Moribund	18	20	18	17
Natural deaths	4	5	13	6
Accidental deaths	3			
Survivors				
Terminal sacrifice	25	25	19	27
Animals examined microscopically	70	70	70	70
15-Month Interim Evaluation				
Alimentary System			445	
Mesentery Lipoma			(1) 1 (100%)	(2)
Cardiovascular System None				
Endocrine System Adrenal gland, medulla Pheochromocytoma benign	(10) 1 (10%)	(1)		(10)
Pituitary gland	(10)	(2)		(10)
Pars distalis, adenoma Thyroid gland	(10)	1 (50%)		(10)
C-cell, adenoma	1 (10%)	(1)		1 (10%)
General Body System None				
Genital System			······	
Preputial gland	(10)	(1)	(1)	(8)
Adenoma	2 (20%)	. 715	1 (100%)	
Testes Rilatoral intermittial call adonoma	(10)	(1)	(6)	(10) 6 (60%)
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	4 (40%) 6 (60%)	1 (100%)	5 (83%) 1 (17%)	4 (40%)
Hematopoietic System None				
Integumentary System None				

TABLE A1
Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
15-Month Interim Evaluation (continued) Musculoskeletal System None	-		· · · · · · · · · · · · · · · · · · ·	
Nervous System None				
Respiratory System None				
Special Senses System None				
Urinary System				
Kidney Liposarcoma	(10)	(1) 1 (100%)	(2)	(10)
2-Year Study	· · · · · · · · · · · · · · · · · · ·			
Alimentary System				
Intestine large, rectum Adenocarcinoma	(49)	(47)	(49)	(47) 1 (2%)
Adenoma	(40)	1 (2%)	(40)	. (48)
ntestine small, jejunum Adenoma	(48)	(49) 1 (2%)	(49)	(47)
Liver	(50)	(50)	(50)	(49)
Cholangioma	(50)	(00)	(55)	1 (2%)
Fibrous histiocytoma, metastatic, skin			1 (2%)	()
Hepatocellular adenoma		4 (8%)	4 (8%)	2 (4%)
Hepatocellular adenoma, multiple		2 (4%)		1 (2%)
Sarcoma, metastatic, uncertain primary site	(4)	1 (2%)	(3)	(8)
Mesentery Pancreas	(4) (50)	(4) (50)	(3) (50)	(8) (48)
Stomach, forestomach	(50)	(50)	(50)	(49)
Papilloma squamous		1 (2%)		1 (2%)
Stomach, glandular	(50)	(50)	(50)	(48)
Tongue Positione agreement	(1)		(1)	(1)
Papilloma squamous Squamous cell carcinoma			1 (100%)	. 1 (1000)
Tooth		(1)	(1)	1 (100%) (1)
Gingiva, squamous cell carcinoma			(-)	1 (100%)
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Chemodectoma benign			1 (2%)	
Hemangiosarcoma				1 (2%)

TABLE A1
Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
Endocrine System				
Adrenal gland, cortex	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	ì (2%)	` '	` '
Adrenal gland, medulla	(50)	(50)	(50)	(49)
Pheochromocytoma malignant	ì (2%)	2 (4%)	` '	` '
Pheochromocytoma benign	7 (14%)	10 (20%)	7 (14%)	5 (10%)
Bilateral, pheochromocytoma benign	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Islets, pancreatic	(50)	(50)	(50)	(49)
Adenoma	2 (4%)	ì (2%)	5 (10%)	ì (2%)
Parathyroid gland	(46)	(46)	(50)	(49)
Adenoma	ì (2%)	` '		` '
Pituitary gland	(50)	(50)	(49)	(49)
Pars distalis, adenoma	8 (16%)	6 (12%)	7 (14%)	9 (18%)
Pars intermedia, adenoma	` ,	1 (2%)	` ,	, ,
Thyroid gland	(50)	(49) ` ′	(50)	(49)
Bilateral, C-cell, adenoma	ı́ (2%)	1 (2%)	1 (2%)	ì (2%)
C-cell, adenoma	9 (18%)	6 (12%)	11 (22%)	8 (16%)
Follicle, adenoma	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Genital System			**	
Epididymis	(50)	(50)	(50)	(49)
Preputial gland	(50)	(50)	(50)	(49)
Adenoma	1 (2%)	2 (4%)	4 (8%)	3 (6%)
Prostate	(48)	(48)	(50)	(49)
Seminal vesicle	(49)	(48)	(50)	(49)
Testes	(50)	(50)	(50)	(49)
Bilateral, interstitial cell, adenoma	39 (78%)	42 (84%)	43 (86%)	43 (88%)
Interstitial cell, adenoma	3 (6%)	5 (10%)	6 (12%)	4 (8%)
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Lymph node	(50)	(50)	(50)	(50)
	(50)	(50)	(30)	(30)
Pancreatic pheochromocytoma malignant				
Pancreatic, pheochromocytoma malignant,	1 (2%)		450	(50)
metastatic, adrenal gland	1 (2%)	(49)	(50)	
metastatic, adrenal gland Lymph node, mandibular	(50)	(49) (47)	(50) (47)	(50) (48)
metastatic, adrenal gland Lymph node, mandibular Lymph node, mesenteric	(50) (48)	(47)	(47)	(48)
metastatic, adrenal gland Lymph node, mandibular Lymph node, mesenteric Spleen	(50) (48) (50)			
metastatic, adrenal gland Lymph node, mandibular Lymph node, mesenteric Spleen Leiomyosarcoma	(50) (48) (50) 2 (4%)	(47) (50)	(47) (50)	(48) (50)
metastatic, adrenal gland Lymph node, mandibular Lymph node, mesenteric Spleen	(50) (48) (50)	(47)	(47)	(48)

TABLE A1
Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene (continued)

$S_{\Omega_{\mathcal{A}}}(a)$	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
Integumentary System		(07)	(25)	(40)
Mammary gland	(36)	(37)	(35)	(42)
Fibroadenoma	(40)	(50)	(50)	1 (2%)
Skin	(49)	(50)	(50)	(49)
Basal cell adenoma		1 (2%)	1 (2%)	
Basal cell carcinoma	2 (40)	1 (2%)		
Basosquamous tumor malignant	2 (4%)		1 (20)	1 (20)
Basosquamous tumor benign	0 (40%)	2 (40)	1 (2%)	1 (2%)
Keratoacanthoma	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Papilloma squamous	1 (2%)	1 (2%)	1 (2%)	
Subcutaneous tissue, fibroma	1 (2%)	2 (4%)	3 (6%)	2 (4%)
Subcutaneous tissue, fibrous histiocytoma			1 (2%)	
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma	()	1 (2%)	1 (2%)	1 (2%)
		- (-,-)	- \	- ()
Nervous System				
Brain	(50)	(50)	(50)	(50)
Carcinoma, metastatic, Zymbal's gland			1 (2%)	
Granular cell tumor benign	1 (2%)			
Oligodendroglioma benign	1 (2%)			
Respiratory System	· · · · · · · · · · · · · · · · · · ·		_	
	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	2 (4%)	1 (20%)	1 (201)	
Alveolar/bronchiolar carcinoma		1 (2%)	1 (2%)	
Carcinoma, metastatic, Zymbal's gland			1 (2%)	
Fibrous histiocytoma, metastatic, skin			1 (2%)	•
Pheochromocytoma malignant, metastatic,		1 /0~		
adrenal gland		1 (2%)		
Squamous cell carcinoma	(FO)	1 (2%)	(50)	(#0)
Nose	(50)	(50)	(50)	(50)
Papilloma squamous			1 (2%)	
Special Senses System				
Ear	(2)			(1)
Middle ear, papilloma squamous				(*)
	1 (50%)		,	1 (100%)
Pinna, fibrosarcoma	1 (50%)			1 (100%)
Pinna, papilloma squamous	1 (30%)	(1)	(2)	
Zymbal's gland		(1)	(2)	
Adenoma		1 (100%)	2 (100%)	
Carcinoma			£ (100%)	

TABLE A1
Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
Urinary System				•
Kidney	(50)	(50)	(50)	(50)
Adenoma	ì (2%)	` '	1 (2%)	` /
Urinary bladder	(49)	(47)	(50)	(47)
Adenoma				1 (2%)
Systemic Lesions	**************************************	**************************************		<u> </u>
Multiple organs ^c	(50)	(50)	(50)	(50)
Leukemia mononuclear	22 (44%)	23 (46%)	19 (38%)	18 (36%)
Lymphoma malignant histiocytic	· · · /	· · · · · · · · · · · · · · · · · · ·	1 (2%)	- ()
Lymphoma malignant mixed	1 (2%)		- ()	
Mesothelioma malignant	` /	2 (4%)		1 (2%)
Neoplasm Summary				
Total animals with primary neoplasms ^d				
15-Month interim evaluation	10	3	8	10
2-Year study	45	49	50	50
Total primary neoplasms	•			
15-Month interim evaluation	14	3	8	11
2-Year study	114	124	128	114
Total animals with benign neoplasms				
15-Month interim evaluation	10	2	8	10
2-Year study	44.	48	50	48
Total benign neoplasms		_		
15-Month interim evaluation	14	2	8	11
2-Year study	86	93	103	89
Total animals with malignant neoplasms				
15-Month interim evaluation	•	1		
2-Year study	26	28	24	23
Total malignant neoplasms		•		
15-Month interim evaluation	20	1	0.5	
2-Year study	28	31	25	25
Total animals with metastatic neoplasms			2	
2-Year study	1	3	3	
Total metastatic neoplasms				
2-Year study	. 1	3	4	
Total animals with malignant neoplasms				
uncertain primary site		4		
2-Year study		• 1		

Number of animals examined microscopically at site and number of animals with lesion

No neoplasms were found at the 3-month interim evaluation.

Number of animals with any tissue examined microscopically

Primary neoplasms: all neoplasms except metastatic neoplasms

Table A2					
Individual Animal	Tumor Pathology	of Male Rats	in the 2-Year	Feed Study of	Triamterene: 0 ppm

mber of Days on Study		8	8		3	7	8	8	0	3	3	8	1	2	4	6 5 3	5	5	7	8	0	0		7 1 9	7 2 5	7 2 6	
rcass ID Number	, A	0 9	0 9	0 9	0 3	1 3	0 6	0 5	1 3	1 1	0 4	0 3	1 4	0 2	0 1	0 0 5 2	1 4	0 1	1 0	0 1	0 3	1 3	0 4	0 2	1 1	0 4	
mentary System								_					_													-	
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large		+	+	+	+	+	+	<u>.</u>	+	+		+	+	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+	+	
Intestine large, cecum		+	<u>.</u>	+	À	÷	+	<u>.</u>	÷	·	+	+	<u>.</u>	+	+	+	+	÷	+	<u>.</u>	<i>.</i>	<u>.</u>	+	+	·	<u>.</u>	
Intestine large, colon		+	<u>,</u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	·	<u>.</u>	
Intestine large, rectum		<u>.</u>	<u>'</u>	÷	Δ	÷	+	Ţ	<u>.</u>	Ţ	+	+	+	<u>.</u>	<u>.</u>	<u> </u>	+	i	<u>.</u>	<u> </u>	÷	Ţ	Ţ	<u> </u>	Ţ	i	
Intestine small		÷	÷	+	1	i	<u>.</u>	÷	<u>,</u>	<u>.</u>	÷	+	+	<u>.</u>	<u>.</u>	<u>.</u>	<u>.</u>	Ţ	i	Ţ	<u>.</u>	·	i	Ţ	·	÷	
Intestine small, duodenum		+	<u>.</u>	·	4	+	+	+	+	÷	+	+	+	+	+	+	+	1	<u>.</u>	÷	<u>.</u>	<u>.</u>	+	+	<u>.</u>	<u>.</u>	
Intestine small, ileum		1	i	÷	Δ	<u>.</u>	<u>.</u>	<u>.</u>	<u>,</u>	i	Ţ	+	Ļ	<u>.</u>	÷	<u>.</u>	<u>.</u>	i	<u>,</u>	4	÷	<u> </u>	<u>.</u>	4	<u>.</u>	<u>.</u>	
Intestine small, jejunum		<u>.</u>	·	<u>.</u>	+	+	+	M	÷	+	+	+	+	+	÷	+	<u>.</u>	<u>.</u>	÷	+	÷	+	<u>.</u>	+	+	+	
Liver		+	ì	+	÷	+		+	·	÷	÷	<u>.</u>	÷	+	Ţ	<u>.</u>	+	+	<u>.</u>	+	+	·	i	÷		+	
Mesentery		•	•	•	+	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	+	٠	+	•	•	•	•	
Pancreas		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands		+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	<u>.</u>	+	+	+	+	+	4	
Stomach, forestomach		+	+	+	+	+	+			+	+	+				+		+.	+	+	+	+	+	+	+	+	
Stomach, glandular		+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	
Tongue															•			·		•				·	•		
rdiovascular System Blood vessel Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
docrine System															•	_											
Adrenal gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	
Adenoma		•	٠	•	•	•	•	٠	•	•	•	٠	•	•	•	•	•	•		•	٠	•	•	X		٠	
Adrenal gland, medulla		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	
Pheochromocytoma malignant											•	•								•		•	•			•	
Pheochromocytoma benign																		X						X			
Bilateral, pheochromocytoma benign																											
Islets, pancreatic		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma														X													
Parathyroid gland		+	+	+	+	+	M	+	+	+	+	+	+		+	M	+	+	+	+	M	+	+	+	+	+	
Adenoma						•	•						-								-						
Pituitary gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pars distalis, adenoma											X					+	X			X							
Thyroid gland		+	+	+	+	+	+	+	+	+	+	+				+										+	
Bilateral, C-cell, adenoma								v	X							Х									X		
Bilateral, C-cell, adenoma C-cell, adenoma								Λ	Λ							~~											

^{+:} Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 0 ppm (continued)

		7	-	7	7		7						7		7											
Number of Days on Study	2 9	2 9	9	9	9	9		9	0					0	0		1									
	0	0													0											
Carcass ID Number	0	0	0	1											0									1	1	Total
	_			0		_									7									2	4	Tissues
	3	5	2	2	3	4	2	3	1	3	5	1	3	4	1	3	3	4	1	2	5	1	3	5	1	Tumor
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+							+							+	+		+	50
Intestine large	+	+	+	+	+	+	+	+		+			+				+	+		+	+	+	+	-	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+		+	49
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	+	+	+	+	+	+	49
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	50 50
Intestine small, duodenum	+	+	+	+	+	+	+	+		+	+	•	+	-				+	+	+	+	+	+	+		50
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	+	+	+	+	-	+	49
Intestine small, jejunum	+	+		+	+	+	+	+	+	+	+	+		+		+	+	+	+			+				48 50
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	_	T	+	т	_	+	+	_	_	T	4
Mesentery Pancreas	+	_	_		_	_	_		+	+	_	_	_	_	_	_	+		_	_	+	_	_	_	_	50
Salivary glands				+	т Т			т Т	T	т Т	T	+		T	+	+	+		+	+			т Т		т Т	50
Stomach					т _		+	+	+	+	+	+	+	+			+	+	+	+	·	+	, +	+	+	50
Stomach, forestomach	·	<u>.</u>	÷	+	·	<u>.</u>	+	+		+	+	+		+				+	+			+	+		+	50.
Stomach, glandular	+	+	+	+	+	+	+				+				+							+	+			50
Tongue		+																								1
Cardiovascular System					_				-																	
Blood vessel			+																							1
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										,
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	50
Adenoma																										1
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant																					X					1
Pheochromocytoma benign			X	X						X				X											X	7
Bilateral, pheochromocytoma benign		X					X																			2
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma											X															2
Parathyroid gland	+	+	+	+	+	+	+	+	+	M	[+	+	+			+	+	+	+	+	+	+	+	+	+	46
Adenoma														X						_						1
Pituitary gland	+	+			+			+			+	+	+	+	+	+	+	+	+			+	+	+	+	50
Pars distalis, adenoma			X			X			X											X	٠,				X	8
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, C-cell, adenoma		v	X				х		v				х			Х										1 9
C-cell, adenoma		Λ	X				^		Х				Λ												-	1
Follicle, adenoma			Λ																							1

			_	_	_	_				_ `	_	_	_		_	-	_			_	,	_	_	_	_	_	_		
Number of Days on Study		,	8			3 6	7	8	8	0	3	3	8	1	2	4.		5	5	7	8	0	0	1	1	2	2		
Carcass ID Number	fs v		0 0 9 2	0 9	0 9	0 0 3 5	1 3	0. 6	0 5	1 3	1 1	0 4	0 3	1 4	0 2	0 1	0	1 4	0 1	1 0	0 1	0 3	1 3	0 4	0 2	1 1	0 4		
General Body System None	·		-		-						_										-					•			
Genital System		J							-						•	-				٠.								-	
Epididymis			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Preputial gland			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma																							X					•	
Prostate			+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Seminal vesicle			+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Testes			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Bilateral, interstitial cell, adenor Interstitial cell, adenoma	na								Х	X			Х	Х	X	Х	Х	X	Х	Х	X		Х	Х	Х	X	X		
Hematopoietic System							- ~				-	•																	
Bone marrow			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Pancreatic, pheochromocytoma malignant, metastatic, adrenal gland																							٠,						
Lymph node, mandibular			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node, mesenteric			+	+	+	+	M	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+		
Spleen			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Leiomyosarcoma Thymus			+	+	+	M	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	M	+	+	+	+	+		
Integumentary System												_					· ·												
Mammary gland			+	м	+	+	м	м	M	+	+	+	+	M	+	+	+	M	+	+	+	+	М	+	+	М	M		
Skin	*		+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	<u>.</u>	+	+	+	+	+	+	+		
Basosquamous tumor malignant			•	•	•	•	٠.	•	•	•	٠	•	•	•	•	X		•	•	•	•	·	Ċ	•	•	•			
Keratoacanthoma																X													
Papilloma squamous																4 %													
Subcutaneous tissue, fibroma																							X						
Musculoskeletal System															٠													•	
Bone			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Nervous System																													
Brain			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Granular cell tumor benign		,																									X		
Oligodendroglioma benign								X																					

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 0 ppm (continued)

Illigia aggrega Againanga I managa I melianga									<u>.</u>																		
Number of Days on Study	7 2 9	2	2 2	2	2		-	2		7 3 0	7 3 0	7 3 0	3		3	7 3 0	7 3 0	7 3 1	7 3 1	3		7 3 1	7 3 1	7 3 1	7 3 1	3	
Carcass ID Number	0 0 5 3	7	7 8) 3	1 0	1 0	1 3	1 4	1 4	0 1	0 3	0 5	0 6	0 6	0 6	0 ¹ 0 7	0 7	0 8	0 8	0 9	1 1	1 1	1 2	1 2	1 2	1 4	Total Tissues, Tumors
General Body System None						-										***											
Genital System		_		_				_																			
Epididymis	4		+ .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	,		+ .	+	+	+	<u>.</u>	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma	7		•	•	•	•	•	'		•	•		•	•	•	'	'	'	'	•	'	•		•	'	•	1
Prostate	4		+ -	+	+	+	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	+	+	+	+	+	48
Seminal vesicle			· + ·		÷	<u>.</u>	<u>.</u>	÷	+	+	+	+	+			+			+	+	÷	<u>.</u>	+	+	+	+	49
Testes	4		· +	<u>.</u>	<u>.</u>	<u>.</u>	+		+	+		+	+	+		+				+			+	+	+	+	50
Bilateral, interstitial cell, adenoma	>		x :	X	X				-	X						X											39
Interstitial cell, adenoma	_			_				X		-	_	X					•		• -			•-		-			3
Hematopoietic System				_							-																
Bone marrow	-	٠ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node	4		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pancreatic, pheochromocytoma malignant, metastatic, adrenal gland																						X					1
Lymph node, mandibular	-	٠.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	50
Lymph node, mesenteric	4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Spleen	-	٠.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Leiomyosarcoma				X																						X	2
Thymus	N	1	+]	M	+	+	+	M	+	+	+	+	M	+	M	+	+	+	+	+	+	, + ,	+	+	+	+	42
Integumentary System																		_									
Mammary gland	N	1	+	+	+	+	M	+	+	+	+	+	M	+	+	+	M	+	+	M	+	+	+	+	+	+	36
Skin	4		+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Basosquamous tumor malignant													X														2
Keratoacanthoma																	X										2
Papilloma squamous Subcutaneous tissue, fibroma																Х											1 1
Musculoskeletal System Bone	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Nervous System											-									_							
Brain	+	٠ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Granular cell tumor benign Oligodendroglioma benign																											1

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 0 ppm (continued)

Number of Days on Study	0 8 3	0 8 3		3 3 6				0	5 3 0	3	8	1	2	4	6 5 3	5	5	7				1	1		2	
Constant ID Number	. 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Carcass ID Number		9	9	0 3 5	3	6	5	3	1	4	3	4	2	1		4	1	0	1	3		4	2	1	4	
Respiratory System																				7-4						
Lung Alveolar/bronchiolar adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nose Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+	
Special Senses System							•	-					-											_		
Ear Middle ear, papilloma squamous															+											•
Pinna, papilloma squamous Eye														+	X						+					
rinary System																										
Kidney Adenoma				+																				X		
Urinary bladder	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions Multiple organs	_	_	_		_	_	_	_	_	_	_		_	_	_		_		_	ساس		. د	. لـ	ı	+	
Leukemia mononuclear Lymphoma malignant mixed	+	т	T	т	_	т	т	X	X	т	X	X	X	т	X	X	X	X	т	X	7	X	X		T	

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 0 ppm (continued)

Number of Days on Study	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 1	_																
Carcass ID Number	0 0 5 3	0 0 7 5	0 0 8 2	0 1 0 2	0 1 0 3	0 1 3 4	0 1 4 2	0 1 4 3	0 0 1 1	0	0 5	0	0 6	0 0 6 4	0 7	0	0 8	0 8	-	1 1	1 1	1 2	1 2	1 2			Total Tissues/ Tumors
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Trachea	+	+++	+	+	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ X + +	+ + +		+ + +	+ + +	+ + +	+ + +	X	+ + +	·	· +		50 2 50 50
Special Senses System Ear Middle ear, papilloma squamous Pinna, papilloma squamous Eye							+	•						-	+ X					_							2 1 1 3
Urinary System Kidney Adenoma Urinary bladder	+	+			+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	. +	- +	-	50 1 49
Systemic Lesions Multiple organs Leukemia mononuclear Lymphoma malignant mixed		+ X		+ X	+	+ X	+ X	+	+	+	+	+	+	+ X		+	+	+		X		+	+		- + X X		50 22 1

Table A2	
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene:	150 ppm

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Umber of Days on Study		· ,																						· -					
Carcass ID Number	1	Number of Days on Study		.2	6	3	4	1	1	1	1	1	1	4	5	5	5	5	6	7	7	8	0	0	1	1	1	2		
Limentary System	Sophagus	Carcass ID Number		1 9	2	2 1	2 0	1 6	2 0	1 7	2 0	2 8	2 1	2 4	2 5	2 8	1 9	2 2	2 0	1 5	1 7	2 7	1 7	1 8	2 6	1 5	1 5	1 5	 	
Esophagus	Esophagus	limentary System																				•							 	
Intestine large	Intestine large			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, cecum Intestine large, coton Intestine large, coton Intestine large, coton	Intestine large, cecum			+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, colon Intestine large, rectum M + + + + + + + + + + + + + + + + + + +	Intestine large, colon			+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	Α	+	+		
Intestine large, rectum	Intestine large, rectum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma Intestine small, diodenum	Adenoma Intestine small Intestine small, duodenum Intestine small, duodenum Intestine small, diuodenum Intestine small, diuodenum Intestine small, diuom Intestine small, diuodenum Intestine small, det hat hat hat hat hat hat hat hat hat ha	Intestine large, rectum		M	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	Α	+	+		
Intestine small	Intestine small, diuodenum Intestine small, diuodenum Intestine small, iglum																													
Intestine small, duodenum	Intestine small, duodenum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+		•
Intestine small, ileum	Intestine small, ileum			+	+	+	+	+	+	+	+	+	+	+	+							+	+	+	+	+	+	+		
Intestine small, jejunum	Intestine small, jejunum			+	+	+	+	+	+	+	+	+	+	+												+	+	+		
Adenoma Liver	Liver			+	+	+	+	+	+	+	+	+	+	+												+	+	+		
Liver Hepatocellular adenoma Hepatocellular adenoma, multiple Sarcoma, metastatic, uncertain primary site Mesentery Pancreas ++++++++++++++++++++++++++++++++++++	Liver			•	•	•	•	•	٠	•	•	•	•	•	•		•		,			•	•	•	•		•			
Hepatocellular adenoma	Hepatocellular adenoma			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Hepatocellular adenoma, multiple	Hepatocellular adenoma, multiple			•	•	•	•		•	•	•	٠	•	•	•	•	•				·	•			•					
Sarcoma, metastatic, uncertain primary site Mesentery + + + + + + + + + + + + + + + + + + +	Sarcoma, metastatic, uncertain primary site Mesentery + + + + + + + + + + + + + + + + + + +								Х																					
Mesentery Pancreas	Mesentery Pancreas		ry																					٠						
Pancreas	Pancreas	site																X												
Salivary glands Stomach Stomach Stomach, forestomach Papilloma squamous Stomach, glandular Tooth Cardiovascular System Blood vessel Heart He	Salivary glands Stomach Stomach, forestomach Papilloma squamous Stomach, glandular Tooth ardiovascular System Blood vessel Heart + + + + + + + + + + + + + + + + + + +						+																+					+		
Stomach	Stomach, forestomach			+	+	+	+	+	+	+	+	+	+	+											+	+	+	+		
Stomach, forestomach	Stomach, forestomach	Salivary glands		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+		
Papilloma squamous Stomach, glandular	Papilloma squamous Stomach, glandular			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, glandular Tooth Cardiovascular System Blood vessel Heart + + + + + + + + + + + + + + + + + + +	Stomach, glandular Tooth ardiovascular System Blood vessel			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Cardiovascular System	Tooth																													
Cardiovascular System	ardiovascular System Blood vessel	Stomach, glandular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Heart	Heart	Tooth																												
Blood vessel	Heart	Pardiovascular System		_												_													 	
Heart + + + + + + + + + + + + + + + + + + +	Heart + + + + + + + + + + + + + + + + + + +																								+	+				
Endocrine System Adrenal gland	ndocrine System Adrenal gland + + + + + + + + + + + + + + + + + + +	,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adrenal gland	Adrenal gland	,																_		_										
Adrenal gland, cortex	Adrenal gland, cortex		*4																	••		*		•						
Adenoma Adrenal gland, medulla + + + + + + + + + + + + + + + + + +	Adenoma Adrenal gland, medulla + + + + + + + + + + + + + + + + + +			+	+	+	+	+	+	+	+	+	+	+	+	_+	+	+	+	+	+	+	+	+	+	+	+	+		
Adrenal gland, medulla + + + + + + + + + + + + + + + + + +	Adrenal gland, medulla + + + + + + + + + + + + + + + + + +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Pheochromocytoma malignant Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + + + + + + + + + + +	Pheochromocytoma malignant Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + + + + + + + + + + +			.1	_1	.1	.1.	ட	.1		.1	.1	_	.1ـ	Д	_	_	_						_		т.	_	T		
Pheochromocytoma benign X X X Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + + + + + + + + + + +	Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + + + + + + + + + + +				_	7	т	т	т	т	т	~		~		т	т	. —	Г	-	Т	г	т	τ'	т	т	τ.	т		
Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + + + + + + + + + + +	Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + + + + + + + + + + +																			Y		x		Y				,		
Islets, pancreatic $++++++++++++++++++++++++++++++++++++$	Islets, pancreatic + + + + + + + + + + + + + + + + + + +				,															^		^		^						
Adenoma	Adenoma									.1				.1			.1				.1.	_1_		٠	.1.	'۔		٠.		
				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	_	+	Ŧ	_	Τ.		
raratnyrolu gianu + + + + + + + + + + + + + + + + + + +	raratnyrolu gianu +++++M++++M++++++++++++++++++++++++++				٠,				3.						3.4			٠		J		_1	.1	.1		1.7		.1		
		raratnyroid giand		+	+	+	+	+	M	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	ΙVΙ	+	+		

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 150 ppm (continued)

4 .																•										
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0			7 3 0			7 3 0	7 3 0		7 3 1		7 3 1	7 3 1		7 3 1			
	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Carcass ID Number	1 6 3	6	1 7 2	1 7 5	2 0 4	2 3 5		7	8	8	1 9 1	9	2			2 3 2	2 3 3	2 3 4		7	2 7 2	7		8		Total Tissues/ Tumors
Alimentary System													-													
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+			+		+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	48
Intestine large, colon	+	·	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	+	+	+	+	50
Intestine large, rectum	<u>.</u>	+	+	+	+	+	÷	÷	+	+	+	-		+		+	+	+	+	+	+	+	+	+	+	47
Adenoma	,	-		•	•	'	•	•	'	•	X	•	•	•	•	•	4	•	•	•	•	•	1			1
Intestine small	_	4	+	+	4	+	+	_	_	+	+	+	+	+	4	+	+	_	+	4	4	_	_	1	_	49
Intestine small, duodenum	.L		T	т _	T.	.L	T.		_T	<u>.</u>	+	T	Τ.	. T	<u>.</u>	+	_T	_L			ı	T	T	<u>т</u>	7	49 49
Intestine small, ileum					+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	49 49
Intestine small, jejunum				T		+			+		+	+		+		+	+			+		T	+	+	+	49 49
Adenoma	7	т	т	т	т	Ŧ	т	X	т	т	Ŧ	т	_	т	T	т	т	T	т	_	т	т	Ŧ	т	Ŧ	
Liver										,											i					1
Hepatocellular adenoma	+	+ X		+	+	+	+	+	+	+	+	X	+	+	+	+	+	+	+	+	+	+	+	+		50
Hepatocellular adenoma, multiple Sarcoma, metastatic, uncertain primary		^										^								X				Х		4 2
site																										1
Mesentery					+																					4
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Papilloma squamous											X							•		•			•		•	1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Tooth	+		·	•	·	٠	•	·	٠	•	•	•	•	·	·	•		•	·	•	·		•	•	·	1
Cardiovascular System						-																_				
Blood vessel							+																			3
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System						•																				
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma																X										1
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant						X				Х																2
Pheochromocytoma benign									\mathbf{x}	Х		Х		Х			X	X				X				10
Bilateral, pheochromocytoma benign			X																			_				1
Islets, pancreatic	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma														X												1 .
Parathyroid gland			+											+		+										46

			-	5			6			-							-		-					7		
Number of Days on Study																								1		
	4	0	9	2	U	U	1	1	′	y	U	2	3	3	9	U	4	4	3	2	Z	U	3	5	2	
to the second of		<u> </u>			_	_	·	<u> </u>				_	_			_			_		_	_			_	
Carcass ID Number	1	0 2	•	2			0						_	1	_		-	-	-	_	-	-	_	0 1	-	
outtuss iis ivallisei	9	_					7								2									5		
	5																							1		
		-															-			_						
Endocrine System (continued) Pituitary gland		_	_	4.		_	.1.	_	_	4-	_	_	_	.1.	_	.1.	_	_	_	_	_	1			_	
Pars distalis, adenoma	т	т	т	_	т	Τ	ा	Г	-	7	-	_	+ X		: F		-	г	+	X		Τ.		X	+	
Pars intermedia, adenoma													Ą							Λ				^		
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	N	1 +	+	
Bilateral, C-cell, adenoma		•	·	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	·	·	•	•		•	•	
C-cell, adenoma					X				\mathbf{x}	\mathbf{X}																
Follicle, adenoma												X														
General Body System None Genital System Epididymis Preputial gland Adenoma	++	++	+++	++	+ + X		++	+++	+++	+++	+++	+++	++	++	++	++	+++	++	++	++	+++	++	 +	· +	++	,
Prostate	+	+	+	+			+	+	+	+	+	м	+	+	+	+	+	+	+	+	+	+	. 4	. +	+	
Seminal vesicle	+	+	+																					. +	+	
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma			X	X	Х	X	x	X	X	X	x		x	Х	Х	X	X	X	X		Х	X	. X	X	X	
Iematopoietic System										_					_											······································
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	
Lymph node	+	+	+	+	+	÷	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	
Lymph node, mandibular	+	+	+	+			+	+	+	+			,	+	+	+	+	+	+	+	+	+	M	1 ÷	+	
Lymph node, mesenteric	+	+	+		M		+	+	+	+		M		+	+	+	+	+	+	+	+	+	+	+	+	
Spleen	+																							+		
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	M	+	+	+	+	+	
Squamous cell carcinoma, metastatic, lung																		X								
ntegumentary System										-			_											-		-
Mammary gland	+	+	+	M	M	+	+	M	+	+	+	+	M	M	+	+	+	+	+	M	M	I M	í +	+	+	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	+	
Basal cell adenoma																										
The state of the s																										
Basal cell carcinoma																										
Basal cell carcinoma Keratoacanthoma Papilloma squamous												x														

TABLE A2				
Individual Animal Tum	or Pathology of Ma	le Rats in the 2-Year	r Feed Study of Triam	terene: 150 ppm (continued)

7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
2 9	9	9	9	9	9																				
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1	1	1	1	2	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	Total
6	6	7	7	0	3	4	7	8					2	2						7			_		Tissues/
3	5	2	5	4	5	2	5	1	2	1	2	2	3	5	2	3	4	2	1	2	4	1	3	4	Tumors
+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
			X					Х												X					6
_																						X			1
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	49
v			v													Х								v	1 6
Λ			^																					Λ	1
									_																
										-			-											-	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
										X															2
+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
+	+	+				+	+	-	-			•		-		-	+			+					48
																									50
Х		. х	. ж	Х	Х	λ	х			х	А	x		Λ	х	х	Х	х	Х	Х	Х	Х	Х	Х	42 5
									_																<u> </u>
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+	•	· IV	ι +	+	+	+	М	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46 1
ъ.						p./	h #							N /				3.4							25
				+	+					+	+	+											+	+	37 50
7	T	7	~	т.	т	Τ'	T	т	т	т	т'	т	т		т		г	т	_					-	1
													x							Λ					1
					X			x					4 L												2
																									1
	0 1 6 3 3 ++ ++ ++ ++ XX	9 9 9 0 0 0 1 1 6 6 6 3 5 5 + + + + + + + + + + + + + + + + +	9 9 9 0 0 0 1 1 1 6 6 7 3 5 2 + + + + + + + X +	9 9 9 9 9 0 0 0 0 0 1 1 1 1 6 6 7 7 3 5 2 5 + + + + + X X X X + + + + + + + + + + + + + + + + +	9 9 9 9 9 9 0 0 0 0 0 0 1 1 1 1 2 6 6 7 7 0 3 5 2 5 4 + + + + + X	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0	9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0	2 2 2 2 2 2 2 2 2 3 3 3 3 9 9 9 9 9 9 9	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 9 9 9 9 9	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 9 9 9 9	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3	2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3

Table A2	
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 150 ppm	(continued)

Individual Animal Tumor Patholo	gy of f	VI MI		\a					-16	a1	ге	-	31	Du.	, u			4111		CII	- -	13	<u>ا</u> ب			com	inue	a)	
•		3	3	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	7	7	7	7	7	7			
Number of Days on Study		2	6	3	4	1	1	1	1	1	1	4	5	5	5	5	6	7	7	8	0	0	1	1	1	2			
y		4	6	9												9			4			2		3	5				
····		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Carcass ID Number		1	2	2	2	1	2	1	2	2		2			1				1		-	1		1	1	1			
		9	4	1	0	6	0	7						8	9	2		5							5	5			
		5	1	3	1	2	5	3	2							4						5		2	1	3			
Musculoskeletal System										•						_		-	-					-					
Bone		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Osteosarcoma			X																										
Nervous System																_					_			-			٠.		
Brain		+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Spinal cord			+				•																						
Respiratory System	,																			-									
Lung		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Alveolar/bronchiolar carcinoma																													
Pheochromocytoma malignant,																													
metastatic, adrenal gland																													
Squamous cell carcinoma																			\mathbf{X}										
Nose		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Trachea		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Special Senses System									-			<u> </u>		-															
Eye															+										+				
Zymbal's gland								+																					
Adenoma	_							X																					
Jrinary System																													
Kidney		+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Urinary bladder		+	+	+	+	. +	+	+	+	+	+	+	M	+	+	A	+	+	+	+	+	+	+	+	+	+			
Systemic Lesions																													
Multiple organs		+	+	+	+	+	+	+	+							+	+	+	+	+	+	+	+	+	+	+			
Leukemia mononuclear				X	X									\mathbf{x}			X	Х				X				X			
Mesothelioma malignant					X																								

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 150 ppm (continued)

																			-									
Number of Days on Study		2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		7 3 0	7 3 0	7 3 0	7 3 0		7 3 0								7 3 1			3	
Carcass ID Number	1	1 5	1 6	1 7	1 7	2 0	2	0 2 4 2	2 7	1 8	1 8	1 9	1 9	2	2	2	2	2	2 3	2 5	2 7	2 7	2 7	2 8	2 8	8	2	Total Tissues/ Tumors
Musculoskeletal System Bone Osteosarcoma		+	+	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50 1
Nervous System Brain Spinal cord		+	+	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+		+	50 1
Respiratory System Lung Alveolar/bronchiolar carcinoma Pheochromocytoma malignant,		+	+	+	+	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X		+		+	50 1
metastatic, adrenal gland Squamous cell carcinoma Nose Trachea		+	+	+	+	. +	X - +		+	+	+	++	+	+	+	++	+	++	+	++	+	+	. +	- +				1 1 50 50
Special Senses System Eye Zymbal's gland Adenoma								-	•																			2 1 1
Urinary System Kidney Urinary bladder		+	+	. +	· · +	- +	+ +	+ +	- +	+ +	+ M	+	+	+	+	+	+	+	+	+	+	. +	- +	- +	- +	-	+	50 47
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant		+	+	X			+ + {	+ +	- + X	+ X X	+ X	+	+	+	+	+	+ X	+	+	+ X	+ X		- + >	- +	- +		+ X	50 23 2

TABLE A2						
Individual Animal	Tumor Pathology	of Male Rats	in the 2-Year Fe	eed Study of	Triamterene: 3	00 ppm

																	٠									 	
	5														6												
Number of Days on Study	3 1				7 2										7 1												
						_									•											 	
Carcass ID Number	3	0 4	0 4								0 3				0 3				0					0 4	-		
	2	0	2	0	7	1	2	3	4	2	9	0	7	1	5	9	9	0	3	0	9	1	6	0	8		
Alimentary System																										 	
Esophagus	+	+	+	+	4.	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	+	+	+	+	+		
Intestine large	·	+	+	+	+	+	<u>.</u>	<u>.</u>	+	<u>.</u>	+	+	+	<u>.</u>	+	<u>.</u>	+	<u>.</u>	<u>.</u>	À	÷	+	+	+	<u>+</u>		
Intestine large, cecum	·	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+						+			+	+	<u>.</u>	+		
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	<u>.</u>	+	+	+		+			+			·	+	+	+		
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+			+	+	+	+		
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+		+		+	+	+	+	+		
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+		+	+	+	+	+		
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+		
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+		
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Fibrous histiocytoma, metastatic, skin Hepatocellular adenoma													x						x						X		
Mesentery													+									+					
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Tongue														+													
Papilloma squamous Tooth			•	·										Х													
Cardiovascular System																							_			 	
Blood vessel																					+		+				
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Chemodectoma benign																					X						
Endocrine System							·			,																	
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+		+	+					
Pheochromocytoma benign	•	·	·		•	•	•	•	•	•	•	•	X	٠	X		•	•	•		•	x	•	•	•		
Bilateral, pheochromocytoma benign																											
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma					\mathbf{x}			\mathbf{x}							X						\mathbf{X}						
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Pars distalis, adenoma									Х	\mathbf{x}				X			X				Х						
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Bilateral, C-cell, adenoma																		_									
C-cell, adenoma				X					X				X					X							X		
Follicle, adenoma																											

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 300 ppm (continued)

Number of Days on Study	7 0	7 0	7 1	7 1		7		7	7	7	7	7	7 2	7	7	7 3		7	7		7	7 3	7		7	
	2	5		8	9	6	9				9				0									1		
		_	0												0											
Carcass ID Number	3	2	3	3	3	3	-		3		3	3	3	3		3		3	3	3		4	4		4	Total
									1						2 5									2		Tissues Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Liver Fibrous histiocytoma, metastatic, skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	.+	50 1
Hepatocellular adenoma																		X			X					4
Mesentery						+																				3
Pancreas	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Tongue																										1
Papilloma squamous																										1
Tooth					+																					1
Cardiovascular System																										
Blood vessel		+																								3
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Chemodectoma benign																										1
Endocrine System	-																									
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						+		50
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma benign														Х					X				X			7
Bilateral, pheochromocytoma benign						X																				1
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma											X															5
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pituitary gland	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma									X					X												7
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, C-cell, adenoma												X														1
C-cell, adenoma	X				X		X		X														X			11
Follicle, adenoma			X																		X					2

Brain

Carcinoma, metastatic, Zymbal's gland

Number of Days on Study 5 5 5 5 5 5 6 6	TABLE A2 Individual Animal Tumor Pathology	of Mal	le]	Rat	ts i	n t	the	2-	Yea	ar	Fee	ed	Stı	udy	7 O	f T	ria	am	ter	en	e:	30	0 I	pr	n (cont	inued)	
Number of Days on Study 3					_	_			<u>.</u>	<u> </u>		<u> </u>	6		6	6	<u></u>	6	6	_	6	-		6		7		
1 9 1 2 2 2 7 6 6 5 9 6 8 0 1 2 0 8 1 3 3 4 8 1 2	Number of Days on Study	_				7																						
Carcass ID Number 0		1	9	1																								
Carcass ID Number		. "				_	_	_	_	^	_	_			^	^	_	^	^	_	_	_	_	_		_		
2 0 2 0 7 1 1 2 3 4 2 9 0 7 1 5 9 9 0 3 0 9 1 6 0 8 2 3 4 1 4 3 1 1 1 5 4 1 5 4 1 5 4 4 3 3 2 3 5 2 3 5 4 2	Carcass ID Number									-	-			-								-	-	-				
Chemodectoma benign		2		2	0	7	1	2	3	4	2	9	0	7	1	5	9	9	0	3	0	9	1	6	0	8		
Cenital System	General Body System	<u>.</u>						_											-									
Senital System Epididymis	Tissue NOS																											
Figlidymis	Chemodectoma benign																						Х					
Fightidymis	Genital System											•	-															
Penis	Enididymis	- +	+	+	+	+	+	+	+	+	+	+	4	+	+	÷	+	+	+	+	+	+	+	+	+	+		
Preputial gland		•	•	•	•	•	•	•	٠	•	٠	•	•			,	•	•	٠	٠	•	+	•	•	•	•		
Adenoma		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+	+	+		
Seminal vesicle		Х					X			X																		
Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma X	Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma X	Seminal vesicle	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Interstitial cell, adenoma	Testes	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Bone marrow Lymph node + + + + + + + + + + + + + + + + + + +		X			Х	Х	Х	Х	х	X		Х	х	X	X	X	X	X	X	Х	X			Х	X	Х	*	÷
Bone marrow Lymph node + + + + + + + + + + + + + + + + + + +	Hematopoietic System																											-
Lymph node Lymph node, mandibular Lymph node, mandibular Lymph node, mandibular Lymph node, mesenteric Lymph node, mandibular Lymph node, mesenteric Lymph node, mesenteric Lymph node, mesenteric Lymph node, mandibular Lymph node, mesenteric Lymph node,		. +	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node, mandibular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+		
Lymph node, mesenteric Spleen H + + + + + + + + + + + + + + + + + +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+		+	+	+				
Spleen	Lymph node, mesenteric	+	+	+	+	+	+	+	÷	+	+	+	+										+	+				
Thymus		+	+	+	+	+	+	+	+	+	+	+	+									+	+	+	+	+		
Mammary gland M + + M + M + M + M M M M + + M M + + M +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	M	+	+	+	+	M	+		•
Mammary gland M + + M + M + M + M M M M + + M M + + M +	Integumentary System													_														
Skin		М	1	+	м	4	м	+	+	м	м	М	М	+	+	М	M	+	+	М	+	+	+	+	м	+		
Basal cell adenoma Basosquamous tumor benign Keratoacanthoma		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Basosquamous tumor benign Keratoacanthoma X Papilloma squamous Subcutaneous tissue, fibroma Subcutaneous tissue, fibrous histiocytoma X Musculoskeletal System Bone + + + + + + + + + + + + + + + + + + +		•	•	·	•	•		•	Ċ			•	·		·				•	·	•	•	·	·		•		
Keratoacanthoma Papilloma squamous Subcutaneous tissue, fibroma Subcutaneous tissue, fibrous histiocytoma Musculoskeletal System Bone + + + + + + + + + + + + + + + + + + +																												
Papilloma squamous Subcutaneous tissue, fibroma Subcutaneous tissue, fibrous histiocytoma X X Musculoskeletal System Bone + + + + + + + + + + + + + + + + + + +								х																				
Subcutaneous tissue, fibroma Subcutaneous tissue, fibrous histiocytoma X Musculoskeletal System Bone + + + + + + + + + + + + + + + + + + +																						Х						
Subcutaneous tissue, fibrous																				X		7		,				
histiocytoma X Musculoskeletal System Bone + + + + + + + + + + + + + + + + + + +																							٠.					
Bone + + + + + + + + + + + + + + + + + + +																										X		
Bone + + + + + + + + + + + + + + + + + + +	Musculoskeletal System	· · · · ·					_				_											<u>.</u>						
		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
		,	•	į		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	x	,	ľ	•	,	•		
	lervous System																											

umber of Days on Study	. 7																									
umber of Days on Study		-	,	1	1	2	7	7	7	7	7	2	2	7	7		2	2	2	2	2	2	2	2	7	
	0 2	0 5	3	8	9	2 6	9	9	9	2 9	2 9	2 9	2 9	3 0		3 0	3 0	3 0	3 0	3 1	3 1	3 1	1	3 1	3 1	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
arcass ID Number	3	2	3	3	3	3	3	3	3			3		3			3	3	3	3	4	4	4	4	4	Total
	8	9	7	0	6	3	0	0	1			4	9	2			4	5	5	7	1	1	1	2	2	Tissues
	4	1	3	2	1	2	3	4	1	3	4	2	5	4	5			1	5	2	1	2	5	1	2	Tumors
eneral Body System																										
Tissue NOS																										1
Chemodectoma benign																							•			1
enital System																						-				
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Penis																										1
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	50
Adenoma																					X					4
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
	+	X	+		+ X	+		+	+				+		+				+		+			X	+	50
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	X		X		Λ	^	^	X		^	Х	X		^	^	^	^	^	^	^	^	^		Λ	,	43 6
ematopoietic System																										
Bone marrow	+	+	+	4	_	+	+	+	+	+	+	_	+	+	_	_	_	_	_	_	_	_	_	_	_	50
Lymph node		+	+	+	+	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		_ _	-	50
Lymph node, mandibular	·	+	•	÷	+	+	+	+	+	+	+	+	+	+	+	÷	÷	+	+	+	+	+	+	+	+	50
Lymph node, mesenteric	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	·	+	+	47
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Thymus	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
ntegumentary System					-															-						
Mammary gland	+	+	+	+	+	M	+	+	M	+	M	+	+	M	+	+	+	+	+	+	+	+	+	+	+	35
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Basal cell adenoma																Х										1
Basosquamous tumor benign										Х																1
Keratoacanthoma																										1
Papilloma squamous																										1
Subcutaneous tissue, fibroma				X															X							3
Subcutaneous tissue, fibrous histiocytoma																										1
fusculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Osteosarcoma																										1,

Table A2	
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 300 ppm (continued)

			_											_												
	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	7	7	
Number of Days on Study	3	3	4	5			1	2	2	3	4	6	6	7	7	7	8	8	9	9	9	9	9	0	0	
	1	9	1	2	2	2	7	6	6	5	9	6	8	0	1	2	0	8	1	3	3	4	8	1	2	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Carcass ID Number	3	4	4	3	3	3	3	3			3	4	3			3	2	4	3	3		4	3	4	3	
	2	0	2	0	7	1	2	3	-		9	Ó	7		5	-	9	0	3	_		1	-	0	_	
	2	3	4	1	4	3	1				4	1			4		3							4	2	
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar carcinoma							X																			
Carcinoma, metastatic, Zymbal's gland																										
Fibrous histiocytoma, metastatic, skin																									X	
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Papilloma squamous		X																								
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System		•																								
Eye																		+								
Zymbal's gland																		+								
Carcinoma																		X								
Carcinonia																										
Urinary System																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																										
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions																										
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ '	
Leukemia mononuclear	·		X	X		-			X				X								X					
Lymphoma malignant histiocytic																						Х				

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 300 ppm (continued)

Number of Days on Study	7 0 2	7 0 5	7 1 3	7 1 8	7 1 9	7 2 6	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0			7 3 1	7 3 1	7 3 1		
Carcass ID Number	0 3 8 4	0 2 9 1	0 3 7 3	0 3 0 2	0 3 6 1	0 3 3 2	0 3 0 3	0 3 0 4	0 3 1 1	0 3 2 3	0 3 3 4	0 3 4 2	0 3 9 5	0 3 2 4	0 3 2 5	0 3 4 3	0 3 4 4	0 3 5 1	0 3 5 5	0 3 7 2	0 4 1 1	0 4 1 2	0 4 1 5	0 4 2 1	0 4 2 2	Total Tissues/ Tumors
Respiratory System Lung Alveolar/bronchiolar carcinoma Carcinoma, metastatic, Zymbal's gland Fibrous histiocytoma, metastatic, skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	50 1 1 1
Nose Papilloma squamous Trachea	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•		+			50 1 50
Special Senses System Eye Zymbal's gland Carcinoma																		+ X								1 2 2
Urinary System Kidney Adenoma Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	X		+			+	50 1 50
Systemic Lesions Multiple organs Leukemia mononuclear Lymphoma malignant histiocytic	+ X		+ X		+		* X	+	+	+ X	+ X			+	+	+	+	+	+	+	+	+	+	+	+	50 19 1

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 600 ppm

						***			•			•				2 - 1								•			
Number of Days on Study	s	3 6 8		5 1 9	5 2 2	5 4 2	5 5 8	_	5 9 2	6 1 6	6 3 4	6 4 5	6 5 3	-	6 7 4	7			6 9 5	7 0 2	7 0 3	7 0 9	7 1 2	7 1 5	7 2 9		
,	. ,		_								_						_	_	_	_	_	_	_	_	_		
Name of the Manual of		Ű	0	0	U	0	0	0	-	0	-	0	-	0	-	-	-		-	0	-	-	0	-	0	0	
Carcass ID Number		3	4	3	4	4	4	4	5			4	5				4					4	4	5	4	4	
		4	3	1	5		7			3			3		4										3		
		1	4	5	5	3	1	5	1	Z	3	1	3	2	4	4	4	4	2	1	3	4	1	3	3	3	
llimentary System																											
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large		Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	• .
Intestine large, cecum		Α	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	
Intestine large, colon		Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	
Intestine large, rectum		Α	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	A	+	+	
Adenocarcinoma																										X	•
Intestine small		·A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	
Intestine small, duodenum		A		+	+	+	+	+	+	M		+	+	+	+	+	+	+	+	+	` +	+	+	+	+	+	*
Intestine small, ileum		A		+	+	+	+	+	+	+	+	À	+	+	+	+	+	À	+	+	+	+	+	À	+	+	
Intestine small, jejunum	•	A		+	+	+	+	+	+	+	+	A	+	+	+	+	+	A	+	+	+	. +	+	+	+	+	
Liver		A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cholangioma					-						·		-	-			X		·	•	·	·	·	·	·	•	
Hepatocellular adenoma			Х																								
Hepatocellular adenoma, multiple																											
Mesentery				_	_								_													_	
Pancreas		Δ	_	<u>.</u>	<u>.</u>	+	4	_	_	Δ	+	_	<u>.</u>	+	_	_	_	_	_	1	_	_	_	_	_	·	
Salivary glands			1	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	1	Δ.	1	1	<u>+</u>	<u>,</u>	<u> </u>	+	+	+	+	T	+	+	<u> </u>				
Stomach		, A	, ,	<u>'</u>	<u>.</u>	i	i	i	<u>'</u>	<u>'</u>	<u>'</u>	<u>.</u>			Ţ	i	Ţ	Ţ	Ţ	<u>.</u>	т —	<u> </u>	<u> </u>				
Stomach, forestomach		Δ	<u> </u>	Ţ	<u>.</u>	<u>'</u>	i	i	ż	Ţ	4	i	Ţ	Ţ	i	Ţ	<u>.</u>	<u>.</u>	Ţ	·	<u>'</u>			<u>'</u>	1		
Papilloma squamous		Λ	T	1	1	,	,	'	,	1	7	т	т	т.	7	т.	_	_	Т	7	Т	т		т	7		
Stomach, glandular		Δ	+	_	_		_	_	_	_	1	_	_	_	_	_	_	_	_	_	_	_		_	_	_	
Tongue		Α.		т	т		т		т	т	+	Т	т	т	т	т	_			7	т	т	т	т	т	т	
Squamous cell carcinoma											X																
Tooth											+																
Gingiva, squamous cell carcinoma											X									٠.,			*	•			200
Olligiva, squamous cen caremonia											^																
						•													- 1								· · · · · · · · · · · · · · · · · · ·
Cardiovascular System																											
Blood vessel															+												
Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hemangiosarcoma																					X						
																				·							
Endocrine System																											
Adrenal gland		+	+	+	+	+	+	+	+	+	+	+	+	,+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	
Adrenal gland, medulla		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign																										X	
Bilateral, pheochromocytoma benign																							X				
Islets, pancreatic		Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
					X																						
Adenoma																											

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 600 ppm (continued)

Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0		7 3 0	7 3 0	7 3 0	7 3 0	3	7 3 0	3	3	3	3	3	7 3 1	3	7 3 1	3	3	
Carcass ID Number	0 4 4 3		0 4 9 2	5 0	5 2	5 6	5 6	4 8	4 9	4 9	4 9	5 0	0 5 0 3	5 0	5 1	5 2	4 6	5 3	5 3	5 4	5 4	5 5	5 5	5 5	5 5	Total Tissues Tumors
Alimentary System	•																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large		+		+	·	÷	÷	÷	<u>.</u>	·	·	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	48
Intestine large, cecum	ż	÷	·	<u>.</u>	÷	i	<u>.</u>	÷	÷	i	÷	÷	<u>.</u>	÷	+	+	+	+	<u>.</u>	+	+		+	+	·	47
Intestine large, colon	·	·	·	i	÷	i	÷	Ţ	÷	÷	ì	÷	<u>.</u>	Ţ	<u>.</u>	<u>.</u>	<u>.</u>	·	÷	·	+	+	·	+	+	48
Intestine large, colon	-T	1	4	1			Ţ	<u> </u>	<u>.</u>	<u>.</u>	Ţ	Ţ	Ţ	Ţ	<u>'</u>	+	<u>'</u>	<u> </u>	<u> </u>	<u>,</u>	-	+	<u>.</u>	Ţ	<u>.</u>	47
Adenocarcinoma	7	7	7		т	т	т	г	г	г	r	-	г	•	г	Τ'	т'		т.	17	141	т′	т.	Τ'	r	1
Intestine small						.1		ı	_I.	.1	J.	٠١.	.1.	. الـ	.1.	.1.		.1	.1	.1	_	_		.4.		49
	+	+	+	+	+	+	+	+	+	+		+	+	7	7			T		T.	T-		+	7	7	
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Cholangioma																										1
Hepatocellular adenoma																	X									2
Hepatocellular adenoma, multiple			Х																							1
Mesentery				+									+			+		+								8
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Papilloma squamous				X																						1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	, 48
Tongue																										1
Squamous cell carcinoma																										1
Tooth																										1
Gingiva, squamous cell carcinoma				•																						1
Cardiovascular System												-														
Blood vessel																										1
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										1
Endocrine System																										
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		49
Pheochromocytoma benign										X			X									X		X		5
Bilateral, pheochromocytoma benign			Х							_																2
Islets, pancreatic	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	+	+	49
Adenoma		•	·	•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	,		·	•	•	·	•	1
Parathyroid gland	_				+	+	+	+	+	+	+	4	+	+	+	+	+	4	+	+		4		_	+	49
Luranity rold Bland	т-	-	-	7	т,	т.	т.	- 1	т.	Τ.	т.	т-	т,	т-	- T		7	- 1	-T-	7	~	7		~	- T	47

TABLE A2	
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 600 ppm (c	ontinued)

	S
Number of Days on Study	3 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7
Carcass ID Number	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Endocrine System (continued) Pituitary gland Pars distalis, adenoma Thyroid gland Bilateral, C-cell, adenoma C-cell, adenoma Follicle, adenoma	+ + + + + + + + + + + + + + + + + + +
General Body System None	
Genital System Epididymis Preputial gland Adenoma Prostate Seminal vesicle Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ + + + + + + + + + + + + + + + + + +
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+ + + + + + + + + + + + + + + + + + +
Integumentary System Mammary gland Fibroadenoma Skin Basosquamous tumor benign Keratoacanthoma Subcutaneous tissue, fibroma	+ + M + + + + + + + + + + + + + + + + +
Musculoskeletal System Bone Osteosarcoma	+ + + + + + + + + + + + + + + + + + +

Table A2								
Individual Animal	Tumor	Pathology	of Male	Rats in	the 2-Year	· Feed Stud	ly of Triamterene	: 600 ppm (continued)

Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0		7 3 0	7 3 1		7 3 1	7 3 1	7 3 1	7 3 1	7 3 1		7 3 1		
Carcass ID Number	0 4 4 3	-	4 9	0 5 0 5	5 2	0 5 6 4	5 6	0 4 8 4	4 9	4 9	4 9	5 0	0 5 0 3	5 0	5 1	5 2			0 5 3 5					5			Total Tissues/ Tumors
Endocrine System (continued) Pituitary gland Pars distalis, adenoma Thyroid gland Bilateral, C-cell, adenoma C-cell, adenoma Follicle, adenoma	Х		1 + X		+		+ X + X	+	+ X +					+	+ + X				+ X			+ X +		+			49 9 49 1 8 2
General Body System None				•																	•						
Genital System Epididymis Preputial gland Adenoma Prostate Seminal vesicle Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ + + + + X				+ + + + + X			X + + +	+++	+ + X	+ + + + X		+ + + X		+ + + X	++++	+ + + X	+ + + + X	X + +	X + +	++++		+ + X	+			49 49 3 49 49 49 43 4
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+ + + + +	- + - + - + - +	- + - + - + - +		+ + + + + M	+ + + + + + +	+ + + + +	•	•			+++	+++	+++++	+ + + + +	+ + + + M	+++++	+++++	+++++	+ + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + + +	· + · + · +	-	50 50 50 48 50 41
Integumentary System Mammary gland Fibroadenoma Skin Basosquamous tumor benign Keratoacanthoma Subcutaneous tissue, fibroma					1 +												X +								· +	-	42 1 49 1 1 2
Musculoskeletal System Bone Osteosarcoma	-1	- +	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	- +	-	50

TABLE A2

Number of Days on Study			3 6 8		1	2	5 4 2		8	9	6 · 1 : 6 ·	3		6 5 3	6	7	7	8	8		7 0 2					7 2 9	7 2 9	-	
Carcass ID Number			0 5 4 1	0 4 5 4	0 5 1 5					3	5 3	3	0 (4 : 9 : 1 :	5	5	5 4	2	3	4			0 4 7 3				0 4 3 3			
Nervous System Brain			+	+	+	+	+	+	+	+	+	+	+ .	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Respiratory System Lung Nose Trachea	÷		+ + +	++	, + + +	+ +	+ + + +	+ + +	++++	+ + +	+++++	+ +	+ + +	+++++++++++++++++++++++++++++++++++++++	+ + +	+ + +	+++++	+++	+ + +	+++	++++	+ + +	+ + +	+++	++++	++++	++++	•	
Special Senses System Ear Pinna, fibrosarcoma Eye						+															·						+		
Jrinary System Kidney Urinary bladder Adenoma		,	+ A	++	+	++	+++	+++	+ +	+ +	+ +		+ M	+ +	+ M	+	+++		+	+ + X	+++	+++	+	+	++	+++	++	•	
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant			+ X	+ X	+ X	+	,+	+ X	,+, X	+ X	<u>,</u> +	+	+ X	+	+	+	+	+	+	+	+	+	+	, ₋ +	+,	+	 +	. = 114	

TABLE A2
Individual Animal Tumor Pathology of Male Rats in the 2-Year Feed Study of Triamterene: 600 ppm (continued)

		_	_		_	_			_	_							_	_	_				$\overline{}$	_	_			
Number of Days on Study	 7 2 9	: :		7 2 3	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	_		7 3 1	7 3 1	
Carcass ID Number	. 0		4 8	4	5	5	0 5 6 4	6	-	0 4 9 3	0 4 9 4	0 4 9 5	0			0 5 1 4	0 5 2 1		0 5 3 4	0 5 3 5	4	0 5 4 5		5	1	0 5 5 4	5	Total Tissu Tumo
Nervous System Brain		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	+ -	+	+	50
Respiratory System Lung Nose Trachea	-	++.	+ + +	+ + +	+++	+ + .+	+++	++++	+	++++	+++++	++++	++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++	++++	++++	++++	++++	++++	+++++	+++	· +	+ +	++++	++++	50 50 50
Special Senses System Ear Pinna, fibrosarcoma Eye														+ X														1 1 2
Urinary System Kidney Urinary bladder Adenoma	-	+	+	+	+	+	+	+	+	+	+	+	+	- +	+ +	+	+	+	+	+	+	+	- +	- +	+	+	+	50 47 1
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant		+	•	+ X		+	+ x	+ X		+	+ X		+	- +	- + X		+	+ X		+		+ X		+ +	+	+	+ X	50 18 1

TABLE A3
Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene

•	0 ppm	150 ppm	300 ppm	600 ppm
Adrenal Medulla: Benign Pheochromocytoma	·····			
Overall rates ^a	9/50 (18%)	11/50 (22%)	8/50 (16%)	7/49 (14%)
Adjusted rates ^b	32.6%	38.1%	29.0%	25.7%
Terminal rates ^c	7/25 (28%)	8/25 (32%)	3/19 (16%)	6/26 (23%)
First incidence (days)	659	674	668	712
Life table tests ^d	P=0.238N	P=0.403	P=0.556	P=0.359N
Logistic regression tests ^d	P = 0.227N	P=0.431	P=0.469N	P=0.368N
Cochran-Armitage test ^d	P = 0.270N			. 0.50011
Fisher exact test ^d		P = 0.402	P = 0.500N	P = 0.410N
Adrenal Medulla: Benign or Malignant Pheoch	romocytoma			
Overall rates	10/50 (20%)	12/50 (24%)	8/50 (16%)	7/49 (14%)
Adjusted rates	36.4%	41.8%	29.0%	25.7%
Terminal rates	8/25 (32%)	9/25 (36%)	3/19 (16%)	6/26 (23%)
First incidence (days)	659	674	668	712
Life table tests	P=0.158N	P=0.405	P=0.561N	P=0.263N
Logistic regression tests	P=0.145N	P = 0.431	P = 0.368N	P=0.271N
Cochran-Armitage test	P = 0.182N	. 051	1 0.50011	0.2/111
Fisher exact test		P = 0.405	P = 0.398N	P=0.314N
Liver: Hepatocellular Adenoma				
Overall rates	0/50 (0%)	6/50 (12%)	4/50 (8%)	3/49 (6%)
Adjusted rates	0.0%	20.9%	15.6%	9.3%
Terminal rates	0/25 (0%)	4/25 (16%)	2/19 (11%)	2/27 (7%)
First incidence (days)	_e (0,0)	610	668	508
Life table tests	P = 0.368	P=0.020	P=0.054	P=0.140
Logistic regression tests	P=0.355	P=0.021	P=0.069	P=0.108
Cochran-Armitage test	P=0.320	. 0.021	. 0.007	1 -0.100
Fisher exact test	1 0.020	P = 0.013	P = 0.059	P = 0.117
Pancreatic Islets: Adenoma				
Overall rates	2/50 (4%)	1/50 (2%)	5/50 (10%)	1/49 (2%)
Adjusted rates	6.5%	4.0%	14.8%	2.1%
Terminal rates	1/25 (4%)	1/25 (4%)	1/19 (5%)	0/27 (0%)
First incidence (days)	624	729 (T)	572	522
Life table tests	P=0.490N	P=0.494N	P = 0.221	P=0.469N
Logistic regression tests	P=0.565N	P=0.478N	P=0.216	P=0.551N
Cochran-Armitage test	P=0.532N		. 0.210	1 0.55114
Fisher exact test	1 0100011	P = 0.500N	P = 0.218	P=0.508N
Pituitary Gland (Pars Distalis): Adenoma				
Overall rates	8/50 (16%)	6/50 (12%)	7/49 (14%)	9/49 (18%)
Adjusted rates	26.6%	20.2%	22.1%	28.9%
Terminal rates	5/25 (20%)	3/25 (12%)	2/19 (11%)	6/26 (23%)
First incidence (days)	539	653	626	522
Life table tests	P=0.409	P=0.378N	P=0.562N	P=0.551
Logistic regression tests	P=0.393	P=0.336N	P=0.468N	P=0.541
Cochran-Armitage test	P=0.350	1 0.00011	. 0.70011	1 = 0.541
A MARITUM TOUR	1 - 0.550			

TABLE A3
Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
Preputial Gland: Adenoma				
Overall rates	1/50 (2%)	2/50 (4%)	4/50 (8%)	3/49 (6%)
Adjusted rates	3.3%	6.1%	11.3%	11.1%
Terminal rates	0/25 (0%)	1/25 (4%)	1/19 (5%)	3/27 (11%)
First incidence (days)	709	610	531	729 (T)
Life table tests	P = 0.248	P = 0.515	P = 0.181	P = 0.327
Logistic regression tests	P = 0.212	P = 0.517	P = 0.150	P = 0.319
Cochran-Armitage test	P = 0.213			
Fisher exact test		P = 0.500	P = 0.181	P = 0.301
skin: Keratoacanthoma, Basal Cell Adenoma	, or Carcinoma			
Overall rates	3/50 (6%)	5/50 (10%)	3/50 (6%)	1/50 (2%)
Adjusted rates	10.5%	18.2%	10.4%	3.7%
Terminal rates	2/25 (8%)	4/25 (16%)	1/19 (5%)	1/27 (4%)
First incidence (days)	645 `	652	617	729 (T)
Life table tests	P = 0.147N	P = 0.366	P = 0.613	P = 0.279N
Logistic regression tests	P = 0.137N	P = 0.389	P = 0.633N	P = 0.277N
Cochran-Armitage test	P = 0.157N			
Fisher exact test		P = 0.357	P = 0.661N	P = 0.309N
Skin (Subcutaneous Tissue): Fibroma				
Overall rates	1/50 (2%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
Adjusted rates	3.3%	6.2%	12.4%	4.7%
Terminal rates	0/25 (0%)	1/25 (4%)	1/19 (5%)	0/27 (0%)
First incidence (days)	709	611	691	558
Life table tests	P = 0.423	P = 0.510	P = 0.245	P = 0.523
Logistic regression tests	P = 0.409	P = 0.517	P = 0.313	P = 0.482
Cochran-Armitage test	P = 0.404			
Fisher exact test		P = 0.500	P = 0.309	P = 0.500
l'estes: Adenoma				
Overall rates	42/50 (84%)	47/50 (94%)	49/50 (98%)	47/49 (96%)
Adjusted rates	100.0%	100.0%	100.0%	100.0%
l'erminal rates	25/25 (100%)	25/25 (100%)	19/19 (100%)	27/27 (100%
First incidence (days)	488	539	531	508
Life table tests	P = 0.431	P = 0.308	P = 0.038	P = 0.453
Logistic regression tests	P = 0.212	P = 0.564	P = 0.425	P = 0.390
Cochran-Armitage test	P = 0.026			
Fisher exact test		P = 0.100	P = 0.015	P = 0.049
Fhyroid Gland (C-cell): Adenoma				
Overall rates	10/50 (20%)	7/49 (14%)	12/50 (24%)	9/49 (18%)
Adjusted rates	32.1%	21.7%	41.5%	27.9%
Terminal rates	6/25 (24%)	4/25 (16%)	5/19 (26%)	6/27 (22%)
First incidence (days)	488	610	552	519
Life table tests	P = 0.512N	P = 0.282N	P = 0.282	P = 0.424N
Logistic regression tests	P = 0.539N	P = 0.282N	P = 0.464	P = 0.465N
Cochran-Armitage test	P = 0.510			
Fisher exact test		P = 0.314N	P = 0.405	P = 0.520N

TABLE A3
Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
All Organs: Mononuclear Cell Leukemia		<u></u>		
Overall rates	22/50 (44%)	23/50 (46%)	19/50 (38%)	18/50 (36%)
Adjusted rates	57.6%	55.9%	50.0%	49.3%
Cerminal rates	10/25 (40%)	9/25 (36%)	4/19 (21%)	11/27 (41%)
First incidence (days)	508	539 ` ´	541 ` ´	368
ife table tests	P = 0.163N	P=0.552	P = 0.463N	P=0.208N
ogistic regression tests	P = 0.176N	P=0.567	P = 0.279N	P = 0.240N
Cochran-Armitage test	P = 0.178N			
isher exact test		P=0.500	P = 0.342N	P = 0.270N
dl Organs: Benign Neoplasms				٠.
Overall rates	44/50 (88%)	48/50 (96%)	50/50 (100%)	48/50 (96%)
Adjusted rates	100.0%	100.0%	100.0%	100.0%
Cerminal rates	25/25 (100%)	25/25 (100%)	19/19 (100%)	27/27 (100%)
First incidence (days)	484	539	531	508
ife table tests	P=0.486	P=0.378	P=0.061	P=0.529
ogistic regression tests	P = 0.620	P=0.792	P=0.676	P=0.688
Cochran-Armitage test	P = 0.077			
isher exact test		P = 0.134	P = 0.013	P = 0.134
All Organs: Malignant Neoplasms				
Overall rates	26/50 (52%)	29/50 (58%)	24/50 (48%)	23/50 (46%)
Adjusted rates	67.0%	66.9%	59.0%	59.0%
Perminal rates	13/25 (52%)	12/25 (48%)	5/19 (26%)	13/27 (48%)
irst incidence (days)	508 ` ′	366 ` ´	541 ` ′	368
ife table tests	P = 0.188N	P = 0.434	P = 0.560N	P = 0.256N
ogistic regression tests	P = 0.202N	P=0.418	P = 0.321N	P = 0.292N
Cochran-Armitage test	P = 0.208N			
isher exact test		P = 0.344	P=0.421N	P = 0.345N
all Organs: Benign or Malignant Neoplasms				
Overall rates	45/50 (90%)	49/50 (98%)	50/50 (100%)	50/50 (100%)
Adjusted rates	100.0%	100.0%	100.0%	100.0%
Perminal rates	25/25 (100%)	25/25 (100%)	19/19 (100%)	27/27 (100%)
First incidence (days)	484	366	531	368
ife table tests	P = 0.437	P=0.386	P = 0.084	P = 0.475
ogistic regression tests	P=0.138	P=0.366	P = 0.638	P=0.266
Cochran-Armitage test	P=0.009			
isher exact test		P = 0.102	P = 0.028	P = 0.028
colore colored term		3 0.202		

⁽T)Terminal sacrifice

Not applicable; no neoplasms in animal group

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, bone marrow, brain, epididymis, heart, kidney, larynx, liver, lung, nose, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, testes, thyroid gland, and urinary bladder; for other tissues, denominator is number of animals necropsied.

Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Observed incidence at terminal kill

Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in a dose group is indicated by N.

Table A4 Historical Incidence of Liver Neoplasms in Untreated Male F344/N Rats $^{\rm a}$

•	Incidence in Controls									
Study	Hepatocellular Adenoma	Hepatocellular Carcinoma	Hepatocellular Adenoma or Carcinoma							
Historical Incidence at Battelle Columbus	s Laboratory									
2,4-Dichlorophenol	4/50	3/50	5/50							
5,5-Diphenylhydantoin	0/50	0/50	0/50							
Ethylene thiourea	0/50	0/50	0/50							
Polybrominated biphenyls (Firemaster FF-1®)	1/50	0/50	1/50							
Overall Historical Incidence										
Total	19/799 (2.4%)	7/799 (0.9%)	24/799 (3.0%)							
Standard deviation	2.9%	1.8%	3.4%							
Range	0%-8%	0%-6%	0%-10%							

^a Data as of 3 April 1991

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene^a

	0 ppm	150 ppm	300 ppm	600 ppm
Disposition Summary				
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
15-Month interim evaluation	10	10	10	10
2-Year study				
Early deaths				
Moribund	18	20	18	17
Natural deaths	4	5	13	6
Accidental deaths	3			
Survivors			40	
Terminal sacrifice	25	25	19	27
Animals examined microscopically	70	70	70	70
3-Month Interim Evaluation				
Alimentary System				
Intestine large, colon	(10)			(10)
Parasite metazoan	2 (20%)			1 (10%)
Liver	(10)			(10)
Periportal, inflammation, chronic	2 (20%)			(10)
Pancreas	(10)			(10) 1 (10%)
Acinus, atrophy	(10)			(10%)
Salivary glands	(10)			(10)
Acinus, parotid gland, cytoplasmic alteration, focal				1 (10%)
Acinus, parotid gland, vacuolization				1 (1070)
cytoplasmic, focal				1 (10%)
Stomach, forestomach	(10)		(1)	(10)
Inflammation, focal, chronic	1 (10%)		(-)	()
Inflammation, subacute, focal	1 (10%)			
Epithelium, acanthosis, focal	2 (20%)			
Epithelium, hyperkeratosis, focal	2 (20%)		1 (100%)	
Stomach, glandular	(10)			(10)
Inflammation, subacute, focal	1 (10%)			
Mucosa, hyperplasia, focal	1 (10%)			
Cardiovascular System				
Blood vessel				(1)
Aorta, inflammation, focal,				
chronic				1 (100%
Heart	(10)			(10)
Myocardium, inflammation,	A /AAA*\			0 (000)
multifocal, chronic	9 (90%)			3 (30%)
Endocrine System				(4.5)
Adrenal gland, cortex	(10)			(10)
Hyperplasia, nodular	1 (10%)	•		
General Body System				

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
3-Month Interim Evaluation (continued)	·		· .
Genital System				
Preputial gland	(10)			(10)
Inflammation, chronic				1 (10%)
l'estes	(10)			(10)
Right, interstitial cell, hyperplasia Right, seminiferous tubule, atrophy				1 (10%) 1 (10%)
Hematopoietic System				
ymph node, mandibular	(10)			(10)
Infiltration cellular, histiocyte	2 (20%)			
Lymph node, mesenteric	(10)			(9)
Infiltration cellular, histiocyte	7 (70%)			5 (56%)
Integumentary System None				
Nervous System None		•		
Respiratory System				
Lung	(10)			(10)
Alveolus, hemorrhage, multifocal				1 (10%)
Artery, mineralization, focal	4 (400)			1 (10%)
Bronchus, foreign body, single Bronchus, epithelium,	1 (10%)	•		
hyperplasia, multifocal	1 (10%)			
Interstitium, inflammation,	1 (10%)			
focal, chronic				1 (10%)
Peribronchial, inflammation, focal,		•		- (10,0) -
chronic				1 (10%)
Peribronchiolar, inflammation,				` '
multifocal, chronic	4 (40%)			
Nose Sinus, inflammation, chronic active	(10) 1 (10%)			(10)
Special Senses System				
Special Senses System Harderian gland	(2)			(1)

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

$(x_i,x_i) \in S_{i+1} \times \{x_i,x_i\}$	0 ppm	150 ppm	300 ppm	600 ppm
3-Month Interim Evaluation (continued)	· ,	•		
Urinary System			•	•
Kidney	(10)			(10)
Interstitial tissue, inflammation,				
multifocal, chronic	4 (40%)			(4.0)
Urinary bladder Lumen, hemorrhage	(10) 2 (20%)			(10) 3 (30%)
Edition, nemorriage	2 (20%)	•		3 (30%)
5-Month Interim Evaluation		••		
Mimentary System				
ntestine large, colon	(10).	(1)	•	(10)
Parasite metazoan	1 (10%)			1 (10%)
Liver	(10)	(6)	(5)	(10)
Basophilic focus		3 (50%)	2 (40%)	4 (40%)
Clear cell focus Degeneration, cystic		1 (17%)	1 (20%)	4 (40%)
Eosinophilic focus		1 (17%)		1 (10%)
Hepatodiaphragmatic nodule		2 (33%)	1 (20%)	1 (1070)
Inflammation, granulomatous	3 (30%)	- (00/0)	2 (40%)	,
Mixed cell focus	\		1 (20%)	2 (20%)
Necrosis, coagulative	•	1 (17%)	, ,	` ,
Mesentery		(1)	(2)	
Inflammation, chronic	44.01			2 (100%)
Pancreas	(10)	(1)		(10)
Acinus, atrophy Duct, ectasia	2 (20%)			1 (10%)
Stomach, glandular	(10)	(1)		1 (10%) (10)
Mucosa, mineralization	1 (10%)	(-)		(10)
Cardiovascular System				
Blood vessel				(1)
Aorta, inflammation, chronic				1 (100%)
Heart	(10)	(10)	(10)	(10)
Coronary artery, inflammation,	• •		` '	` '
chronic		1 (10%)		
Myocardium, degeneration,				
multifocal	6 (60%)	7 (70%)	6 (60%)	10 (100%)
Endocrine System	S			
Adrenal gland, cortex	(10)	(1)		(10)
Angiectasis	• •	1 (100%)		
ituitary gland	(10)	(2)		(10)
Pars distalis, cyst				1 (10%)
Pars distalis, hyperplasia,			r	4 /4 ***
nodular	. (10)	(1)		1 (10%)
Thyroid gland C-cell, hyperplasia	(10)	(1)		(10) 8 (80%)
с-сен, пурстріавіа	10 (100%)			8 (80%)
General Body System				
None				

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ррт	150 ppm	300 ppm	600 ppm
5-Month Interim Evaluation (continu	ed)			
Genital System	·			
Preputial gland	(10)	(1)	(1)	(8)
Hyperplasia	()	1 (100%)	• • • • • • • • • • • • • • • • • • • •	
Inflammation, chronic	5 (50%)	1 (100%)		5 (63%)
Prostate	(10)	(1)		(10)
Inflammation, chronic	5 (50%)	(-)		1 (10%)
Testes	(10)	(1)	(6)	(10)
Seminiferous tubule, hypoplasia	1 (10%)	(-)	(9)	(==)
Hematopoietic System				
Lymph node	(10)	(1)		(10)
Mediastinal, pigmentation,				-
hemosiderin	1 (10%)			
Lymph node, mandibular	(10)	(1)		(10)
Hyperplasia, lymphoid	1 (10%)	` '		. ,
Sinus, ectasia				2 (20%)
Lymph node, mesenteric	(10)	(1)		(10)
Infiltration cellular, mononuclear	\-·/	` '		` /
cell		1 (100%)		
Spleen	(10)	(1)		(10)
Fibrosis	(/	(-)		1 (10%)
Hematopoietic cell proliferation		1 (100%)		- (/)
Thymus	(10)	(1)		(10)
Atrophy	()	1 (100%)		(()
Arteriole, giant cell		(/		1 (10%)
Integumentary System None				
Musculoskeletal System			,	
Bone	(10)	(1)		(10)
Femur, osteopetrosis	. ,	.,		1 (10%)
Nervous System				
None		•		
Respiratory System				
Lung	(10)	(1)		(10)
Interstitium, inflammation,				
chronic				1 (10%)
Special Senses System				

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
15-Month Interim Evaluation (continuation)	nued)			
Urinary System	,			
Kidney	(10)	(1)	(2)	(10)
Cyst	()	. (-)	1 (50%)	(10)
Nephropathy, multifocal	10 (100%)	1 (100%)	2 (100%)	10 (100%)
2-Year Study				,
Alimentary System				
Esophagus	(50)	(50)	(50)	(50)
Dilatation			ì (2%)	(/
ntestine large, cecum	(49)	(48)	(49) ` ´	(47)
Edema		1 (2%)		
Inflammation, chronic	1 (2%)			
Parasite metazoan	4 /88/		2 (4%)	
Ulcer	1 (2%)	(50)	(40)	1 (2%)
ntestine large, colon Edema	(50)	(50)	(48)	(48)
Mineralization	1 (2%)			1 (2%)
Parasite metazoan	1 (270)	1 (2%)	5 (10%)	
ntestine large, rectum	(49)	(47)	(49)	(47)
Edema	1 (2%)	1 (2%)	(- /	
Mineralization	1 (2%)	` '		4
Parasite metazoan	1 (2%)	3 (6%)	2 (4%)	2 (4%)
ntestine small, duodenum	(50)	(49)	(50)	(48)
Ulcer		1 (2%)	1 (2%)	
ntestine small, ileum	(49)	(49)	(48)	(46)
Mineralization	1 (2%)	(40)	(40)	(45)
ntestine small, jejunum Ulcer	(48)	(49) 1 (2%)	(49)	(47)
Liver	(50)	(50)	(50)	(49)
Angiectasis, focal	(30)	2 (4%)	(50)	1 (2%)
Bacterium	1 (2%)	2 (1/0)	1 (2%)	1 (270)
Basophilic focus	16 (32%)	10 (20%)	3 (6%)	19 (39%)
Clear cell focus	4 (8%)	5 (10%)	4 (8%)	7 (14%)
Degeneration, cystic	10 (20%)	6 (12%)	10 (20%)	8 (16%)
Eosinophilic focus	2 (4%)	3 (6%)	2 (4%)	8 (16%)
Fatty change		2 (4%)		
Fibrosis, focal		0 (40%)	0 ((#)	1 (2%)
Hepatodiaphragmatic nodule		2 (4%)	3 (6%)	3 (6%)
Hyperplasia Inflammation, granulomatous	4 (8%)	3 (6%)	5 (10%) 3 (6%)	10 (20%)
Mixed cell focus	7 (0/0)	6 (12%)	8 (16%)	2 (4%) 12 (24%)
Necrosis, coagulative	2 (4%)	1 (2%)	4 (8%)	12 (24%) 1 (2%)
Sinusoid, congestion	- (1/0)	1 (2%)	. (0/0)	- (270)
Mesentery	. (4)	(4)	(3)	(8)
Inflammation, chronic	1 (25%)		\-/	(-)
Pigmentation, hemosiderin	` /	•		1 (13%)
Fat, necrosis	3 (75%)	2 (50%)	3 (100%)	5 (63%)
Pancreas	(50)	(50)	(50)	(48)
Ectopic tissue	•		1 (2%)	1 (2%)
Acinus, atrophy	14 (28%)	19 (38%)	17 (34%)	15 (31%)
Artery, inflammation, chronic	14 (28%)	6 (12%)	11 (22%)	12 (25%)
Salivary glands	(50)	(49)	(50)	(50)
Periductular, fibrosis			1 (2%)	

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
Alimentary System (continued)				
Stomach, forestomach	(50)	(50)	(50)	(49)
Acanthosis	(30)	(30)	3 (6%)	4 (8%)
Hyperkeratosis			3 (6%)	4 (8%)
Inflammation, chronic		2 (4%)	1 (2%)	2 (4%)
Mineralization	2 (4%)	2 (470)	1 (2%)	2 (470)
Ulcer	2 (4%)	6 (12%)		3 (6%)
			2 (4%)	3 (6%)
Stomach, glandular Inflammation, chronic	(50)	(50)	(50)	(48)
· ·	4 (8%)	6 (120%)	1 (2%)	2 (60%)
Ulcer	8 (16%)	6 (12%)	4 (8%)	3 (6%)
Mucosa, mineralization	6 (12%)	3 (6%)	7 (14%)	4 (8%)
Tongue	(1)		(1)	(1)
Acanthosis	1 (100%)			
Hyperkeratosis	1 (100%)	(1)	41)	
Tooth	(1)	(1)	(1)	
Peridontal tissue, inflammation,				
chronic		1 (100%)		
Pulp, inflammation, suppurative		1 (100%)		•
Cardiovascular System				
Blood vessel	(1)	(3)	(3)	(1)
Aorta, mineralization	1 (100%)	3 (100%)	3 (100%)	1 (100%)
Heart	(50)	(50)	(50)	(50)
Atrium, dilatation	1 (2%)	(30)	(30)	(30)
Atrium, thrombus	1 (2%)		1 (2%)	
Myocardium, degeneration		14 (00%)		26 (720)
	34 (68%)	44 (88%)	42 (84%)	36 (72%)
Myocardium, inflammation, suppurative	1 (2%)			
	` ,	2 (40%)	2 (60%)	2 ((0))
Myocardium, mineralization	2 (4%)	2 (4%)	3 (6%)	3 (6%)
Valve, inflammation, chronic active	1 (2%)			
Endocrine System				
Adrenal gland, cortex	(50)	(50)	(50)	(50)
Ectopic tissue		ì (2%)	· <i>'</i>	• •
Hemorrhage	1 (2%)	` ,		
Hyperplasia	8 (16%)	14 (28%)	18 (36%)	14 (28%)
Adrenal gland, medulla	(50)	(50)	(50)	(49)
Hyperplasia	12 (24%)	14 (28%)	16 (32%)	6 (12%)
Infarct	1 (2%)	1 (2%)	` /	` ,
Parathyroid gland	(46)	(46)	(50)	(49)
Hyperplasia	4 (9%)	3 (7%)	11 (22%)	8 (16%)
Pituitary gland	(50)	(50)	(49)	(49)
Abscess	()	()	1 (2%)	(17)
Pars distalis, cyst		2 (4%)	- (=/0)	
Pars distalis, hyperplasia	10 (20%)	5 (10%)	7 (14%)	6 (12%)
Pars intermedia, cyst	10 (2070)	1 (2%)	/ (17/0)	0 (12/0)
Thyroid gland	(50)	(49)	(50)	(49)
C-cell, hyperplasia	(50)		(50)	(49)
	33 (66%)	32 (65%)	28 (56%)	36 (73%)
Follicle, dilatation	3 (6%)	2 (4%)		1 (2%)

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
General Body System				
None				
			·	
Genital System				
Epididymis	(50)	(50)	(50)	(49)
Granuloma sperm		1 (2%)		
Inflammation, chronic		1 (2%)	1 (2%)	
Inflammation, suppurative		1 (2%)		
Preputial gland	(50)	(50)	(50)	(49)
Hyperplasia		2 (4%)	3 (6%)	
Inflammation, chronic	39 (78%)	38 (76%)	40 (80%)	41 (84%).
Duct, dilatation	(40)	1 (2%)	(50)	//0
Prostate	(48)	(48)	(50)	(49)
Cyst	22 (400)	19 (050)	1 (2%)	00 (45%)
Inflammation, suppurative	23 (48%)	17 (35%)	13 (26%)	22 (45%)
Seminal vesicle	(49)	(48)	(50)	(49)
Inflammation, suppurative	1 (2%)	2 (4%)	(50)	(40)
Testes	(50)	(50)	(50)	(49)
Necrosis, coagulative	1 (2%)	1 (20%)	1 (20%)	1 (20%)
Interstitial cell, hyperplasia Seminiferous tubule, atrophy	4 (8%) 12 (24%)	1 (2%)	1 (2%)	1 (2%)
Schilliterous tubule, attrophy	12 (24%)	15 (30%)	12 (24%)	7 (14%)
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Hyperplasia, histiocytic	` /	` '	` '	1 (2%)
Lymph node	(50)	(50)	(50)	(50)
Mediastinal, pigmentation,	` '	` '	` '	` /
hemosiderin			1 (2%)	
Mediastinal, sinus, ectasia	1 (2%)	1 (2%)	` '	1 (2%)
Renal, ectasia	` '	` '	2 (4%)	` ,
Renal, sinus, ectasia		1 (2%)	` '	
Lymph node, mandibular	(50)	(49)	(50)	(50)
Hyperplasia, plasma cell	1 (2%)	2 (4%)	í (2%)	
Sinus, ectasia	` '	1 (2%)	` ,	•
Lymph node, mesenteric	(48)	(47) ` ´	(47)	(48)
Hyperplasia, plasma cell	, ,	ì (2%)	, ,	. ,
Infiltration cellular, histiocyte		` '	1 (2%)	
Sinus, ectasia		3 (6%)	1 (2%)	1 (2%)
Spleen	(50)	(50)	(50)	(50)
Depletion lymphoid	1 (2%)	• •		
Fibrosis	4 (8%)	6 (12%)	4 (8%)	7 (14%)
Hematopoietic cell proliferation	1 (2%)	1 (2%)	1 (2%)	` /
Hyperplasia, lymphoid	` '	1 (2%)	` ,	
Infarct	1 (2%)	1 (2%)	1 (2%)	4 (8%)
Inflammation, granulomatous	` '	` '	1 (2%)	
Thymus	(42)	(46)	(46)	(41)
Ectopic parathyroid gland	• •	ì (2%)	• •	
Ectopic thyroid		1 (2%)		
Inflammation, chronic		1 (2%)		
Artery, mineralization		•	1 (2%)	

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				-
Integumentary System		•		
Mammary gland	(36)	(37)	(35)	(42)
Hyperplasia, cystic	17 (47%)	Š (14%)	5 (14%)	8 (19%)
Skin	(49)	(50)	(50)	(49)
Abscess	ì (2%)	2 (4%)	1 (2%)	` /
Cyst epithelial inclusion	` ,	3 (6%)	` '	1 (2%)
Hemorrhage		, ,		1 (2%)
Ulcer		1 (2%)	1 (2%)	` '
Epidermis, acanthosis		1 (2%)		1 (2%)
Epidermis, hyperkeratosis		1 (2%)		1 (2%)
Hair follicle, hyperkeratosis		1 (2%)		
Sebaceous gland, hyperplasia		1 (2%)		
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Osteopetrosis		• •	. ,	ì (2%)
Femur, fibrous osteodystrophy	4 (8%)	3 (6%)	5 (10%)	2 (4%)
Synovial tissue, inflammation,				
suppurative	1 (2%)			1 (2%)
Tarsal, fracture healed				1 (2%)
Nervous System				
Brain	(50)	(50)	(50)	(50)
Gliosis	1 (2%)	()		()
Hydrocephalus	- ()			1 (2%)
Infarct	3 (6%)	1 (2%)	6 (12%)	2 (4%)
Inflammation, suppurative	` /		· · · /	1 (2%)
Hypothalamus, compression	4 (8%)	4 (8%)	2 (4%)	3 (6%)
Spinal cord	• •	(1)	` ,	` /
Lumbar, atrophy		1 (100%)		
Respiratory System			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Lung	(50)	(50)	(50)	(50)
Inflammation, granulomatous	` '	` '	` '	1 (2%)
Alveolus, inflammation, subacute			1 (2%)	2 (4%)
Interstitium, inflammation, chronic	2 (4%)	2 (4%)	3 (6%)	3 (6%)
Interstitium, mineralization	2 (4%)	2 (4%)	2 (4%)	- (***)
Vose	(50)	(50)	(50)	(50)
Fungus	1 (2%)	V -7	(- · /	1 (2%)
Nares, foreign body	` '		1 (2%)	- (-,0)
Nares, inflammation, suppurative	3 (6%)		2 (4%)	2 (4%)
Гrachea	(50)	(50)	(50)	(50)
Inflammation, subacute	• •		1 (2%)	` /

TABLE A5
Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)			· ·	
Special Senses System	att a constant		,	
Ear	(2)			(1)
Middle ear, abscess	ì (50%)	•		• •
Eye	(3)	(2)	(1)	(2)
Phthisis bulbi	1 (33%)			
Cornea, inflammation, necrotizing	•		1 (100%)	and the second
Cornea, mineralization	1 (33%)	•		1 (50%)
Lens, cataract	1 (33%)	1 (50%)		1 (50%)
Sclera, mineralization		1 (50%)		
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Cyst	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Hydronephrosis	1 (2%)			
Inflammation, suppurative	1 (2%)			
Nephropathy	47 (94%)	49 (98%)	50 (100%)	49 (98%)
Urinary bladder	(49)	(47)	(50)	(47)
Ectasia			1 (2%)	
Hemorrhage			1 (2%)	
Inflammation, necrotizing	1 (2%)			
Inflammation, suppurative	1 (2%)			

^a Number of animals examined microscopically at site and number of animals with lesion

APPENDIX B SUMMARY OF LESIONS IN FEMALE RATS IN THE 2-YEAR FEED STUDY OF TRIAMTERENE

TABLE B1	Summary of the Incidence of Neoplasms in Female Rats	
	in the 2-Year Feed Study of Triamterene	118
Table B2	Individual Animal Tumor Pathology of Female Rats	
	in the 2-Year Feed Study of Triamterene	122
TABLE B3	Statistical Analysis of Primary Neoplasms in Female Rats	
	in the 2-Year Feed Study of Triamterene	146
Table B4	Historical Incidence of Liver Neoplasms in Untreated Female F344/N Rats	
	Summary of the Incidence of Nonneoplastic Lesions in Female Rats	
	in the 2-Year Feed Study of Triamterene	151

TABLE B1
Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene^a

	0 ppm	150 ppm	300 ppm	600 ppm
Disposition Summary				
Animals initially in study	70	70	70	70
3-Month interim evaluation ^b	10	10	10	10
15-Month interim evaluation	10	10	10	10
2-Year study				
Early deaths				
Moribund	17	11	12	18
Natural deaths	4	5	4	3
Survivors				
Terminal sacrifice	29	34	34	29
Animals examined microscopically	70	70	70	70
15-Month Interim Evaluation Alimentary System None				
Cardiovascular System None				
Endocrine System				
Pituitary gland Pars distalis, adenoma	(10) 1 (10%)	(3) 1 (33%)	(2)	(10)
General Body System None			·	
Genital System			·	
Uterus	(10)	(1)		(10)
Polyp stromal	1 (10%)	ì (100%)		
Hematopoletic System None				
Integumentary System Mammary gland Fibroadenoma	(9) 1 (11%)			(9)
Musculoskeletal System				
None			· .	
Nervous System				

TABLE B1
Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
15-Month Interim Evaluation (continued	1			
Respiratory System	•,		•	
None				n de la companya de La companya de la co
				tale te
Special Senses System				
Ear Pinna, schwannoma malignant				(1) 1 (100%)
II.: C				
Urinary System None				
2-Year Study			· · · · · · · · · · · · · · · · · · ·	
Alimentary System				
Liver	(50)	(50)	(50)	(50)
Hepatocellular adenoma	` '	` '		ì (2%)
Hepatocellular adenoma, multiple				1 (2%)
Mesentery	(3)	(2)	(3)	(1)
Pancreas	(50)	(50)	(50)	(50)
Stomach, forestomach	(50)	(50)	(50)	(50)
Stomach, glandular	(50)	(50)	(50)	(50)
Cardiovascular System	······································			
Heart	(50)	(50)	(50)	(50)
Endocrine System				
Adrenal gland, cortex	(50)	(50)	(50)	(50)
Adenoma	2 (4%)	(50)	1 (2%)	(50)
Adrenal gland, medulla	(50)	(50)	(50)	(50)
Pheochromocytoma malignant	ì (2%)	ì (2%)	()	
Pheochromocytoma benign	` '	1 (2%)		1 (2%)
slets, pancreatic	(50)	(50)	(50)	(50)
Adenoma	3 (6%)	` '	2 (4%)	1 (2%)
ituitary gland	(50)	(50)	(50)	(50)
Pars distalis, adenoma	21 (42%)	20 (40%)	25 (50%)	28 (56%)
Pars distalis, carcinoma		1 (2%)		,
Pars intermedia, adenoma		1 (2%)		
Thyroid gland	(50)	(50)	(50)	(50)
C-cell, adenoma	5 (10%)	11 (22%)	5 (10%)	10 (20%)
C-cell, adenoma, multiple			1 (2%)	
C-cell, carcinoma			1 (2%)	
Follicle, adenocarcinoma Follicle, adenoma	•		1 (2%) 1 (2%)	1 (2%)
General Body System	/1>			
Chemodestoma malignant	(1)			
Chemodectoma malignant	1 (100%)			

TABLE B1
Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
No. of Contract Contr		· ·		
2-Year Study (continued)				
Genital System	,			
Clitoral gland	(42)	(49)	(50)	(48)
Adenoma	3 (7%)	3 (6%)	4 (8%)	2 (4%)
Carcinoma	1 (2%)			
Bilateral, adenoma				1 (2%)
Ovary	(50)	(50)	(50)	(50)
Granulosa cell tumor malignant	1 (2%)			
Granulosa cell tumor benign				1 (2%)
Jterus	(50)	(50)	(50)	(50)
Leiomyoma		, ,		2 (4%)
Polyp stromal	4 (8%)	6 (12%)	5 (10%)	5 (10%)
Cervix, squamous cell carcinoma	1 (2%)	` '	` ,	` /
	- (- ^-)	· · · · · · · · · · · · · · · · · · ·		
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Lymph node	(50)	(50)	(50)	(50)
Lymph node, mandibular	(48)	(50)	(49)	(50)
Lymph node, mesenteric	(48)	(48)	(50)	(48)
Spleen	(50)	(50)	(50)	(50)
Thymus	(44)	(46)	(46)	(45)
Mediastinum, schwannoma malignant	1 (2%)	()	(**)	()
Integumentary System				
Mammary gland	(48)	(49)	(49)	(47)
Adenoma	¥ (8%)	` ,	4 (8%)	ì (2%)
Fibroadenoma	15 (31%)	11 (22%)	14 (29%)	12 (26%)
Fibroadenoma, multiple	4 (8%)	5 (10%)	2 (4%)	1 (2%)
Skin	(50)	(50)	(50)	(50)
Keratoacanthoma	()	\ <i>/</i>	· /	1 (2%)
Subcutaneous tissue, fibroma		2 (4%)		- (-/-)
Subcutaneous tissue, fibrosarcoma	1 (2%)	- (. / ~)		•
Subcutaneous tissue, neurofibrosarcoma	- (**/°)			1 (2%)
Subcutaneous tissue, neuronorosateonia	• •		<u> </u>	. (270)
Musculoskeletal System				
Skeletal muscle	Δij			
	(1) 1 (100%)			
Sarcoma	1 (100%)			
Nervous System				
Brain	(50)	(50)	(50)	(50)
		(30)	(30)	.(30)
Peripheral nerve	(1)		(1)	
Sciatic, schwannoma malignant	1 (100%)			

TABLE B1
Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)	* " *****			
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Adenocarcinoma, metastatic, thyroid gland			1 (2%)	
Alveolar/bronchiolar adenoma	1 (2%)	2 (4%)		1 (2%)
Carcinoma, metastatic, thyroid gland			1 (2%)	
Granulosa cell tumor malignant, metastatic,	1 (20)			
ovary Mediastinum, schwannoma malignant	1 (2%) 1 (2%)			
Mediastinali, servanioni mingiani	1 (2/0)			
Special Senses System				
Ear				(1)
Pinna, fibroma			1 (100%)	
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Urinary bladder	(49)	(49)	(50)	(50)
Systemic Lesions				
Multiple organs ^c	(50)	(50)	(50)	(50)
Leukemia mononuclear	8 (16%)	11 (22%)	7 (14%)	9 (18%)
Mesothelioma malignant	1 (2%)	()	, (••,••)	7 (1070)
Nonlage Summan				
Neoplasm Summary Total animals with primary neoplasms ^d				
15-Month interim evaluation	3	2		1
2-Year study	3 46	2 43	42	1 41
Total primary neoplasms	40	43	42	71
15-Month interim evaluation	3	2		1
2-Year study	81	75	7 4	80
Total animals with benign neoplasms				
15-Month interim evaluation	3	2		
2-Year study	40	37	40	37
Total benign neoplasms				
15-Month interim evaluation	3	2		
2-Year study	62	62	65	70
Total animals with malignant neoplasms				
15-Month interim evaluation	1.0	10	•	1
2-Year study	16	13	9	9
Total malignant neoplasms 15-Month interim evaluation				1
2-Year study	19	13	9	1 10
Total animals with metastatic neoplasms	17	13	7	10
2-Year study	1		2	
Total metastatic neoplasms	•		~	

Number of animals examined microscopically at site and number of animals with lesion

No neoplasms were found at the 3-month interim evaluation.

Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms

TABLE B2				
Individual Animal Tumo	r Pathology of Female	e Rats in the 2-Yea	r Feed Study of	Triamterene: 0 ppm

S 3 5 1 4 4 4 4 5 6 6 7 7 5 2 0 3 1 2 5 2 2 0 3 1 2 2 2 2 2 2 2 2 2	7 7 9 1 3 6 0 0 0 6 6 6 3 7 0 2 5 5 +	6 6 6 6 6 6 7 7 7 7 0 1 3 6 0 0 0 0 0 5 6 5 6 5 6 7 5 9 2 5 5 5 2 5 5 5 5 2 5 5 5 5 5 5 5 5	7 8 6 0 0 0 6 6 8 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	9 0 0 6 5 3 8 4 2 + + + + + + + + + + + + + + + + + +	0 0 0 6 6 6 4 5 2 2 2 + + + + + + + + + + + + + + + +	0 0 0 6 5 7 7 8 8 3 1 1 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	0 0 7 8 0 0 5 5 5 7	5 0 6 3 3 5 + + + + + + + + + + + + + + + + +	2 5 5 6 6 1 5 6 6 1 5 6 6 1 5 6 6 1 6 6 1 6 6 1 6 6 1 6 6 1 6 1	0 0 5 5 8 8	9 0 5 9 4 - + + + + + + + + + + + + + + + + + +	9 0 6 0 1 1 + + + + + + + + + + + + + + + + +	-	
Carcass ID Number	1 3 6 0 0 0 6 6 6 3 7 0 2 5 5 + + + + + + +	0 1 3 6 0 0 0 0 0 5 6 5 6 7 5 9 2 5 5 2 5 + + + + + + + + +	0 0 0 6 6 8 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	8 4 0 0 6 5 3 8 4 2 + + + + + + + + + + + + + + + + + +	4 4 0 0 0 6 6 4 5 2 2 + + + + + + + + + + + + + +	5 7 7 0 0 0 6 5 5 1 8 8 3 1 1 + + + + + + + + + + + + + + + + +	7 8 0 0 5 5 5 3 7 2 + + + + + + + + + + + + + + + + + + +	5 0 6 3 3 5 + + + + + + + + + + + + + + + + +	5 9 0 6 1 5 6 1 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1	9 9 9 9 0 0 0 5 5 5 8 8 8 4 5 5 + + + + + + + + + + + + + + + + +	9 0 5 9 4 - + + + + + + + + + + + + + + + + + +	9 0 6 0 1 1 + + + + + + + + + + + + + + + + +		
Carcass ID Number	0 0 0 0 6 6 6 6 3 7 0 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	0 0 0 0 0 0 5 6 5 6 5 6 7 5 9 2 5 5 5 2 5 5 5 2 5 5 5 5 2 5 5 5 5	0 0 6 6 8 4 4 4	0 0 0 6 5 3 8 4 2 + + + + + + + + + + + + + + + + + +	0 0 0 6 6 4 5 2 2 2 + + + + + + + + + + + + + + + +	0 0 0 6 5 1 8 8 3 1 1 + + + + + + + + + + + + + + + + +) 0 0 5 5 5 3 7 2 + + + + + + + + + + + + + + + + + +	0 6 3 5 + + + + + + + + + + + + + + + + + +	0 6 5 5 6 6 5 5 6 6 6 6 6 6 6 6 6 6 6 6	0 0 0 5 5 5 3 8 8 4 5 5 + + + + + + + + + + + + + + + + +	0 5 9 4 - + + - + + - + + - + + - + +	0 6 0 1 1 + + + + + + + + + + + + + + + + +		
Carcass ID Number	6 6 6 3 7 0 2 5 5 +	5 6 5 6 5 6 7 5 9 2 5 5 5 2 5 5 5 2 5 5 5 2 5 5 5 5 2 5 5 5 5 2 5	6 6 8 4 4 4	6 5 3 8 4 2 + + + + + + + + + + + + + + + + + +	6 6 4 5 2 2 2 + + + + + + + + + + + + + + + +	6 5 1 8 8 3 1 1 8 8 8 8 8 8 8 8 8 8 8 8 8 8	+ + + + + + + + + + + + + + + + + + + +	6 3 5 + + + + + + + + + + + + + + + + + +	6 : 1 : 5 · · · · · · · · · · · · · · · · · ·	+ + + + + + + + + + + + + + + + + + + +	5 9 4	6 0 1 + + + + + + + + + + + + + + + + + +		·
Carcass ID Number	6 6 6 3 7 0 2 5 5 +	5 6 5 6 5 6 7 5 9 2 5 5 5 2 5 5 5 2 5 5 5 2 5 5 5 5 2 5 5 5 5 2 5	6 6 8 4 4 4	6 5 3 8 4 2 + + + + + + + + + + + + + + + + + +	6 6 4 5 2 2 2 + + + + + + + + + + + + + + + +	6 5 1 8 8 3 1 1 8 8 8 8 8 8 8 8 8 8 8 8 8 8	+ + + + + + + + + + + + + + + + + + + +	6 3 5 + + + + + + + + + + + + + + + + + +	6 : 1 : 5 · · · · · · · · · · · · · · · · · ·	+ + + + + + + + + + + + + + + + + + + +	5 9 4	6 0 1 + + + + + + + + + + + + + + + + + +		
S 2 0 3 1 2 2 3 1 2 2 3 1 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2	3 7 0 2 5 5 +	7 5 9 2 5 5 5 2 5 + + + + + + + + + + + + + + + + + + +	6 8 4 4	3 8 4 2 + + + + + + + + + + + + + + + + + + +	4 5 2 2 + + + + + + + + + + + + + + + + +	1 8 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	+ + + + + + + + + + + + + + + + + + + +	3 5 + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + +	9 4	0 1 + + + + + + + + + + + + + + + + + +		
Sophagus	2 5 5 +	+ + + + + + + + + + + + + + + + + + +	4 4	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	3 1	+ + + + + + + + + + + + + + + + + + + +	5 + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	4 + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +		
Esophagus + + + + Intestine large + + + + Intestine large, cecum + + + + Intestine large, colon + + + + Intestine samell + + + + Intestine small + + + + Intestine small, duodenum + + + Intestine small, ileum + + + Intestine small, jejunum + + + Liver + + + Mesentery Pancreas + + + Salivary glands + + + Salivary glands + + + Stomach + + + Stomach + + + Stomach, forestomach + + + Tongue + + + Endocrine System	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Esophagus + + + + Intestine large + + + + Intestine large, cecum + + + + Intestine large, colon + + + + Intestine samell + + + + Intestine small + + + + Intestine small, duodenum + + + + Intestine small, ileum + + + + Intestine small, jejunum + + + + Liver + + + Mesentery Pancreas + + + + Salivary glands + + + + Salivary glands + + + + Stomach + + + + Stomach, forestomach + + + + Stomach, glandular + + + + Tongue Cardiovascular System Heart + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine large Intestine large, cecum Intestine large, colon Intestine large, colon Intestine large, rectum Intestine small Intestine small, duodenum Intestine small, ileum Intestine small, jejunum Intestine small Intestine large Inte	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine large, cecum Intestine large, colon Intestine large, rectum Intestine small Intestine small Intestine small, duodenum Intestine small, ileum Intestine small, jejunum Intestine small, duodenum Intestine small	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	. + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine large, colon Intestine large, rectum Intestine small Intestine small, duodenum Intestine small, duodenum Intestine small, ileum Intestine small, jejunum Intestine small, duodenum Intestine small, duodenum Intestine small, duodenum Intestine small, duodenum Intestine small In	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + · + + · + + · + +	+ + + + + + M + + + + +	+ + + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine large, rectum Intestine small Intestine small, duodenum Intestine small, ileum Intestine small, ijejunum Liver Mesentery Pancreas Salivary glands Stomach Stomach Stomach, forestomach Stomach, glandular Tongue Cardiovascular System Heart Heart + + + Endocrine System	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + · + + · + + · + +	+ + + + + + M + + + + +	+ + + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine small + + + + Intestine small, duodenum + + + + Intestine small, ileum + + + + Intestine small, jejunum + + + + Liver + + + + Mesentery Pancreas + + + + Salivary glands + + + + Stomach + + + + Stomach, forestomach + + + + Stomach, glandular + + + + Tongue Cardiovascular System Heart + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + · + + · + + · + +	+ + + + + + M + + + + +	+ + + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine small, duodenum + + + + Intestine small, ileum + + + + Intestine small, jejunum + + + + Liver + + + + Mesentery Pancreas + + + + Salivary glands + + + + Stomach + + + + Stomach, forestomach + + + + Stomach, glandular + + + + Tongue Cardiovascular System Heart + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + · + + · + + · + +	+ + + + + + M + + + + +	+ + + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine small, ileum + + + + Intestine small, jejunum + + + + Liver + + + + Mesentery Pancreas + + + + Salivary glands + + + + Stomach + + + + Stomach, forestomach + + + + Stomach, glandular + + + + Tongue Cardiovascular System Heart + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + · + + · + + · + +	+ + + + + + M + + + + +	+ + + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + + +	+++++++	+ + + + + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Intestine small, jejunum Liver Mesentery Pancreas Salivary glands Stomach Stomach, forestomach Stomach, glandular Tongue Cardiovascular System Heart Heart + + + Endocrine System	+ + + + + + + + + + + +	+ + + + + + + + + + + + + + + +	· + + · + + · + +	+ + + + M + + + + +	+ + + + + + + + + + +	· + + · + + · + +	+ + + + + + + +	+ + + + +	+ + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Liver Mesentery Pancreas + + + + Salivary glands + + + + Stomach Stomach, forestomach Stomach, glandular Tongue Cardiovascular System Heart + + + Endocrine System	+ + + + + + + + + + + +	+ + + + + + + + + + + + + + + +	· + + · + + · + +	+ + + + M + + + + +	+ + + + + + + + + + +	· + + · + + · + +	+ + + + + + + +	+ + + + +	+ + + + +	+ + + + + + + +	· + · + · +	+ + + + + +		
Mesentery Pancreas + + + + Salivary glands + + + + Stomach + + + + Stomach, forestomach + + + + Stomach, glandular + + + Tongue Cardiovascular System Heart + + +	+ + + + + + + + + + + +	+ + + + + + + + + + + +	· + + · + + · + +	+ + M + + +	+ + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + +	+++++	+++++		- + - + - +	+++++		
Pancreas + + + + + Salivary glands + + + + + Stomach + + + + + Stomach, forestomach + + + + + Tongue Cardiovascular System Heart + + + + + + + + + + + + + + + + + + +	+ + + + + + + + +	+ + + + + + + + + + + +	· + + · + +	M + + + + +	+ + + + +	· + +	+ + + + + +	+ + +			+	+ + + +		
Salivary glands + + + + Stomach + + + + Stomach, forestomach + + + + Stomach, glandular + + + + Tongue Cardiovascular System Heart + + + Endocrine System	+ + + + + + + + +	+ + + + + + + + + + + +	· + + · + +	M + + + + +	+ + + + +	· + +	+ + + + + +	+ + +			+	+.		
Stomach Stomach, forestomach Stomach, glandular Tongue Cardiovascular System Heart + + + Endocrine System	+ + + + + + + + + + + + + + + + + + + +	+ + + +	- + + - + +	+ + +	+ +	+ +	+ +	+			+	+.		
Stomach, forestomach + + + + + Stomach, glandular + + + + + Tongue Cardiovascular System Heart + + + + Endocrine System	+ + + + + + + + + + + + + + + + + + + +	+ + + +	+ +	+ +	+ +	+ +	+ +	+			+	+.		
Stomach, glandular + + + + Tongue Cardiovascular System Heart + + + Endocrine System	+ + +													
Tongue Cardiovascular System Heart + + + Endocrine System		+ + + +	• + +	+ +	+ +	+ +	+ +	+	+	+ +	+	+		
Cardiovascular System Heart + + + Endocrine System														
Endocrine System	+ + +	+ + + +	. + +	+ +	+ +	. + -	+ +	+	+	+ +	+	+	·	4
	•			_	,									<u> </u>
Adrenal gland + + + +	+ + +	+ + + +	- + +	+ +	+ +	+ -	+ +	+	+	+ +	+	+		
Adrenal gland, cortex + + + + Adenoma	+ + +	+ + + +	- + +	+ +	+ +	+ -	+ +	+	+	+ +	- +	+		
9 ,	+ + +	+ + + +	+ +	+ +	+ +	+ -	+ +	+	+	+ +	+	+		
Pheochromocytoma malignant	X													
Islets, pancreatic + + +		+ + + +	. + +	+ +	+ +	+ -	+ +	+	+	+ +		+		
Adenoma		X		_							X			
		+ + + +												
Pituitary gland + + + +	+ + +	+ + + +		+ +							- +	+		
Pars distalis, adenoma X			$\mathbf{x} \mathbf{x}$			X	X		\mathbf{X}					
Thyroid gland + + + + C-cell, adenoma	+ + +	+ + + +	- + +	+ +	*+ +	+ -	+ +	+	+	+ +	- ;+	+		
General Body System			<u> </u>	<u> </u>										
Tissue NOS	+													
Chemodectoma malignant	x													

^{+:} Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

	,					•					• •								`							
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
lumber of Days on Study	2	2	2	2	2	3	-	3	3		3	-	-	3					3		3			3		
ambor or Bujo on Stady	9	_	_	9	9	0	0								0											
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Carcass ID Number	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	5	5	6	6	6	6	6	7	7	7	Total
	1														8											Tissue
	2	2													1											Tumo
Mimentary System																	 -									
Esophagus	4	- 4	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	4	- 4	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	4	- +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	4	- +	+ +	- +	: +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	4	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	4	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	4	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	4	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	4	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	4	- 4	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Mesentery									+																	3
Pancreas	4	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	- +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach	4	- +	+ +	+ +	+	+	+	+	+	+	+	+			+		+	+	+	+	+	+	+		+	50
Stomach, forestomach	4	- +	+ +	+ +	+	+	+	+	+	+		+			+				+	+	+	+	•		+	50
Stomach, glandular Tongue	4		- 1	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Cardiovascular System									•																	
Heart	4		+ +	⊢ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System						· · · · · · · · ·																				
Adrenal gland	4		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	4		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma		>	ζ.	X																						2
Adrenal gland, medulla	4		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant																										1
Islets, pancreatic Adenoma	+		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 3
Parathyroid gland	4	-	+ +	+ +	+	+	+	+	+	+	+	+	M	+	M	+	+	+	+	+	+	M	+	+	+	46
Pituitary gland	4	٠ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pars distalis, adenoma	>				X				\mathbf{X}		Х				X		X					\mathbf{X}		X		21
Thyroid gland	4		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+		+	+	50
C-cell, adenoma				Х	X										X	X						X				5
General Body System	•									.,																
Tissue NOS Chemodectoma malignant																										1
Chemodectoma malignant																										1

TABLE B2	,					
Individual Animal 7	Fumor Pathology of	Female Rats in	the 2-Year Feed S	Study of Triamter	ene: 0 ppm	(continued)

Number of Days on Study	5	3	5	5 7	· 7	9	6	7	7	7	7	8	9	0	0	0	0	0	0	1	2	2	2	7 2 9	2		
Carcass ID Number	0 6 5 3	6	7) 3	6	6 0	5 7	6 5	5 9	6 2	6	6 8	6 3	5 8	6 4	6 5	6 1	5 8	5 7	6 3	6 1	5 8	5 8	0 5 9 4	6 0		
Genital System Clitoral gland Adenoma Carcinoma Ovary Granulosa cell tumor malignant Uterus Polyp stromal	+	. 4	- +	+ -	+ +	- +	1 +	- M	+ +	M + +	M + +	+++	+ + +	+ + +	+ + X	+ +	+ + +		+++	x		X		+ + X	+		
Cervix, squamous cell carcinoma Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus Mediastinum, schwannoma malignant	+ + + + +	· + + + + + + + + + + + + + + + + + + +			+ + + + + + + + N	- + - + - + - +	- + - + - + - +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + +	+ + + + +	+ + + + + +	+	+ + + + +	++++	+ + + + +	+ + + + + +	+ + + + M	+ + + + + +	+ + + + +	+ + + + M	+++++	+ + + + + +		+	£	
Integumentary System Mammary gland Adenoma Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibrosarcoma	+ X			2	+ + K + +	+ +	- +		+ × +			\mathbf{X}		X X	x	x				X		+ X +		+	+		
Musculoskeletal System Bone Skeletal muscle Sarcoma	+	- +		+ -	· + +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+ + X		+	+	+		
Nervous System Brain Peripheral nerve Sciatic, schwannoma malignant		- +		+ ·	+ +	+ 4	- +	+	+	+	+	+	+	+	+	+ + X	+	+	+	+	+	+	+	+	+		,

Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0				3	7 3 0				7 3 1					7 3 1		
Carcass ID Number	0 6 1 2	0 6 2 2	0 6 2 3	6	3	6	6	6 4	6 5	6	6	6	6 7	6 7	0 6 8 1	5 8	5 9	6 7	9	6	6	6		0 7 0 4	7	Total Tissues/ Tumors
Genital System Clitoral gland Adenoma Carcinoma Ovary Granulosa cell tumor malignant Uterus Polyp stromal Cervix, squamous cell carcinoma	+ + +	+ + +	+ + +	+	M + +	+	+	+	+	+	+	+	+	+ X	++++	+	+	+	X + .	+	+	+	+	+	+	42 3 1 50 1 50 4 1
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus Mediastinum, schwannoma malignant	+ + + + +	+ + + + +	++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+ + + + +	+ + + + + +	+++++	+ + + + M	+ + + + M	+ + + + + +	+++++	+ + + + + +	+++++	+ + + + + +	+++++	+ + + + + +	+++++	+ + + M + +	+ + + + +	+ + M +	+ + + + +	+ + + + +	+ + + + + +	+++++	50 50 48 48 50 44
Integumentary System Mammary gland Adenoma Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibrosarcoma	+	+	+ X		M +	+	+ x + x	+	+	+	+	+ X +	+	+	+	+ X +	+ X +		+	+ X +	+ X +	+	+	+ X +	+ X +	48 4 15 4 50
Musculoskeletal System Bone Skeletal muscle Sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 1
Nervous System Brain Peripheral nerve Sciatic, schwannoma malignant	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<i>+</i>	50 1 1

																					_ `					
Number of Days on Study	5	5 3 4	5 5 4	5 7 1	5 7 3	5 9 6	6 6 0	6 7 1	6 7 3	6 7 6	6 7 6	6 8 0	6 9 8	7 0 4	7 ,0 4	7 0 4	7 0 5	7 0 7	7 0 8	7 1 5	7 2 5	7 2 9	7 2 9	7 2 9	7 2 9	
Carcass ID Number	0 6 5 3	0 6 2 1	0 7 0 2	0 6 3 2	0 6 7 5	0 6 0 5	0 5 7 5	0 6 5 5	5	6	0 6 6 4	0 6 8 4	0 6 3 4	5	0 6 4 2	0 6 5 2		0 5 8 1	0 5 7 2	3	0 6 1 5	0 5 8 4	0 5 8 5	•		
Respiratory System Lung Alveolar/bronchiolar adenoma Granulosa cell tumor malignant, metastatic, ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Mediastinum, schwannoma malignant Nose Trachea	+	+	X + +	+	+	+	+	+	+	+	+	++	+	+	+	+	+	+	+	+	+	++	+	+	+	
Special Senses System Eye	·										+															
Urinary System Kidney Urinary bladder	+	+	+	++	++	++	+++	++	++	+	+	++	+	+	++	++	++	+	++	+	++	+	++	++	++	
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+	+ X		+	+	+	+ X	+ X	+	+	+	+ X		+	+	+			+ X	+	+ X		+	+	+	

	_					_	_	_	_	_	_	_						_	_	_	_	_	_		_	
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	9	9	9	9	0	0	0	3 0	3 0	3	3 0	3 0	3 0	3	3	3	3	3 1	3	3	3 1	3 1	3 1	3 1	
	9	9	9	9	9	U	U	U	·	U	U	U	U	<u> </u>	U	1	1	1	1	1		1	1		1	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Carcass ID Number	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	5	5	6	6	6	6	6	7	7	7	Total
	1	2	2	2	3	4	4	4	5	6	6	6	7	7	8	8	9	7	9	9	9	9	0	0	0	Tissues/
	2	2	3	4	3	1	3	4	4	1	2	5	1	2	1	3	1	4	2	3	4	5	1	4	5	Tumors
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma											X															1
Granulosa cell tumor malignant,																										_
metastatic, ovary														X												1
Mediastinum, schwannoma malignant																									,	1 50
Nose Trachea	+	. +	+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	+	50 50
									_																	
Special Senses System																										
Eye																						+				2
Urinary System																										*****
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	49
Systemic Lesions					-																					
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Leukemia mononuclear						X																				8
Mesothelioma malignant																										1

General Body System None

TABLE B2 Individual Animal Tumor Pat	tho	log	y o	f Fei	na	le	R	ats	ir	ı tl	hė	2-	Yea	ar i	Fe	ed	St	udy	y o	fТ	`ria	m	ter	en	e: :	15() p	pm	1 (3		- 3	
						5 :	<u> </u>	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		-t	
Number of Days on Study				7			9		-		6			Ó	Ó	Ó	0	1.	1	1	2	2	2	2	2	2	2	2	2			
Number of Days on Study		•		- 6	-										-		8					9		9	9		9	9	9			
· · ·								0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0			
Carcass ID Number				7		3 '		-	-	-	7	7		8	7	7	8	7	7	7		7	7	7			7	-	-			
Curcuss III I (united				4		3 (3				7				1	2			5					
						_					1										1											
Alimentary System								,		,										-												
Esophagus				4	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine large				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			* *
Intestine large, cecum				A		+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+		•	
Intestine large, colon				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	,		
Intestine large, rectum				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+,			•
Intestine small, duodenum				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, ileum				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, jejunum				4	- ;	+	+	+	+	+	+	+	+	+	+	+	Α	. +	+	+	+	+	+	+	+	+	+	+	+			
Liver				4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Mesentery										+																						
Pancreas				4		+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Salivary glands				+	-	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach				+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach				. +		+:	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+	+	+		,	
Stomach, glandular				+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•+	+			
Cardiovascular System	•																															
Heart				+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Endocrine System																																.:
Adrenal gland				. +	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	2		
Adrenal gland, cortex				+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠		
Adrenal gland, medulla				+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Pheochromocytoma malignant																																
Pheochromocytoma benign																																
Islets, pancreatic				-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Parathyroid gland							+	+	+	M		+	+	+	+	+	+	M		+	+	+	+	+	+	+	+	+				
Pituitary gland				-	٠,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				,
Pars distalis, adenoma					•	X					X		X					Х	X		**	X		X			·X	Х				•
Pars distalis, carcinoma				_																	X					• *	•			•	•	
Pars intermedia, adenoma					(_														٠.						
Thyroid gland				+	-	+	+	+	+	+	+		+	+	+	+	+			+	+		+			+	+	+	+			
C-cell, adenoma												X						Х			Х			Х					Х			

General Body System None

TABLE B2
Individual Animal Tumor Pathology of Female Rats in the 2-Year Feed Study of Triamterene: 150 ppm (continued)

Number of Days on Study	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0		7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7· 3 0		7 3 1	7 3 1		7 3 1	3	7 3 1	7 3 1		7 3 1		3	
	. 0	0	0				0	0	0		0		0				0				0			_	0	
Carcass ID Number	7	7	7	7	7	7	7	7	7	7	8		8	-	7	7		8		8	8	8	8	-	8	Total
	6 2	6 3	7 1	7 2	8 2	8 4	8 5	9 1	9 2	9 4	0 1	0 2	0 3	0 4	2 5	7 4		1 5	2 1		2 5		4 1	-	4	Tissues, Tumors
Alimentary System	·																								-	***************************************
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	ť	+	+	+	49
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Mesentery							+																			2
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System											Ť															
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																					_					
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant																				X						1
Pheochromocytoma benign											Х															1
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pars distalis, adenoma	•			X	X		\mathbf{X}	X			Х					Х	X			X		X			X	20
Pars distalis, carcinoma																										1
Pars intermedia, adenoma																										1
Thyroid gland	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	50
C-cell, adenoma	X					X				X						X		Х				X				11

TABLE B2

Number of Days on Study				4 7 6	5 2 2	5 9 2	6 0 0	6 1 1	4	6 6 2	6	7	7 0 0	7 0 1	7 0 8	7 0 8	1	7 1 5	1	2	2	7 2 9								
Carcass ID Number	*:			7	,8 3	6	8	0 7 2 2	2	7	7 2	7	8	3	7	8	7	0 7 7 3	7 5	1	7 1.	1	2	2	5		5	6		
Genital System Clitoral gland Adenoma Ovary Uterus Polyp stromal Vagina				+++	+	++	+++++++++++++++++++++++++++++++++++++++	M + + +	++++	+ + +	+ + +	++++	+ + +	+		+		+++		+++	++++	+++	+++	+	+	+++	+	+		
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus				+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+++++++++++++++++++++++++++++++++++++++	++++++	+ + + + +	+ + + + + +	+++++	+ + + M + +	+++++	+ + + + + +	+ + + + +		+ + + + M	+ + M +	+++++	+ + + + + +	+ + + + +	+ + + + + +	+++++	+ + + + +	+ + + + + +	+ + + + + +	+ + + + +	+ + + + + +		
Integumentary System Mammary gland Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibroma		**		+	. +	+	+	+ *		+ X +	+	+	+	+	+ X +	+	+ X +	+		+	+	+	x		x	x		+ X +		
Musculoskeletal System Bone				+	. +	. +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		<u>-</u>
Nervous System Brain				· +	. +	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Trachea			,	+	· +	· +	+	+	+++	+ X + +	+ + +	+ + +	+ + +	+ + +	+++	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ +	+++	+++	+++	+++	+ + +		
Special Senses System Eye Lacrimal gland	•																				+						-		·	

TABLE B2
Individual Animal Tumor Pathology of Female Rats in the 2-Year Feed Study of Triamterene: 150 ppm (continued)

Number of Days on Study	7 2 9	2		2			7 3 0	7 3 0		3		3		3	3	7 3 1	3	3	3	7 3 1	3	3	3	7 3 1	3	3		
Carcass ID Number	7 6	7	5 '	7 7	7 7	7 8		7 8	7 9	7	7 9	8 0	8 0	8 0	8 0		7 7	8 1	8 1	8 2	8 2	8 2	8 3	8	8 4	8		Total Tissues/ Tumors
Genital System Clitoral gland Adenoma Ovary Uterus Polyp stromal Vagina			+		X	+ + +		+++	++	+ + X	+ + +	+++	+ + +	+++	+	+	++	+	X +	+	+	+	+	+	+	. 4	+	49 3 50 50 6 1
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+ + + + +		++++++	+	+++++	+++++	+++++	+ + + + M			+			+	+	+		+ + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + +	+++++++++++++++++++++++++++++++++++++++	· + · + · + · +		+ + +	50 50 50 48 50 46
Integumentary System Mammary gland Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibroma				X	X		+	+ X +					X		X	X	X			X	+			· +	х			49 11 5 50 2
Musculoskeletal System Bone	4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		ŀ	50
Nervous System Brain			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4		<u> </u>	50
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Trachea	-1 -1 -1		++++	+++	+ + +	+ X + +	+ + +	+ + +	+ + +	+++	+++	+ + +	+++	+ + +	+++	+++	+ + +	+ + +	+ + +	+ + +	+++	+++	+	· +	· + · +		+ + +	50 2 50 50
Special Senses System Eye Lacrimal gland	.A.v.										+				,				-									1 1

TABLE B2

Individual Animal Tumor	Pat	hology	y of	Fen	nale	e F	Rat	s i	n t	he	2-	Ye	ar	Fe	ed	St	ud	y. o	f 7	ria	ım	ter	en	e:	150) p	рņ	1 (c	onti	nued)	
		• • •		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		-	
Number of Days on Study				2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
				9	9	9	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	,		
			-	. 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		-	_
Carcass ID Number				7	7	7	7	7	7	7	7	7	7	8	8	8	8	7	7	8	8	8	8	8	8	8	8	8		Total	
				6	6	7	7	8	8	8	9	9	9	0	0	0	0	2	7	1	1	2	2	2	3	4	4	4		Tissu	
•		٠.,		2	3	1	2	2	4	5	1	2	4	1	2	3	4	5	4	3	5	1	4	5	4	1	2	4		Tumo	rs
Urinary System	•			•													,				_										-
Kidney				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		. •	
Urinary bladder				+	+	+	+	+	+	+	+	+	+	+	+	+	+	·	+	+	+	+	+	+	+	+	+	+		.,,	
Systemic Lesions							-				_					-	_				_										-
Multiple organs				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. · ·		
Leukemia mononuclear				·	X	X	X	·	X	X	X		X	·	·	X		·	X	·	·	·	Ċ		·		X				

Number of Days on Study	7 2 9	7 2 9	7 2 9	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1											
Carcass ID Number	•	7	7	0 7 7 2	0 7 8 2	0 7 8 4	0 7 8 5	0 7 9 1	0 7 9 2	0 7 9 4	0 8 0 1	0 8 0 2	0 8 0 3	0 8 0 4	2	0 7 7 4	0 8 1 3	0 8 1 5	0 8 2 1	2	0 8 2 5	8	•		8	Total Tissues/ Tumors
Urinary System Kidney Urinary bladder	+	+	- +	- +	+	+	+	++				•	•	•	•	•	•	-	+		•	+			+	
Systemic Lesions Multiple organs Leukemia mononuclear	+	- +	- +	+	. +	+	+	+	+	+	+	+ X		+	+	+	+	+	+	+	+	+	+	+	+	50 11

TABLE B2						
Individual Animal T	umor Pathology	of Female	Rats in	the 2-Year	Feed Study	of Triamterene: 300 ppm

				3									6			7		7	7	7	7	7	7	7	7	7	7		
umber of Days on Study															9 6		0 7	2		2 9		2 9	2 9			2 9			
·								_			_				_					*									
arcass ID Number																	0 8												
arcass ID Number			7						8							4			5										
																	3												
limentary System																													
Esophagus			+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, cecum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, colon		,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, rectum	-		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine small			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, duodenum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+		
Intestine small, ileum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ .		
Intestine small, jejunum			+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Liver			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Mesentery																		+											
Pancreas			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Salivary glands	•		+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, forestomach			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, glandular			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Tongue																												•	
Tooth																						+							
	•	 									·			_						-								 	
ardiovascular System																													
Heart			+	+	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
ndocrine System																		-											
Adrenal gland			Ĺ	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_		· _	_	_	_	_		
Adrenal gland, cortex						T	4		T	т Т	т Т		T 	T	T		1	т Т	т Т	T	T.	T		т Т	T				
Adenoma			4		т	•		т	1	•	т	Τ.	-	1	т	•	•	т	7	•	-	т	т	•	Т		т.		
Adrenal gland, medulla			_		_				ı.	_		_	_	_	.1.		_	_		_	_	1.	_	_	_		_		
Islets, pancreatic				+		T	T			T _	.1		+		T		T	T .	T	т Т	T _1	T	T	T	T.	+			
Adenoma			_	т	т	т	т	T	т	Τ.	т	_	. T		т	т	т	т	т	•	7	_	т	т	т	_	т		
Parathyroid gland			+	_	+	_	_	+	ı	_	_	_	+	i	_	_	_	_	_	_	_	_	_	_	_	٠ ـــ	M		
Pituitary gland							+		+	+	T	+		+	T	+	+	+	+	+	+	+	+		+				
Pars distalis, adenoma		٠	Т	т	T	-	-		X					X		Т	-	X	т	-	X	-		-	т	-	X		
Thyroid gland					ı	_	ı	Λ	Ŷ	<u>τ</u>	Λ _	Υ.					+	Λ Λ	_	_	Α.	Υ •	7	_	ı				
			T	+	+	_	Ŧ	+	т	7	+	+	T	+	+	_	_	X		т	_	+	7	т	+	+			
C-cell, adenoma C-cell, adenoma, multiple																		^	^								X		
C-cell, carcinoma																							x						
Follicle, adenocarcinoma Follicle, adenoma																							^						

TABLE B2
Individual Animal Tumor Pathology of Female Rats in the 2-Year Feed Study of Triamterene: 300 ppm (continued)

Number of Days on Study	7 2	7	7 3	7 3	7 3	7	7	7 3	7 3	7	7	7	7 3	7 3	7 3	7	7 3	3	7	7	7	7	7	7 3	7 3	
camosi or bays on occasy	9	9	ō	_	0	_	0	0		0			0													
	0	-	-	_	0	-		0	_	0	0		0		0	0	0	0	-	0	0	0	0	0	0	
Carcass ID Number	8	9	9	9	9	9	9	9	9	9			9		9	9	9	9	-	9	9	9	9	9	9	Total
	9	0	1	1	1	2	3	3	3	4	4	5	5	5	5	6	6	6	7	7	8	8	8	8	8	Tissue
	3	5	1	3	5	3	3	4	5	1	5	1	2	5	5	1	4	5	1	4	1	2	3	4	5	Tumor
limentary System																										
Esophagus	+	+	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	+	+	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	. +	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	. +	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	. +	- +	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	+	٠ +	- +	- +	. +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	. +	- +	- +	+	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	٠ +	- +	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	+	- +	- +	- +	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	+	- +	. +	- +	• +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Mesentery																		+						+		3
Pancreas	+		- +	- +	- +		- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	• +	- +	- +	• +	- +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 50
Stomach	+	- +	- +	- +	• •	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	• •	- +	- +	* *	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular Tongue	7	٠ ٦	- 1	7	- 1		- 7	•	+	1	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	50 1
Tooth																				_			+			2
Cardiovascular System									_						_					_						
Heart	+	- +	- +	- 1	- +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System													****							•						
Adrenal gland	4	- 4	- 1	+ +	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	- 4	- +	- +	- +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma													X													1
Adrenal gland, medulla	4	- 4	- +	+ +	- +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic	+	- +	- 1	- +	- +	+ +			+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	50
Adenoma							X														X					2
Parathyroid gland	4	- +		+ +	- +	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pituitary gland	4	- 4	- +	⊦ +	- +	+ +	- +	. +	+	+		+	+	+	+	+	+	+	+	+	+	+	+		+	50
Pars distalis, adenoma			λ		X			Х	X	. X	X	Х				X					X			X		25
Thyroid gland	4	- +	- +	+ +	- +	+ +	+ +	- +	+	+	+		+		+	+	+	+	+	+	+	+	+	+	+	50
C-cell, adenoma											X		X													5
C-cell, adenoma, multiple																				X						1
C-cell, carcinoma										Х	•															1
Follicle, adenocarcinoma																٠,										1
Follicle, adenoma																X										1

General Body System

None

TABLE B2		
Individual Animal Tumor Pathology of Female Rats	s in the 2-Year Feed Study of	Triamterene: 300 ppm (continued)

																		•								
lumber of Days on Study	7	8	9	1	2	3	5	6	8	8	8	8	9	0	7 0 7	2	2	2	2	2	2	2	2	2	2	
		-			_						_						_									
arcass ID Number	9 7	3	8	8 6	9 1	9	8	8 7	9 7	9 2	9 5	9 7	9	9 4	0 8 6	9 0	8 5	8 5	8 6	8 7	8 7	8 7	8	8	8	
	5	1	1	5	2	2	3	4	2	5	3	3	2	3	3	1	1	3	4	1	3	5	1	4	5	
Senital System																										
Clitoral gland	+	+	+		+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	
Adenoma				X	,											X	,	,	_		_	_				
Ovary	+	+	+	+	+	+	+		+	+	+				+								+	+	+	
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	
Polyp stromal																X										
Iematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mandibular	+	+	+	M	+	+	+	-	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	+	+	+	+	-	+	+	+	+	+	+		+	+	-	+	+	+	+	+	+	+	
Spleen	+	+	+	+	+	+			+	+	+	+			+									+		
Thymus	+	+	+	+	+					+	+	+			+											
Integumentary System Mammary gland Adenoma Fibroadenoma Fibroadenoma, multiple Skin	+	+ x +		+	+			+ X +	+	+	+	+		+ X +	+ X +	+	+ X +	+	+	+	+			+ X +		
Ausculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Peripheral nerve															+											
Spinal cord															+											
Respiratory System																	_									
Lung		_	_	_	_	4	4	_	_	_	_	_	+	4	_	_	_	_	ı	.ـــ	.1.	Д	_	.1.		
Adenocarcinoma, metastatic, thyroid	+	+	+	+	+	+	Τ	Τ.	~	*	7	+	Τ	Τ	+	Τ.	7	+	+	+	+	+	+	+	+	
gland																					X					
Carcinoma, metastatic, thyroid gland Nose				,	,				_		_			_	_	_		,	,						,	
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					+		
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

Number of Days on Study	7 2 9	_	3			7 3 0	7 3 0		7 3 0				7 3 0		3		3	3	3	3	3			7 3 1		
Carcass ID Number	0 8 9 3	9	9	9	9		0 9 3 3		9	4	9 4	5	9 5	8 5	5	9	9 6	9	0 9 7 1	9 7				0 9 8 4	9	Total Tissues, Tumors
Genital System Clitoral gland Adenoma Ovary Uterus Polyp stromal	+	+	X		· +		+ + X	++++	+++	+ + +	+ + +	+ + X	+	+++			X +	+	+ + X		+	+ + +	+++	+	+	50 4 50 50 50
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+++++++++++++++++++++++++++++++++++++++	· + · · · · · · · · · · · · · · · · · ·	- + - + - +	+ + + + + + + +		-	+ + + + +	+ + + + + +	+++++	+++++	+ + + + +	+++++	+++++	+ + + + +	+ + + + +	+++++	+++++	+ + + + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + +	++++++	+ + + + + + +	50 50 49 50 50 46
Integumentary System Mammary gland Adenoma Fibroadenoma Fibroadenoma, multiple Skin		· +		 	- + x x	X	X	+ X +		+ X +		+ X +		X	X				+	X					M +	49 4 14 2 50
Musculoskeletal System Bone	+	- +	- -	⊦ ⊣	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	. +	+	50
Nervous System Brain Peripheral nerve Spinal cord	+		.	⊦ ⊣		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	. +	+	50 1 1
Respiratory System Lung Adenocarcinoma, metastatic, thyroid gland Carcinoma, metastatic, thyroid gland	+	_	- -	+ -	 - +	- +	+	+	+	+ x		+	+	+	+	+	+	+	+	+	+	+	- +	. +	+	50 1 1
Nose Trachea	+	 	⊦ - ⊦ -	+ -	- + - +	- + - +	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	- +	· +	+	50 50

Individual Animai Tumor Pau	iology	OI I	rein	laic		ais	111		IC 2	16	aı	re	cu	Su	uu			1 10		ici	CII	. .	<i>-</i>	, h	Իա	(60	JIII 1110	ieu)	
Number of Days on Study			3 7 8	3 8 3	3 9 7	6 1 9	6 2 8	6 6 3 5	6 6 5 6 2 2	6 6 6 8 2 0	6 8 2	6 8 9	6 8 9	6 9 6	7 0 4	7 0 7	7 2 3	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9			
Carcass ID Number.			0 9 7 5	0 9 3 1	0 8 9	0 8 6 5	0 9 1 2	0 9 8 0 8 2 8	0 (8 8 8 7 3 4	0 0 3 9 7 7 4 2	0 9 2 5	0 9 5 3	0 9 7 3	0 9 2 2	0 9 4 3	0 8 6 3	0 9 0 1	0 8 5 1	0 8 5 3	0 8 6 4	0 8 7 1	0 8 7 3	0 8 7 5	0 8 8	0 8 8 4	0 8 8 5			
Special Senses System Ear Pinna, fibroma Eye			•								,																		_
Jrinary System Kidney Urinary bladder	* 3		, +	+ +	++	<u>_</u> +	+	+ +	+ -	+ +	+ +	+	ı.+	+ ~+	+ .+	+	+	+	++	++	+	++	++	+	+	+			_
Systemic Lesions Multiple organs Leukemia mononuclear			+	`+	+	+ X	+ X	+	+	+ +	+ + < x	+	+	+ X	+	+ X	+	+	+	+	+	+	+	+	+	+			

TABLE B2

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		
Number of Days on Study	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
	9	9	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1		
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	_	
Carcass ID Number	8	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	·9 '		Total
	9	0	1	1	1	2	3	3	3	4	4	5	5	5	5	6	6	6	7	7	8	8	8	8	8		Tissues/
	3	5	1	3	5	3	3	4	5	1	5	1	2	5	5	1	4	5	1	4	1	2	3	4	5		Tumors
Special Senses System Ear									_												+						1
Pinna, fibroma																					x						1
Eye							+						+				+										3
Urinary System		_			-																	_					
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		50
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		50
Systemic Lesions	****	_							_										_								
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		50

TABLE B2					•		
Individual Animal	Tumor Patholo	gy of Female	Rats in the	2-Year Fee	d Study of	Triamterene:	600 ppm

Number of Days on Study	6	0	3	4	4	8	1	2	2	3	4	4	4	8	6 9 5	9	9	0	0	0	1					
Carcass ID Number	. 1 0	0 1	0 5	1 0	0 5	0 6	9 9	0 2	0 9	1 2	0 8	0 3	0 3	9	1 1 2 3	0 3	0 6	0 4	1 0	0 1	0 4	0	0	0 0	0 2	
Mimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	Α	+	+	+	+	+	+	
Liver Hepatocellular adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	
Hepatocellular adenoma, multiple																							X			
Mesentery																			+							
Pancreas													+		+											
Salivary glands															+									+		
Stomach forestomach	7	+	+	+											+											
Stomach, forestomach Stomach, glandular	+	+	+	T											+									+		
Stomach, glandulat	T-		т	_		_		_	т				т	т			т	_	_					т		
Cardiovascular System																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	
Endocrine System																										
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign																		Х								
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																							X			
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	
Pituitary gland	+		+	+	+	+	+	+	+	+	+	+	+	+						+	+	+	+	+	+	
Pars distalis, adenoma	X									X							X					X			X	
Thyroid gland	+	+	+	+	+	+	+	+	+			+		+	+	+	+	+	+	+	+	+			+	
C-cell, adenoma										X	X		X										X			
Follicle, adenoma							•																			

Number of Days on Study	 7 2 9	7 2 9	7 2 9	7 2 9	2	7 3 0		3	3	3	3		3		7 3 0		3	3	3		3	3	3	3	3	
															1											
Carcass ID Number																									1.	
															8 5									4		Tissues, Tumors
Alimentary System				-																						
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular adenoma										X																1
Hepatocellular adenoma, multiple																										1
Mesentery																										1
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System																			,							
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 50
Adrenal gland, medulla Pheochromocytoma benign	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Islets, pancreatic Adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Parathyroid gland	M	! +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pars distalis, adenoma	Х	X	X	X	X	X	X	X	X	X			X				X	X	X		X				X	28
Thyroid gland												+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
C-cell, adenoma	X	X							X					X						X					X	
Follicle, adenoma																				X						1

General Body System

None

-												-		,	-	Ξ,							-	•				•
	4	_		_	-	_	6	6	6	6	6	<u> </u>	<u> </u>	6	6	 6	6	7	7	7	7	7	7	7	7			
										-									-	_			2	2				
		_							-	_													_	9	_			
	_	•	<u> </u>			1		1	1		1	1	1	_	. 1	1	1	1	1	_	1	1	_		1			
	_	1	5																									
	<i>,</i> 2		3		4	3		3	1	1		_	٠		3	1		3	3	3	J	1		<u> </u>	<i></i>			,
								,				-																
	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
																							X					
		•		Х																								
	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +			
	•		•					,	•	•	•		,									•		•				
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4			
	•	•	•	•	•	•		•	•	•	•	•	'	•	•	•	•	•	•	•	•	•	•	•				
							,,							x									Y		Y			
																							^		<u>^</u>			
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
	+	<u>.</u>	÷	<u>.</u>	÷	+	<u>.</u>	<u>.</u>	<u>.</u>	+	÷	<u>.</u>	<u>.</u>	+	<u>.</u>	÷	÷	<u>.</u>	÷	<u>.</u>	+	+	<u>.</u>	·	·			
	·	<u>.</u>	<u>.</u>	<u>.</u>	<u>.</u>	+	+	+	+	м	+	<u>.</u>	+		+	<u>.</u>	+	<u>.</u>	+	+	+	+	+	+	÷			
		<u> </u>	, ,	1	Ĺ	i	i	ż			<u> </u>	i	٠.		i	Ţ	i	i	i	÷		i	i	- 1	i			
					-						+	+	+	+	+	+	+	+	+	M	+	+	+	+	+			
						·					,																	
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	м	+	+			
	•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•	•	•	•	•	•	•••	•	•			
	x	Y							x		x		x							x				x	x			
	Λ	Λ							Λ		7.		^							^				Λ	Λ			
	+	+	+	+	+	+	Ŧ	+	+	+	+	Ŧ	+	+	T	-		+	_	+	_	_	+	_	_			
																	^											
															•													
																												•
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
							_			_		-												_				
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			•
				_													_											
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
																	Х											
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
		4 6 6 1 1 1 0 2 + + + + + + + + + + + + + + + + + +	4 5 6 0 6 9 1 1 1 1 0 0 1 2 2 2 + M + + + + + + + + + + + + + + +	4 5 5 6 0 3 6 9 0 1 1 1 1 0 0 0 1 5 2 2 5 + M + + + + + + + + + + + + M M	4 5 5 5 6 0 3 4 6 9 0 1 1 1 1 1 1 1 1 0 0 1 0 1 5 0 2 2 5 5 + M + + + + + + + + + + + + + + + + +	4 5 5 5 5 6 0 3 4 4 6 9 0 1 2 1 1 1 1 1 1 1 1 1 0 0 1 0 0 1 5 0 5 2 2 5 5 4 + M + + + + + + + + + + + + + + + + +	4 5 5 5 5 5 5 6 0 3 4 4 8 6 9 0 1 2 9 1 1 1 1 1 1 1 1 1 1 1 0 0 1 0 0 0 0 1 5 0 5 6 2 2 5 5 4 5 + M + + + + + + + + + + + + + + + + +	4 5 5 5 5 5 6 6 0 3 4 4 8 1 6 9 0 1 2 9 9 1 1 1 1 1 1 0 1 0 0 1 0 0 9 0 1 5 0 5 6 9 2 2 5 5 4 5 2 + M + X X	4 5 5 5 5 6 6 6 0 3 4 4 8 1 2 6 9 0 1 2 9 9 0 1 1 1 1 1 1 0 1 1 0 0 1 0 0 9 0 0 1 5 0 5 6 9 2 2 2 5 5 4 5 2 3 + M + + + + + + + + + + + + + + X + + + + +	4 5 5 5 5 5 6 6 6 6 6 6 0 3 4 4 8 1 2 2 6 9 0 1 2 9 9 0 0 1 1 1 1 1 1 1 0 1 1 1 1 0 0 1 5 0 5 6 9 2 9 2 2 2 5 5 4 5 2 3 1 + M + + + + + + + + + + + + + + + + +	4 5 5 5 5 5 6 6 6 6 6 6 6 6 0 3 4 4 8 1 2 2 3 6 9 0 1 2 9 9 0 0 4 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 0 1 5 0 5 6 9 2 9 2 2 2 2 5 5 4 5 2 3 1 1 + M + + + + + + + + + + + + + + + + +	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 0 3 4 4 8 1 2 2 3 4 6 9 0 1 2 9 9 0 0 4 7 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 6 0 3 4 4 8 1 2 2 3 4 4 4 8 9 9 9 0 0 6 9 0 1 2 9 9 0 0 4 7 8 8 5 5 8 8 7 7 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	4 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7	6 0 3 4 4 8 1 2 2 3 4 4 4 8 9 9 9 0 0 0 1 2 2 2 2 2 6 9 0 1 2 9 9 0 0 4 7 8 8 5 5 8 8 7 7 9 5 9 9 9 9 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1

andividual Allinnian i antitology of	1 011							_		~=					, -								P	P	. (0	· · · · · · · · · · · · · · · · · · ·
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0		7 3 0	7 3 0		3	3	7 3 0	3	3	3	3	3	3		3	7 3 1	3	
Carcass ID Number	0	0	0	1 0 5 1	0 5	0 4	0 4	0 6	0 6	0 7	0 7	0 7	0 7	0 8	8	0 9	0 5	0 6	0 7	0 9	1 1	1 1	1 2	1 2	1 2	Total Tissues Tumors
Genital System Clitoral gland Adenoma Bilateral, adenoma Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+ X +		+	+	+	+	M	+	+	+	+	+	+	48 2 1 50
Granulosa cell tumor benign Uterus Leiomyoma Polyp stromal	+	+	+	+	+	+	+	+	+	+ X	+	+	+ x	+	+	+	+	+ X	+	+	X +	+	+	+	+	1 50 2 5
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	++++++++	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + M +	+ + + + +	+	+ + + + + +	50 50 50 48 50 45
Integumentary System Mammary gland Adenoma Fibroadenoma Fibroadenoma, multiple Skin Keratoacanthoma Subcutaneous tissue, neurofibrosarcoma	+ + X	x +		M +	+ X +		+	+	+	+ X +		+	+	+ X +	+	+	+ x +		+ X +	M +	+	+	+	+	+	47 1 12 1 50 1
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Trachea	+ + +	+ + +	++++	+ +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+++	+ + +	+ + +	+ + +	+ + +	+ + +	+++	+ + +	+ + + +	+++	+++	+ + +	+++	50 1 50 50

TABLE B2

Individual Animal Tumor Patholo	ogy of	Fen	ale	e F	Rat	s i	n t	he	2-	Ye	ar	Fe	ed	St	ud	y o	f T	ria	am	ter	en	e:	60	0 p	pn	1 (6	con	tinue	d)
		4	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7			
Number of Days on Study		6 6	9	3 0	4 1	4 2	8 9	1 9	2 0	2 0	3 4	4 7	4 8	4 8	8 5	9 5	9 8	9 8	0 7	0 7	0 9	1 5	9	9	2 9	9			
		1	1	1	1	1	1	0	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1			
Carcass ID Number		. 1	0	0	1	0	0	9	0	0	1	0	0	0	9	1	0	0	0	1	0	0	0	0	0	0			
		2	2	5	5	4	5	2	3	1	1	2	4	5	1	3	1	2	3	3	3	5	1	3	4	5			
Special Senses System Eye	· · · · · · · · · · · · · · · · · · ·										+	+																	
Harderian gland																+													
Urinary System	*****																												
Kidney Urinary bladder		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		٠.	
Systemic Lesions																													
Multiple organs		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Leukemia mononuclear							X		X							X				Х	Х	X	٠.			Х	٠.		

50 9

TABLE B2

Systemic Lesions

Multiple organs Leukemia mononuclear

Individual Animal Tumor Patholog	y of	· Fe	nal	e I	Rats	s is	n t	he	2-	Ye	ar	Fe	ed	St	ud	y o	f 7	`ria	ım	ter	en	e:	6(M) p	pm	1 (c	ontinued)
		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study		2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
•		9	9	9	9	9	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Carcass ID Number		. 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	Total
		3	3	4	5	5	4	4	6	6	7	7	7	7	8	8	9	5	6	7	9	1	1	2	2	2	Tissues
		. 2	3	4	1	3	1	2	3	4	1	2	3	4	1	5	2	2	1	5	3	1	2	2	4	5	Tumors
Special Senses System Eye Harderian gland					-							•						+					_				3 1
Urinary System Kidney Urinary bladder			- + - +	+	++	++	++	+++	++	++	++	+	+	+	++	++	++	++	+++	++	+++	++	++	+	+++	++	50 50

TABLE B3
Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene

•	0 ppm	150 ppm	300 ppm	600 ppm
Clitoral Gland: Adenoma				
Overall rates ^a	3/42 (7%)	3/49 (6%)	4/50 (8%)	3/48 (6%)
Adjusted rates ^b	11.5%	8.3%	10.5%	9.1%
Terminal rates ^c	3/26 (12%)	2/34 (6%)	2/34 (6%)	2/28 (7%)
First incidence (days)	729 (T)	708	619	541
ife table tests ^d	P = 0.555	P = 0.540N	P = 0.619	P=0.636N
ogistic regression testș ^d	P = 0.554N	P = 0.564N	P=0.593	P = 0.604N
Cochran-Armitage test ^d	P = 0.543N			
isher exact test ^d		P = 0.585N	P = 0.598	P = 0.596N
Clitoral Gland: Adenoma or Carcinoma				
Overall rates	4/42 (10%)	3/49 (6%)	4/50 (8%)	3/48 (6%)
Adjusted rates	14.4%	8.3%	10.5%	9.1%
Terminal rates	3/26 (12%)	2/34 (6%)	2/34 (6%)	2/28 (7%)
First incidence (days)	715	708	619	541
ife table tests	P = 0.469N	P=0.369N	P = 0.524N	P = 0.475N
ogistic regression tests	P = 0.417N	P = 0.391N	P = 0.547N	P = 0.434N
Cochran-Armitage test	P = 0.405N			• •
isher exact test		P = 0.413N	P=0.541N	P = 0.425N
Iammary Gland: Fibroadenoma		. •		: · · · · ·
Overall rates	19/50 (38%)	16/50 (32%)	16/50 (32%)	13/50 (26%)
Adjusted rates	47.9%	42.8%	42.5%	34.6%
erminal rates	10/29 (34%)	13/34 (38%)	13/34 (38%)	7/29 (24%)
irst incidence (days)	571	662	383	466
ife table tests	P = 0.184N	P = 0.211N	P = 0.227N	P = 0.197N
ogistic regression tests	P = 0.139N	P = 0.299N	P = 0.339N	P = 0.136N
Cochran-Armitage test	P = 0.130N			
isher exact test		P=0.338N	P=0.338N	P=0.142N
Mammary Gland: Adenoma				
Overall rates	4/50 (8%)	0/50 (0%)	4/50 (8%)	1/50 (2%)
Adjusted rates	10.9%	0.0%	10.6%	3.4%
Cerminal rates	1/29 (3%)	0/34 (0%)	2/34 (6%)	1/29 (3%)
irst incidence (days)	451	_e	662	729 (T)
ife table tests	P = 0.285N	P = 0.055N	P = 0.597N	P = 0.194N
ogistic regression tests	P = 0.252N	P = 0.072N	P = 0.635N	P = 0.162N
Cochran-Armitage test	P = 0.263N			
isher exact test		P = 0.059N	P = 0.643N	P = 0.181N
Mammary Gland: Fibroadenoma or Adenoma				
Overall rates	22/50 (44%)	16/50 (32%)	19/50 (38%)	14/50 (28%)
djusted rates	53.2%	42.8%	48.0%	37.6%
erminal rates	11/29 (38%)	13/34 (38%)	14/34 (41%)	8/29 (28%)
irst incidence (days)	451	662	383	466
ife table tests	P = 0.147N	P = 0.086N	P = 0.231N	P = 0.120N
ogistic regression tests	P = 0.096N	P = 0.140N	P = 0.343N	P = 0.064N
Cochran-Armitage test	P = 0.093N			
Fisher exact test		P = 0.151N	P = 0.342N	P = 0.072N

Lesions in Female Rats

TABLE B3
Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
Pancreatic Islets: Adenoma				
Overall rates	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
Adjusted rates	9.0%	0.0%	5.9%	3.4%
Terminal rates	2/29 (7%)	0/34 (0%)	2/34 (6%)	1/29 (3%)
First incidence (days)	660	-	729 (T)	729 (T)
Life table tests	P=0.353N	P = 0.105N	P=0.444N	P=0.322N
ogistic regression tests	P=0.357N	P=0.118N	P = 0.491N	P=0.321N
Cochran-Armitage test	P = 0.337N			
Fisher exact test		P=0.121N	P = 0.500N	P = 0.309N
rituitary Gland (Pars Distalis): Adenoma				
Overall rates	21/50 (42%)	20/50 (40%)	25/50 (50%)	28/50 (56%)
Adjusted rates	55.7%	50.6%	60.4%	73.1%
Terminal rates	13/29 (45%)	15/34 (44%)	18/34 (53%)	19/29 (66%)
First incidence (days)	451 ` ′	522	635	466 ` ´
ife table tests	P = 0.044	P = 0.305N	P = 0.487	P = 0.126
ogistic regression tests	P = 0.036	P = 0.470N	P = 0.274	P = 0.084
Cochran-Armitage test	P = 0.057			
isher exact test		P = 0.500N	P = 0.274	P = 0.115
rituitary Gland (Pars Distalis): Adenoma or C	Carcinoma			
Overall rates	21/50 (42%)	21/50 (42%)	25/50 (50%)	28/50 (56%)
Adjusted rates	55.7%	53.2%	60.4%	73.1%
Terminal rates	13/29 (45%)	16/34 (47%)	18/34 (53%)	19/29 (66%)
First incidence (days)	451	522	635	466
Life table tests	P = 0.050	P = 0.368N	P = 0.487	P = 0.126
ogistic regression tests	P = 0.042	P = 0.549N	P = 0.274	P = 0.084
Cochran-Armitage test	P = 0.066			
isher exact test		P = 0.580N	P = 0.274	P = 0.115
Thyroid Gland (C-cell): Adenoma				
Overall rates	5/50 (10%)	11/50 (22%)	6/50 (12%)	10/50 (20%)
Adjusted rates	17.2%	30.1%	17.1%	29.7%
Terminal rates	5/29 (17%)	9/34 (26%)	5/34 (15%)	7/29 (24%)
First incidence (days)	729 (T)	666	723	634
ife table tests	P = 0.178	P = 0.146	P = 0.611	P = 0.122
ogistic regression tests	P = 0.166	P = 0.113	P = 0.593	P = 0.110
Cochran-Armitage test	P = 0.217			
isher exact test		P = 0.086	P = 0.500	P = 0.131
Thyroid Gland (C-cell): Adenoma or Carcinom				
Overall rates	5/50 (10%)	11/50 (22%)	7/50 (14%)	10/50 (20%)
Adjusted rates	17.2%	30.1%	20.0%	29.7%
Terminal rates	5/29 (17%)	9/34 (26%)	6/34 (18%)	7/29 (24%)
First incidence (days)	729 (T)	666	723	634
ife table tests	P = 0.171	P = 0.146	P = 0.494	P = 0.122
ogistic regression tests	P = 0.159	P = 0.113	P = 0.472	P = 0.110
Cochran-Armitage test	P = 0.210		i	
Fisher exact test		P = 0.086	P = 0.380	P = 0.131

TABLE B3
Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene (continued)

		· ————————————————————————————————————				
	0 ррт	150 ppm	300 ppm	600 ppm		
Jterus: Stromal Polyp	*** **********************************	11	· · ·			
Overall rates 4 10 140 1	4/50 (8%)	6/50 (12%)	5/50 (10%)	5/50 (10%)		
adjusted rates	11.4%	17.0%	14.3%	16.1%		
erminal rates	2/29 (7%)	5/34 (15%)	4/34 (12%)	4/29 (14%)		
irst incidence (days)	573	715	723	685		
ife table tests	P=0.468	P = 0.460	P = 0.577	P=0.489		
ogistic regression tests	P = 0.455	P=0.383	P=0.502	P = 0.483		
Cochran-Armitage test	P = 0.500	2				
isher exact test		P = 0.370	P = 0.500	P = 0.500		
ll Organs: Mononuclear Cell Leukemia						
overall rates	8/50 (16%)	11/50 (22%)	7/50 (14%)	9/50 (18%)		
djusted rates	19.8%	23.8%	16.2%	24.5%		
erminal rates	1/29 (3%)	2/34 (6%)	1/34 (3%)	3/29 (10%)		
irst incidence (days)	534	522	619	589		
ife table tests	P = 0.499	P = 0.392	P = 0.454N	P = 0.471		
ogistic regression tests	P = 0.487N	P = 0.239	P = 0.484N	P = 0.517		
Cochran-Armitage test	P = 0.538N					
isher exact test		P = 0.306	P = 0.500N	P = 0.500		
ll Organs: Benign Neoplasms						
overall rates	40/50 (80%)	37/50 (74%)	40/50 (80%)	37/50 (74%)		
Adjusted rates	88.7%	85.8%	88.8%	83.8%		
erminal rates	24/29 (83%)	28/34 (82%)	29/34 (85%)	22/29 (76%)		
irst incidence (days)	451	476	383	466		
ife table tests	P = 0.522N	P = 0.117N	P = 0.268N	P = 0.431N		
ogistic regression tests	P = 0.409N	P = 0.285N	P = 0.571	P = 0.358N		
Cochran-Armitage test	P = 0.345N					
isher exact test		P = 0.318N	P = 0.598N	P = 0.318N		
ll Organs: Malignant Neoplasms						
overall rates	16/50 (32%)	13/50 (26%)	9/50 (18%)	9/50 (18%)		
djusted rates	36.5%	28.6%	21.3%	24.5%		
erminal rates	3/29 (10%)	4/34 (12%)	3/34 (9%)	3/29 (10%)		
irst incidence (days)	534	522	619	589		
ife table tests	P = 0.097N	P = 0.264N	P = 0.081N	P = 0.130N		
ogistic regression tests	P = 0.040N	P = 0.401N	P = 0.075N	P=0.068N		
Cochran-Armitage test	P = 0.054N					
isher exact test		P = 0.330N	P = 0.083N	P = 0.083N		
ll Organs: Benign or Malignant Neoplasms						
verall rates	46/50 (92%)	43/50 (86%)	42/50 (84%)	41/50 (82%)		
djusted rates	93.8%	87.7%	89.3%	87.1%		
erminal rates	26/29 (90%)	28/34 (82%)	29/34 (85%)	23/29 (79%)		
irst incidence (days)	451	476	383	466		
ife table tests	P = 0.373N	P = 0.125N	P = 0.105N	P = 0.328N		
ogistic regression tests	P = 0.119N	P = 0.306N	P = 0.191N	P = 0.118N		
Cochran-Armitage test Gisher exact test	P = 0.107N	P=0.262N	P=0.178N	P=0.117N		

Lesions in Female Rats 149

TABLE B3

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Feed Study of Triamterene (continued)

(T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, bone marrow, brain, clitoral gland, heart, kidney, larynx, liver, lung, nose, ovary, pancreas, parathyroid gland, pituitary gland, salivary gland, spleen, thyroid gland, and urinary bladder; for other tissues, denominator is number of animals necropsied.

Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Observed incidence at terminal kill

Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in a dose group is indicated by N.

Not applicable; no neoplasms in animal group

5725

TABLE B4
Historical Incidence of Liver Neoplasms in Untreated Female F344/N Rats^a

• • • • • • • • • • • • • • • • • • •		Incidence in Control	s
Study	Hepatocellular Adenoma	Hepatocellular Carcinoma	Hepatocellular Adenoma or Carcinoma
Historical Incidence at Battelle Columbus	s Laboratory		
2,4-Dichlorophenol	0/50	0/50	0/50
5,5-Diphenylhydantoin	0/50	0/50	0/50
Ethylene thiourea	0/50	0/50	0/50
Polybrominated biphenyls (Firemaster FF-1®)	0/50	0/50	0/50
Overall Historical Incidence	•		
Total	3/800 (0.4%)	1/800 (0.1%)	4/800 (0.5%)
Standard deviation	1.5%	0.5%	1.6%
Range	0%-6%	0%-2%	0%-6%

a Data as of 3 April 1991

ĊŁ.

TABLE B5 Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Feed Study of Triamterene^a

	0 ppm	150 ppm	300 ppm	600 ppm
Disposition Summary				
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
15-Month interim evaluation	10	10	10	10
2-Year study				
Early deaths				
Moribund	17	11	12	18
Natural deaths	4	5	4	3
Survivors				
Terminal sacrifice	29	34	34	29
Animals examined microscopically	70	70	70	70
3-Month Interim Evaluation				
Alimentary System				
Intestine large, colon	(10)			(10)
Parasite metazoan	1 (10%)			` '
ntestine large, rectum	(10)			(10)
Parasite metazoan	· ·			1 (10%)
Liver	(10)	(1)	(3) 3 (100%)	(10)
Inflammation, granulomatous	1 (10%)	ì (100%)	3 (100%)	3 (30%)
Periportal, inflammation, chronic	1 (10%)			1 (10%)
Pancreas	(10)			(10)
Acinus, atrophy	1 (10%)			
Stomach, forestomach	(10)			(10)
Epithelium, acanthosis, diffuse				1 (10%)
Epithelium, hyperkeratosis,				1 (100)
diffuse				1 (10%)
Cardiovascular System				
Heart	(10)			(10)
Myocardium, inflammation,	` ,			` '
multifocal, chronic	1 (10%)			
Endocrine System				
None				
General Body System None				
Genital System None				

TABLE B5
Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ррт	150 ppm	300 ppm	600 ppm
3-Month Interim Evaluation (continued	i)			
Hematopoietic System	,			
Bone marrow	(10)			(10)
Femoral, hyperplasia, RE cell	10 (100%)			9 (90%)
ymph node, mesenteric	(10)			(10)
Infiltration cellular, histiocyte	9 (90%)			10 (100%)
Integumentary System None				
Musculoskeletal System				·
None				
Nervous System				
None				
Respiratory System	1			
Lung	(10)			(10)
Peribronchiolar, inflammation,				
multifocal, chronic	1 (10%)			3
Peribronchiolar, inflammation, multifocal, chronic active				1 (10%)
				
Special Senses System	(0)			(2)
Harderian gland Inflammation, focal, chronic	(8)		• •	(2) .
Inflammation, multifocal, chronic	7 (88%)			2 (100%)
Inflammation, multifocal, chronic	, (0070)			
active	1 (13%)			•
Urinary System	· · · · · · · · · · · · · · · · · · ·			
Kidney	(10)			(10)
Renal tubule, mineralization,	()		•	(-*)
multifocal	2 (20%)			
15-Month Interim Evaluation				
Alimentary System				
Liver	(10)	(10)	(8)	(10)
Angiectasis, focal	(10)	2 (20%)	(9)	(10)
Basophilic focus	5 (50%)	9 (90%)	3 (38%)	4 (40%)
Hepatodiaphragmatic nodule	\	1 (10%)	` /	2 (20%)
Inflammation, granulomatous	5 (50%)	6 (60%)	. 8 (100%)	5 (50%)
Vacuolization cytoplasmic, focal	, ,	1 (10%)	•	, ,

TABLE B5
Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
5-Month Interim Evaluation (continued)		· · · · · · · · · · · · · · · · · · ·		
Alimentary System (continued)				
Mesentery	(1)		(1)	
Inflammation, chronic	1 (100%)		1 (100%)	(10)
Pancreas	(10) 3 (30%)			(10) 2 (20%)
Acinus, atrophy	3 (30%)			2 (20%)
Cardiovascular System				
Blood vessel	(1)			
Aorta, inflammation, chronic	1 (100%)			44.00
Heart	(10)			(10)
Myocardium, degeneration,	2 (2001)			2 (2007)
multifocal	3 (30%)			3 (30%)
Endocrine System				
Adrenal gland, cortex	(10)			(10)
Hyperplasia, nodular	1 (10%)	· ·	(0)	40
Pituitary gland	(10)	(3)	(2)	(10)
Pars distalis, angiectasis Pars distalis, degeneration, cystic	1 (10%)			1 (10%)
Pars distalis, hyperplasia	1 (10%)	2 (67%)	2 (100%)	1 (10%) 1 (10%)
Thyroid gland	(10)	2 (07/0)	2 (100%)	(10)
C-cell, hyperplasia	9 (90%)			8 (80%)
General Body System None				
Genital System	· · · · · · · · · · · · · · · · · · ·	 		
Clitoral gland	(10)			(10)
Inflammation, chronic	1 (10%)			. ,
Inflammation, suppurative	1 (10%)			
Uterus	(10)	(1)		(10)
Dilatation				1 (10%)
Hematopoietic System				
Bone marrow	(10)			(10)
Femoral, atrophy	1 (10%)			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Lymph node, mandibular	(10)	(1)		(10)
Sinus, ectasia		1 (100%)		1 (10%)
Integumentary System None				

TABLE B5
Summary of the Incidence of Nonneoplastic Lesions in Female Rats and in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
15-Month Interim Evaluation (continued)				
Musculoskeletal System				
Bone	(10)			(10)
Femur, osteopetrosis	2 (20%)	•		1 (10%)
Nervous System None				
Respiratory System	(10)			. (10)
Lung Interstitium, inflammation,	(10)			(10)
chronic				1 (10%)
Special Senses System				
None		<u> </u>	·	· · · · · · · · · · · · · · · · · · ·
Urinary System	(10)	(10)	(10)	(10)
Kidney Nephropathy, multifocal	(10) 7 (70%)	(10) 8 (80%)	(10) 5 (50%)	(10) 8 (80%)
repiropatny, mutitocai	7 (70%)	8 (80%)	3 (30%)	8 (80%)
2-Year Study				
Alimentary System				
Intestine large, cecum	(50)	(47)	(50)	(50)
Ulcer		1 (2%)		
Intestine large, colon	(50)	(50)	(50)	(49)
Parasite metazoan	1 (2%)	6 (12%)	3 (6%)	4 (8%)
Intestine large, rectum	(50)	(50)	(50)	(50)
Parasite metazoan	2 (4%)	(50)	(50)	(50)
Intestine small, duodenum	(50)	(50)	(50)	(50)
Ulcer	·.	1 (2%)	(50)	(50)
Liver	(50)	(50)	(50)	(50)
Angiectasis, focal	1 (2%)	3 (6%)	24 ((00%)	24 ((00)
Basophilic focus	37 (74%)	36 (72%)	34 (68%)	34 (68%)
Clear cell focus	3 (6%)	3 (6%)	4 (8%)	9 (18%) 1 (2%)
Degeneration, cystic Eosinophilic focus			1 (2%)	1 (2%) 3 (6%)
	1 (2%)		1 (2%)	3 (6%)
Fatty change Hepatodiaphragmatic nodule	2 (4%)	6 (12%)	1 (2%)	5 (10%)
Hyperplasia	1 (2%)	3 (6%)	3 (6%)	2 (4%)
Hyperplasia, histiocytic, lymphoid	1 (2%)	5 (0/0)	3 (070)	2 (770)
Inflammation, granulomatous	17 (34%)	8 (16%)	11 (22%)	6 (12%)
Mixed cell focus	2 (4%)	2 (4%)	8 (16%)	13 (26%)
Necrosis, coagulative	1 (2%)	2 (4%)	· ()	1 (2%)
Serosa, hemorrhage	- (-/0)	- (''')		1 (2%)
Mesentery	(3)	(2)	(3)	(1)
Inflammation, chronic	\ -/	(2) 1 (50%)		
Fat, necrosis	3 (100%)	` '	2 (67%)	

TABLE B5
Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
Alimentary System (continued)				
Pancreas	(50)	(50)	(50)	(50)
Inflammation, chronic	1 (2%)	(30)	(50)	(30)
Acinus, atrophy	12 (24%)	6 (12%)	11 (22%)	13 (26%)
Artery, inflammation, chronic	1 (2%)	1 (2%)	11 (22/0)	1 (2%)
Salivary glands	(49)	(50)	(49)	(50)
Inflammation, acute	(12)	(30)	(32)	1 (2%)
Stomach, forestomach	(50)	(50)	(50)	(50)
Acanthosis	2 (4%)	(30)	(30)	(50)
Cyst	2 (1,0)	1 (2%)		
Hyperkeratosis	2 (4%)	1 (270)		
Inflammation, chronic	£ (170)			2 (4%)
Ulcer	2 (4%)	2 (4%)	1 (2%)	3 (6%)
Stomach, glandular	(50)	(50)	(50)	(50)
Inflammation, chronic	1 (2%)	(50)	(50)	1 (2%)
Ulcer	3 (6%)	3 (6%)	3 (6%)	3 (6%)
Mucosa, mineralization	- (0,0)	2 (0/0)	2 (4%)	3 (070)
Tongue	(1)		(1)	
Acanthosis	1 (100%)		1 (100%)	
Hyperkeratosis	1 (100%)		1 (100%)	
Tooth	1 (100%)		(2)	
Peridontal tissue, inflammation,			(2)	
chronic			2 (100%)	
		,	2 (100%)	
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Atrium, thrombus		2 (4%)		• •
Endothelium, hyperplasia	1 (2%)	, ,		
Myocardium, degeneration	32 (64%)	39 (78%)	30 (60%)	27 (54%)
Endocrine System				
Adrenal gland, cortex	(50)	(50)	(50)	(50)
Hematopoietic cell proliferation	1 (2%)	(50)	(50)	(50)
Hyperplasia	13 (26%)	18 (36%)	10 (20%)	16 (200)
Adrenal gland, medulia		18 (36%)	10 (20%)	16 (32%)
Hematopoietic cell proliferation	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	6 (120)		F /40~
Pituitary gland	6 (12%) (50)	6 (12%)	(50)	5 (10%)
Necrosis, liquefactive	(30)	(50)	(50)	(50)
Pars distalis, angiectasis		2 (601)	1 (2%)	
Pars distalis, cyst	6 (120%)	3 (6%)	1 (2%)	
Pars distalis, cyst Pars distalis, hyperplasia	6 (12%)	1 (2%)	4 (8%)	6 (12%)
	11 (22%)	10 (20%)	7 (14%)	13 (26%)
Pars intermedia, hyperplasia	1 (2%)		(50)	.
Thyroid gland	(50)	(50)	(50)	(50)
C-cell, hyperplasia Follicle, dilatation	43 (86%)	32 (64%) 2 (4%)	37 (74%)	35 (70%)
			2 (4%)	2 (4%)

TABLE B5
Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued) General Body System None				
Genital System		-		
Clitoral gland	(42)	(49)	(50)	(48)
Inflammation, chronic	15 (36%)	17 (35%)	28 (56%)	22 (46%)
Ovary	(50)	(50)	(50)	(50)
Cyst	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Inflammation, granulomatous	1 (2%)	2 (0,0)	1 (270)	2 (170)
Follicle, cyst	2 (270)		2 (4%)	
Jterus	(50)	(50)	(50)	(50)
Dilatation	(55)	2 (4%)	1 (2%)	(50)
Hemorrhage		2 ()	1 (2%)	
Cervix, épithelium, hyperplasia	2 (4%)		1 (270)	
Endometrium, hyperplasia, cystic	2 (4%)	2 (4%)	1 (2%)	
Vagina	(1)	2 (170)	1 (270)	
Infiltration cellular,	(-)			
polymorphonuclear		1 (100%)		·
Polymorphoneuc		. (100%)		
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Femoral, myelofibrosis	()	()	(5.5)	1 (2%)
ymph node	(50)	(50)	(50)	(50)
Inguinal, sinus, ectasia	1 (2%)	. ()	()	(55)
Lumbar, sinus, ectasia	- (=/-)			1 (2%)
Mediastinal, sinus, ectasia	2 (4%)		1 (2%)	1 (2%)
Pancreatic, hematopoietic cell	- ()		- (-/-)	
proliferation		•		1 (2%)
Pancreatic, hyperplasia, plasma				1 (2%)
cell			1 (2%)	
Pancreatic, infiltration cellular,			- (-70)	
histiocyte				1 (2%)
symph node, mandibular	(48)	(50)	(49)	(50)
Hyperplasia, plasma cell	(40)	2 (4%)	1 (2%)	(30)
Sinus, ectasia		1 (2%)	2 (4%)	
Lymph node, mesenteric	(48)	(48)	(50)	(48)
Sinus, ectasia	3 (6%)	(40)	1 (2%)	4 (8%)
spleen	(50)	(50)	(50)	(50)
Depletion lymphoid	1 (2%)	(50)	1 (2%)	(50)
Fibrosis	1 (2%)		1 (270)	
Hematopoietic cell proliferation	4 (8%)	1 (2%)		3 (6%)
Hyperplasia, lymphoid	1 (2%)	1 (270)		3 (6%)
Infarct	2 (4%)	2 (4%)		•
Inflammation, granulomatous	1 (2%)	2 (470)	2 (4%)	
initianination, granulomatous	1 (270)		2 (470)	

TABLE B5
Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Feed Study of Triamterene (continued)

	0 ppm	150 ppm	300 ppm	600 ppm
2-Year Study (continued)				
ntegumentary System				
Mammary gland	(48)	(49)	(49)	(47)
Hyperplasia, cystic	17 (35%)	25 (51%)	22 (45%)	24 (51%)
Skin	(50)	(50)	(50)	(50)
Ulcer		, ,		1 (2%)
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Osteopetrosis	1 (2%)	5 (10%)	1 (2%)	
Nervous System				***
Brain	(50)	(50)	(50)	(50)
Infarct	3 (6%)	2 (4%)	1 (2%)	
Hypothalamus, compression	10 (20%)	7 (14%)	11 (22%)	14 (28%)
Respiratory System				, .
Lung	(50)	(50)	(50)	(50)
Abscess	(-)	· /	` /	1 (2%)
Foreign body			1 (2%)	1 (2%)
Inflammation, granulomatous			2 (4%)	4
Alveolus, inflammation, subacute		2 (4%)	1 (2%)	1 (2%)
Interstitium, inflammation, chronic		1 (2%)	3 (6%)	1 (2%)
Nose	(50)	(50)	(50)	(50)
Nares, inflammation, suppurative		1 (2%)		3 (6%)
				
Special Senses System Eye	(2)	(1)	. (2)	. (2)
Hemorrhage	(2)	(1)	(3) 1 (33%)	(3)
Lens, cataract	1 (50%)	1 (100%)	2 (67%)	1 (33%)
Harderian gland	1 (30%)	1 (100%)	2 (0170)	(1)
Inflammation, suppurative				1 (100%)
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Cyst	(50)	(30)	1 (2%)	(50)
Hydronephrosis		• .	1 (270)	1 (2%)
Nephropathy	38 (76%)	45 (90%)	45 (90%)	45 (90%)
Urinary bladder	(49)	(49)	(50)	(50)
	· · · /	, · · ,		()

^a Number of animals examined microscopically at site and number of animals with lesion

APPENDIX C SUMMARY OF LESIONS IN MALE MICE IN THE 2-YEAR FEED STUDY OF TRIAMTERENE

TABLE C1a	Summary of the Incidence of Neoplasms in Male Mice	
	in the 2-Year Feed Study of Triamterene: First Study	161
TABLE C1b	Summary of the Incidence of Neoplasms in Male Mice	
	in the 2-Year Feed Study of Triamterene: Second Study	165
TABLE C2a	Individual Animal Tumor Pathology of Male Mice	
	in the 2-Year Feed Study of Triamterene: First Study	170
Table C2b	Individual Animal Tumor Pathology of Male Mice	
	in the 2-Year Feed Study of Triamterene: Second Study	198
Table C3a	Statistical Analysis of Primary Neoplasms in Male Mice	
	in the 2-Year Feed Study of Triamterene: First Study	210
Table C3b	Statistical Analysis of Primary Neoplasms in Male Mice	
	in the 2-Year Feed Study of Triamterene: Second Study	214
Table C4	Historical Incidence of Liver Neoplasms in Untreated Male B6C3F, Mice	217
TABLE C5a	Summary of the Incidence of Nonneoplastic Lesions in Male Mice	
	in the 2-Year Feed Study of Triamterene: First Study	218
TABLE C5b	Summary of the Incidence of Nonneoplastic Lesions in Male Mice	
	in the 2-Year Reed Study of Triamterene: Second Study	224

ing the state of the state west years have explained become and the security of the explained by

en de la composition La composition de la

e de la companya de la co

gradiente de la composition della composition de

,这是一个时间,我们就是一个时间,这一个时间,这一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们也会一个时间,我们也会一个时间,我们也会一个 1997年,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们

TABLE C1a Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: First Study^a

	0 ppm	100 ppm	200 ppm	400 ppm
Disposition Summary			<u> </u>	
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
15-Month interim evaluation	10	10	10	0
2-Year study				
Early deaths				
Moribund	1	2	2	6
Natural deaths	2	3	2	8
Survivors				
Terminal sacrifice	47	45	46	46
Animals examined microscopically	70	70	70	70
15-Month Interim Evaluation				
Alimentary System				
Liver	(10)	(3) 3 (100%)	(10)	
Hepatocellular adenoma	1 (10%)	3 (100%)	2 (20%)	
Cardiovascular System None				
Endocrine System None				
General Body System None				
Genital System None			· · · · · · · · · · · · · · · · · · ·	
Hematopoietic System None				
Integumentary System None	,			
Musculoskeletal System None		-		
Nervous System None				

TABLE C1a
Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
5-Month Interim Evaluation (continu	ed)			
Respiratory System	ŧ			
Lung	(10)	(1)	(10)	
Alveolar/bronchiolar adenoma	2 (20%)	1 (100%)	e week s	
Special Senses System None				
Jrinary System	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		
None		•		
2-Year Study		· ·		
Alimentary System				
Gallbladder	(48)	(46)	(50)	(54)
ntestine large, cecum	(50)	(50)	(50)	(54)
ntestine large, colon	(50)	(49)	(50)	(57)
ntestine small, duodenum	(50)	(50)	(49)	(55)
Adenocarcinoma	` '			1 (2%)
ntestine small, ileum	(49)	(49)	(50)	(55)
ntestine small, jejunum	(50)	(50)	(49)	(55)
Adenocarcinoma				1 (2%)
Liver	(50)	(50)	(50)	(60)
Hemangiosarcoma	1 (2%)	1 (2%)	3 (6%)	
Hepatoblastoma	4 (00)	1 (2%)	1 (2%)	12 (220)
Hepatocellular carcinoma	4 (8%)	7 (14%)	3 (6%)	13 (22%)
Hepatocellular carcinoma, multiple	1 (2%) 13 (26%)	11 (22%)	11 (22%)	9 (15%)
Hepatocellular adenoma Hepatocellular adenoma, multiple	4 (8%)	11 (22%)	8 (16%)	11 (18%)
	(3)	(3)	(4)	(2)
Mesentery Pancreas	(50)	(50)	(50)	(60)
Stomach, forestomach	(49)	(50)	(50)	(58)
Papilloma squamous	(17)	(00)		1 (2%)
Stomach, glandular	(50)	(50)	(50)	(59)
Cardiovascular System				
		·		
Endocrine System		# · ·	, (f0)	(50)
Adrenal gland	(50)	(50)	(50)	(59)
Capsule, adenoma	1 (2%)	(50)	(48)	(60)
Adrenal gland, medulla	(50)	(50) 1 (2%)	(48)	(60)
Pheochromocytoma malignant	(50)	(50)	(50)	(60)
Thyroid gland C-cell, adenoma	(50)	(50)	1 (2%)	(/
C-con, auchoma		1 (2%)	1 (2%)	2 (3%)

,是是这个人,也是这个人,我们也是不是这个人,我们就是这个人,我们就是这个人,我们也是这个人,我们也是这个人,我们也是这个人,我们也是这个人,我们也是这个人,也是 1997年,我们也是这个人,我们也是不是这个人,我们就是这个人,我们就是这个人,我们就是这个人,我们就是这个人,我们就是这个人,我们就是这个人,我们就是这个人,

TABLE C1a Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm				
2-Year Study (continued)		· · · · · · · · · · · · · · · · · · ·						
General Body System								
None								
Genital System								
Epididymis	(50)	(50)	(50)	(60)				
Prostate	(50)	(50)	(50)	(60)				
Seminal vesicle	(50)	(50)	(50)	(60)				
Testes .	(50)	(50)	(50)	(60)				
Interstitial cell, adenoma	,	í (2%)	. ,	1 (2%)				
Hematopoietic System		<u> </u>		· · · · · · · · · · · · · · · · · · ·				
Bone marrow	(50)	(50)	(50)	(60)				
Lymph node	(50)	(50)	(50)	(60)				
Lymph node, mandibular	(47)	(48)	(49)	(60)				
Lymph node, mesenteric	(46)	(46)	(44)	(45)				
Spleen	(50)	(50)	(50)	(60)				
Spicen Hemangioma	(50)	(50)	1 (2%)	(~~)				
Hemangiosarcoma		1 (2%)	2 (4%)					
	(36)	(40)	(37)	(39)				
Thymus Alveolar/bronchiolar carcinoma, metastatic,	(36)	(30)	(31)	(37)				
		1 (2%)						
lung		1 (3%)						
Integumentary System				***				
Skin	(49)	(50)	(49)	(60)				
Subcutaneous tissue, fibroma	ì (2%)	` ,	` ,	` /				
Subcutaneous tissue, hemangioma	- ()	1 (2%)						
Musculoskeletal System	· · · · · · · · · · · · · · · · · · ·							
Bone	(50)	(50)	(50)	(59)				
Femur, hemangiosarcoma, metastatic, spleen	(00)	(00)	1 (2%)	(-1)				
Skeletal muscle	(1)	(2)	(1)					
Alveolar/bronchiolar carcinoma, metastatic,	(*)	(~)	(~)					
lung		1 (50%)						
Nervous System								
Brain	(50)	(50)	(50)	(60)				
Respiratory System		<u> </u>	. 45, 45, 44, 44					
Lung	(50)	(50)	(50)	(60)				
Adenocarcinoma, metastatic, harderian gland	1 (2%)	(50)	(~~)	(30)				
Alveolar/bronchiolar adenoma	3 (6%)	9 (18%)	9 (18%)	9 (15%)				
Alveolar/bronchiolar adenoma, multiple	3 (0/0)	2 (1070)	1 (2%)) (15/0)				
Alveolar/bronchiolar carcinoma	A (Q0%)	1 (20%)	4 (8%)	4 (7%)				
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, multiple	4 (8%)	1 (2%)						
	2 (4%)	2 (4%)	2 (4%)	1 (2%) (60)				
Nose	(50)	(50)	(50)	(00)				

TABLE Cla Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
A **			Marine Services	
2-Year Study (continued)				
Special Senses System Harderian gland	(3)	(3)	(6)	(2)
Adenocarcinoma	1 (33%)	(3)	(0)	1 (50%)
Adenoma	- (,	1 (33%)	3 (50%)	1 (50%)
Urinary System			and the second of the second	
Kidney	(50)	(50)	(50)	(60)
Urinary bladder	(50)	(50)	(49)	(60)
Systemic Lesions				3
Multiple organs ^c		(50)	(50)	(60)
Lymphoma malignant histiocytic	()	()	1 (2%)	1 (2%)
Lymphoma malignant lymphocytic	1 (2%)		• • • • • •	
Lymphoma malignant mixed	5 (10%)	3 (6%)	4 (8%)	4 (7%)
Total animals with primary neoplasms ^d 15-Month interim evaluation 2-Year study	3 32	4 38	2 35	38
			33	
Total primary neoplasms	* ,		2	
Total primary neoplasms 15-Month interim evaluation	3 41	4	2 55	60
Total primary neoplasms 15-Month interim evaluation 2-Year study	3		2 55	
Total primary neoplasms 15-Month interim evaluation 2-Year study	3	4		
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study	3 41	4 52	55	
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms	3 41 3 21	4 52 4 26	55 2 29	60
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation	3 41 3 21	4 52 4 26	55 2 29 2	60 27
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study	3 41 3 21 3 22	4 52 4 26	55 2 29	60
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study Total animals with malignant neoplasms	3 41 3 21 3 22	4 52 4 26 4 35	55 2 29 2 35	60 27 34
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study Total animals with malignant neoplasms 2-Year study	3 41 3 21 3 22	4 52 4 26	55 2 29 2	60 27
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study Total animals with malignant neoplasms 2-Year study Total malignant neoplasms	3 41 3 21 3 22	4 52 4 26 4 35	55 2 29 2 35 16	60 27 34 22
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study Total animals with malignant neoplasms 2-Year study Total malignant neoplasms 2-Year study	3 41 3 21 3 22 17	4 52 4 26 4 35	55 2 29 2 35	60 27 34
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study Total animals with malignant neoplasms 2-Year study Total malignant neoplasms 2-Year study Total malignant neoplasms 2-Year study Total malignant neoplasms	3 41 3 21 3 22 17	4 52 4 26 4 35	55 2 29 2 35 16	60 27 34 22
Total primary neoplasms 15-Month interim evaluation 2-Year study Total animals with benign neoplasms 15-Month interim evaluation 2-Year study Total benign neoplasms 15-Month interim evaluation 2-Year study Total animals with malignant neoplasms 2-Year study Total malignant neoplasms	3 41 3 21 3 22 17 19	4 52 4 26 4 35	55 2 29 2 35 16 20	60 27 34 22

Number of animals examined microscopically at site and number of animals with lesion No neoplasms were found at the 3-month interim evaluation.

Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms

,是一个人,这个人,我们就是一个人,这个人,我们就是一个人,我们就是一个人,我们就是一个人,我们也不会会看到一个人,我们也不会会看到一个人,我们就是一个人,我们 第一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就

TABLE C1b Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study^a

•	0 ppm	400 ppm	
Disposition Summary			
Animals initially in study	60	60	
5-Month interim evaluation	10	10	
2-Year study			
Early deaths			
Moribund	3	4	
Natural deaths	4	7	
Survivors			
Died last week of study	1		
Terminal sacrifice	42	39	
Animals examined microscopically	60	60	
15-Month Interim Evaluation			
Alimentary System	·		
Liver	(9)	(10)	
Hepatocellular adenoma	` '	1 (10%)	
Cardiovascular System None			
Endocrine System			
Islets, pancreatic	(10)	(10)	
Adenoma	1 (10%)	(10)	
/ suctiona	1 (10%)		
General Body System None			
Genital System			
None			
Hematopoietic System			
None		·	
Integumentary System	·		
None			
Musculoskeletal System			
None			·
Nervous System			
None			

TABLE C1b
Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

		•	opm ·	,	400	hhiii			
15-Month Interim Evaluation (continu Respiratory System None	ued)		·	: .					
Special Senses System None							- <u></u>	 	
Urinary System								 	
None									
2 W C4 - I									1.
2-Year Study									
Alimentary System		(40)			(40)				
Gallbladder		(48)			(48)				
Intestine large, cecum		(49)	(001)		(50)				
Fibrosarcoma			(2%)		(50)				
Intestine large, colon		(48)			(50) (50)				
Intestine large, rectum		(49)			(50)				
Intestine small, duodenum Intestine small, jejunum		(47) (49)			(30)				
Liver		(50)			(50)				
Hemangiosarcoma		(30)	(4%)		(50)				
Hemangiosarcoma, multiple		. 2	(470)		1	(2%)			•
Hepatoblastoma						(2%)			
Hepatocellular carcinoma		. 8	(16%)			(16%)			•
Hepatocellular carcinoma, multiple			(2%).			(6%)			
Hepatocellular adenoma			(20%)			(24%)			
Hepatocellular adenoma, multiple			(22%)		24	(48%)			
Mesentery		(2)	` ′		(1)	` ,			
Adenocarcinoma		ìí	(50%)		` '				• •
Fibrosarcoma, metastatic, skeletal musc	le		(50%)						
Pancreas	•	(48)	` ,		(50)				
Fibrosarcoma, metastatic, skeletal musc	le	1	(2%)						*
Salivary glands		(50)			(50)				
Stomach, forestomach		(49)			(50)				
Stomach, glandular		(49)		٠.	(50)				
Cordiovacaular System							-	 	
Cardiovascular System		(50)			(50)				
Heart	ala.	(50)	(2%)	.,	(50)				
Fibrosarcoma, metastatic, skeletal musc Hepatocellular carcinoma, metastatic, li		1	(2%)		1	(2%)			•

,这是这个时间,一个时间,我们就是一个时间,我们就是一个时间,我们也不是一个时间,我们就是一个时间,我们就是一个时间,这一个时间,我们就是

TABLE C1b Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
-Year Study (continued)			-
Endocrine System		•	
Adrenal gland, cortex	(50)	(50)	
Spindle cell, adenoma		í (2%)	
Adrenal gland, medulia	(50)	(50)	
slets, pancreatic	(47)	(49)	
Carcinoma	1 (2%)		
ituitary gland	(50)	(48)	
Pars distalis, adenoma	` ,	1 (2%)	
Thyroid gland	(50)	(50)	
Follicular cell, adenoma	1 (2%)		
General Body System			<u></u>
None			
Genital System		(40)	
Epididymis	(50)	(50)	
Prostate	(50)	(50)	
Seminal vesicle	(50)	(50)	
Testes	(50)	(50)	
Hematopoletic System			
Bone marrow	(50)	(50)	
Hemangiosarcoma	1 (2%)	, ,	
Lymph node	(50)	(50)	
Fibrosarcoma, metastatic, lymph node	1 (2%)	` ,	
Lymph node, mandibular	(50)	(50)	
Lymph node, mesenteric	(41)	(44)	
Spleen	(47)	(50)	
Hemangiosarcoma	2 (4%)	, ,	
Γhymus	(40)	(43)	
Fibrosarcoma, metastatic, skeletal muscle	1 (3%)		
Integumentary System			
Skin	(50)	(50)	
Osteosarcoma, metastatic, bone	1 (2%)		
Subcutaneous tissue, hemangioma		1 (2%)	
Musculoskeletal System		<u></u>	
Bone	(50)	(50)	
Maxilla, fibrosarcoma	1 (2%)		
Vertebra, coccygeal, osteosarcoma	1 (2%)		
Skeletal muscle	(1)	(2)	
Hindlimb, fibrosarcoma	1 (100%)	/-/	

TABLE C1b
Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ррт	400 ppm	
2-Year Study (continued)			
Nervous System			
Brain	(50)	(50)	
Respiratory System			
Lung	(50)	(50)	
Alveolar/bronchiolar adenoma	6 (12%)	9 (18%)	
Alveolar/bronchiolar adenoma, multiple	- (/-)	1 (2%)	
Alveolar/bronchiolar carcinoma	7 (14%)	5 (10%)	
Alveolar/bronchiolar carcinoma, multiple	(2.73)	1 (2%)	
Fibrosarcoma, metastatic, skeletal muscle	1 (2%)	(2.17)	
Hepatocellular carcinoma, metastatic, liver	1 (2%)	3 (6%)	
Hepatocellular carcinoma, metastatic, multiple	:	1 (2%)	
Special Senses System			
Ear	(1)		
Fibrosarcoma	1 (100%)	C.	
Harderian gland	(4)	(6)	
Adenoma	1 (25%)	6 (100%)	
Urinary System			
Kidney	(50)	(50)	
Carcinoma	1 (2%)		
Fibrosarcoma, metastatic, skeletal muscle	1 (2%)	•	
Hepatocellular carcinoma, metastatic, liver	1 (2%)	4 (00)	
Artery, hepatocellular carcinoma, metastatic	(50)	1 (2%)	
Urinary bladder	(50)	(50)	
Papilloma		1 (2%)	
Systemic Lesions			
Multiple organs ^b	(50)	(50)	
Lymphoma malignant histiocytic		1 (2%)	
Lymphoma malignant mixed	5 (10%)	8 (16%)	
Neoplasm Summary	·		
Total animals with primary neoplasms ^c			
15-Month interim evaluation	1	1	
2-Year study	37	44	
Total primary neoplasms	.	••	
15-Month interim evaluation	1	1	
2-Year study	63	84	
Total animals with benign neoplasms		••	
15-Month interim evaluation	1	1	
2-Year study	25	39	

,这种是一种,这种是一种,这种是一种,是一种,我们就是一种,我们就是一种,我们就是一种,我们也是一种,我们也是一种,我们也是一种,我们也是一种,我们也是一种,我们就是我们就是一种,我们就是一种,我们就是我们就是我们就是一种,我们就是我们就是我们就是我们就是我们就是我们就

TABLE C1b Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
Neoplasm Summary (continued)			
Total benign neoplasms			
15-Month interim evaluation	1	1	
2-Year study	29	56	
Total animals with malignant neoplasms			
2-Year study	25	26	
Total malignant neoplasms			
2-Year study	34	28	
Total animals with metastatic neoplasms			
2-Year study	4	4	
Total metastatic neoplasms			
2-Year study	10	6	

Number of animals examined microscopically at site and number of animals with lesion

Number of animals with any tissue examined microscopically
 Primary neoplasms: all neoplasms except metastatic neoplasms

TABLE C2a Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: First Study: 0 ppm

			6	6	7		7	7	7		-	7	7	7	7 7		7	7	7	7	7	7	7		7	
Number of Days on Study		8 5	2	9 0	2 9	2 9	2 9	_			2 9	_	_		2 3 9 (3 0		3 0	3 0	3 0	3 0	3 0	3 0	3 0	3 0	
									,																,	
			0	0	-	-	-					0				0		0			0			0		
Carcass ID Number		6	6	0						1						1 9		2				2			-	
,		4	0		3		5		9			3														
<u> </u>		1	1	1	1	1	1	1	1	1	1		1	1		1		1		1		1	1	1	1	
dimentary System																										
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Gallbladder		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	M	+	+	+	+	M	
Intestine large		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Intestine large, cecum		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Intestine large, colon		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Intestine large, rectum		+	+	+	+	+	+	+	+	+	+	+	+	+	+` •	+ +	- +	+	+	+	+	+	+	+	+	
Intestine small		+	+	+	+	+	+	+	+	+	+	+	+	+	+ .	+ +	- +	+	+	+	+	+	+	+	+	
Intestine small, duodenum		+	+	+	+	+	+	+	+	+	4	+	+	+	+ .	, + +		+	+	+	+	+	+	+	+	
Intestine small, ileum		M	+	+	+	+	+	+	+	+	+	+	+	+	+ .	+ +	. 4		+	+	+	+	+	+	+	
Intestine small, jejunum		+	+	·	<u>.</u>	<u>.</u>	+	<u>.</u>	<u>.</u>	<u>.</u>	+	+	+	+	· + ·	+ 4			+	+	+	÷	+	+	+	
Liver		<u> </u>	<u>.</u>	<u>.</u>	<u>.</u>	<u>.</u>	<u>,</u>	. +	<u>.</u>	<u>,</u>	i	+	+			+ +			<u>.</u>	+	<u>.</u>	+	+	+	÷	-
Hemangiosarcoma		т-	-1-	r	4	•		•		7	•	•	'	1		' '	•	,	1-		•	,	•	X	•	
Hepatocellular carcinoma															,	x								^		
Hepatocellular carcinoma, multiple															•	``										
									x		х		X	v			v	X				х		х		*
Hepatocellular adenoma Hepatocellular adenoma, multiple									^		^		^	^	,	X	Λ	. ^		х		^		Λ		
Mesentery									_					_	•	^				^						
Pancreas			_	_		_	_	_	+	_		_	_	+	+	+ +			+	_	_	_	_			
Salivary glands		T				T	т		T	<u> </u>	T	T	т _	T.	т 1	r 7								т _	.L	
		+	+		+	+	+	+	+	+	T.	7		Τ.	Τ.		- -	· •		7	T	T.	Ţ	T	,	
Stomach		7	+	+	+	+	+	+	+	+	+	_	+		+	T 1	- +			7	7	+		7	+	
Stomach, forestomach		+	+	+	+	+	+	+	+	+	+	+	•			M I				+	+	+	+	*	+	
Stomach, glandular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	
Cardiovascular System																										
Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	
Endocrine System															_									_		
Adrenal gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	
Capsule, adenoma	:	•	•	•	x	٠	•	•	•	•	•	•		•	•	, ,	·	•	•	•	•	•	•	•	-	
Adrenal gland, cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ 4	- 4	. +	+	+	+	+	+	+	+	
		Ţ	·	i	4	<u>,</u>	<u>,</u>	+	· +	<u>,</u>	1	<u>,</u>	<u>.</u>	+	+	· -	· ·	. 4		<u>.</u>	÷	+	+	+	+	
Adrenal gland, cortex		т. Т.	- T-		1	1	<u>.</u>	<u>,</u>	+	+		+	+	+	<u>.</u>	. T	· ·	. 4	. 4		4	1	1	4	+	
Adrenal gland, medulla				т.	т	т	т	-F	-		<u></u>	M		Ţ	<u>.</u>	, 7 L -	, T	, ,	۳ باسی	T-	4	T.	- I -	· ·	+	
Adrenal gland, medulla Islets, pancreatic				4	_		ـــاـــ							7	1.	-	T	7	7	7	~		- T	7	-	
Adrenal gland, medulla Islets, pancreatic Parathyroid gland		+	+	+	+	+	+	+	+	т Т	Ţ	T-	i	_	_	4 -	ا ا	. 1	(_	_	4.		_	4	+	
Adrenal gland, medulla Islets, pancreatic Parathyroid gland Pituitary gland		+ + .	+	+	+	+	+	+	+	+	+	+	+	+	+	+ - _	⊦ + ∟ .ı	- M	(+	+	+	+	+	+	+	
Adrenal gland, medulla Islets, pancreatic Parathyroid gland		+++	+++	+++	++++	++++	+++	+ + +	+++	++	++	+++	+	+	+	+ - + -	+ + + +	- M	(+ · +	+	+	+	+	+	+	

General Body System

None

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

^{+:} Tissue examined microscopically A: Autolysis precludes examination

e de la companya del la companya de la companya del la companya de la companya de la companya de la companya de la companya del la com

None

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 0 ppm (continued)

Number of Days on Study	7 3 0	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2		7 3 2	7 3 2	7 3 2	7 3 2	7 3 2								7 3 3	3	3	3	-	7 3 3	,
Carcass ID Number	3 5	0 3 6	3	0 4 1	0 4 3	4	0 4 6	4 7	4 8	4 9	5 3	5 4	5	5 6	5 7	5 8	5 9	6 1	6 2	6 5	6 6	6 7	6 8	9	7 0	Total Tissues
	1	1	1	1 —	1	1	1	1 —	1	1	1	1	1	1	<u> </u>	1	1	1					1 —	1	ı ——	Tumor:
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										1
Hepatocellular carcinoma				Х											X		Х									4
Hepatocellular carcinoma, multiple										X																1
Hepatocellular adenoma	X	X									X									X				X		13
Hepatocellular adenoma, multiple						X				X																4
Mesentery			+																							3
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, glandular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System	***			~-							_		 -												-	
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																		_					-			
Adrenal gland	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Capsule, adenoma																										1
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	· N	1 +	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Pituitary gland	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Thyroid gland	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50

Number of Days on Study	5 8 5	6 2 3	-) ;		7 2 9	7 2 9	7 2 9	7 2 9		7 2 9	7 2 9	7 2 9	7 2 9			7 3 0			7 3 0	-	-	-		-	7 3 0	-		
V St. n. t. t.						_					_															_	_		
														0															
Carcass ID Number	4	0	6	5	3	4	5	8	9	0	2	3	5	1 6 1	7	8	9	3	4	5	6	7	8	3	1	3	4		
Genital System	<u>, </u>	<u>. </u>			_																								
Epididymis	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		
Penis																													
Preputial gland					+													+							+				
Prostate Seminal vesicle	+	7	⊦ - ∟ -	r L	† 	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4		+	+	+	+		
Testes	+	+	- -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		
Hematopoietic System		_		_						_	_												_	_		_		·	
Bone marrow	+	4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		
Lymph node	+	4	- ۱	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		
Lymph node, mandibular	+	+	- ۱	۲	+	+	-							+						+				+	+	+	+		
Lymph node, mesenteric	M	[-	- ۱	+	+	+	M	+	+	+	+	+													+				
Spleen	+				+									+															
Thymus	M	[-	- ۱	+	+	+	+	+	M	Ι	+	+	+	+	+	M	+	+	+	+	+	· N	1	+	M	M	+		
Integumentary System										-		_																7	
Mammary gland	M	[N	A I	M :	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	1 N	1	M	M	M	M		
Skin	+	N	1 -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +		+	+	+	+		
Subcutaneous tissue, fibroma																													
Musculoskeletal System																													
Bone	+	-	⊦ -	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	. 4	-	+	+	+	+		
Skeletal muscle																+		_											
Nervous System								•																,					
Brain	+	-	٠ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	-	+	+	+	+		
Respiratory System																													
Lung	+	-	٠ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠ +	-	+	+	+	+		
Adenocarcinoma, metastatic, harderian																													
gland	X																												
gland Alveolar/bronchiolar adenoma	Х		_														X												
gland Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,	х		ĸ							X		X	X				Λ								x				
gland Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	X +		Κ + ·	+	+	+	+	+	+	x +	+	X +	X	+	+	+	+	+	+	+	+	. 4	-	+	X +	+	+		

,他们的时候,这一时间,这一时间,也不是一个,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的 1995年,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们的时候,我们

									_				_													
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	•
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	0	2	2	2	2	2	2	2	2	2		2	2	3	3	3	3	3	3	3	3	3	3	3	3	
		0	_	_	^	^	0	Λ	^	^	_	<u> </u>	<u> </u>		<u> </u>			0	0	0	_ ^	0	0	0	0	
Carcass ID Number	3	3	3	4	4	4	4	4	4	4			5									6		6	_	Total
Curcuss ID Number	_	_	_	1				-	8	-														9		Tissue
	-																							1		Tumoi
Genital System		_				w,				_																
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Penis											+															1
Preputial gland				+		+		+		+			+			+	+							+		11
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hematopoietic System																			_							
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	M	+	47
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Spleen	+	+	+	+	+	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Thymus	+	+	+	M	+	+	+	+	+	M	+	M	+	+	+	+	M	M	M	+	+	+	+	M	+	36
Integumentary System													_	*					_	_			_			
Mammary gland	М	M	M	I M	M	М	M	M	M	M	M	M	M	M	M	М	M	M	M	М	М	M	I N	I M	M	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Subcutaneous tissue, fibroma											X															1
Musculoskeletal System				_	_	_															_			_		
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Skeletal muscle																										1
Nervous System		_	_			_												_		_				_		
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenocarcinoma, metastatic, harderian												•									•					
gland																										1
																		X			٠,,			,	\mathbf{X}	3
Alveolar/bronchiolar adenoma																				•	. ,					, , , 4
Alveolar/bronchiolar carcinoma																										•
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,																										•
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, multiple											x															2
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,	+	+	+	+	+	+	+	+	+	+	X +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	2 50 50

			_												_	_		_								
		5	6 (6 7	7 7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study		8	2 9	9 2	2 2	2	. 2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	
		5	3 (0 9	9	9	9	9	9	9	9	9	9	9	0	0	0	0	0	0	0	0	0	0	0	
:																										
*		0	0 (n (0	0	0	0	n	0	0	n	0	^	ò	0	0	0	_	_	^	_	_	
Carcass ID Number					, ,		0	v	U	v	v	V .	v	1	U 1	V 1	2	2	2	2	v	v	2	2	0	
Carcass ID Number		-	•	0 (, ,	. 0	· U	U	1	1	1	1	1	1	1	Ţ	2	2	2	2		2	3	.3	3	
		4	0	6 3	3 4		8	9	0	2	3	5	6	7	8	9	3	4	5	6	7	8	1	3	4	
		1	1	1 1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
·																_		_	_							
Special Senses System	•						•										•									
Harderian gland		+																							+	•
Adenocarcinoma		x																								
														_	_		_			_	_	_	_			
Urinary System																										
Kidney		_	_	.				_	_	_	_	_	_		_	_	_	4	4	4	_	_	_	4		
Urinary bladder		т Т	T _	T .	T 7	. I		1	1	<u> </u>	<u>_</u>	1	<u>-</u>	<u> </u>	т Т	т —	<u>.</u>	<u>+</u>	<u>'</u>	<u>.</u>	<u> </u>	<u> </u>		<u> </u>	1	
Officially bladder					' '	,	,	•	•	'	,	•	•	•	•	•	•	•	•	•	,	•	•	•		
Suntamia Laciona									_																	
Systemic Lesions																										
Multiple organs		+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•
Lymphoma malignant lymphocytic				.,		,					X				37											
Lymphoma malignant mixed				X	X										X											

Number of Days on Study	7 3 0	7 3 2	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3		_											
Carcass ID Number	0 3 5 1	0 3 6 1	0 3 9 1	0 4 1 1	0 4 3 1	0 4 4 1	0 4 6 1	0 4 7 1	0 4 8 1	0 4 9 1	0 5 3 1	0 5 4 1	0 5 5 1	0 5 6 1	0 5 7 1	0 5 8 1	0 5 9	0 6 1	0 6 2 1	0 6 5 1	0 6 6 1	0 6 7 1	0 6 8 1	0 6 9 1	7	Tota Tiss Tun	ues/
Special Senses System Harderian gland Adenocarcinoma											_			+							N.					3	
Urinary System Kidney Urinary bladder	+	+	++	+	++	+	++	+	++	++	+	+	+	+	+	++	++	++	++	++	++	+	++	+	· +	50	
Systemic Lesions Multiple organs Lymphoma malignant lymphocytic Lymphoma malignant mixed	+	+ x	+	+	+	+	+	+	+	+	+	+ x	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 5	

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm

Number of Days on Study		2	5 7	5 9 9	0	6 8 1	2	2	7 2 9	2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	3	
Carcass ID Number	9	9	1 9	1 0 7 1	9	3 8	7	7	7 4	7 5	0 7 6 1	7 7	7 8	9	8 0	8 1	8	8 6	8 7		8 9	9 1	9 2	0 9 3 1	9 7	0 0	
limentary System	-								_			_															
Esophagus		+	+	+		. +		- 4	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder						1 +								+	+	· +	<u>.</u>	<u>.</u>	+	<u>.</u>	+	·	4	<u>'</u>	, +	+	
Intestine large		+	+	+							·	i		i	·	·	<u>.</u>	Ţ	<u>.</u>	i	<u>.</u>	·	_	Ţ	<u>.</u>	i	
Intestine large, cecum		<u>.</u>	+	+			- 4	· •		. +	. 4	+	+	+	+	<u>,</u>	<u>.</u>	+	+	+	+	+	+	+	+	<u>,</u>	
Intestine large, colon		_	Δ	+										+	+	<u>.</u>	÷	+	+	i	+	<u>.</u>	·	<u>.</u>	+	<u>.</u>	
Intestine large, colon		<u>.</u>	۲,	+	_	1 A					, , , .	4	4	+	+	<u>,</u>	<u>,</u>	+	+	4	M	+	+	+	<u>.</u>	+	
Intestine small		<u>.</u>	1	+			. 1			+	۱ ⁻ ـــــ	+	+	+	+	<u>,</u>	+	+	+	+	747	+	+	<u> </u>	4	+	
Intestine small, duodenum		<u>-</u>	T	-T	T L	1		. T L .1				→	→	T			<u>.</u>	+	1		4	1	-I-		т Т	, +	
Intestine small, ileum		T _	A	+			- 4			. 4		1	+	+	<u>,</u>	<u>,</u>	+	<u>'</u>	+	+	<u> </u>	+	<u> </u>	+	<u>,</u>	, +	
Intestine small, jejunum		1	<u></u>	4		- 4		, , L 4				+	+		+	+	+	+	+	+	+	+	+	+	+	<u>,</u>	
Liver		Ė	÷	<u>.</u>		, 	- 4	, - +	· - +	. +		-		+		+		+	+	+	+	+	+	·	<u>.</u>	+	
Hemangiosarcoma	,		'	•				'	,	x		•	•	•	'	•		•		•	٠	•	•		•	•	
Hepatoblastoma						Χ	-			7.																	
Hepatocellular carcinoma			х		X													X							X		
Hepatocellular adenoma			^		- 2	•	,	C X	-			х			Х			"		X				х		x	
Hepatocellular adenoma, multiple							-	L 2	X			Λ.		X			x	X		7.		х		^		71	
Mesentery						4	_			•				1.			•	1.				+					
Pancreas		_	4	_								4	+	+	4	+	+	+	+	+	4	<u>.</u>	4	+	+	+	
Salivary glands		·	i										<u>.</u>	÷	<u>,</u>	·	<u>.</u>	÷	<u>.</u>	+	·	+	+	+	+	·	
Stomach		_	1	1	' اد .	- 4		 	- +			· +	+	+	<u>.</u>	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach		<u>,</u>	, +	4	. 4	- 4	- 4					+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular		+	+	+	. 4	- +	- +	- 1	- +	. +	+	+	+	+	+	+		+	+	+	+		+	+	+	+	
Cardiovascular System		_		_										_			_		_		_						
Heart		+	+	+	٠ +	- 4	- +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
indocrine System																											
Adrenal gland		+	+	+	- +	- 1	+ +	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex		+	+	+	- +	- 4	+ +	+ +	- +	- +	+	+	-		+		+		+	+			+		+	+	
Adrenal gland, medulla		+	+	+	- +	- +		+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma malignant																											
Islets, pancreatic		+	+	+	- +	- 1		+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland		+	+	+	- 4	- 4		+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pituitary gland		M	+	+	- +	+ +		+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	
Thyroid gland		+	+	+	- 4	+ +		+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Follicular cell, adenoma																X											

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm (continued)

Number of Days on Study	7 3 0	3	3	3 2	3 2	3 2		3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	-	7 3 3	3	3	3	3	3	3		3	-	
Carcass ID Number	0 5	0 6	1 0	1 1	1 2	1 4	1 5	1 7	1 8	2 1	2 2	2 3	2 4	2 5	2 6	2 7	3 0	3 1	3 2	3	3 4	3 6	1 3 7 1	3 9	4 0	Total Tissue Tumoi
Alimentary System						_		_								_				_		-				
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										1
Hepatoblastoma																										1
Hepatocellular carcinoma			X			Х																	Х			7
Hepatocellular adenoma		Х						Х					Х		X											11
Hepatocellular adenoma, multiple						X			X		X			Х									X			11
Mesentery														+												3
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•	+	50
Stomach, glandular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System Heart		_	_	_	_	_	.	_	_	_	_		_										+			50
				_	_	_	_	_		_	_		_	_	_	_		_	_	_	_	_		+		50
Endocrine System																										
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+		+						+		+	+	+	+	50
Adrenal gland, medulla	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant								X																		1
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M			48
Pituitary gland Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		48
Follicular cell, adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm (continued)

										_																		
Number of Days on Study	2	5	5 9 9	6 0 1	6 8 1	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0		7 3 0			3			
Carcass ID Number	9 0	1 9	0 7	9 5	1 3 8 1	7 1	7 3	7 4	7 5	7 6	7 7	7 8	7 9	8 0	8 1	8	8 6	8 7	8 8	8 9	9	9	9	9 7	0)	 	
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Interstitial cell, adenoma	+ + + +	+ + + +	+ + + +	+ + + +	+ + +	+ + + +	+ + + +	+ + + +	+ + + + +	+ + + +	+ + + X	+ +++	+ + + +	+ + + +	+	+ + +	+ + + +	+	+ + + +	+ +++	+ + + +	+ + + +	++++	- + + - +	+ + + + + +	+ + +		
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Alveolar/bronchiolar carcinoma, metastatic, lung	+ + + + + M	+++++++++++++++++++++++++++++++++++++++	+ + + + + + X		+ + + M +	+ + + + + + +	+ + + + + +	+ + + M +	+++++++++++++++++++++++++++++++++++++++	+ + + + + M	+++++++	+++++++	+ + + + + +	+ + + + + M	+ + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++	+++++++	+++++++	++++++	+++++++++++++++++++++++++++++++++++++++	· + · · + · · + · · +	+ + + + + + + + + + + + + + + + + + +	 + + M +		-
Integumentary System Mammary gland Skin Subcutaneous tissue, hemangioma					M +																						-	
Musculoskeletal System Bone Skeletal muscle Alveolar/bronchiolar carcinoma, metastatic, lung	+	+	+ + x	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	- 1	+		
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+	 	
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,	, + X	+	+	+	+	+	+	*	*X	+	+	*X			* X		+ X	+	+	+	+ X		+	- +	- +	+	 	
multiple Nose Trachea	+	+	+ +	+	+	+	+	+	+	+ +	+	+	+ +	+ +	+	+	+	+	+	+	+	+	+	. +	- -	+		

7 3	7 3			7 3 2	7 3 2	3	3	3	3	3	3							7 3 3								
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	<u>:</u>	
	6	0	1	2	4	5	7	8	1	2	3	4	5	6	7	0	1	2	3	4	6	7	9	(0	Total Tissues/ Tumors
									_			-														
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
				+				+			+									+	+					12
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
. +	+	+	+	+	+	+	+	+	+											+	+	+	+		+	50
·	•	·	•	,	•	•					·	·	•	·	٠	·		•	•		•	•	•		•	1
												_				_	_	_	_	_	_	_	_	_		// // // // /
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
M	I M	۱ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+	48
+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+	46
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+	50
																	Х									1
+	+	м	м	+	+	М	+	+	+	+	+	+	+	+	+	+			м	+	+		. +		+	40
·	•	•	• • •		·		·	,	•	·		·	·	•	·	·	,		•••		•	·	·		,	1
								_								_			-		_					
M	M	I M	M	M	M	. M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	[N	ĺΝ	I N	1	M	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	. +		+	50
					X										_											1
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	•	+	50
																										2
																										1
			_									-						<u> </u>								
+	+	· +	+	+	+	+ 	+	+	+	+	+	+	+	+	+	+	+	+	+	_+	+	+ —	+	-	+	50
																						_				F0
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠.	+ ,.	50
										Х	Х															9 1
																			Х							2
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			. 4	. 4	. 4	-	+	50
+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4				_	+	50
														_							•					
	1 0 5 1 + + + + + + M + + + + + M + + + + M + + + + M + + + + M + + + M + + + M + + M + + M + + M + + M + + M	0 0 1 1 0 0 5 6 1 1 + + + + + + M M + + + + + +	3 3 3 3 0 0 0 0 1 1 1 1 0 0 1 5 6 0 1 1 1 1 + + + + + + + + + + + + + + +	3 3 3 3 3 0 0 0 0 2 1 1 1 1 1 1 0 0 1 1 1 5 6 0 1 1 1 1 1 1 1 + + + + + + + + + + + +	3 3 3 3 3 3 0 0 0 2 2 1 1 1 1 1 1 1 1 1 5 6 0 1 2 1 1 1 1 1 1 + + + + + + + + + + + + +	3 3 3 3 3 3 3 3 0 0 0 0 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 5 6 0 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3 3 3 3 3 3 3 3 3 3 0 0 0 0 2 2 2 2 2 2	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 0 0 0 0 2 2 2 2	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm (continued)

Number of Days on Study	2	5	9	0	6 8 1	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3	7 3 0	7 3 0	7 3 0	_	7 3 0								
	0			0	1	0	0		0	0	0	_ _ 0	0	0	0	0	0	0	0	0	- 0	- 0	0	 	 1	
Carcass ID Number	9 0 1	_		9 5 1	3 8 1	7 1 1	7 3 1	7 4 1	7 5 1	7 6 1	7 7 1	7 8 1	7 9 1	8 0 1		8 3 1	8 6 1	8 7 1	8 8 1	8 9 1	9 1 1		9 3 1	7	0 0 1	
Special Senses System Harderian gland Adenoma													_	,	- 			+		•						
Urinary System																										
Kidney Urinary bladder	-1 -1	+ +	⊦ + ⊦ +	+ + + +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•		+	+	- +	- +	<u>.</u>
Systemic Lesions Multiple organs Lymphoma malignant mixed	+		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	- +	- 1	-

"说话,也是这个时间,这个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我 "我们的一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: First Study: 100 ppm (continued)

			_																								
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	1	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
•	0	0	0	2	2	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	ş	
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
Carcass ID Number	0	0	1	1	1	1	1	1	1	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	. 4	ŧ	Total
	5	6	0	1	2	4	5	7	8	1	2	3	4	5	6	7	0	1	2	3	4	6	7	9	0)	Tissues/
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Ĺ	Tumors
Special Senses System Harderian gland Adenoma		_	-																-			+	+ >				3
												_												_			
Urinary System																											
Wrinary System Kidney	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4	- 4		+	50
Urinary System Kidney Urinary bladder	+	•	+	+	+	+	+	+	•			•	•	•	•	•	•			•	+			- 1	⊦ - ⊦ -	+	50 50
Kidney Urinary bladder		•	+	+	+	+	+	•	•		•	•	•	•	•	•	•			•				⊦ -{ 	} - } -	+ + 	
Kidney	+	+	· +			+ +	++	+	÷ 	+	+	+	+	+	÷ —	+	+	+	÷ —	+	+	+		+ 4 			

Table C2a	
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of	Triamterene:
First Study: 200 ppm	

umber of Days on Study		1	4	6 8 2	7 0 6	2	7 2 9	7 2 9	2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		3	7 3 0	3	3	3	3	7 3 0	3	7 3 0	3	
		1	 1	1	1	1	1	1	1	1	 1	1	1	1	1	1	1	1	1	1	<u> </u>		 1			1	
arcass ID Number				4		4	4	4	4	4	4	4	5		5		5								7		
						-	-	5	6	7	8	9		2			5	8							1		
•		_												1													
·		•	_		_	•		•	_		_	•	•	•	•	•	•	•	•	•	•	•	•	•	1	•	
limentary System																	,				ì						
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	+	
Intestine small		+		+	+	1	1	4	, +	4	÷	1	_	<u>.</u>	<u>,</u>	+	+	_	<u>+</u>	<u>,</u>	1	<u>+</u>	<u>.</u>	<u>, </u>	T	1	
Intestine small, duodenum		+	+	1	Δ	T .	τ -	T	1	T-	1	τ -	<u>T</u>	7	<u>_</u>	+	+	+	+	<u>+</u>	<u>+</u>	1	<u>, T</u>	т .ь		∓	
Intestine small, ileum		+	1	T.		Τ,	T		T	+		т Д	,L	<u>+</u>	-T-	<u>+</u>	+	4	<u>+</u>	-F		т Т	т "L	т т		_T	
Intestine small, jejunum		1	-	1	Δ.	T		Τ 1	т Т	+	+	+	+	т Т	+	+	+	+	1	→	<u>ب</u>	-T	T	ا	7	<u>ب</u>	
Liver		+	T	+	+	+	+	,T	.T.	•	-	•		+	•			-	T	T	T	⊤	T.	.I.	+	T	
Hemangiosarcoma		+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	
													X														
Hepatoblastoma																	X										
Hepatocellular carcinoma		.,										.,							.,								
Hepatocellular adenoma		X										X							X	Х							
Hepatocellular adenoma, multiple							X										X			,			X	Х			
Mesentery			+																								
Pancreas		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular		+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
En Plans and an Contain	· · ·	_	_	_	_		_				_		_								_				_		
ardiovascular System Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
		_	_	_	_		_		·	·	_	· 	_		_		_	_	_	_	_	_	_	· 	_		
ndocrine System													-														
Adrenal gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, medulla		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+					M	+	+	+	+	
Islets, pancreatic			+	+	+			+	+	+	+		+		+	+	+	+	+	+	+	+	+	+		+	
Parathyroid gland								+				Ţ	<u>.</u>	<u>.</u>	i	+	+	<u>.</u>	+	<u>.</u>	+	<u>+</u>	M			+	
Pituitary gland								M				+	+	+	M	+	<u>,</u>	+	+	+	+	_	+	+		+	
Thyroid gland														+			1	-				<u> </u>		-			
C-cell, adenoma		т	7	_	Τ.	7	Τ.	т	т	•	7	т	т	т	т	7	7	7	-	+	-	X	_	7	т	т	
																						Л					
Follicular cell, adenoma																											

TABLE C2a	
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study o	f Triamterene:
First Study: 200 ppm (continued)	

		_	_			_		_	_	~	_	_	~	_	_	~	_	7	~	7	7	~	7	7	7	
	7	-	-	7		7	7	7	7	7	7	7			7 3	7	7 3	7 3	7	7	7 3	7	7	3	3	•
lumber of Days on Study	3 0					3 2	3 2	3 2	3	3	3 2	3 2	3 2	3	3	3	3	3	3	3	3	3	3	3		
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	
Carcass ID Number	7			7		8	8	8	8	8	8	9	9	9	9	9	9	9	0	0	0	0	0	0	1	Total
	4	5	6	7	0	1	2	3	4	6	7	0	1	4	5	6	8	9	1	2	3	5	6	7	0	Tissue
	1	1	1	1	1			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Tumor
Alimentary System						_														-						
Esophagus	4	- 4	- +	- 1	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	- 4	- 4	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large	4	- +	- 1	+ 4	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	4	- 4	- 4	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	4	- 4	- 4	- 1	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	4	- 4	- 4	- 4	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	4	- 4	- 4	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	4	- 4	- 1	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, ileum	4			+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	4	- +	+ +	۲ ۲	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Liver	4	+ +	+ +	F 4			+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma					X			X																		3
Hepatoblastoma																										1
Hepatocellular carcinoma								X			X			X												3
Hepatocellular adenoma		>	ζ.	>	(X					X			X	X		X									11
Hepatocellular adenoma, multiple								Х														X			X	8
Mesentery								+		+											+					4
Pancreas	4		+ +		+ +	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	- 1			+ +	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	4			+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		50
Stomach, forestomach	4	-		۲ -	+ +	• +	+	+	+	+	+	+		+	+	+	+	+	+	+	+		+	+		50
Stomach, glandular				F →	+ +		+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System				-	•				_																	
Heart			⊢ ⊣	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal gland	4		+ +	- 4	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	4	-	⊦ +	- 4	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, medulla	4	٠ -	- +	+ +	+ +	- M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Islets, pancreatic	+	٠ -	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	٠ -	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	46
Pituitary gland	4	٠ -	+ +	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	M		+	+	+	+	+	+	+	+	44
Thyroid gland	4		- +	-	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
C-cell, adenoma																										1
Follicular cell, adenoma													X													1

General Body System None

,他们是一个时间,这个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是 一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就是一个时间,我们就

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

Number of Days on Study	1	6 4 1	8	7 0 6	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		7 3 0		7 3 0								
Carcass ID Number	7 8	6 0	4	8 5	4	4	1 4 5 1	4 6	4 7	4 8	4 9	5 1	5 2	5 3	5	5 5	5 8	5 9	6 4	6 5	6 7	6 9	7 0	7 1	7 2	
Genital System			_	_			_			_	<u> </u>	_	_			_		_		_		_	_			
Epididymis Penis	+	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Preputial gland	+	+				+		+	+	+	+			+				+		+	+	÷	+		+	
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Seminal vesicle Testes	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hematopoietic System Blood								_																_		
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node	+	·	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mandibular	M	· [+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	M	+	+	+	+	M	+	+	+	+		+	+	+	M	+	+	+	+	+	+	+	
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hemangioma													\mathbf{x}													
Hemangiosarcoma												Х													X	
Thymus	M	M	M	M	+	+	M	+	+	M	M	+	+	+	+	M	+	M	+	+	+	M	+	+	+	
Integumentary System		_					_				_								_		_		_	_		
Mammary gland							M																			
Skin	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Musculoskeletal System											_						_									
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Femur, hemangiosarcoma, metastatic,												٠.														
spleen Skeletal muscle		+										X														
												_						_			_			_		
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System		_				_					_															
Lung	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma										X				X		X								X		
Alveolar/bronchiolar adenoma, multiple			v																				X			
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,			X																							
multiple				_		_					_						,	,			X					
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea																										

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

								_					_			_			_	_						
7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7			7	7	7	7	
0	2	2	2	2	2	2	2	.2	2	2			3											-		
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		1	1	2	2	_		 2	_	_	_	
7	7	7	7	8	8	8	8	8	8	8	9	9	9	9	9	9	9	0	0			-		0	1	Total
4	5	6	7			2																				Tissues/
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		l	1	1	1	Tumors
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	50
																								+		1
					+		+	+				+			+		+			4	•		+		+	23
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	۲	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	۲	+	+	+	+	50
																										1
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• •	-	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	٠ ٠	+	+	+	+	+	50
+	+		+	+	+		+	+		+	-	+			+			+	+	- +	۲,	+	+	+	+	49
+	+	-		+	+					+															+	44
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4	-	+	+	+	+	50
																										1
																										2
+	M	+	+	M	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+		-	+	+	+	+	37
M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	I	1	1	M	M	M	M	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		۲	+	+	+	+	49
										_	_			·	·								_	_		
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	۲	+	+	+	+	50
																										1
																										1
																								_		
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	۲	+	+	+	+	50
	_					,									_		_			_	-	_		_		
										+	+	+	+	+	+	+	+	+	+		-	+	+	+	+	50
+	+	+	+	+	+	+	+	+		•																- -
+	+	+	+	+	+	+	+	+ X	Т	•	•			X		X					•			X	X	9
+	+	+	+	+	+	+	+	X	т	•	•			X		X			•					X	X	
+	+ X	+	+ X	+	+	+	+	X	_	'	·			X		Х			•	,	ζ.			X	Х	9 1 4
+	+ X	+	+ X	+	+	+	+	X	T	•	•			X		X			•	>	ζ.			X	Х	. 1
+ X		+	+ x	+	+	+	+	X	T	•	·			X		X			·	>	ζ			X	X	. 1 4
+ X +				+	+	+	+	*X	+	+	+	+	+	X +	+	X +	+	+	+	,	· {	+	+	X	x +	. 1
	3 0 1 7 4 1 1 + + + + + + + + + + + + + + + + +	3 3 0 2 1 1 7 7 4 5 1 1 + + + + + + + + + + + + + + + + +	3 3 3 0 2 2 1 1 1 7 7 7 7 4 5 6 1 1 1 1 + + + + + + + + + + + + + + +	3 3 3 3 3 0 2 2 2 2 1 1 1 1 1 7 7 7 7 7 4 5 6 7 1 1 1 1 1 + + + + + + + + + + + + + +	3 3 3 3 3 3 3 0 2 2 2 2 2 2 2 2 2 2 2 2	3 3 3 3 3 3 3 3 0 2 2 2 2 2 2 2 2 2 2 2	3 3 3 3 3 3 3 3 3 0 2 2 2 2 2 2 2 2 2 2	3 3 3 3 3 3 3 3 3 3 3 3 0 2 2 2 2 2 2 2	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

rist study. 200 ppm (commute)									٠																		 	
•		6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		
Number of Days on Study		1	4	8	0	2	2	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3		
		7	1	2	6	9	9	9	9	9	9	9	9	9	9	9	0	0	0	0	0	0	0	0	0	0		
		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	 	
Carcass ID Number		7	6	4	8	4	4	4	4	4	4	4	5	5	5	5	5	5	5	6	6	6	6	7	7	7		
•	•	8	0	1	5	2	3	5	6	7	8	9	1	2	3	4	5					7	9	0	1	2		
•		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
Special Senses System																		-										
Eye																								+				
Harderian gland				+										+			+							+				
Adenoma				X																				Х	•			
Urinary System	-																											
Kidney		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Urinary bladder		+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+		
Systemic Lesions																												
Multiple organs		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 1	
Lymphoma malignant histiocytic Lymphoma malignant mixed			X																			٠						

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

Number of Days on Study	7 3 0	7 3 2	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3												
Carcass ID Number	1 7 4 1	1 7 5 1	1 7 6 1	1 7 7 1	1 8 0 1	1 8 1 1	1 8 2 1	1 8 3 1	1 8 4 1	1 8 6 1	1 8 7 1	1 9 0 1	1 9 1 1	1 9 4 1	1 9 5 1	1 9 6 1	1 9 8 1	1 9 9	2 0 1	2 0 2 1	2 0 3 1	2 0 5 1	2 0 6 1	2 0 7 1	1 (_	Total Tissues Tumor
Special Senses System Eye Harderian gland Adenoma					+																		+ X				1 6 3
Urinary System Kidney Urinary bladder	 +		++	+	+	+	+	+	+	+	+	+	+	+	++	++	++	++	++	+	+	+	+	+ +	+	+	50 49
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant mixed	 +	+	+	+	+ X	+ X	+	+	+	+	+ X	+	+	+	+	+	+	+	+ X	ĺ	+	+	+	- +	-	+	50 1 4

Table C2a Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: First Study: 400 ppm

Number of Days on Study	8	8	8	8	8	8	2 8 5	8	8	8	8	8	2	1	2	2	2	2	2	2	2	2	7 2 9	_	7 2 9	
Carcass ID Number	3	1		5 4	5 7	5 2	2 6 0 1	7 3	3 5	3 9	5 8	2 4	5 6	6 1	1 1	1 2	1 3	1 4	5	1 6	1 8	0	1	2	3	·
Alimentary System						_						_		_							_					
Esophagus	_					_	_	_	_	_	_	_	+	_	_	_	_	_	_	_	_	_				
Gallbladder	, _	, د	. 4	. A	<u> </u>		+	<u>_</u>	<u>,</u>	4						<u>+</u>	i	1	1	<u>+</u>	M	<u> </u>		+	T	
Intestine large							+																т Т	1		
Intestine large, cecum							À																+	+	1	
Intestine large, colon							+																		÷	
Intestine large, rectum							+														+		÷	÷	-	
Intestine small							+																+		-	
Intestine small, duodenum Adenocarcinoma							+																	+		
Intestine small, ileum	+	+	· A	A	+	+	+	+	+	+	+	+	Α	A	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum Adenocarcinoma		_					+									+	•					+		·	+	
Liver	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+				+	
Hepatocellular carcinoma																X	X					X		X		
Hepatocellular adenoma														٠,		X			Х	Х	X			•		
Hepatocellular adenoma, multiple														X								Х		X		
Mesentery																				+						
Pancreas	+	· +	- +	+	+		+																		+	
Salivary glands Stomach	4			. +			+																		+	
Stomach, forestomach					. +								+			+				+	I	+	+		+	
Papilloma squamous	7	7		А	. т	7	-	7	1	т	7	т.	Т	1	т		,	•	-	1		7		-	7	
Stomach, glandular	+	-	- A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System										-																
Heart	+	. 4	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	·+ —-	+	+	+	+	+	
Endocrine System																										
Adrenal gland	+						+						+							+	+	+	+	+	+	
Adrenal gland, cortex	+						+						+										+	+	+	
Adrenal gland, medulla	+	٠ +	- +	•	_	+	+	Т	т	-	-	-1	-	7					+	+	+	+	+	+	+	
Islets, pancreatic	+	. +	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland	+	+	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pituitary gland	+	٠ ١	- +	• +	+	+	+	+	+	+			+						+	+	+	+	+	+	+	
Thyroid gland Follicular cell, adenoma	+	٠ ٦	- +	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	. +	+	+	
CONCUME CER. AUCHORIA														^												

,这种是一种,我们是一种,我们是一种,我们是一种,我们是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种, 第二章 第二章 是一种,我们是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,我们就是一种,

TABLE C2a	!								
Individual Animal Tumor	Pathology	of Male	Mice in	the	2-Year	Feed	Study	of	Triamterene:
First Study: 400 ppm (con	tinued)								

Number of Days on Study	7 2 9		7 3 0	7 3 0	7 3 0		7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	3		3	3	3	3	3	7 3 2	7 3 2	7 3 2	7 3 2	3	
Carcass ID Number	2 5	7	8	2	3	3	3 2	2 3 3 1	3 7	4 1	4 2	4	4	4 5	2 4 6 1	4 8	4 9	5 0	1	5 3	5 5	5 9	2	6 3	6 5	
Alimentary System							_													-	_					
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	M	i	4	Ţ	<u>.</u>	<u>.</u>	+	<u>.</u>	+	+	<u>.</u>	+	+				+	+	+	+		M	<u>.</u>	+	+	
Intestine large	+		+	·	+	<u>.</u>	+	+	+	+	÷	+	+		+		+	+	÷	4-	÷	+	<u>.</u>	<u>.</u>	i	
Intestine large, cecum	, ,	÷	Ţ	<u>.</u>	<u>.</u>	<u>.</u>	<u> </u>	+	i	+	Ţ	÷	+	+	+	<u>.</u>	+	+	<u>.</u>	<u>.</u>	+	+	+	<u>.</u>	<u>,</u>	
Intestine large, colon	T	+	+	<u>.</u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon Intestine large, rectum		+	+	1	+	+	+				+	+	+		+		+	+	+	+	+	+	+	+	+	
Intestine small		<u>.</u>	i	<u>'</u>	<u>.</u>		+	+	+	+	+						+	+	+	÷	Ţ	Ţ	<u>.</u>	Ţ	÷	
Intestine small, duodenum	т	+		T	T			+					+		+				+	<u>.</u>	1	1	-L	<u>-</u>	, ·	
Adenocarcinoma	т	X	7	т	7'	7	Τ,	۲	т-	7	.4.	τ	1	'	'	,	,			•			•	•	•	
Intestine small, ileum	B. 4		. 1	+	_1_	_1	.1.	.1.	.1.	.1	.1.	.1.	.1_	_	_			<u>.</u> L			.1.	.اـ	JL.	_L	4-	
·															+				7				T	T	+	
Intestine small, jejunum Adenocarcinoma	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Liver	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocellular carcinoma	X		X			х																X		X		
Hepatocellular adenoma Hepatocellular adenoma, multiple Mesentery		X			x	_		x			x		X				x					+	X	-	X	
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+				+				+				+	+	+	+	+	+	+	
Papilloma squamous									X																	
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System																								_		
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System																			-							
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Islets, pancreatic	+	+	+	+	+	+	+								+							+	+	+	+	
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	M	+	+	+	+	M	+	+	+	
Pituitary gland	+	+													+											
Thyroid gland Follicular cell, adenoma	+	+													+											

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 400 ppm (continued)

First Study: 400 ppm (continued)		
Number of Days on Study	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 3 3 3 3 3	
	2 2 2 2 2 2 2 2 2 2	
Carcass ID Number	6 6 7 7 7 7 7 7 8	Total
,	7 9 0 1 4 5 6 7 9 0	Tissues
	1 1 1 1 1 1 1 1 1 1	Tumor
limentary System		
Esophagus	+ + + + + + + + +	60
Gallbladder	. + + + + + M + + + +	54
Intestine large	+ + + + + + + + + +	59
Intestine large, cecum	+ + + + + + + + +	54
Intestine large, colon	+ + + + + + + + +	57
Intestine large, rectum	+ + + + + + + + +	58
Intestine small	+ + + + + + + + + +	57
Intestine small, duodenum Adenocarcinoma	+ + + + + + + + +	55 1
Intestine small, ileum	+ + + + + + + + +	55
Intestine small, jejunum	+ + + + + + + + +	55
Adenocarcinoma		1
Liver	+ + + + + + + + +	60
Hepatocellular carcinoma	X X X	13
Hepatocellular adenoma	X	9
Hepatocellular adenoma, multiple	X X	11
Mesentery		2
Pancreas	+ + + + + + + + +	60
Salivary glands	+ + + + + + + + + + + + + + + + + + + +	60
Stomach	+ + + + + + + + +	59
Stomach, forestomach	+ + + + + + + + + + + + + + + + + + + +	58
Papilloma squamous		1
Stomach, glandular	+ + + + + + + + +	59
Cardiovascular System		
Heart	+ + + + + + + + + +	60
Endocrine System		
Adrenal gland	+ + + + + + + + +	59
Adrenal gland, cortex	` + + + + + + + + +	60
Adrenal gland, medulla	+ + + + + + + + +	60
Islets, pancreatic	+ + + + + + + + +	60
Parathyroid gland	M + + + + + + + + +	56
Pituitary gland	+ + + + + + + + +	58
Thyroid gland	+ + + + + + + + + +	60
Follicular cell, adenoma		2
General Body System		
None		

在 2000年,1911年,191

TABLE C2a	
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of	Triamterene:
First Study: 400 ppm (continued)	

					_			_	_			_		_	_	_	_			_	_	_					 	
Number of Days on Study	8	3	2 : 8 : 4 :	8	8	8	8	8	8	8	8	8	2 8 8	2	1	7 2 9	2	2	7 2 9			7 2 9	7 2 9	2	7 2 9	2		
C ID Namb		2 :		2		2										2 1											-	
Carcass ID Number		4	1 9 1	7	4	7	2	0	3	5	9	8	4	6	1	1 1	2	3	4	5	6	8	0	1	2	3		
Genital System																	-										 	
Epididymis		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Preputial gland																+	+			+	+			+				
Prostate		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Seminal vesicle		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Testes		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Interstitial cell, adenoma																٠												
Hematopoietic System																	-,-								_		-	
Bone marrow		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node, mandibular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node, mesenteric		+	+	Α	+	+	M	M	+	+	+	+	+	+	M	M	+	M	M	+	+	M	+	+	+	+		
Spleen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Thymus																M												
Integumentary System																				_			_				 	
Mammary gland		+	M	M	M	M	+	M	+	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M	I M	M		
Skin		+	+	+	+	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Musculoskeletal System																										7.		
Bone		+	+	+	A	+	+	+	•+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Nervous System		-											-															
Brain		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	 	
Respiratory System																												
Lung		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+		
Alveolar/bronchiolar adenoma																						X						
Alveolar/bronchiolar carcinoma																Х	X											
Alveolar/bronchiolar carcinoma, multiple																			X									
Nose		+	+	+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Trachea		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	 <u>. </u>	
Special Senses System																												
Harderian gland Adenocarcinoma Adenoma																												

TABLE C2a Individual Animal Tumor Pathology First Study: 400 ppm (continued)	y of Ma	le i	Mi	ce	in	the	e 2	-Ye	ear	·F	eed	S	tuć	ły (o f '	Tri	ian	ite	rei	ne:		ţ.,						
Number of Days on Study	7 2 9	3		3	7 3 0			3	7 3 0	3	3	3	3	3	7 3 2	3	3	3	7 3 2	3	3	3	3	3	_	3	<u></u>	 .
Carcass ID Number	2 2 5 1		8	2 9	3 0	3 1	3 2	3	2 3 7 1	4 1	4 2	4 3	4	5	4	4 8	9	5	1	5 3	5 5	5 9	6	6 3	5	; ;		
Genital System																				_								
Epididymis	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+		
Preputial gland				+					+				+	+	+		+			+	+	+						
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+		
Testes Interstitial cell, adenoma	+	7	T	_	T	_	+	т	+	+	+	_	7	_	_	7	_	_	т	_	X		+	7		Г		
Hematopoietic System																_												
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+		
Lymph node	+	+	+	+	+										+						+		+	. +		+		
Lymph node, mandibular	+	+	+	+					+															. +		+		
Lymph node, mesenteric		(+		+					+																	+		
Spleen Thymus									+															- + 1 N				
Integumentary System		-																										
Mammary gland	M	I M	I M	I M	M	M	М	M	M	М	М	M	M	М	M	М	M	M	M	[M	I M	1 N	1 N	1 N	1 N	M		
Skin									+																			
Musculoskeletal System		-			-		_									-	_	_		_	_							
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	- +	٠ -	+		
Nervous System														_										٠.				
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	+	. +	- +	- 1		+		
Respiratory System			,																						L			
Lung		· +		+	+	+ X		+	+	+ X		+	+	+	+		+ X		+	+	+	+	- +	- 1	г .	т		
Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,	Х		•			Λ				۸						Λ	Λ	X										
multiple						_																						
Nose	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	. +	+	+	+	+	- +	• +	٠ +	- +	- 4	٠ ٠	+		

multiple Nose	-		-				-					+						
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Special Senses System																		
Harderian gland							+											
Adenocarcinoma							X											
Adenoma																		

TABLE C2a Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: First Study: 400 ppm (continued)

rust Study. 500 ppmi (continued)		
Number of Days on Study	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 3 3 3 3 3	
Carcass ID Number	2	Total
Carcass and reducer	7 9 0 1 4 5 6 7 9 0	Tissues
	1 1 1 1 1 1 1 1 1	Tumors
Genital System		
Epididymis	+ + + + + + + + +	60
Preputial gland	+	15
Prostate	+ + + + + + + + +	60
Seminal vesicle	+ + + + + + + + +	60
Testes Interstitial cell, adenoma	+ + + + + + + + +	60 1
Hematopoietic System		
Bone marrow	+ + + + + + + + +	60
Lymph node	+ + + + + + + + +	60
Lymph node, mandibular	+ + + + + + + + +	60
Lymph node, mesenteric	+ + + + + M M + + +	45
Spleen	+ + + + + + + + +	60
Thymus	M + + M + + + M + M	39
Integumentary System		
Mammary gland	MMMMMMMM	3
Skin	+ + + + + + + + +	60
Musculoskeletal System		
Bone	+ + + + + + + + +	59
Nervous System		
Brain	+ + + + + + + + +	60
Respiratory System		
Lung	+ + + + + + + + +	60
Alveolar/bronchiolar adenoma	X X	9
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,	X	4
multiple		1
Nose	+ + + + + + + + +	60
Trachea	+ + + + + + + + +	60
Special Senses System		····
Harderian gland	+	2
Adenocarcinoma		1
Adenoma	X	1

TABLE C2a	
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of	Triamterene:
First Study: 400 ppm (continued)	+ X

 _	2	2	2		_						-						-								
	_	_	_	2	2	2	2	2	2	2	2	6	7		7			7	-	7.			7	7.	
 3		4	4	4	5					8 6	8			9									9	9	
 2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
3 4	1 9	4 7	5 4	5 7	5 2																				
 1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
																				_					
 +	+	+							+	+	+	+	+	-	-				-			-			
_		_		_	_	_	1	+		+	+	4	+	4	+	+	+	+	+	+	+	+	+	+	
Т	7		•	т	•		r	Г		Г	Г	x	,	,	1	į	'.	•				r	•	•	
	2 3 4 1	2 2 3 1 4 9 1 1	2 2 2 3 1 4 4 9 7 1 1 1	2 2 2 2 3 1 4 5 4 9 7 4 1 1 1 1	2 2 2 2 2 3 1 4 5 5 4 9 7 4 7 1 1 1 1 1 + + + + + + + + + +	2 2 2 2 2 2 2 3 1 4 5 5 5 4 9 7 4 7 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 3 1 4 5 5 5 6 4 9 7 4 7 2 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 3 1 4 5 5 5 6 7 4 9 7 4 7 2 0 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 3 1 4 5 5 5 6 7 3 4 9 7 4 7 2 0 3 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 2 2 3 1 4 5 5 5 6 7 3 3 4 9 7 4 7 2 0 3 5 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 1 4 5 5 5 6 7 3 3 5 4 9 7 4 7 2 0 3 5 9 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

TABLE C2a Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: First Study: 400 ppm (continued)

Number of Days on Study	_	7 3 0	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 3												
Carcass ID Number	2	2 2 7 1	2 2 8 1	2 2 9 1	2 3 0 1	2 3 1 1	2 3 2 1	2 3 3 1	2 3 7 1	2 4 1 1	2 4 2 1	2 4 3 1	2 4 4 1	2 4 5 1	2 4 6 1	2 4 8 1	2 4 9 1	2 5 0 1	2 5 1	2 5 3 1	2 5 5 1	2 5 9 1	2 6 2 1	6	2 6 5 1	
Urinary System Kidney Urinary bladder	+	++	+	+	+	+	++	++	+	•	++	•	++	++	•	++	•	•	++	٠.	++	•	++		++	
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant mixed	+	+	+ x	+	+	+	+ X		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

TABLE C2a
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
First Study: 400 ppm (continued)

		
	7 7 7 7 7 7 7 7 7 7	
Number of Days on Study	3 3 3 3 3 3 3 3 3 3	
,	3 3 3 3 3 3 3 3 3 3	
	2 2 2 2 2 2 2 2 2 2 2	
Carcass ID Number	6 6 7 7 7 7 7 7 8	Total
	7 9 0 1 4 5 6 7 9 0	Tissues/
	1 1 1 1 1 1 1 1 1	Tumors
Urinary System		
Kidney	+ + + + + + + + +	60
Urinary bladder	+ + + + + + + + +	60
Systemic Lesions		
Multiple organs	+ + + + + + + + +	60
Lymphoma malignant histiocytic	X	1
Lymphoma malignant mixed	X	4
, .		

TABLE C2b
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
Second Study: 0 ppm

					_					_		_														
Number of Days on Study		4.	3	2	7 0 1	0	7 7 1 1 2 7	2	7 2 9	7 2 9	_	2	7 7 2 2 9 9	_	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		
	;'	_			6		6 6		-		-		5 5							6	6	6	6	-		
Carcass ID Number		9					1 1						9 , 9													
	,	1			5 1	4 (0 9 1 1		1				8 9	1												
		1	1	1	1	1 .	1 1	1	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1	1	1		
	·			_	_				<u> </u>			_			_				_	_						
dimentary System																										
Esophagus Gallbladder		+	+	+	+	+	+ +	• +	+	+	+	+	+ -	+	+	+	+	+	+	+	+	+	+	+		
		+	+	+	+ .	A ·	+ +	+	+	+	+	+	+ -	+	+	+	+	+	+	+	+	+	+	M		
Intestine large		+	+	+	+	A ·	+ +	+	+	+	+	+	+ -	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, cecum		. +	+	+	+	A	+ +	+	+	+	+	+	+ -	+	+	+	+	+	+	+	+	+	+	+		
Fibrosarcoma																		٠.			X					,
Intestine large, colon			+	+		A ·			+	+	+	+	+ -	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, rectum		+	+	+	+		+ +		+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+		
Intestine small		+	+	+	+		+ +		+	+	+	+	+ -	+ +	+	. +	+	+	+	+	+	+	+	+		
Intestine small, duodenum		M	+	+	+	A	+ +	+	+	+	+	+	+ -	+	M	+	+	+	+	+	+	+	+	+		
Intestine small, ileum		+	+	+	+	A	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+		
Intestine small, jejunum		+	+	+	+	A	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+		
Liver		+	+	+	+	+	+ +	+	+	+	+	+	+ :	+	+	+	+	+	+	+	+	+	+	+		
Hemangiosarcoma														ζ.				X								
Hepatocellular carcinoma				X		X							X						X			X		X		
Hepatocellular carcinoma, multiple					X		_																,			
Hepatocellular adenoma						X								_	X				X							
Hepatocellular adenoma, multiple					X	2	X						X X	(X				X	•			Х		
Mesentery				+										~												
Adenocarcinoma																										
Fibrosarcoma, metastatic, skeletal																										
muscle				Х																						
Pancreas	•	+	+	+	+	M	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	A		
Fibrosarcoma, metastatic, skeletal				_																					1	
muscle				X																						
Salivary glands		. +	+	+	+	+	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+		
Stomach		+	+	+	+	A ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, forestomach		+	+	+	+	A	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+		
Stomach, glandular	,	+	+	+	+	A ···	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+		
					_			<u>· · ·</u>		_		_					_						<u> </u>	.		
Cardiovascular System																								,		
Heart		+	+	+	+	+	+ +	. +	+	+	+	+	+ -	+	+	+	+	+	+	+	+	+	+	+		
Fibrosarcoma, metastatic, skeletal																									•	
muscle				X																						

^{+:} Tissue examined microscopically

M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

A: Autolysis precludes examination

 $\begin{array}{l} \text{Table C2b} \\ \text{Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:} \\ \text{Second Study: 0 ppm (continued)} \end{array}$

					_				_		_						_	_		_	_	_						
Carcass IID Number 6		•	•	•	-		•	•	•				•	•	•	•			7	•	•	7	7	7	7		•	
Carcass ID Number 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 4 4 4 4	Number of Days on Study	_	_																9			9	9	9			_	
8	 	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	_	 6	
Alimentary System Esophagus Gallbladder + + + + + + + + + + + + + + + + + + +	Carcass ID Number	1	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	4	4	4	4	4	4	4		5	Total
Alimentary System Esophagus Gallbladder + + + + + + + + + + + + + + + + + + +		8	0	1	2	3	4	5	7	8	9	0	2	5	6	7	8	9	0	2	5	6	7	8	9		0	Tissues
Esophagus							1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		1	Tumor
Esophagus	Alimentary System																											
Galibladder		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	- +	-	+	50
Intestine large		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	- +	-	+	48
Intestine large, cecum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	- +	-	+	49
Fibrosarcoma		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	- +	-	+	49
Intestine large, colon																												1
Intestine large, rectum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	- 4	-	+	
Intestine small		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	- 4	-	+	49
Intestine small, ileum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4	- 4	-	+	49
Intestine small, jejunum	Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4	- 4	-	+	47
Intestine small, jejunum	Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	- 4	_	+	49
Liver	Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	- 4	+	+	49
Hepatocellular carcinoma		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4	- 4	-	+	50
Hepatocellular carcinoma, multiple Hepatocellular adenoma	Hemangiosarcoma																											2
Hepatocellular carcinoma, multiple Hepatocellular adenoma								X														Х						8
Hepatocellular adenoma																												
Hepatocellular adenoma, multiple			Х			Х									Х			х					X	C X	(
Mesentery + 2 Adenocarcinoma X 1 Fibrosarcoma, metastatic, skeletal 1 muscle 1 Pancreas + + + + + + + + + + + + + + + + + + +		х																-			х		-		-			
Adenocarcinoma							-																					
Fibrosarcoma, metastatic, skeletal muscle Pancreas + + + + + + + + + + + + + + + + + + +																												
Pancreas	Fibrosarcoma, metastatic, skeletal																											-
Fibrosarcoma, metastatic, skeletal muscle Salivary glands + + + + + + + + + + + + + + + + + + +	Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	- 4	- 4	۲	+	
Salivary glands													·					Ť	·	·	•	·	·			ļ.	•	
Stomach	Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	- 4	+	+	
Stomach, forestomach		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4			-	
Stomach, glandular + + + + + + + + + + + + + + + + + + +	Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	- +				
Heart $+ + + + + + + + + + + + + + + + + + +$	Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠ +	- 4	-	+	49
Heart $++++++++++++++++++++++++++++++++++++$	Cardiovascular System					_													-				-		_	_		
Fibrosarcoma, metastatic, skeletal		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	- 4	- 4	+	+	50
•	Fibrosarcoma, metastatic, skeletal																				,	·			•			
																												1

TABLE C2b
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
Second Study: 0 ppm (continued)

				_			-																		-				
Number of Days on Study	4 4 0	5 3 4	2	0) ()	1	1	2	7 2 9	2	2	2	2				2		7 2 9						7 2 9			
Carcass ID Number	9 1	3	2 6	1 5	. 3	3 4 (1 0	1 9	9 2	9 3	9 5	9 6	9 7	9 8	9 9	6 0 1 1	0 2	0 3	0 4	0 5	0 7	0 8	9)]	1 1	1 3	1 6		
Endocrine System						-						_						*		•				,,	•		•		
Adrenal gland	+	+	- +	- 4	- -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. 4	+ -	+	+	+		
Adrenal gland, cortex	+	+	- +	- 4	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠ +	+ -	+	+	+		
Adrenal gland, medulla	+	+	- +	- +	٠ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		
Islets, pancreatic Carcinoma	+	+	- +	- +	+ 1	M	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+ -	+	+	M		
Parathyroid gland	+	- 4	- 4	- 4	+ 1	М	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	د .	+	+	+	M		
Pituitary gland	+															+								+	+	+	+		
Thyroid gland Follicular cell, adenoma	+	. 4	- +	- +	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		
General Body System None						_											_						_						
Genital System																													
Epididymis	+	. 4	- +		+ -	+	+	+	+	+	+	+	+		+	+				+	+	. +		+	+	+	+		
Epididymis Preputial gland	+	· +	- +		∔ -					++		+	+	+		+	+		+	+				+	+	+	++		
Epididymis Preputial gland Prostate	+	· ન ન	- + - +		+ ·	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+		+	+ + + .	+ + +	+ + +		
Epididymis Preputial gland	+++++	· + + + + + + + + + + + + + + + + + + +	- 4 - 4 - 4		+ -	+	+		+	+	+	+++	+++	+++	+	+	+++++++++++++++++++++++++++++++++++++++	+	++	+	+	+	- 	+++++	++++	+ + + +	+ + + + +		
Epididymis Preputial gland Prostate Seminal vesicle	++++	· + + + + + + + + + + + + + + + + + + +	- + - + - +		+ -	+	+	+ +	+	+	+	+++	+++	+++	+	++	+++++++++++++++++++++++++++++++++++++++	+	++	+	+	+	- 	++++	++++	+ + + +	+ + + + +		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System	+++	ન • ન • ન	- + - + - +		+ -	+ + +	++++	++++	++++	+ + +	+ + +	+ + + +	+ + + +	+ + +	+++	+ + +	+++	++++	+ + +	++	+	· +		+ + + +	+ + + + -	+ + + +	+ + + +	 	
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow	+++	ન • ન • ન	- 4 - 4 - 4 - 4		+ -	+ + +	++++	++++	++++	+ + +	+ + +	+ + + +	+ + + +	+ + +	+++	++	+++	++++	+ + +	++	+	· +		+ + + + +	+++++ + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	 	
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma	+ + +				+ -	+ + ++	+ + +	+ + + +	+ + + +	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + +	+ + + + + +	++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	· +							
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node	+ + +		- - 1		+ -	+ + ++	+ + +	+ + + +	+ + + +	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + +	+ + +	++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	· +						 	
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node	+++++++++++++++++++++++++++++++++++++++	4 · 4 · 4 · 4 · 4	+ + X	 (+ ·	+ + + + + + +	+ + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	· + · + · +		+	+	+	+	 	
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular	+ + + + + + +		⊦ + > + +	 [+ - + -	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + +	+ + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	· + · + · + · +		+	+	+	+		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric	+ + + + + + + + +		+ + > + +	 (+ + + + + + + + + + + + + + + + + + +	+ + + + + + A	+++++++++++++++++++++++++++++++++++++++	+++ + + + ++	+ + + + + + + + + + + + + + + + + + + +	++++++++++	+ + + + + + M	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	· + · + · + · · +		+ + M	++++	+ + +	+		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular	+ + + + + + + + +		+ + > + +	 (+ + + + + + + + + + + + + + + + + + +	+ + + + + + A	+++++++++++++++++++++++++++++++++++++++	+++ + + + ++	+ + + + + + + + + + + + + + + + + + + +	++++++++++	+ + + + + + M	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	· + · + · + · · +		+ + M	++++	+ + +	+ + M		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen	+ + + + + + + +		+ + > + + + +	+ - { -	+ · · · · · · · · · · · · · · · · · · ·	+ + + + + A M	++++++++++	+ + + + + A	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + M +	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	· + · + · · + · · · · · · · · · · · · ·		+ + M +	++++	+ +++	+ + M		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma	+ + + + + + + +		+ + > + + + +	 2 - 1	+ · · · · · · · · · · · · · · · · · · ·	+ + + + + A M	++++++++++	+ + + + + A	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + M +	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	· + · + · · + · · · · · · · · · · · · ·		+ + M +	++++	+ +++	+ + M M		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, skeletal muscle	+ + + + + + + +		+ + + + + +	 2 - 1	+ · · · · · · · · · · · · · · · · · · ·	+ + + + + A M	++++++++++	+ + + + + A	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + M +	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	· + · + · · + · · · · · · · · · · · · ·		+ + M +	++++	+ +++	+ + M M		
Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, skeletal muscle	+ + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+	+ + + + + + + + + + M	+ + + + + + + AM + +	++++++++	+++ + + ++A +	+ + + + + + + M	++++++++	+ + + + + + + + + + + + + + + + + + +	++++ + + + + + M	++++ + + ++++ +	++++ + + +++ M	+ + + + + + + + M	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++	+ + + + + + +	· + · + · + · · + · · +		+ M + +	+ + + +	+ + + +	+ + M M	 	
Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, skeletal muscle Integumentary System	+ + + + + + + + + M	4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 ·	+ + + + + + + + + + + + + + + + + + +	+ 2 + - ! + ! + ! + !	+ + + + + + + + + + M	+ + + + + + + A M + + M	+ + + + + + + + M	++++ + + ++A +	+ + + + + + + M	+ + + + + + + + + M	+ + + + + + + + + + + M	+ + + + + + + + + + M	++++ + + +++ M	++++ + + + + M	+ + + + + + + + + M	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	++++ + ++++ + + ++	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +		+ M + +	+ + + +	+ + + +	+ + M M M	 	

TABLE C2b Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: Second Study: 0 ppm (continued)

Number of Days on Study	7 2 9	2	7 2 9	7 2 9	7 2 9	7 2 9		2	2	2	2	2		2	2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	
Carcass ID Number	1 8	2 0	6 2 1 1	2 2	2	2 4	2 5	2 7	2 8	2 9	3 0	3 2	3 5	3 6	3 7	3 8	3 9	4 0	4 2	4 5	4 6	4 7	4 8	4 9	5 0	Total Tissue Tumor
Endocrine System																								_		
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	·	Ţ	<u>.</u>	+	+	+	+		+			+		+			+		+	+	+			+	+	50
Adrenal gland, medulla	÷	÷	<u>.</u>	+		+			+				+								+				+	50
Islets, pancreatic	+	+	4	+	+	+	+	+	+	+	+	+	+	+	+		+			+			+		+	47
Carcinoma	•	'	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	X	•	•	•	•		•	•	1
Parathyroid gland	ı.	_	1	_	_	_	м	+	_	_	_	_	_	+	+	_	_		_	м	R.A	_			+	44
Pituitary gland	.	T	+	+	+																				+	50
	T .	-																							+	50
Thyroid gland Follicular cell, adenoma	т	_	_	+	Т	т	X	т	т	т	_	_	Т	7	_	+	+	_	_	_	_		_	7		1
None																										
Genital System																										50
Genital System Epididymis	+	<u>-</u>	+	+	+	+		+			+	+		+	+	+	+	+	+	+			. +	+	+	50
Genital System Epididymis Preputial gland	++	 +	++	++-			+	+	+	+	+		+	+	+	++.	+	+	+	+		+			+	40
Genital System Epididymis Preputial gland Prostate	++++	- +++	+++	+	+		+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	40 50
Genital System Epididymis Preputial gland	+ + + + + + + + + + + + + + + + + + + +	· + + + +	+	+	+	++	+++	+ +	+ + +	+ + +	+ + +	+	+	+++++	+++++	+	+	++++	+++	++++	+	+++++	+	+	+	40
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes	+ + + + + +	+	+	+	+	++	+++	+ + +	+ + +	+ + +	+ + +	+	+++++	+++++	+++++	+	++++	++++	+++	++++	+	+++++	+	+	+	40 50 50
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System	+ + + + +	+	+	++++	+ + +	+ + +	+ + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + +	+ + +	+ + + +	+ + + +	+ + +	+ + +	+ + +	+ + +	+ + +	+++	+++++	+	+	+ + +	40 50 50 50 50
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow	+ + + + + + + +	+	+	++++	+ + +	+ + +	+ + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + +	+ + +	+ + + +	+ + + +	+ + +	+ + + +	+ + +	+ + +	+ + +	+++	+++++	+	+	+	40 50 50 50 50
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma		+	++	+ + + + + +	+ + + +	++++++	+ + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + +	+ + +	+ + + + +	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + X	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + + + + + + + + + + + + + + + + +	+++	+ + +	+++++++++++++++++++++++++++++++++++++++	+	+ + + + +	40 50 50 50 50
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node		+	++	+ + + + + +	+ + + +	++++++	+ + + + +	+ + + + +	+ + + + +	+ + + + +	+ + + +	+ + +	+ + + + +	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + X	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + + + + + + + + + + + + + + + + +	+++	+ + +	+++++++++++++++++++++++++++++++++++++++	+	+ + +	50 50 50 50 50
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node	+	+++++	++	+ + + + + +	+ + + +	++++++	+ + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + +	+ + +	+ + + + +	+ + + + + +	+ + + + +	+ + + +	+ + + + + X +	+ + + + +	+ + + + +	+ + + + + + + + + + + + + + + + + + + +	+++	+ + +	+++++++++++++++++++++++++++++++++++++++	+	+ + + + +	50 50 50 50 50 1
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular	+	+++++++++++++++++++++++++++++++++++++++	+++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + +	+ + + + + + + +	+ + + + + + + +	+ + + + + + + +	+ + + + + + + +	+ + + + + +	+ + + + + + + + + +	+ + + + + + +	+ + + + + + +	+ + + + +	+ + + + + X + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric	+ + M	+ + + + + +	+ + + +	+++ + + ++	+ + + + + + + + + + + + + + + + + + + +	+++++++++	+ + + + + + M	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + M	+ + + + + X + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++ + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen	+ + M	+ + + + + +	+ + + +	+++ + + ++	+ + + + + + + + + + + + + + + + + + + +	+++++++++	+ + + + + + M	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + M	+ + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41 47
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma	+ + M +	+ + + + + + + + + + + + + + + + + + + +	+ + + ++	++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+ + + + + + M + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + M +	+ + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	+ + + + + + + X	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41 47 2
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus	+ + M +	+ + + + + + + + + + + + + + + + + + + +	+ + + ++	++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+ + + + + + M + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + M +	+ + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	+ + + + + + + X	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41 47
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma	+ + M +	+ + + + + + + + + + + + + + + + + + + +	+ + + ++	++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+ + + + + + M + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + M +	+ + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	+ + + + + + + X	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41 47 2
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, skeletal muscle	+ + M +	+ + + + + + + + + + + + + + + + + + + +	+ + + ++	++++++++	+++++++++++++++++++++++++++++++++++++++	++++++++++	+ + + + + + M + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + M +	+ + + + + + + + X	+++++++++++++++++++++++++++++++++++++++	++++	++++ + + ++++	+ + + + + + + X	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41 47 2 40
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, skeletal muscle	+ + M + +	++ + + + +	++ + +++ +	+++ + + +++ +	+++++++++	+ + + + + + + M	+ + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	++++++++++	++++ + + ++++	++++ + + + + +	+++++++++	+ + + + + + + M	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + M	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	++++ + + ++++ +	++++ + + + + + + + + + + + + + + + + + +	++++ + + + + + + + + + + + + + + + + + +	+ + + + + + + X +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	50 50 50 50 50 1 50 1 50 41 47 2 40
Genital System Epididymis Preputial gland Prostate Seminal vesicle Testes Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Fibrosarcoma, metastatic, lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, skeletal	+ + M + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	++++ + + +++ M	+ + + + + + + + + + H	+ + + + + + + + M	+ + + + + + + + + + + M	+ + + + + + + + + M	+ + + + + + + + + + M	+ + + + + + + + + + M	+ + + + + + + + + M	+ + + + + + + + + M	+ + + + + + + M	+ + + + + + + + + M	+ + + + + + + + M	+ + + + + + + + + + + M	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + M	+ + + + + + + + + + M	++++ + + + + + + + M	+ + + + + + + X + + X +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	50 50 50 50 50 1 50 1 50 41 47 2 40

TABLE C2b
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
Second Study: 0 ppm (continued)

Second Stady: 6 ppm (continued)														_		_				_						
Number of Days on Study	4 4 0	5 3 4	2	7 0 1	7 0 9	7 1 2	7 1 7	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9								
Carcass ID Number	5 9 1 1	1	6	1 5	3 4	6 1 0	1	9 2	3	9 5		9 7	8	9	6 0 1 1	2	3	4	5	0 7	0 8	9	1 1	3	1	
Musculoskeletal System Bone Maxilla, fibrosarcoma Vertebra, coccygeal, osteosarcoma Skeletal muscle Hindlimb, fibrosarcoma	+		+ X		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ x	+	+	+	+	+	
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Fibrosarcoma, metastatic, skeletal muscle Hepatocellular carcinoma, metastatic,	.+	- + X	- + :	+	+	+	+	+ x	+	+	+	+	+	+ x	+	+ X	+	+	+	+	+	+ X	+	+	+	
liver Nose Trachea	+	- +	- +	X + +	++	++	+	++	++	+	+	+	++	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System Ear Fibrosarcoma Eye Harderian gland Adenoma	•	•							•		-				*X					+		М				
Urinary System Kidney Carcinoma Fibrosarcoma, metastatic, skeletal muscle	+	- +	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocellular carcinoma, metastatic, liver Urinary bladder	.+	- +	- +	. +	X +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions Multiple organs Lymphoma malignant mixed	+ X	+ +	+ +	- +	+	+ X	+ X		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

TABLE C2b Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: Second Study: 0 ppm (continued)

							_	_																			
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		
Carcass ID Number	6 1 8 1	2	2	2	2	2	2	2 7	2 8	2 9	3 0	3 2	3 5	3 6	7	3	3	4 0	4	4 5	4 6	4 7	4 8	4 9	5 0		Total Tissues/ Tumors
Musculoskeletal System Bone Maxilla, fibrosarcoma Vertebra, coccygeal, osteosarcoma Skeletal muscle Hindlimb, fibrosarcoma	+	. +	- +	- +	+	+	+	+	+	*X		+	+	+	+	+	+	+	+	+	+	+	+	+	+		50 1 1 1 1
Nervous System Brain	+	. +	- +	- +	. +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	. +		50
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Fibrosarcoma, metastatic, skeletal muscle Hepatocellular carcinoma, metastatic, liver Nose Trachea	+	· +	- + X		· +	- + - +		+ X		+++	+++	+ X			+ + +	+++	++	+ + +	+ + +	+ X	+	+ X	+	X			50 6 7 1 1 50 50
Special Senses System Ear Fibrosarcoma Eye Harderian gland Adenoma				*		-	+			-	+									+						-	1 1 1 4
Urinary System Kidney Carcinoma Fibrosarcoma, metastatic, skeletal muscle Hepatocellular carcinoma, metastatic, liver Urinary bladder				 + +			. +	. +	+	+ x			+		+		+	+	+	+		. +	- +	- +	- +		50 1 1 1 50
Systemic Lesions Multiple organs Lymphoma malignant mixed	+		+ +		- +	+ +	- +	. +	+	+ X		+	+	+	+	+	+	+ X	+	+	. +	. +	- +	- +	- +	-	50 5

TABLE C2b Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: Second Study: 400 ppm

Number of Days on Study	4 9	2	5	9	3	6	7	6 9	0	1	2	2	2	2	2	7 2			7 2				7 2	7 2	2	
·	4	2	4	3	3	6	1	4	1	8	4	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
V	6							6																		
Carcass ID Number	9	7		_	6			9																		
	1	6 1						7 1																		
Alimentary System																									· · · · · ·	
Esophagus	+	+	+	. 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	+	· N	1 +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large	+	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	. +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	- +	. 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	· N	1 +	. +	+	+	+	+		+	+	+			+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	· N	1 +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Liver	+	+	- 4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	
Hemangiosarcoma, multiple Hepatoblastoma					Х																		X			
Hepatocellular carcinoma	Х							Х														X				
Hepatocellular carcinoma, multiple						Х			X																	
Hepatocellular adenoma								X		X			Х				Х					X	X			
Hepatocellular adenoma, multiple		X			Х	X						X		Х		Х		Х	X		X			X	X	
Mesentery				•		+																				
Pancreas	+	٠ +	٠ +	٠ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	- +	- +	- 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ .	
Stomach	+	- +	- +	- 4	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	٠ +	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System																										
Heart	+	٠ +	. +	٠ +	- +	٠ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocellular carcinoma, metastatic, liver																										
Endocrine System												_														
Adrenal gland	+	- +	- +	- 4	- +	+	+	•	•	•	•	•	•	•	+	•	•	•		•		•	+		+	
Adrenal gland, cortex	+	- +	- 4	- 4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Spindle cell, adenoma															X											
Adrenal gland, medulla	4	- +	- 4	- +	- +	+		+															+	+	+	
Islets, pancreatic	+	- 1						+															+		+	
Parathyroid gland	+	- +						+																		
Pituitary gland	+	- 1	- +	- +	- N	1 +	+	+	+	M	+	+	+	+	+	+	+	+	+	+			+	+	+	
Pars distalis, adenoma	•																				X					
Thyroid gland		- 4	- 4	- 4	- 4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

TABLE C2b
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
Second Study: 400 ppm (continued)

Number of Days on Study	7 2 9																									
	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	
Carcass ID Number	6	7	7	7	7	7	7	7	8	8	8		9	9	9	0	0	0	0	0	0	0	0	0	1	Total
	9	0	1	2	3	4	8	9	0	6	7	8	2	6	8	1	2	3	4	5	6	7	8	9	0	Tissues
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Tumors
Alimentary System				-					-																	
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	48
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma, multiple																										1
Hepatoblastoma																										1
Hepatocellular carcinoma		Х						•		х						Х				Х			Х			8
Hepatocellular carcinoma, multiple																									X	3
Hepatocellular adenoma		Х		х			x	x	X											Х						12
Hepatocellular adenoma, multiple	X		x			X		-	-		x	x	Х			x	X		x				x	X	x	24
Mesentery																	-									1
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	<u> </u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	. +	+	+	50
Stomach	<u> </u>	·	·	·	+	÷	+	+	+	+	+	+	4	+	+	+	+	+	+	+	+	4	. +	+	+	50
Stomach, forestomach		·		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	<u>.</u>	50
Stomach, glandular	+	+	+	+	+	+	+	+		+	+	+	-	+		+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System		_	_	_					_	_				_						_	_	_				
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular carcinoma, metastatic,																										
liver		X	•																							1
Endocrine System		_	_		_	_							_	_				_	_	_				_		
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	. +	+	+	50
Adrenal gland, cortex	, 1			+	+	+	+	+	+	+	+	+					+			+		+		. +	-	50
Spindle cell, adenoma	т	-1	-	-	4		,	,	'	1	1	•	'			.,	,-	'	•	,	•	,	-		'	1
Adrenal gland, medulla	1			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+		. 4	4	50
Islets, pancreatic	1			4	4	4	+	+	+			+					+				+			. 4	+	49
Parathyroid gland	<u>.</u>		+	4	+	+	+	+	-								+				. +				+	47
Pituitary gland	1		. +		+	+	+		+															+		48
Pars distalis, adenoma	,	-1	-1	-	Τ-	7	-1-	4.	7	7	7	-1	7"	-	Τ'	7	•	•		7	-	-1	Т	7	г	1
Thyroid gland	_			4		_		+	+	+	+	4		4	+	+	+	+	+	_				+	-	50
Lilytoid giand	т-	7	-	Τ.	7	7	7	٦.	т.	Τ.	-7"	7	-7"	Τ.	т.	~		٠,	-	- 1	- 1	- T			-T	30

Nervous System Brain

			4	- 4		6	_	~	_	7	7	7	7	7	, ,	, ,		7	7	7	7	7	7	7	7	
mber of Dave on Study						3									2 :				2	2	2	2	2	2	2	
mber of Days on Study						3																9	9			
					. ,			-	_		_			_						_	_	_		_		
rcass ID Number						6								5												
icass ID Number						4																				
•				1 1										1												
·											_									_		_				
neral Body System None						:															-					
nital System																										
Epididymis			+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	
Preputial gland				+ .	+ +	+ +				+		+			+	+ -	+ +	- +		+			+	+	+	
Prostate			+	+ -	+ -	+ +	+	+	+	+	+	+	+	•	+	•	+ +			•		+	+	+	+	
Seminal vesicle		•	+	+ -	+ +	+ +	+	+	+	+	+	+	+	•		+ -	+ +	- +		+	•	+	+	+	+	
Testes			+	+ -	+ -	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	
matopoietic System																										
Bone marrow			+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	
Lymph node			+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+ -	+ 1	- +	+	+	+	+	+	+	+	
Lymph node, mandibular			+	+ -	+ -	+ +	+	+		+		+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	
Lymph node, mesenteric	,		+	+ -	+ -	+ +	· M	+						+			+ +		+	+	+	+	+	+	+	
Spleen			+	+ -	+ -	+ +	+	+		+				+	•	+ -	+ +		+	+	+	. +	+	+	+	
Thymus			+	+ ·	+ -	+ +	+	+	+	М	+	М	+	+	+	+ -	+ +	- +	+	+	M	. +	+	+	+	
egumentary System											-				.,**			_								
Mammary gland			M	M I	M N	M M	1 M	I M	M	M	M	M	M	M	M	M I	M N	1 N	I M	I M	M	I M	I N	ΙM	1 M	
Skin			+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	
Subcutaneous tissue, hemangioma	3																									

1. "我是我们的是一个人,我们就是一个

TABLE C2b Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: Second Study: 400 ppm (continued)

Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		7 2 9	7 2 9	7 2 9	7 2 9	7 2 9			2	7 2 9	2	2								
Carcass ID Number	6	7	7	7	7	7	7 8	7 9	8	8 6	8 7	8	9 2	9 6	6 9 8 1	0 1	0 2	0 3	0 4	0 5	0 6	0 7	0 8	0 9	1 0	Total Tissue: Tumor
General Body System None							-	-	-								-									
Genital System							_					_						_						_		<i>F</i> 0
Epididymis	+	+	+	+	+	+			+			+	+	+	+	+		+	+	+	+	+	+	+	+	50
Preputial gland	+	+	+	+	+	+			+	+	+	+	+	+	.1	+	+	+	+	ر		+	+	+	+	37
Prostate Seminal vesicle	+		+			+			+				+			+			+					+	+	50 50
Testes	+			+	-	+			+						+			+		•	-			-	+	50
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node, mandibular	+	+	+	+	+				+	+	+	+	+	+		+			+				+		+	50
Lymph node, mesenteric	+	+	M							+	+	+	+	+		+			+						+	44
Spleen Thymus	+	+	+	+ M					+	+		+	+	+	+	+		+			+				+ [+	50 43
Integumentary System																					-					<u> </u>
Mammary gland	M	M	M	M	M	M	M	М	M	M	M	M	M	M	M	M	M	M	[M	M	M	M	I M	M	M	
Skin																									+	
Subcutaneous tissue, hemangioma																X										1
Musculoskeletal System					-															-				_		
Bone Skeletal muscle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 2
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+		50

TABLE C2b
Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene:
Second Study: 400 ppm (continued)

Number of Days on Study	4	5 2	5 5	_	6 3	6		6		7	7 2	7 2	7 2	7 2	7 2	7 2	7 2	7 2	7 2	7 2	7 2	7 2	7 2	2	7 2	
	4	2	4	3	3	6	1	4	1	8	4	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
Carcass ID Number	9	7	5	6	6	9	9	9	8	9	0	5	5	5	5	5	5	5	6	6	6	6	6	6	6	
	5 1			4																						
Respiratory System		-							-													-				
Lung Alveolar/bronchiolar adenoma	+ X		+	+	+	+	+	+	+	+	+	+ X	+	+	+ X	+	+	+ X	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma, multiple	^											71			71			71							х	
Alveolar/bronchiolar carcinoma																							X			
Alveolar/bronchiolar carcinoma,																										
multiple Hepatocellular carcinoma, metastatic,																										• ,
liver																										
Hepatocellular carcinoma, metastatic, multiple									x																	
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System						-							-	-												
Ear																			M							
Eye Harderian gland															4	+							+			
Adenoma																X							X			
Urinary System											_															
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•
Artery, hepatocellular carcinoma, metastatic																										
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	
Papilloma																							X			
Systemic Lesions																										
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymphoma malignant histiocytic Lymphoma malignant mixed		X	×	X			х			x	x						X							х		
Lymphonia manghant mixeu		Λ	. ^				Λ			1	1													,,		

Table C2b Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of Triamterene: Second Study: 400 ppm (continued)

become beauty too promises,										_											_					
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	
Carcass ID Number	6	7 0	1	6 7 2 1	3	7	7 8	7	8 0	8	8 7	8	2	9 6	9 8	0 1	0 2	0 3		0 5	0 6		0 8	0	0	Total Tissue: Tumor
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma,	+	+	+ x	+ x		+	+	+ X		+ X	+	+	+	+	+	+ x	X		+ x	*	+	+	+	+ X	+	50 9 1 5
multiple Hepatocellular carcinoma, metastatic, liver Hepatocellular carcinoma, metastatic,		X	:										X							x					x	1 3
multiple Nose Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 50 50
Special Senses System			_				_			_	_	_				_	_				_				_	
Ear Eye Harderian gland Adenoma		M	1		+ + X			+ X		+ X																1 6 6
Urinary System Kidney Artery, hepatocellular carcinoma,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
metastatic Urinary bladder Papilloma	+	X +		+	+	+	+	+	+	+	+	+	. +	+	+	+	+	+	+	+	+	. +	+	- +	· +	1 50 1
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant mixed	+	. +	. +	+	+	+	+	+	+	+	. +	+ X		+	+	+	+	+	+	+	+	. +	. +	- +	- +	50 1 8

TABLE C3a Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: First Study

	0 ppm	100 ppm	200 ppm	400 ppm
Harderian Gland: Adenoma				
Overall rates ^a	0/50 (0%)	1/50 (2%)	3/50 (6%)	1/60 (2%)
Adjusted rates ^b	0.0%	2.2%	6.3%	2.2%
Terminal rates ^c	0/47 (0%)	1/45 (2%)	2/46 (4%)	1/46 (2%)
First incidence (days)	_e ` ´	729 (T)	682	729 (T)
ife table tests ^d	P = 0.350	P=0.491	P = 0.121	P=0.496
ogistic regression tests ^d	P = 0.357	P=0.491	P = 0.115	P = 0.496
Cochran-Armitage test ^d	P = 0.416			
isher exact test ^d		P = 0.500	P = 0.121	P = 0.545
Harderian Gland: Adenoma or Carcinoma				,
Overall rates	1/50 (2%)	1/50 (2%)	3/50 (6%)	2/60 (3%)
Adjusted rates	2.0%	2.2%	6.3%	4.3%
Terminal rates	0/47 (0%)	1/45 (2%)	2/46 (4%)	2/46 (4%)
First incidence (days)	585	729 (T)	682	729 (T)
ife table tests	P = 0.323	P = 0.751	P = 0.304	P = 0.490
ogistic regression tests	P = 0.381	P = 0.667N	P = 0.238	P = 0.560
Cochran-Armitage test	P = 0.400			
Fisher exact test		P = 0.753N	P = 0.309	P=0.569
Liver: Hemangiosarcoma			A 180 / 200	0/60 (02)
Overall rates	1/50 (2%)	1/50 (2%)	3/50 (6%)	0/60 (0%)
Adjusted rates	2.1%	2.2%	6.5%	0.0%
Terminal rates	1/47 (2%)	1/45 (2%)	3/46 (7%)	0/46 (0%)
First incidence (days)	729 (T)	729 (T)	729 (T)	- D 0.50401
Life table tests	P=0.413N	P=0.752	P=0.298	P=0.504N
ogistic regression tests	P=0.413N	P = 0.752	P = 0.298	P = 0.504N
Cochran-Armitage test	P = 0.351N	D 0.752N	D-0.200	D_0 456N
Fisher exact test		P = 0.753N	P=0.309	P=0.455N
Liver: Hepatocellular Adenoma	17/50 (34%)	22/50 (44%)	19/50 (38%)	20/60 (33%)
Overall rates	36.2%	48.9%	40.3%	42.6%
Adjusted rates	17/47 (36%)	22/45 (49%)	18/46 (39%)	19/46 (41%)
Terminal rates First incidence (days)	729 (T)	729 (T)	617	711
` ' '	P=0.387	P=0.154	P=0.388	P=0.310
Life table tests	P=0.391	P=0.154	P = 0.417	P=0.314
Logistic regression tests Cochran-Armitage test	P=0.359N	1 -0.154	1 ~0.417	1 -0.514
Fisher exact test	1 -0.55714	P = 0.206	P = 0.418	P = 0.550N
Liver: Hepatocellular Carcinoma				
Overall rates	5/50 (10%)	7/50 (14%)	3/50 (6%)	13/60 (22%)
Adjusted rates	10.6%	14.8%	6.5%	28.3%
Terminal rates	5/47 (11%)	5/45 (11%)	3/46 (7%)	13/46 (28%)
First incidence (days)	729 (T)	557	729 (T)	729 (T)
Life table tests	P=0.019	P = 0.353	P=0.368N	P = 0.030
Logistic regression tests	P = 0.022	P = 0.448	P = 0.368N	P = 0.030
Cochran-Armitage test	P = 0.055			
Fisher exact test		P = 0.380	P = 0.357N	P = 0.081

TABLE C3a Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
Liver: Hepatoblastoma or Hepatocellular	Carcinama			
Overall rates	5/50 (10%)	8/50 (16%)	4/50 (8%)	13/60 (22%)
Adjusted rates	10.6%	16.6%	8.7%	28.3%
racjusted rates Ferminal rates	5/47 (11%)	5/45 (11%)	4/46 (9%)	13/46 (28%)
First incidence (days)	729 (T)	557	729 (T)	729 (T)
Life table tests	P = 0.027	P=0.256	P=0.513N	P=0.030
Logistic regression tests	P=0.031	P=0.346	P=0.513N	P = 0.030
Cochran-Armitage test	P=0.072	1-0.540	1 0.51011	. 0.050
Fisher exact test	1 - 0.072	P = 0.277	P = 0.500N	P = 0.081
Liver: Hepatocellular Adenoma or Carcin	oma			
Overall rates	20/50 (40%)	26/50 (52%)	19/50 (38%)	29/60 (48%)
Adjusted rates	42.6%	55.3%	40.3%	61.7%
Terminal rates	20/47 (43%)	24/45 (53%)	18/46 (39%)	28/46 (61%)
First incidence (days)	729 (T)	557	617	711
Life table tests	P=0.077	P = 0.116	P = 0.533N	P = 0.043
Logistic regression tests	P = 0.074	P = 0.136	P = 0.500N	P = 0.043
Cochran-Armitage test	P = 0.343			
Fisher exact test		P = 0.158	P = 0.500N	P = 0.248
Lung: Alveolar/bronchiolar Adenoma				
Overall rates	3/50 (6%)	9/50 (18%)	10/50 (20%)	9/60 (15%)
Adjusted rates	6.4%	20.0%	21.7%	19.6%
Terminal rates	3/47 (6%)	9/45 (20%)	10/46 (22%)	9/46 (20%)
First incidence (days)	729 (T)	729 (T)	729 (T)	729 (T)
Life table tests	P = 0.095	P = 0.053	P = 0.034	P = 0.057
Logistic regression tests	P = 0.095	P = 0.053	P = 0.034	P = 0.057
Cochran-Armitage test	P = 0.205			
Fisher exact test		P = 0.061	P = 0.036	P = 0.114
Lung: Alveolar/bronchiolar Carcinoma				
Overall rates	6/50 (12%)	3/50 (6%)	6/50 (12%)	5/60 (8%)
Adjusted rates	12.5%	6.2%	12.7%	10.9%
Terminal rates	5/47 (11%)	1/45 (2%)	5/46 (11%)	5/46 (11%)
First incidence (days)	623	522	682	729 (T)
Life table tests	P=0.554	P = 0.267N	P=0.606	P=0.516N
Logistic regression tests	P=0.469N	P = 0.115N	P = 0.613	P = 0.499N
Cochran-Armitage test	P = 0.430N			
Fisher exact test		P = 0.243N	P = 0.620N	P = 0.373N
Lung: Alveolar/bronchiolar Adenoma or	0.000 44.000	10/60 (04%)	1 (150 (000)	14/(0 /00%)
Overall rates	9/50 (18%)	12/50 (24%)	16/50 (32%)	14/60 (23%)
Adjusted rates	18.7%	25.4%	34.0%	30.4%
Terminal rates	8/47 (17%)	10/45 (22%)	15/46 (33%)	14/46 (30%)
First incidence (days)	623	522	682	729 (T)
Life table tests	P=0.140	P=0.281	P=0.079	P=0.158
Logistic regression tests	P=0.157	P = 0.376	P = 0.083	P = 0.159
Cochran-Armitage test	P = 0.325	D 0.212	D 0.002	D 0.200
Fisher exact test		P = 0.312	P = 0.083	P = 0.328

TABLE C3a
Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ррт	100 ppm	200 ppm	400 ppm
All Organs: Hemangiosarcoma				
Overall rates	1/50 (2%)	2/50 (4%)	4/50 (8%)	0/60 (0%)
Adjusted rates	2.1%	4.4%	8.7%	0.0%
Terminal rates	1/47 (2%)	2/45 (4%)	4/46 (9%)	0.0%
First incidence (days)	729 (T)	729 (T)	729 (T)	0/40 (0%)
Life table tests	P=0.377N	P=0.485	P=0.174	P = 0.504N
Logistic regression tests	P = 0.377N	P=0.485	P=0.174	P = 0.504N
Cochran-Armitage test	P = 0.307N	1 -0.405	1 ~0.174	1 -0.50414
Fisher exact test	1 -0.30714	P = 0.500	P = 0.181	P=0.455N
All Organs: Hemangioma or Hemangiosarc	oma			
Overall rates	1/50 (2%)	3/50 (6%)	5/50 (10%)	0/60 (0%)
Adjusted rates	2.1%	6.7%	10.9%	0.0%
Ferminal rates	1/47 (2%)	3/45 (7%)	5/46 (11%)	0/46 (0%)
First incidence (days)	729 (T)	729 (T)	729 (T)	-
Life table tests	P = 0.348N	P=0.290	P=0.099	$P \approx 0.504N$
Logistic regression tests	P = 0.348N	P=0.290	P=0.099	P = 0.504N
Cochran-Armitage test	P = 0.272N			
Fisher exact test		P = 0.309	P≈0.102	P = 0.455N
All Organs: Malignant Lymphoma or Histi	ocytic Sarcoma			
Overall rates	6/50 (12%)	3/50 (6%)	5/50 (10%)	5/60 (8%)
Adjusted rates	12.5%	6.7%	10.6%	10.6%
Terminal rates	5/47 (11%)	3/45 (7%)	4/46 (9%)	4/46 (9%)
First incidence (days)	690 `´´	729 (T)	641	620
Life table tests	P = 0.554N	P = 0.268N	P = 0.512N	P = 0.515N
Logistic regression tests	P = 0.520N	P = 0.257N	P = 0.507N	P = 0.488N
Cochran-Armitage test	P = 0.419N			
Fisher exact test		P = 0.243N	P=0.500N	P = 0.373N
All Organs: Benign Neoplasms				
Overall rates	21/50 (42%)	26/50 (52%)	29/50 (58%)	27/60 (45%)
Adjusted rates	44.7%	57.8%	60.4%	57.4%
Terminal rates	.21/47 (45%)	26/45 (58%)	27/46 (59%)	26/46 (57%)
First incidence (days)	729 (T)	729 (T)	617	711
Life table tests	P = 0.138	P = 0.149	P = 0.068	P = 0.133
ogistic regression tests	P = 0.137	P = 0.149	P = 0.080	P = 0.135
Cochran-Armitage test	P = 0.510			
Fisher exact test		P = 0.212	P = 0.081	P = 0.451
All Organs: Malignant Neoplasms				
Overall rates	17/50 (34%)	17/50 (34%)	16/50 (32%)	22/60 (37%)
Adjusted rates	34.0%	34.0%	33.3%	46.8%
Terminal rates	14/47 (30%)	12/45 (27%)	14/46 (30%)	21/46 (46%)
First incidence (days)	585 ` ′	522	641	620
Life table tests	P = 0.165	P = 0.522	P = 0.524N	P=0.192
Logistic regression tests	P = 0.239	P = 0.460N	P = 0.500N	P = 0.207
Cochran-Armitage test	P = 0.414			
Fisher exact test		P = 0.583N	P = 0.500N	P = 0.465

	0 ppm	100 ppm	200 ppm	400 ppm
All Organs: Benign or Malignant Neoplasms				
Overall rates	32/50 (64%)	38/50 (76%)	35/50 (70%)	38/60 (63%)
Adjusted rates	64.0%	76.0%	71.4%	79.2%
Terminal rates	29/47 (62%)	33/45 (73%)	32/46 (70%)	36/46 (78%)
First incidence (days)	585	522	617	620
Life table tests	P = 0.185	P = 0.112	P = 0.306	P = 0.124
Logistic regression tests	P = 0.203	P = 0.168	P = 0.345	P = 0.106
Cochran-Armitage test	P=0.328N			
Fisher exact test		P = 0.138	P = 0.335	P = 0.551N

(T)Terminal sacrifice

Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Observed incidence at terminal kill

e Not applicable; no neoplasms in animal group

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, bone marrow, brain, epididymis, gallbladder, heart, kidney, larynx, liver, lung, nose, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, testes, thyroid gland, and urinary bladder; for other tissues, denominator is number of animals necropsied.

Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

TABLE C3b Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study

	0 ррт	400 ppm	
Harderian Gland: Adenoma			
Overall rates ^a	1/50 (2%)	6/50 (12%)	
Adjusted rates ^b	2.3%	15.4%	
Terminal rates ^c	1/43 (2%)	6/39 (15%)	
First incidence (days)	729 (T)	729 (T)	•
Life table tests ^d		P = 0.044	
Logistic regression tests ^d Fisher exact test ^d		P=0.044 P=0.056	
Liver: Hepatocellular Adenoma			
Overall rates	21/50 (42%)	36/50 (72%)	
Adjusted rates	44.7%	81.7%	
Terminal rates	17/43 (40%)	31/39 (79%)	
First incidence (days)	701	522	
Life table tests		P = 0.001	
Logistic regression tests		P = 0.001	
Fisher exact test	•	P = 0.002	
Liver: Hepatocellular Carcinoma	0.50 (10%)	11/50 (000)	
Overall rates	9/50 (18%)	11/50 (22%)	
Adjusted rates	19.3%	25.0%	
Terminal rates	6/43 (14%) 622	7/39 (18%) 494	
First incidence (days) Life table tests	022	P=0.329	
Logistic regression tests		P=0.422	
Fisher exact test		P = 0.402	
Liver: Hepatoblastoma or Hepatocellula	r Carcinoma		
Overall rates	9/50 (18%)	12/50 (24%)	
Adjusted rates	19.3%	26.7%	
Terminal rates	6/43 (14%)	7/39 (18%)	
First incidence (days)	622	494	
Life table tests	•	P=0.254	
Logistic regression tests		P=0.338	
Fisher exact test		P=0.312	
Liver: Hepatocellular Adenoma or Carc	•		
Overall rates	25/50 (50%)	38/50 (76%)	•
Adjusted rates	52.1%	82.5%	
Terminal rates	20/43 (47%)	31/39 (79%) 494	
First incidence (days)	622	P=0.004	
Life table tests Logistic regression tests		P=0.005	
Fisher exact test		P=0.006	
Lung: Alveolar/bronchiolar Adenoma		,	• • ,
Overall rates	6/50 (12%)	10/50 (20%)	
Adjusted rates	14.0%	24.6%	
Terminal rates	6/43 (14%)	9/39 (23%)	
First incidence (days)	729 (T)	494	
Life table tests		P = 0.154	
Logistic regression tests		P = 0.201	•
Fisher exact test		P = 0.207	<i>i</i> *

TABLE C3b
Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene:
Second Study (continued)

	0 ppm	400 ppm	
ung: Alveolar/bronchiolar Carcinoma			
Overall rates	7/50 (14%)	6/50 (12%)	
Adjusted rates	15.7%	15.4%	
Terminal rates	6/43 (14%)	6/39 (15%)	
First incidence (days)	534	729 (T)	
life table tests		P=0.570N	
Logistic regression tests		P = 0.505N	
Fisher exact test		P = 0.500N	
Lung: Alveolar/bronchiolar Adenoma o	or Carcinoma		
Overall rates	13/50 (26%)	16/50 (32%)	
Adjusted rates	29.4%	39.7%	
Terminal rates	12/43 (28%)	15/39 (38%)	
First incidence (days)	534	494	
Life table tests		P = 0.231	
Logistic regression tests		P = 0.321	
Fisher exact test		P = 0.330	
All Organs: Hemangiosarcoma		1 (50 (20)	
Overall rates	4/50 (8%)	1/50 (2%)	
Adjusted rates	9.3%	2.6%	
Terminal rates	4/43 (9%)	1/39 (3%)	
First incidence (days)	729 (T)	729 (T)	
Life table tests		P=0.210N	
Logistic regression tests		P=0.210N	
Fisher exact test		P=0.181N	
All Organs: Hemangioma or Hemangi	sarcoma	0/50 (40%)	
Overall rates	4/50 (8%)	2/50 (4%)	
Adjusted rates	9.3%	5.1%	
Terminal rates	4/43 (9%)	2/39 (5%)	
First incidence (days)	729 (T)	729 (T)	
Life table tests		P=0.383N	
Logistic regression tests		P=0.383N	-
Fisher exact test		P = 0.339N	
All Organs: Malignant Lymphoma (H		0/50 (18%)	
Overall rates	5/50 (10%)	9/50 (18%) 19.4%	
Adjusted rates	10.7%		
Terminal rates	2/43 (5%)	3/39 (8%) 533	
First incidence (days)	440	522 P=0 177	
Life table tests		P=0.177	
Logistic regression tests	•	P=0.247 P=0.194	
Fisher exact test		1 ~V.1/T	
All Organs: Malignant Lymphoma or	Histiocytic Sarcoma 5/50 (10%)	9/50 (18%)	
Overall rates Adjusted rates	10.7%	19.4%	
Terminal rates	2/43 (5%)	3/39 (8%)	
	440	522	
First incidence (days) Life table tests	470	P=0.177	
		P=0.247	
Logistic regression tests		P=0.194	
Fisher exact test		1 -0.27	

TABLE C3b
Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

•	0 ррт	400 ppm	
All Organs: Benign Neoplasms			
Overall rates	25/50 (50%)	39/50 (78%)	
Adjusted rates	53.2%	86.5%	
Terminal rates	21/43 (49%)	33/39 (85%)	
First incidence (days)	701	494	
Life table tests		P = 0.001	
ogistic regression tests		P = 0.002	
Fisher exact test		P = 0.003	
All Organs: Malignant Neoplasms			
Overall rates	25/50 (50%)	26/50 (52%)	
Adjusted rates	50.0%	52.0%	
Terminal rates	18/43 (42%)	15/39 (38%)	
First incidence (days)	440	494	
Life table tests		P = 0.369	
Logistic regression tests		P = 0.465N	
Fisher exact test		P = 0.500	
All Organs: Benign or Malignant Neo	plasms		
Overall rates	37/50 (74%)	44/50 (88%)	
Adjusted rates	74.0%	88.0%	
Terminal rates	30/43 (70%)	33/39 (85%)	
First incidence (days)	440	494	
Life table tests		P = 0.048	
Logistic regression tests		P = 0.093	
Fisher exact test		P = 0.062	

(T)Terminal sacrifice

Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Observed incidence at terminal kill

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, bone marrow, brain, epididymis, gallbladder, heart, kidney, larynx, liver, lung, nose, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, testes, thyroid gland, and urinary bladder; for other tissues, denominator is number of animals necropsied.

d Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and the exposed group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Fisher exact test compares directly the overall incidence rates. For all tests, a lower incidence in the exposure group is indicated by N.

TABLE C4 Historical Incidence of Liver Neoplasms in Untreated Male B6C3F $_1$ Mice^a

		Incidenc	e in Controls	
Study	Hepatocellular Adenoma	Hepatocellular Carcinoma	Hepatocellular Adenoma or Carcinoma	Hepatoblastoma
Historical Incidence at Battelle C	olumbus Laboratory			
2,4-Dichlorophenol	4/50	7/50	10/50	0/50
5,5-Diphenylhydantoin	19/50	13/50	29/50	0/50
Dowicide EC-7 pentachlorophenol	5/35	1/35	6/35	0/35
Ethylene thiourea	11/49	13/49	20/49	0/49
Polybrominated biphenyls (Firemaster	FF-19) 9/50	8/50	16/50	0/50
Technical grade pentachlorophenol	5/32	2/32	7/32	0/32
Overall Historical Incidence				
Total	145/865 (16.8%)	122/865 (14.1%)	249/865 (28.8%)	0/865 (0.0%)
Standard deviation	8.2%	7.2%	10.9%	` ,
Range	4%-38%	3%-27%	17%-58%	

a Data as of 3 April 1991

TABLE C5a Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of Triamterene: First Study^a

	0 ppm	100 ppm	200 ppm	400 ppm
Disposition Summary				
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
15-Month interim evaluation	10	10	10	0
2-Year study	••		10	. •
Early deaths		•		
Moribund	1	2	2	6
Natural deaths	2	3	2	8
Survivors	- ·		•	9
Terminal sacrifice	47	45	46	46
Animals examined microscopically	70	70	70	70
3-Month Interim Evaluation				
Alimentary System				
None		,		
Cardiovascular System None				
	 			
Endocrine System None				•
General Body System None				
Genital System	·			
Testes	10		(10)	
Bilateral, seminiferous tubule,	-		(20)	
atrophy, focal	2 (20%)		1 (10%)	
Seminiferous tubule, atrophy, focal	4 (40%)		7 (70%)	
Hematopoietic System None	<u> </u>	·		
		· .		
Integumentary System None				• •
Musculoskeletal System None				

TABLE C5a Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm .	200 ppm	400 ppm
3-Month Interim Evaluation (continued Respiratory System None				
Special Senses System None				
Urinary System	40	/A\	(1)	(10)
Kidney Nephropathy	(10) 1 (10%)	(4) 4 (100%)	(1) 1 (100%)	(10) 1 (10%)
15-Month Interim Evaluation				
Alimentary System				
Liver	(10)	(3)	(10)	
Basophilic focus Vacuolization cytoplasmic	3 (30%)	2 (67%) 1 (33%)	1 (10%) 1 (10%)	
Vacuolization cytopiasmic Pancreas	(10)	1 (3370)	(10)	
Acinus, necrosis, acute	1 (10%)		(,	
Cardiovascular System None				
Endocrine System				
Parathyroid gland	(9)		(10)	
Cyst Thyroid gland	(10)		1 (10%)	
Cyst	(10)	•	(10) 1 (10%)	
General Body System None				
Genital System				
Preputial gland	(1)	(2)	(1)	
Dilatation	ì (100%)	2 (100%)	ì (100%)	
Hematopoietic System None				
Integumentary System None				
Musculoskeletal System			<u> </u>	

TABLE C5a
Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ррт	100 ppm	200 ppm	400 ppm
15-Month Interim Evaluation (contin Nervous System None	ued)			
Respiratory System None				
Special Senses System None				
Urinary System				
Kidney Nephropathy	(10) 8 (80%)	(10) 9 (90%)	(10) 9 (90%)	
2-Year Study				
Alimentary System				
Gallbladder	(48)	(46)	(50)	(54)
Inflammation, chronic active	1 (2%)	1 (2%)	(5.5)	1 (2%)
Intestine small, ileum	(49)	(49)	(50)	(55)
Inflammation, acute	、 /	\ /	í (2%)	` /
Peyer's patch, necrosis			` '	1 (2%)
Liver	(50)	(50)	(50)	(60)
Basophilic focus	6 (12%)	3 (6%)	10 (20%)	5 (8%)
Basophilic focus, multiple		1 (2%)		
Clear cell focus	1 (2%)	9 (18%)	4 (8%)	10 (17%)
Clear cell focus, multiple				1 (2%)
Eosinophilic focus	7 (14%)	12 (24%)	11 (22%)	3 (5%)
Hematopoietic cell proliferation	1 (2%)	1 (2%)		
Inflammation, chronic active	1 (2%)	1 (2%)		
Necrosis, acute		1 (2%)		1 (2%)
Bile duct, cyst		1 (2%)		1 (270)
Bile duct, inflammation	(3)	(3)	(4)	(2)
Mesentery Ectopic tissue	(3)	(3)	(7)	(2) 1 (50%)
Inflammation, chronic active	1 (33%)	1 (33%)		. (/-/
Fat, necrosis	2 (67%)	2 (67%)	3 (75%)	1 (50%)
Pancreas	(50)	(50)	(50)	(60)
Inflammation, chronic active	1 (2%)	1 (2%)		•
Acinus, atrophy	1 (2%)	•		
Duct, ectasia				1 (2%)
Stomach, forestomach	(49)	(50)	(50)	(58)
Acanthosis		1 (2%)	3 (6%)	3 (5%)
Diverticulum		1 (2%)		A 1901
Inflammation, acute	(50)	(50)	(50)	4 (7%)
Stomach, glandular	(50)	(50)	(50) 2 (4%)	(59) 1 (2%)
Inflammation, acute Inflammation, chronic active	1 (2%) 1 (2%)		2 (470)	1 (270)

TABLE C5a Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
2-Year Study (continued)				
Cardiovascular System				
Heart	(50)	(50)	(50)	(60)
Inflammation, chronic active	1 (2%)	` '		
Thrombus	, ,		1 (2%)	
Endocrine System				
Adrenal gland	(50)	(50)	(50)	(59)
Capsule, hyperplasia	10 (20%)	6 (12%)	3 (6%)	5 (8%)
Adrenal gland, cortex	(50)	(50)	(50)	(60)
Angiectasis	1 (2%)			
Hyperplasia	1 (2%)	2 (4%)		
Hypertrophy	26 (52%)	16 (32%)	7 (14%)	16 (27%)
Infarct	(#0)	1 (2%)	(40)	((0)
Adrenal gland, medulla	(50)	(50)	(48)	(60)
Infarct	(50)	1 (2%)	(60)	//A\
Islets, pancreatic	(50)	(50)	(50)	(60)
Hyperplasia	1 (2%)	6 (12%)	1 (2%)	
Inflammation, acute	1 (2%)	(40)	(44)	(50)
Pituitary gland	(49)	(48)	(44)	(58)
Pars distalis, cyst Pars intermedia, hypertrophy	1 (2%)	4 (8%)	1 (2%)	1 (2%) 1 (2%)
Thyroid gland	(50)	(50)	(50)	(60)
Ultimobranchial cyst	(30)	1 (2%)	(30)	(00)
Follicular cell, hyperplasia	3 (6%)	8 (16%)	16 (32%)	20 (33%)
General Body System None				
Canital System				
Genital System	(50)	(50)	(50)	(60)
Epididymis Granuloma sperm	(50)	(50)	(50)	(60)
Inflammation, chronic active			1 (2%) 1 (2%)	
Preputial gland	(11)	(12)	(23)	(15)
Dilatation	8 (73%)	10 (83%)	21 (91%)	13 (87%)
Inflammation, chronic active	3 (27%)	3 (25%)	2 (9%)	2 (13%)
Seminal vesicle	(50)	(50)	(50)	(60)
Dilatation	1 (2%)	` /	` '	\ · /
Hyperplasia	` /		1 (2%)	
Inflammation, chronic active	1 (2%)		` '	
Testes	(50)	(50)	(50)	(60)
Atrophy			1 (2%)	
Degeneration	5 (10%)	2 (4%)	2 (4%)	5 (8%)
Granuloma sperm, multiple	1 (2%)			
Hematopoietic System				
	(50)	(50)	(50)	(60)
Bone marrow			` '	` '
Bone marrow Myelofibrosis	(5.7)	, ,	3 (6%)	
	(50)	(50)	3 (6%) (50)	(60)

TABLE C5a
Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
2-Year Study (continued)				
Hematopoietic System (continued)				
Lymph node, mandibular Necrosis	(47)	(48)	(49)	(60) 1 (2%)
Lymph node, mesenteric Congestion	(46)	(46)	(44)	(45) 1 (2%)
Infiltration cellular, histiocyte Necrosis			1 (2%)	1 (2%)
Spleen	(50)	(50)	(50)	(60)
Fibrosis	,	0 (40%)		1 (2%)
Hematopoietic cell proliferation Necrosis		2 (4%)		4 (7%)
Thymus	(36)	(40)	(37)	(39)
Necrosis	(55)	(1.5)	()	7 (18%)
Integumentary System				
Skin	(49)	(50)	(49)	(60)
Alopecia	2 (4%)	3 (6%)	1 (2%)	4 (7%)
Inflammation, chronic active		1 (2%) 1 (2%)		
Ulcer		1 (2%)		
Musculoskeletal System Bone	(50)	(50)	(50)	(59)
Rib, cartilage, fracture healed	(50)	(50) 1 (2%)	(30)	(37)
Nervous System None				
Respiratory System				
Lung	(50)	(50)	(50)	(60)
Hemorrhage			1 (2%)	
Inflammation, chronic Thrombus		1 (2%)	1 (2%)	
Alveolar epithelium, hyperplasia	4 (8%)	3 (6%)	2 (4%)	1 (2%)
Bronchiole, epithelium, hyperplasia	. (0,0)	- (0,0)	- ()	1 (2%)
Nose	(50)	(50)	(50)	(60)
Angiectasis	• •			2 (3%) 2 (3%)
Inflammation, acute			1 (2%)	2 (3%)
Special Senses System				
Eye			(1)	
Cornea, angiectasis	(2)	(2)	1 (100%)	(2)
Harderian gland	(3) 2 (67%)	(3) 2 (67%)	(6) 4 (67%)	(2)
Hyperplasia Inflammation	2 (0/%)	2 (0170)	1 (17%)	
IIII allination			- (,)	

等,是是一个人,就是一个人,也是一个人,

TABLE C5a Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
2-Year Study (continued)	· · · · · · · · · · · · · · · · · · ·			
Urinary System				•
Kidney	(50)	(50)	(50)	(60)
Cyst			2 (4%)	3 (5%)
Infarct	2 (4%)		` ,	1 (2%)
Inflammation, acute	` '		1 (2%)	` '
Nephropathy	49 (98%)	48 (96%)	49 (98%)	58 (97%)
Pigmentation	` '	1 (2%)	` ,	` /

^a Number of animals examined microscopically at site and number of animals with lesion

TABLE C5b Summary of the Incidence of Nonneoplastic Lesions in Male Mice at the 15-Month Interim Evaluation and in the 2-Year Feed Study of Triamterene: Second Study^a

	0 ррт	400 ppm	
Disposition Summary			
Animals initially in study	60	60	
15-Month interim evaluation	10	10	
2-Year study			
Early deaths			
Moribund	3	4	
Natural deaths	4	7	
Survivors			
Died last week of study	1		
Terminal sacrifice	42	39	
Animals examined microscopically	60	60	
15-Month Interim Evaluation			
Alimentary System			
Liver	(9)	(10)	
Basophilic focus	1 (11%)		
Clear cell focus		1 (10%)	
Vacuolization cytoplasmic		2 (20%)	
Cardiovascular System None			
Endocrine System			
Pituitary gland	(10)	(9)	
Pars distalis, hyperplasia	1 (10%)	1 (11%)	
General Body System None			
Genital System	(10)	(10)	
Epididymis	(10)	(10)	
Inflammation, chronic active	(1)	1 (10%)	
Preputial gland Dilatation	(1) 1 (100%)		
		(10)	
Testes Degeneration	(10) 1 (10%)	(10)	
Degeneration	1 (1070)		
Hematopoietic System			
None			

TABLE C5b Summary of the Incidence of Nonneoplastic Lesions in Male Mice at the 15-Month Interim Evaluation and in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ррт	400 ppm	
15-Month Interim Evaluation (continued)			
Integumentary System			
Skin	(10)	(10)	
Subcutaneous tissue, abscess		1 (10%)	
Musculoskeletal System			
None			
Nervous System None			
Respiratory System None			
9-119			
Special Senses System	415		
Harderian gland	(1)		
Hyperplasia	1 (100%)		
Urinary System			
Kidney	(10)	(10)	
Nephropathy	10 (100%)	10 (100%)	
2-Year Study			
Alimentary System			
Intestine small, duodenum	(47)	(50)	
Ulcer	()	1 (2%)	
Intestine small, jejunum	(49)	(49)	
Peyer's patch, infiltration cellular,			
histiocyte	450	1 (2%)	
Liver	(50)	(50)	
Basophilic focus	7 (146)	7 (14%)	
Clear cell focus	7 (14%)	4 (8%)	
Clear cell focus, multiple Congestion	1 (2%)	2 (4%)	
Eosinophilic focus	11 (22%)	2 (4%)	
Eosinophilic focus, multiple	11 (22%) 1 (2%)	10 (20%)	
Hematopoietic cell proliferation	1 (2%)		
Infarct	1 (2%)	1 (2%)	
Inflammation, chronic active	1 (2%)	1 (2/0)	
Regeneration	. (270)	1 (2%)	
Hepatocyte, necrosis		1 (2%)	
Mesentery	(2)	(1)	
Fat, necrosis	` '	1 (100%)	

TABLE C5b
Summary of the Incidence of Nonneoplastic Lesions in Male Mice at the 15-Month Interim Evaluation and in the 2-Year Feed Study of Triamterene: Second Study (continued)

н	0	ppm	400	ppm		
2-Year Study (continued)						
Alimentary System (continued)						
Pancreas	(48)		(50)			
Acinus, atrophy	2	(4%)		(8%)		
Duct, cyst	-	(1,0)		(2%)		
Stomach, forestomach	(49)		(50)	(270)		
Acanthosis		(4%)		(4%)	•	
Inflammation, chronic active		(1/3)		(2%)		
Stomach, glandular	(49)		(50)	(=,-)		
Inflammation, acute	1	(2%)	1	(2%)		
Inflammation, chronic active		(2%)	•	(270)		
Mucosa, mineralization		(2%)				
Cardiana canton Suntan						
Cardiovascular System	/EM		(50)			
Heart Inflammation chronic active	(50)	(2%)	(50)			
Inflammation, chronic active	. 1	(270)				
Endocrine System						
Adrenal gland	(50)		(50)			
Capsule, hyperplasia		(16%)		(2%)		
Adrenal gland, cortex	(50)		(50)			
Hypertrophy		(38%)		(16%)		
Islets, pancreatic	(47)		(49)			
Hyperplasia	2	(4%)		(4%)		
Pituitary gland	(50)		(48)			
Pars distalis, cyst		(2%)			,	
Pars distalis, hyperplasia			2	(4%)		
Thyroid gland	(50)		(50)			
Follicular cell, hyperplasia		•	16	(32%)		
Course Dady System						
General Body System None					,	
						
Genital System	(50)		(50)	-:		
Epididymis	(50)			(2%)		
Granuloma sperm	1	(2%)				
Inflammation, chronic	(40)	(2%)		(4%)		
Preputial gland	(40)		(37)	(100%)		
Dilatation		(88%)	31	(100/0)		
Inflammation, acute		(3%)	. 1	(3%)		
Inflammation, chronic active		(8%)		(3%)		
Seminal vesicle	(50)	(20%)	(50)			
Inflammation, acute		(2%)	(50)			
Testes	(50)			(4%)		
Degeneration	4	2 (4%)	2	(470)		

Table C5b Summary of the Incidence of Nonneoplastic Lesions in Male Mice at the 15-Month Interim Evaluation and in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
2-Year Study (continued)			
Hematopoietic System			
Bone marrow	(50)	(50)	
Myelofibrosis	1 (2%)	44.0	
Lymph node, mesenteric	(41)	(44)	
Congestion	2 (5%) 1 (2%)	2 (5%)	
Hematopoietic cell proliferation Inflammation, granulomatous	1 (2%)	2 (5%)	
Spleen	(47)	(50)	
Hematopoietic cell proliferation	3 (6%)	í (2%)	
Integumentary System			
Skin	(50)	(50)	
Subcutaneous tissue, abscess	1 (2%)		
Musculoskeletal System None			
Nervous System	· · · · · · · · · · · · · · · · · · ·		
Brain	(50)	(50)	
Compression	1 (2%)	()	
Hemorrhage	1 (2%)		
Respiratory System			
Lung	(50)	(50)	
Alveolar epithelium, hyperplasia	1 (2%)	2 (4%)	
Nose Concretion	(50)	(50)	
Inflammation, acute	1 (2%) 4 (8%)	2 (4%)	
amamaton, dedic	4 (0%)	2 (470)	
Special Senses System Ear	(1)		
Inflammation, acute	(1) 1 (100%)		
Eye	(1)	(1)	
Cornea, inflammation, chronic active	(-/	1 (100%)	
Harderian gland	(4)	(6)	
Hyperplasia	3 (75%)		
Urinary System			
Kidney	(50)	(50)	
Inflammation, suppurative	1 (2%)		
Nephropathy	45 (90%)	43 (86%)	
Urinary bladder Inflammation, acute	(50) 1 (2%)	(50)	
minamination, acute	1 (270)		

Number of animals examined microscopically at site and number of animals with lesion

APPENDIX D SUMMARY OF LESIONS IN FEMALE MICE IN THE 2-YEAR FEED STUDY OF TRIAMTERENE

TABLE D1a	Summary of the Incidence of Neoplasms in Female Mice	
	in the 2-Year Feed Study of Triamterene: First Study	230
TABLE D1b	Summary of the Incidence of Neoplasms in Female Mice	
	in the 2-Year Feed Study of Triamterene: Second Study	235
TABLE D2a	Individual Animal Tumor Pathology of Female Mice	
	in the 2-Year Feed Study of Triamterene: First Study	240
TABLE D2b	Individual Animal Tumor Pathology of Female Mice	
	in the 2-Year Feed Study of Triamterene: Second Study	268
TABLE D3a	Statistical Analysis of Primary Neoplasms in Female Mice	
	in the 2-Year Feed Study of Triamterene: First Study	280
TABLE D3b	Statistical Analysis of Primary Neoplasms in Female Mice	
	in the 2-Year Feed Study of Triamterene: Second Study	284
TABLE D4	Historical Incidence of Liver Neoplasms in Untreated Female B6C3F, Mice	287
TABLE D5a	Summary of the Incidence of Nonneoplastic Lesions in Female Mice	
	in the 2-Year Feed Study of Triamterene: First Study	288
TABLE D5b		
	in the 2-Year Feed Study of Triamterene: Second Study	294

TABLE D1a Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study^a

	0 ррт	100 ppm	200 ppm	400 ppm
Disposition Summary	· · · · · · · · · · · · · · · · · · ·			
Animals initially in study	70	70	70	70
3-Month interim evaluation ^b	10	10	10	10
5-Month interim evaluation	10	10	10	20
2-Year study				
Early deaths				
Moribund	8	5	1	10
Natural deaths	4	2	6	7
Survivors Died last week of study			4.0	
Terminal sacrifice	1 37	2 41	1 42	43
Terminal Sacrifice	31	41	42	43
Animals examined microscopically	70	70	70	70
5-Month Interim Evaluation Alimentary System		 		
Liver	(10)	(2)	(10)	
Hepatocellular adenoma	2 (20%)	(2) 2 (100%)	2 (20%)	
•	_ (,	_ (/	- ()	
Cardiovascular System None				
Endocrine System None				
Carrant Bada Santan				
General Body System None				
Tolle				
				
Genital System				
None			•	
		, .		
Hematopoietic System	(10)			
Spleen Lymphoma malignant histiocytic	(10)		(9) 1 (11%)	
Lymphoma mangnant mstocytic			1 (1170)	
Integumentary System				
None			•	
	· · · · · · · · · · · · · · · · · · ·			
W 1 1 1 4 1 C :				
None.				
Musculoskeletal System None	•			
None.			·	
Jama.	·· ·			

TABLE D1a Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
5-Month Interim Evaluation (continued)				
Respiratory System				
Lung	(10)		(10)	
Alveolar/bronchiolar adenoma	1 (10%)			
Special Senses System None				
Urinary System None				
Systemic Lesions				
Multiple organs ^c Lymphoma malignant histiocytic	(10)	(10)	(10) 1 (10%)	
2-Year Study				
Alimentary System	•			
Gallbladder	(48)	(47)	(49)	(55)
Intestine large, cecum	(47)	(50)	(50)	(60)
Intestine small, ileum	(47)	(49)	(49)	(57)
Intestine small, jejunum	(47)	(48)	(48)	(59)
Adenocarcinoma	1 (2%)			
Liver	(50)	(50)	(50)	(60)
Hemangiosarcoma	1 (2%)		1 (2%)	
Hepatocellular carcinoma	3 (6%)	3 (6%)	3 (6%)	6 (10%)
Hepatocellular carcinoma, multiple	1 (2%)	1 (2%)	10 (040()	2 (3%)
Hepatocellular adenoma Hepatocellular adenoma, multiple	6 (12%) 4 (8%)	10 (20%) 12 (24%)	12 (24%) 11 (22%)	22 (37%)
Hepatocholangiocarcinoma	1 (2%)	12 (24/0)	11 (2270)	14 (23%)
Osteosarcoma, metastatic, bone	- (-70)		1 (2%)	
Serosa, adenocarcinoma, metastatic, ovary		1 (2%)	- ()	
Mesentery	(8)	(10)	(8)	(5)
Adenocarcinoma, metastatic, ovary		1 (10%)	• •	• /
Hemangiosarcoma	1 (13%)			
Hepatocholangiocarcinoma, metastatic, uterus Osteosarcoma, metastatic, uncertain primary	1 (13%)			
site	440	(50)	454	1 (20%)
Pancreas material and a second	(49)	(50)	(50)	(60)
Adenocarcinoma, metastatic, ovary Hepatocholangiocarcinoma, metastatic, uterus	1 (20%)	1 (2%)		
Salivary glands	1 (2%) (49)	(49)	(50)	(60)
Stomach, forestomach	(49)	(50)	(50)	(60) (60)
Papilloma squamous	()	(30)	1 (2%)	1 (2%)
Squamous cell carcinoma			1 (2%)	1 (270)

TABLE D1a
Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
2-Year Study (continued)				
Cardiovascular System				
Heart	(50)	(50)	(50)	(60)
Endocrine System				
Adrenal gland, cortex	(50)	(50)	(50)	(60)
Spindle cell, adenoma	3 (6%)	(40)	3 (6%)	2 (3%)
slets, pancreatic	(49)	(49)	(50)	(59)
Adenoma	(40)	1 (2%)	(48)	(58)
Pituitary gland Pars distalis, adenoma	(49) 7 (14%)	(47) 5 (11%)	(46) 3 (6%)	(38) 5 (9%)
Pars intermedia, adenoma	, (1770)	5 (1170)	2 (4%)	1 (2%)
Thyroid gland	(49)	(49)	(50)	(60)
Follicular cell, adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Follicular cell, carcinoma	1 (2%)	• /	` '	` '
General Body System None				
Genital System	(48)	(50)	(50)	(59)
Ovary Adenocarcinoma	(40)	1 (2%)	(50)	(32)
Cystadenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Granulosa cell tumor benign	- (- · ·)	· /	1 (2%)	` '
Hemangiosarcoma			1 (2%)	
Hepatocholangiocarcinoma, metastatic, uterus	1 (2%)			
Mixed tumor benign	4 /00"			1 (2%)
Teratoma	1 (2%)	(50)	(50)	(6N)
Uterus	(48)	(50)	(50)	(60)
Adenoma Hemangiosarcoma		2 (4%)	1 (2%)	
Hemangiosarcoma Polyp stromal		1 (2%)	2 (4%)	2 (3%)
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(60)
Hemangiosarcoma	` '	í (2%)	1 (2%)	ì (2%)
Lymph node	(49)	(50)	(50)	(60)
Axillary, liposarcoma, metastatic, skin		1 (2%)		
Inguinal, squamous cell carcinoma, metastatic, skin				1 (2%)
Mediastinal, hepatocellular carcinoma,			1 (2%)	
metastatic, liver			1 (270)	
Mediastinal, hepatocholangiocarcinoma, metastatic, uterus	1 (2%)			
Renal, hepatocholangiocarcinoma, metastatic,	- (-/-)			

TABLE D1a Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm 100 ppm 200 ppm					
2-Year Study (continued)						
Hematopoietic System (continued)						
Lymph node, mandibular	(46)	(49)	(50)	(58)		
Adenocarcinoma, metastatic, ovary	(42)	1 (2%)	(46)	(54)		
Lymph node, mesenteric Hepatocholangiocarcinoma, metastatic, uterus	(43) 1 (2%)	(45)	(46)	(54)		
Spleen	(49)	(50)	(49)	(60)		
Hemangiosarcoma	1 (2%)	()	3 (6%)	ì (2%)		
Thymus	(38)	(44)	(44)	(50)		
ntegumentary System						
Mammary gland	(36)	(43)	(46)	(51)		
Skin	(50)	(49)	(49)	(60)		
Basal cell carcinoma				1 (2%)		
Squamous cell carcinoma	2 (601)		1 (20%)	1 (2%)		
Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, hemangioma	3 (6%)	1 (2%)	1 (2%)	3 (5%)		
Subcutaneous tissue, hemangiosarcoma		1 (270)		1 (2%)		
Subcutaneous tissue, liposarcoma		1 (2%)		- (=)		
Musculoskeletal System						
Bone	(50)	(50)	(50)	(60)		
Vertebra, osteosarcoma		1 (2%)	1 (2%)			
Skeletai muscle	(1)	(1)				
Adenocarcinoma, metastatic, ovary	1 (100%)	1 (100%)				
Hepatocholangiocarcinoma, metastatic, uterus	1 (100%)	·				
Nervous System						
None						
Respiratory System						
Lung	(50)	(50)	(50)	(60)		
Adenocarcinoma, metastatic, ovary Alveolar/bronchiolar adenoma	1 (901)	1 (2%)	9 (101)	1 /00/5		
Alveolar/bronchiolar carcinoma	4 (8%)	5 (10%) 1 (2%)	2 (4%)	1 (2%) 3 (5%)		
Hepatocellular carcinoma, metastatic, liver	1 (2%)	1 (2%)	1 (2%)	3 (370)		
Hepatocholangiocarcinoma, metastatic, uterus	1 (2%)	- (3/7)	- (=/-/			
Liposarcoma, metastatic, multiple, skin	, ,	1 (2%)				
Osteosarcoma, metastatic, bone		1 (2%)	1 (2%)			
Osteosarcoma, metastatic, uncertain primary site				1 (2%)		
Special Senses System	· · · · · · · · · · · · · · · · · · ·					
Harderian gland	(1)	(3)	(3)	(2)		
Adenoma	1 (100%)	3 (100%)	2 (67%)	\-/		

TABLE D1a
Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

Year Study (continued) rinary System dney Capsule, adenocarcinoma, metastatic, ovary rinary bladder stemic Lesions Ultiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed coplasm Summary ratal animals with primary neoplasms 15-Month interim evaluation 2-Year study ratal primary neoplasms 15-Month interim evaluation 2-Year study ratal animals with benign neoplasms 15-Month interim evaluation 2-Year study ratal benign neoplasms 15-Month interim evaluation 2-Year study ratal animals with malignant neoplasms 15-Month interim evaluation 2-Year study ratal animals with malignant neoplasms 15-Month interim evaluation 2-Year study ratal malignant neoplasms 15-Month interim evaluation 2-Year study ratal malignant neoplasms 15-Month interim evaluation 2-Year study ratal malignant neoplasms 15-Month interim evaluation 2-Year study	0 ppm	100 ppm	200 ppm	400 ppm
2-Year Study (continued)	· · · · · · · · · · · · · · · · · · ·			
Urinary System				
Kidney	(50)	(50)	(50)	(60)
•	()	í (2%)	` ,	
Urinary bladder	(48)	(49)	(49)	(60)
Systemic Lesions			·	
	(50)	(50)	(50)	(60)
	1 (2%)	3 (6%)	4 (8%)	3 (5%)
	2 (4%)	1 (2%)	(a)	2 (3%)
Lymphoma malignant mixed	9 (18%)	5 (10%)	9 (18%)	6 (10%)
Neonlasm Summary				
	3	2	3	
	34	40	40	46
•			, * · ·	
	3	2	3	
	53	60	67	81
•				
	3	2	2	
	22	31	28	36
Total benign neoplasms				
15-Month interim evaluation	3	2	2	
2-Year study	28	42	41	51
Total animals with malignant neoplasms				
15-Month interim evaluation			1	
2-Year study	20	17	21	25
Total malignant neoplasms				
			1	
2-Year study	25	18	26	30
Total animals with metastatic neoplasms				_
2-Year study	2	4	2	2
Total metastatic neoplasms				•
2-Year study	9	11	.4	3
Total animals with malignant neoplasms				
uncertain primary site				4
2-Year study				1

Number of animals examined microscopically at site and number of animals with lesion

b No neoplasms were found at the 3-month interim evaluation.

c Number of animals with any tissue examined microscopically

d Primary neoplasms: all neoplasms except metastatic neoplasms

TABLE D1b Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study^a

	0 ppm	400 ppm	
Disposition Summary			
Animals initially in study	60	60	
15-Month interim evaluation	10	9	
2-Year study			
Early deaths			
Moribund	7	4	
Natural deaths	3	9	
Survivors			
Terminal sacrifice	40	38	
Animals examined microscopically	60	60	
15-Month Interim Evaluation			
Alimentary System			
Liver	(10)	(9)	
Hepatocellular carcinoma	1 (10%)	` '	
Lymphoma malignant mixed	` '	1 (11%)	
Pancreas	(10)	(9)	
Lymphoma malignant mixed	` ,	ì (11%)	
Cardiovascular System None Endocrine System			
None General Body System			
None			
Genital System None			
Hematopoietic System			
Lymph node	(10)	(9)	
Renal, lymphoma malignant mixed	(**)	1 (11%)	
Lymph node, mandibular	(10)	(9)	
Lymphoma malignant mixed	(/	1 (11%)	
Lymph node, mesenteric	(10)	(9)	
Lymphoma malignant mixed	()	1 (11%)	
Spleen	(10)	(9)	
Lymphoma malignant mixed	(/	2 (22%)	
Thymus	(9)	(9)	
Lymphoma malignant mixed	(7)	1 (11%)	
~Jpiionia manghant mixed		1 (11/0)	

TABLE D1b
Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
15-Month Interim Evaluation (continued) Integumentary System None			
Musculoskeletal System None			
Nervous System None			
Respiratory System None			
Special Senses System None			
Urinary System Kidney Lymphoma malignant mixed	(10)	(9) 1 (11%)	
Systemic Lesions Multiple organs ^b Lymphoma malignant mixed	(10)	(9) 2 (22%)	
2-Year Study Alimentary System			
Gallbladder	(50)	(50)	
Intestine large, cecum	(49)	(51)	
Intestine large, colon	(50)	(51) 1 (2%)	
Fibrosarcoma, metastatic, uterus Intestine large, rectum	(50)	(50)	
Intestine small, ileum	(49)	(51)	
Intestine small, jejunum	(49)	(51)	
Liver	(50)	(51)	
Hepatocellular carcinoma	5 (10%)	9 (18%)	
Hepatocellular carcinoma, multiple		2 (4%)	
Hepatocellular adenoma	4 (8%)	9 (18%) 19 (37%)	
Hepatocellular adenoma, multiple Pancreas	3 (6%) (49)	(50)	
Salivary glands	(50)	(51)	
Stomach, forestomach	(50)	(51)	
Papilloma squamous		1 (2%)	
Stomach, glandular	(50)	(51)	

TABLE D1b Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
2-Year Study (continued)			
Cardiovascular System			
Heart	(50)	(51)	
Endocrine System			
Adrenal gland, cortex	(50)	(51)	
Spindle cell, adenoma	2 (4%)	2 (4%)	
Adrenal gland, medulla	(49)	(51)	
Islets, pancreatic	(49)	(48)	
Adenoma	1 (2%)		
Pituitary gland	(49)	(47)	
Adenoma Pore distalla adenoma	1 (2%)	1 (2%)	
Pars distalis, adenoma		2 (4%)	
Pars distalis, carcinoma		1 (2%)	
General Body System None			
Genital System			
Clitoral gland	(7)	(4)	
	1 (14%)		
Clitoral gland Hemangiosarcoma Ovary	(7) 1 (14%) (50)	(49)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign	1 (14%)	(49) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign	1 (14%) (50)	(49) 1 (2%) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus	1 (14%) (50)	(49) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma	1 (14%) (50)	(49) 1 (2%) 1 (2%) (51)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma	1 (14%) (50) (50) 1 (2%)	(49) 1 (2%) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma	1 (14%) (50) (50) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%) (51)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma	1 (14%) (50) (50) 1 (2%)	(49) 1 (2%) 1 (2%) (51)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%) (51)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%) (51) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System Lymph node	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%) (51) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System Lymph node Lymph node, mandibular	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%) (51) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System Lymph node Lymph node, mandibular Mast cell tumor malignant	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%) (50) (50)	(49) 1 (2%) 1 (2%) (51) 1 (2%) (51) (51) (51) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System Lymph node Lymph node, mandibular Mast cell tumor malignant Lymph node, mesenteric	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%) (50) (50) (50)	(49) 1 (2%) 1 (2%) (51) 1 (2%) (51) (51) (51) 1 (2%) (47)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System Lymph node Lymph node, mandibular Mast cell tumor malignant Lymph node, mesenteric Spleen	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%) (50) (50) (47) (49)	(49) 1 (2%) 1 (2%) (51) 1 (2%) (51) (51) (51) 1 (2%)	
Clitoral gland Hemangiosarcoma Ovary Granulosa cell tumor benign Teratoma benign Uterus Adenocarcinoma Fibrosarcoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal Hematopoietic System Lymph node Lymph node, mandibular Mast cell tumor malignant Lymph node, mesenteric	1 (14%) (50) (50) 1 (2%) 1 (2%) 1 (2%) 1 (2%) (50) (50) (50)	(49) 1 (2%) 1 (2%) (51) 1 (2%) (51) (51) (51) 1 (2%) (47)	

TABLE D1b
Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm
2-Year Study (continued) Integumentary System Skin Subcutaneous tissue, mast cell tumor malignant Subcutaneous tissue, myxosarcoma Subcutaneous tissue, neurofibrosarcoma	(50) 1 (2%) 1 (2%)	(51) 1 (2%)
Musculoskeletal System Bone Fibrosarcoma	(50) 2 (4%)	(51)
Nervous System Brain	(50)	(51)
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Hepatocellular carcinoma, metastatic, liver	(50) 2 (4%) 1 (2%) 1 (2%)	(51) 1 (2%) 4 (8%)
Special Senses System Harderian gland Adenoma	(4)	(4) 3 (75%)
Urinary System Kidney Urinary bladder Fibrosarcoma, metastatic, uterus	(50) (50)	(51) (50) 1 (2%)
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed Lymphoma malignant undifferentiated cell	(50) 1 (2%) 8 (16%)	(51) 3 (6%) 2 (4%) 10 (20%) 1 (2%)

TABLE D1b Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

		0 ррт	400 ppm	
Neoplasm Summary				
Total animals with primary neoplasms ^c				•
15-Month interim evaluation		1	2	
2-Year study		29	43	
Total primary neoplasms				
15-Month interim evaluation		1	2	•
2-Year study		40	71	
Total animals with benign neoplasms				
2-Year study		12	31	,
Total benign neoplasms				
2-Year study		13	39	
Total animals with malignant neoplasms				
15-Month interim evaluation		1	2	
2-Year study		23	28	
Total malignant neoplasms				
15-Month interim evaluation		1	2	
2-Year study		27	32	
Total animals with metastatic neoplasms				
2-Year study	•	2	5	
Total metastatic neoplasms		-	-	
2-Year study		2	6	
•				

Number of animals examined microscopically at site and number of animals with lesion Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms

Table D2a							
Individual Animal Tumor	Pathology of	Female	Mice in	the	2-Year Feed	Study of	f Triamterene:
First Study: 0 ppm				•			

First Study: V ppm																													
Number of Days on Study	2	2	1		3	9	Ó	5 3 0	8	9		7 2 3	7 2 5	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	_			
Carcass ID Number		 3 1			3	3	2	3	3		3	2 8	3	2	2	2 8	2	2 9	2	2	2	3	3	3	3 0	3			
Carcass ID Number	3	3	6	1	8	7	6	9	4	5	6	9	5	1	3	8	3	4	6	7	8	2	0	5	7	8			
·			1	F _	1	1	,	1		<u>,</u>	1.			,	1		,	'	<u> </u>	,	<u>'</u>	<u>'</u>	1	<u>'</u>	1	1			
Alimentary System				•						,																			
Esophagus	-	H	+	+	+	+:	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠+	+			
Gallbladder	_	F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+			
Intestine large		ļ-	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine large, cecum		١			+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+			
Intestine large, colon					+		+	+	+	<u>.</u>	+	+	+	+	+	4	+	+	+	+	+	+	+	+	+	+			
Intestine large, rectum							+		+	M	+		·	+	·	·	+	<u>.</u>	+	÷	+	+	+	<u>.</u>	<u>.</u>	<u>.</u>		•	
Intestine small					+		<u>.</u>	Ţ	i	141	·	<u>.</u>	·	·	Ţ	Ţ	Ţ	·	÷	<u>.</u>	<u>.</u>		Ţ	÷		<u>.</u>			
· ·			-	-	+		T	+						1				1	1		Ţ	Ţ	<u> </u>		Ĺ	+			
Intestine small, duodenum							+		+		Ţ		7	Ţ		7				Ţ			T M						
Intestine small, ileum						+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	IVI	-		Ť.			
Intestine small, jejunum Adenocarcinoma	1	4	A	A	+	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Liver		L	ı	_	_	_	_	_	_	_	_	4	1	4	+	_	4	_	+	_	_	+	_	4	4	+			
	,	_	т	•	7	т	т	_		7	X	7	-	7	-1	Т	т	7	•	Г	7	•	1	7		1			
Hemangiosarcoma									v		Λ																		
Hepatocellular carcinoma									X																				
Hepatocellular carcinoma, multiple								٠. ٠	•																				
Hepatocellular adenoma															X				X										
Hepatocellular adenoma, multiple Hepatocholangiocarcinoma												X																	
Mesentery					4								+																
Hemangiosarcoma					•								'																
Hepatocholangiocarcinoma, metastatic,																											•		
uterus												Х																	
Pancreas		+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		, .	•
Hepatocholangiocarcinoma, metastatic,												х																	
uterus																						٠.							
Salivary glands	•	+	+	A	+	+	+	+	+	+	+	+	+	+	*		7	+		Τ,		7		•	T.		:		
Stomach		+	+	Α	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach	•	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, glandular	•	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Cardiovascular System														_		<u> </u>													
Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
					_		_											-											
Endocrine System																													
Adrenal gland	•	+	+	+	+	+	+	+	+	+	+	+	+	+		+			+	+	+	+	+	+	+	+			
Adrenal gland cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	.+	+			
Adrenal gland, cortex												X				X										,			
Spindle cell, adenoma																1	t.	_		t									
Spindle cell, adenoma Adrenal gland, medulla	٠.	+	+	+	+	M	+							+			1		т	+	7	+	+	+	+	_			
Spindle cell, adenoma	٠.	+			+		+			+					+				+	+		+	+	+	+	+			

^{+:} Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 0 ppm (continued)

	7	7	7	7	7	7	7	7	7	7	7	7 .	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3 0	3 0	3 0	3 0	3 0	3 0	3· 2	3 2	3 2	3 2	3	3 2	3 2	3 2		3 2	3	3	3	3	3	3	3	3	3	,
	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
Carcass ID Number	0	1	1	1	1	1	2	2	2	2	2	3	3	3	3	3	3	3	3	4	4	4	4	4	4	Total
•	9 1	0 1	3 1	5 1	7 1	9 1	1 1	3 1	5 1	8 1	9 1	0 1	1 1	2 1	3 1	6 1	7 1	8 1	9 1	1 1	2 1	4 1	6 1	7 1	-	Tissue Tumor
Alimentary System					_													-	٠.	_						
Esophagus	_	4	_	_	+	_	4	_	+	+	+	+	4	+	+	+	+	_	4	+	+	+	+	_	_	50
Gallbladder			1		1		<u> </u>	1	+	1	<u> </u>	1	1	+			+	_			M	<u> </u>	1	T	<u> </u>	48
Intestine large		<u> </u>		т. —			-					—	+		+	+	-	T_	+	—	141	+	+	+	<u> </u>	49
Intestine large, cecum			T _				-T		T _			T	т Т	+	+	+	т Т	T	T	T		T	+	+	т _	47
Intestine large, colon		1							T			т Т	т Т		т _	T	т Т	т Т	T	T		т Т			T _L	48
Intestine large, colon	T	T	T 	T 	.I.		,L.	T.	T.	т Т	т Т	ᆂ	<u></u>	<u> </u>	+	T _	т "	∓	T	T.	, <u>r</u>		工工	T _1	T	
Intestine large, rectum Intestine small	+ .i	+	+	+	+	+	+	+	7	T	.t.	.t		+		+	7	+	+	+	+	+	+	+	T .	48 40
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	,±	+	+	+	+	+	+	+	+	+ _L	+	+	+	•	+	48 47
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small, ileum	+	+	+	+	+	+	+	+				+	-	+			+	+	+	+	+	+	+		+	47
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+.	47
Adenocarcinoma											X															1
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										. 1
Hepatocellular carcinoma				X																				Х		3
Hepatocellular carcinoma, multiple								X																		1
Hepatocellular adenoma																X		X				X			X	6
Hepatocellular adenoma, multiple Hepatocholangiocarcinoma	Х							X											X							4 1
Mesentery								+			+					+			+			+				8
Hemangiosarcoma																X										1
Hepatocholangiocarcinoma, metastatic, uterus																										1
Pancreas	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Hepatocholangiocarcinoma, metastatic, uterus																										1
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach	·	+	. +	÷	+	+	+	+	+		+	+	+	+	+	+	+	÷	+	·	+	+	+	+	+	49
Stomach, forestomach	·	+	. +	+	+	+	+	+	+	Ļ	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	49
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	49
Cardiovascular System																			•			_				
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																_				_						
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Spindle cell, adenoma	•	•	•		٠	•	•	•	•	•	•	X		٠	•	•	•	•	•	·	•	•	•	`	•	3
				R.A		_		+	+	+	+			+	+	M	+	+	+	+	+	_	_	_	+	47
	+	-	-																							
Adrenal gland, medulla Islets, pancreatic	+	+	. +	+	. T	+	+	· +	·	+	+			+	+		+	+	+	+	÷	·	+	+	÷	49

TABLE D2a	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Trian	iterene:
First Study: 0 ppm (continued)	

																					_				 	
Number of Days on Study	:	0 1 2 1 3 4	1 (3 4 5 3 2 1			5 3 0		6 7 9 1 6 1		7 2 5	7 2 9	7 2 9		7 2 9				7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0		
Carcass ID Number	-	3 (l (3 3 0 1 1 8 1 1.	2 7	6	4 9	3 !	5 6	8 9	4 5	8 1	8 3	8 8	9 3	9 4	9 6		9 8	2	0	5		0 ·	,	
Endocrine System (continued) Pituitary gland Pars distalis, adenoma Thyroid gland Follicular cell, adenoma Follicular cell, carcinoma				M +		+	+ +	+	+ -	+ + +	+	+	+ X +	+ + X	+	+ . +	+	+	+ X +	+	+	+	+ X +	+ +		
General Body System Tissue NOS			+						•				÷									-	-			
Genital System Clitoral gland Ovary Cystadenoma Hepatocholangiocarcinoma, metastatic, uterus Teratoma Uterus			x	м + 4 +	+	+.	+	+	+ •	+ + X	- - - - -	+	+	+	+	+	+	+	+	+ +	+	+	++++	+		
Hematopoietic System Bone marrow Lymph node Mediastinal, hepatocholangiocarcinoma, metastatic, uterus Renal, hepatocholangiocarcinoma, metastatic, uterus Lymph node, mandibular Lymph node, mesenteric Hepatocholangiocarcinoma, metastatic, uterus Spleen Hemangiosarcoma Thymus		+ + 1	+ 1 M 1 + 4	+ + + + M + M + M + M M M	+ +	+++++++++++++++++++++++++++++++++++++++	++	+ ; + ;	+ +	X + + + + + +	<td>. М - +</td> <td>+</td> <td>+</td> <td>+</td> <td>+ ++ +</td> <td>+ + + +</td> <td></td> <td>+ `</td> <td>+</td> <td>++ ++ ++</td> <td>++ ++ ++ +++</td> <td>++ ++ ++</td> <td>++ ++ ++</td> <td></td> <td>5</td>	. М - +	+	+	+	+ ++ +	+ + + +		+ `	+	++ ++ ++	++ ++ ++ +++	++ ++ ++	++ ++ ++		5
Integumentary System Mammary gland Skin Subcutaneous tissue, fibrosarcoma		+ +		м м + +		+ +	+ + X	+	M + X				i + +		M +			+			M +	+ +			į	

TABLE D2a Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: First Study: 0 ppm (continued)

						_			_			_	_	_		_		_	_		_	_	_	_		
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3 0	3 0	0	3 0	3 0					3 2			3 2				3		3							
	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	-
Carcass ID Number	0	1	1	1	1	1	2	2	2	2	2	3	3	3	3	3	3	3	3	4	4	4	4	4	4	Total
	9												1													Tissues
		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	I	I	1	1	1	1	1	Tumors
Endocrine System (continued)																										
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma			X		X										X				X							7
Thyroid gland Follicular cell, adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1
Follicular cell, carcinoma																x										- 1
			_			_	_					_											_			
General Body System																										
Tissue NOS								+																		2
Genital System					_										_					_						
Clitoral gland																										1
Ovary	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Cystadenoma																						X				1
Hepatocholangiocarcinoma, metastatic,																										
uterus Teratoma																										1
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 48
Hematopoietic System		_	_	_	<u> </u>					_									_	_	_		<u> </u>	_		
Bone marrow	4				i	_	_	_	ı.	_	ı	_	_	_	_	_	_		_	_	_		_	_		50
Lymph node	+	. +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Mediastinal, hepatocholangiocarcinoma,		•	·	·	·	·		•	•	·	·	·	٠	•	•	·	•	Ċ	•	·		·	,	'	•	72
metastatic, uterus																										1
Renal, hepatocholangiocarcinoma,																										
metastatic, uterus																										- 1
Lymph node, mandibular	-			M		-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Lymph node, mesenteric Hepatocholangiocarcinoma, metastatic,	N	1 +	+	+	+	+	+	M	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
uterus																										1
Spleen	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Hemangiosarcoma													·			X		•			Ĭ.			·	·	1
Thymus	+	+	+	+	+	+	+	M	+	+	+	+	+	+			+	+	+	+	+	+	M	+	+	38
Integumentary System		_	_	•	_		_				_	_		_		-		_					_			
Mammary gland	+	. +	+	+	М	М	+	+	M	+	+	+	+	+	+	M	+	М	+	+	+	+	+	+	+	36
				. +	+		+	+	+		+	+	+	+	+	+			+	+	+	+	+	+	+	50
Skin			•																							

TABLE D2a	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Tri	iamterene:
First Study: 0 ppm (continued)	

rust Study. o ppin (continued)																_													
Number of Days on Study	-	0 2 3	1 1 4	3 6 2	4 3 1	4 9 4	5 0 9			6 9 6	7 1 1	7 2 3	7 2 5	7 2 9	7 3 0	7 3 0	7 3 0												
Carcass ID Number	·	3	3		3					2 9		2 8	3 4		2 8		2 9	2 9	2	2 9	2 9	3	3 2	3	3	-			
	-	3	6	1	8	7	6	9	4	5	6	9	5	1	3	8	3	4	6	7	8	2	0	5	7	_			
Musculoskeletal System Bone			_							_					_				_	•	_						***************************************		
Skeletal muscle		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+			
Hepatocholangiocarcinoma, metastatic,																•													
uterus	'											x													_	•			
V				-	,*-				-									_						_					
Nervous System																										٠.			
Brain		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
																	_			_			_					-	
Respiratory System																													
Lung Alveolar/bronchiolar adenoma		+	+	+	+	+	+	+	+	1	+	+	+	+	+	+	+	+	+	+	+	X	+	+	+	+			
Hepatocellular carcinoma, metastatic,																						^							
liver									\mathbf{x}																				
Hepatocholangiocarcinoma, metastatic,																													0
uterus												Х															,		
Nose		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Trachea		.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+	+			
		_				_							_											_				,	
Special Senses System Harderian gland											•									٠.									
Adenoma															75														
1 sacroma															٠.			٠.				1.5							
Irinam System			-																										
Urinary System Kidney	••		.	_	_	_	_	1	_	· •	+	_	_	_	1	_	_	4	_	_	1	_	_	_	4	Т.			
Urinary bladder		+	+	A	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. `		
		_					_	_			_					_				_				_					
Systemic Lesions																											-		
Multiple organs		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Multiple organs		•	-	•				X			-	-						-					-						
Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed													٠	Х															

TABLE D2a Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: First Study: 0 ppm (continued)

Number of Days on Study	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 2	7 3 2	7 3 2	7 3 2	_	7 3 2	-	7 3 2	-	7 3 2	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	
Carcass ID Number	3 0 9 1	1 0	3 1 3 1	3 1 5 1	3 1 7 1	1 9	2	2	2 5	2 8	2 9	3 0	3	3 2	3	6		3 3 8 1	9	3 4 1	-	3 4 4 1	3 4 6 1		3 4 8 1	Total Tissues/ Tumors
Musculoskeletal System Bone Skeletal muscle Hepatocholangiocarcinoma, metastatic, uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver	+	+	+	+ X	+	+	+	+	+	+	+	+	* X	+	+	+	+ X	+	+	+	+	+	+	+	+	50 4
Hepatocholangiocarcinoma, metastatic, uterus Nose Trachea	+	· +	+	+	++	++	++	++	++	+ +	++	+++	+	+++	++	++	+ +	++	++	++	++	++	+	+	++	1 50 50
Special Senses System Harderian gland Adenoma																	+ X									1
Urinary System Kidney Urinary bladder	+	- +	. +	+	+	+	+	++	++	+	+	++	+	+	+	+	+	+	+	+	+	+	+	+	++	50 48
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed	-1	- +	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+ x		+	+	. +	+ x	50 1 2 9

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm

	2		6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		
	5				6	7	8	2	2	2	2	2				2	2	2	3					3			
	0	9	9	9	4	0	3	9	9	9	9	9	9	9	9	9	9	9	0	0	0	0	0	0	0		
•		_	-	4	3	3	3	3			3	3	3								-	_			-		
,																											
!	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Ţ	1	1	1	1	1	1	i	1	1		
· .44,					_									_				-		_							
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+		+		+	+	+	+	+	+	+	+	+	+		M	+	+	+	+	+	+	+		
	+	+	+	+	+		+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+		
1.	+	+	+	+	+		+	+	+	+		+	+		+	+	+	+	+	+	+	+	+	+	+		,
-	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		٠,
. ,	+	+	+	+	+,	M	+	.+	.+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+		
٠.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	M	+	+	+	+				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
														X					X			X					
												Х				Х		•		Х	,			Х	X		
							X	-																			
							+	+	+		+	+					+										
							Х																				
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
							Х																				
	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
•	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+	+	+	+	+	+	+	,+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	_	_			_								_		_						_			_			
	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	•										_			-													
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
	М	+	+	+			+	+	+	+	+	+	М	М	+	М	+	+	+	+	+	+	+	+	+		
	+	+	+	+														+	+	+	+	+	+	+	+		
	•	•	•	•	•		•	•	•	•				•		•	•		•	•	•	•	•	•	·		
	M	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+		
		-	•	•				-		•		-					-						ĺ				
		8 3 1 + + + + + + + + + + + + + + + + + +	8 9 3 0 1 1 + + + + + + + + + + + + + + + + + +	8 9 1 3 0 2 1 1 1 1 +	8 9 1 1 3 0 2 4 1 1 1 1 1 +	8 9 1 1 6 3 0 2 4 4 1 1 1 1 1 + + + + + + + + + + + + + + +	8 9 1 1 6 6 3 0 2 4 4 2 1 1 1 1 1 1 1 + + + + + + + + + + + + + + + + + + +	8 9 1 1 6 6 5 3 0 2 4 4 2 8 1 1 1 1 1 1 1 1 + + + + + + + + + + + + + + + + + + +	8 9 1 1 6 6 5 5 3 0 2 4 4 2 8 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	X + + + + + + + + + + + + + + + + + + +	X + + + + + + + + + + + + + + + + + + +	X + + + + + + + + + + + + + + + + + + +	8 9 1 1 6 6 5 5 5 5 5 5 5 5 5 5 3 0 2 4 4 2 8 2 4 6 7 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 9 1 1 6 6 5 5 5 5 5 5 6 3 0 2 4 4 2 8 2 4 6 7 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 + + + +	8 9 1 1 6 6 5 5 5 5 5 5 6 6 6 3 0 2 4 4 2 8 2 4 6 7 9 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 + + + +	8 9 1 1 6 6 5 5 5 5 5 6 6 6 6 6 6 7 9 1 3 5 1	8 9 1 1 6 6 5 5 5 5 5 5 5 6 6 6 6 6 3 0 2 4 4 2 8 2 4 6 7 9 1 3 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 + + + + + + + + + + + + + + + + + + +	8 9 1 1 6 6 5 5 5 5 5 5 6 6 6 6 6 6 3 0 2 4 4 2 8 2 4 6 7 9 1 3 5 6 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 9 1 1 6 6 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6	8 9 1 1 6 6 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 7 8 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 9 1 1 6 6 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6	8 9 1 1 6 6 5 5 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7	8 9 1 1 6 6 5 5 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7	X X X X X X X X X X X X X X X X X X X	X X X X X X X X X X X X X X X X X X X	8 9 1 1 6 6 5 5 5 5 5 6 6 6 7 7 7 7 8 8 8 3 0 2 4 2 8 2 7 9 1 2 5 9 1 3 5 6 7 8 2 7 8 9 1 2 5 1 2 2	8 9 1 1 6 6 5 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 7

TABLE D2a Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: First Study: 100 ppm (continued)

											_				_	<u> </u>		_	_	_				_			$\overline{}$
y I OD COL	7			7	7	7	7	7	7	7	7	7	7	7	7	7	7	7 '	7	7	7 3	7	7 3	7	7 3	7 3	
Sumber of Days on Study	3 0	0	_							2	2	3 2	3 2						_					3	_	_	
	3		3 3	3	3	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
Carcass ID Number	8	8	3 9	•	9	9	9	9	9	0	0	0	0	0	0	0	0 :	2 (0	0	1	1	1	1	1	1	Total
	6	9) 1	1	2	4	7	8	9	0	1	2	3	4	5	6	7	0	8	9	0	1	5	7	8	9	Tissues
	1	1	1	l	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Tumor
Alimentary System		-	,**		_															_							
Esophagus	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	٠ -	+ -	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small	4	٠ ٠	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	4	٠ ٠	+ .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	4	٠ ٠	+ •	+	+	+	+	+	+	+	+	+	+	+	+		•		+	+	+	+	+	+	+	+	48
Liver	4	٠ ١	+ ·	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	+		+	50
Hepatocellular carcinoma																	X	X							X		3
Hepatocellular carcinoma, multiple									37	X	37																1
Hepatocellular adenoma		,						X	Х		Х	X		v	X				v	x	v	X					10
Hepatocellular adenoma, multiple Serosa, adenocarcinoma, metastatic, ovary	>	•			Х		X							Х						А							12 1
Mesentery							+	+						+						+							10
Adenocarcinoma, metastatic, ovary							Ċ	•						·													1
Pancreas	-	+	+ .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenocarcinoma, metastatic, ovary		•	•					·	·	·	·		·	·								•				•	1
Salivary glands	+	٠.	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System			_	_	_																				_		
Heart	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System		_																									
Adrenal gland	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	-	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, medulla	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Adenoma																											1
Parathyroid gland					M									+							+	+	+	+	+	+	41
Pituitary gland	-	+			+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	+	+	47
Pars distalis, adenoma				X														X		X							5 .
Thyroid gland Follicular cell, adenoma	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	49 1

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm (continued)

																_										
	2	5	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	5	7	-	3		7	8	2	2	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	
differ of Days on Study	-										_	9	9	-	_		9									
																						_		_		
		3											3										_	3	-	
Carcass ID Number	8												6													
•	3 1												1 1													
General Body System None																							-			
Genital System				_		_											_				_			_	-	
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenocarcinoma	т	•	'	•	'	'	X		•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•		'	
Cystadenoma							Λ																			
Uterus	_	4	4	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma		7	_	т-	т	-	т	т		Т	-	-	-	-	7	7	-	٦	X	т	т	~	~	~	т	
Polyp stromal																			А							
		_		_			_						<u></u>	_			_				_					
Bone marrow	_		4	+	_	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hemangiosarcoma	т.	,	r	1	1	'	'	,	'	•	'	1	'	'	•	1	'	•	'	•	'				'	
Lymph node			4	1	_	1	+	_	+	1	+	+	+	+	+	+	+	4	+	1	+	4	4.	+	+	
Axillary, liposarcoma, metastatic, skin		7	-	т	т	т	т		Τ.	т	т	T	т	т.	т	т	т	7	т	т	т	т	т		- 1	
Lymph node, mandibular						١,,									1.											
	+	+	_	+	+	IVI			+	7	+	+	+	+	~	_	+	+	Ţ	_	+	+	7	+	-	
Adenocarcinoma, metastatic, ovary							X																			
Lymph node, mesenteric	+	+	+	+		M				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•
Spleen	+								+		+	+		+	+	+	+	+	+	+	+	+	+		+	
Thymus	. +	+	M	[+	+	M	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Integumentary System																							_			
Mammary gland	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	
Skin	+	+	+	+							+	+	+	+	+	+	+									
Subcutaneous tissue, hemangioma	,	•	•	•	•		•	•	•	•	•	•	•	•		,	•	•			•	•	-	•	•	
Subcutaneous tissue, liposarcoma																										
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Vertebra, osteosarcoma	X																									
Skeletal muscle							+																			
Adenocarcinoma, metastatic, ovary							X																			
Nervous System		_	_																							
Brain	+		4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Peripheral nerve	+		r	,-	1.	τ.			'	•	,	'	'	•	•	'	'	,	•	٠			,		•	
i oripiiciai nerve																										
Spinal cord	+																									

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm (continued)

			_	_								_				_				_		_	_			
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
lumber of Days on Study	3 0	3 0	3 0	3 0	3 2	3 2						3 2						3 3	3 3		3	3	3	3		
										_	_	_	_	_	_	_	_	_	_	_	_	_	_			
Carcass ID Number	3 8	3 8	3 9	9		9		-	-	•	•	4 0	-	•	•	4 0	•	4 0	•	4	4	4	4	4		Total
ourcuss in Named	6	9	1	2	4	7	8	9	0	1	2		4		6		0 1		9	0	1	5	7	8	9	Tissue: Tumor
General Body System None	· <u> </u>																					_				
Genital System											_	_	_	_	_		_		_			_	_			
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenocarcinoma		•	٠	•	•		•	-	-				-				•		•							1
Cystadenoma		X																								1
Uterus	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma																	X									2
Polyp stromal		Х																								1
lematopoietic System							,																			
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																						X				1
Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	50
Axillary, liposarcoma, metastatic, skin																	X									1 49
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenocarcinoma, metastatic, ovary	A.	. .	M			_	_	_	_	_	_	_	_	_	+	+	+	_	_	_	_	+	N.A	+		1 45
Lymph node, mesenteric Spleen	IV	[+		+	+	+	+	+	+	+	+	+	T	T	т Т	+	+	+	+	+	+	+	141		+	50
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			-		-	+	+	+			44
Integumentary System		_	_		_	_	_			_				_	_	_	_	_		_			_			
Mammary gland	+	· N	1 +	+	M	+	+	+	+	+	+	+	+	M	+	M	M	+	+	+	+	+	+	+	+	43
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Subcutaneous tissue, hemangioma																						X				1
Subcutaneous tissue, liposarcoma																	X									1
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Vertebra, osteosarcoma																										1
Skeletal muscle																										1
Adenocarcinoma, metastatic, ovary																					_	_				1
Nervous System																										
Brain	4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Peripheral nerve Spinal cord																										1 1

First Study: 100 ppm (continued)				_													:						_				
	2	5	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	, 7	7	7	7	7	
Number of Days on Study			9														2 9										
	3	 3	4	4	3	3	3	3	 3	 3	3	3	3	3	3	3	3	3	3	3		3 3		3	3	3	
Carcass ID Number	₄ 8	9	1	1	6	6	5	5	5	5	5	5	6	6	6	6	6	6	7	7	7	7	7	8	8	8	
			1																								
Respiratory System						-												_									
Lung Adenocarcinoma, metastatic, ovary Alveolar/bronchiolar adenoma	. +	• +	- +	+	+	+	*X	+	+	+	+	+	+	+	+	+	+ x	+	+	٠ ٦	٠ ٠	+ -	+	+	+	+	
Alveolar/bronchiolar carcinoma Hepatocellular carcinoma, metastatic, liver																			:		٠						
Liposarcoma, metastatic, multiple, skin Osteosarcoma, metastatic, bone	х																										
Nose	+		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 4	٠ -	+ -	+	+	+	+	
Trachea	. +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠ +	٠ -	+ -	+	+	+	+	
Special Senses System																											
Eye					+																						
Harderian gland Adenoma									+ X																		
Urinary System							•						•														
Kidney Capsule, adenocarcinoma, metastatic, ovary	+		+ +	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	- +	٠ ٠	+ ·	+	+	+	+	
Urinary bladder	+		+ +	+	+	M	_		+	+	+	+	+	+	+	+	+	+	+	- 4	٠ ٠	+ ,	+	+	+	+	
Systemic Lesions				-																						-	*
Multiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic	+		+ + X		+	+ X		+	+	+	+	+	+	+	+	+	+	+ X		• +	٠ ٠	+ ·	+	+	+	+	
Lymphoma malignant mixed																X											

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 100 ppm (continued)

Number of Days on Study	7 3 0	7 3 0	7 3 0	7 3 0	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	7 3 3	3	
Carcass ID Number	3 8 6 1	3 8 9 1	3 9 1 1	3 9 2 1	3 9 4 1	3 9 7 1	3 9 8 1	3 9 9	4 0 0 1	4 0 1	4 0 2 1	4 0 3 1	4 0 4 1		4 0 6 1	4 0 7 1	4 2 0 1	4 0 8 1	9	4 1 0 1	4 1 1	5	4 1 7 1	4 1 8 1	9	l	Total Tissues/ Tumors
Respiratory System Lung Adenocarcinoma, metastatic, ovary Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	+	+	+ x	+	+	+	+	+	+	+ X	+ X	+	+	+	+ X	+	+	+	+	+	+	+	+	+		+ X	50 1 5
Hepatocellular carcinoma, metastatic, liver Liposarcoma, metastatic, multiple, skin Osteosarcoma, metastatic, bone Nose Trachea	++	+	+	+	++	+++	++	++	++	+	++	++	++	++	+ +	+ +	X + +	+	+	+	++	++	+	+		+	1 1 1 50 50
Special Senses System Eye Harderian gland Adenoma					_		+ X										+ X	-									1 3 3
Urinary System Kidney Capsule, adenocarcinoma, metastatic, ovary Urinary bladder	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +		+	50 1 49
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed	+	. +	+	· +	-	+ X	+ x	+	+	+	+	+	+	+ X		+	+	+	+	+	+ X		+	. +	-	+	50 3 1 5

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm

_ 																	_										
Number of Days on Study	4 9 0		2	6		6		7 1 2	2		2	2	2	7 2 9	7 2 9	2	7 2 9	7 2 9		7 2 9				7 3 0	3	7 3 0	
Carcass ID Number	4 5 4 1		1	4 3 5 1	9	7		4 4 5 1	1		6	7	8		4	6		0		2	2				9		
Alimentary System					_	_			_																		
Esophagus	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	4	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large	4	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	-4	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	4	+	+	+	+	+		M								+		+	+	+	+	+	+	+	+	+	
Intestine large, rectum	4	+	+	+	+	+	+	+	+				+	+	+		+	+	+	+	+	+	+	+	+	+	
Intestine small	· -	+	+	+	+	+	+		+			+				+				+	+	+	+	+	+	+	
Intestine small, duodenum	4	+	+	+	+		+					+				+				+	+	+	+	+	+	+	
Intestine small, ileum	· ·	-	+	+	+	÷		+						+		+			+	+	+	+	+	+	+	+	
Intestine small, jejunum	4	۲	+	+	+	+		M			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Liver	4	+	+	+				+												+	+	+	+	+	+	+	
Hemangiosarcoma												X															
Hepatocellular carcinoma																							Х				
Hepatocellular adenoma								X	X	X									X								
Hepatocellular adenoma, multiple												X			X						X				Х		
Osteosarcoma, metastatic, bone				X																							
Mesentery											+		+							+		+				+	
Pancreas	+	۲	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach	4	۲	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	
Papilloma squamous																							X				
Squamous cell carcinoma																											
Stomach, glandular	4	۲	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System	*	_	•			_								•													
Heart	-	۲	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System	-	_										_															
Adrenal gland	-	۲	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex	_	⊦	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Spindle cell, adenoma										X										X							
		⊦	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, medulla	-			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•
Adrenal gland, medulla Islets, pancreatic	-	۲	+	,							_	+	+	+	+	+	+	M	+	M	M	+	+	M	! +	+	
Islets, pancreatic	-	⊦ ⊦	+	+		+	+	+	+		7	,														_	
	- - -	⊦ ⊦ ⊦	+++	++	+			+ M						+	+	+	+	+	+	+	+	+	+	+	+	M	
Islets, pancreatic Parathyroid gland	- - -	+ +	+++	+	+									+	+	+	+	+	+	+	+	+	+	+	+	M	
Islets, pancreatic Parathyroid gland Pituitary gland	- - -	⊦ ⊦	+++	++	+									+	+	+	+	+	+	+	+	+	+	+	+	М	
Islets, pancreatic Parathyroid gland Pituitary gland Pars distalis, adenoma	- - -	++	+++++	+++	+						+		+			+		+		+						М +	

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

lumber of Days on Study	7 3	3		7 3	3	3	3	3	3	3	3	_														
	0	0	0	0	0	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	
	•	4	4	4	4	4	4		4	-		4					4	•	4		4	4	4	•	4	
arcass ID Number	5	5	5	5		6	6				7			7			7			8		8	8	8		Total
	1						4 1										7		9 1				8			Tissue Tumo
				_			_			_	_			_		_		_				_	_	_		
limentary System																										5 0
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, ileum	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																										1
Hepatocellular carcinoma															Х	Х										3
Hepatocellular adenoma				X	X			Х							X			X		X	X		X			12
Hepatocellular adenoma, multiple Osteosarcoma, metastatic, bone	Х						X		X	X	X	X													X	11 1
Mesentery										+	+		+													8
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Papilloma squamous																										1
Squamous cell carcinoma						X																				1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
ardiovascular System				_		_			_			_									_					
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
ndocrine System				_	_	_	_																	_		
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Spindle cell, adenoma	·											-		•		•		•		•	X	•	•	•		3
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	+	+	+	+	M	(+	+	+	+	+	+	+	+	М	M	+	+	+	+	+	+	+	+	+	43
Pituitary gland	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	<u>.</u>	+	<u>.</u>	+	48
Pars distalis, adenoma	•	•	X	•	•	•	•		X	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	3
Pars intermedia, adenoma	X							4	1	Х																2
Thyroid gland		+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	_	+	_	+	4	50
Follicular cell, adenoma	т	-	7		Τ.	-,-	т	т	Τ,	-	т.	.17	т.	T	Т	Г	•	Т	-	т	т		7	т	77	30 1

	4			5					7	7	7	7	7	7	7										7		
lumber of Days on Study	9						1 2		2 9			2 9	2 9	2 9	2 9												
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4		
Carcass II) Number	5 4	7	3	-	-	4			2	_					3 6					4		4		4	-		
	-														1												
ieneral Body System None												•														· · · · · · · · · · · · · · · · · · ·	
enital System								*			****				-												
Overy	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Cystadenoma Granulosa cell tumor benign																						х					
Hemangiosarcoma																	x										
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+		
Hemangiosarcoma														X													
Polyp stromal											X																
lematopoietic System	-															•											
Blood							+																				
Bone marrow	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Hemangiosarcoma Lymph node	_	_	_	_	_	_	_	_	_		X	4	+	_	4	_	+	_	_	+	+	_	4	_	_		
Mediastinal, hepatocellular carcinoma, metastatic, liver	•	•	•	ļ	1	•	'	•	•	·	•	•	•	•	•	·	•	•	•	•		•	•		•		
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node, mesenteric															+									+	+		
Spleen	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	Α	+	+	+	+	+	+		
Hemangiosarcoma Thymus	+	+	+	M	+	M	M	+	+	+			X M	+	+	+	+	+	+	+	+	+	+	+	+		
ntegumentary System		_													-										*		
Mammary gland	+	+	+	M	+										+										+		
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Subcutaneous tissue, fibrosarcoma		_													_					_			_		X		
Iusculoskeletal System			-			_																					
Bone Vertebra, osteosarcoma	+	+	+ X	+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
											-																
ervous System																											

50

50

Musculoskeletal System

Vertebra, osteosarcoma

Bone

Nervous System Brain

Number of Days on Study	7 3	3	3		3	3	7	3		3	3	3	3		3		3	3	3		3		3		3	
		0	0	0	0	2	2	2	2	2	2		2	2	3	3	3	3	3	3	3			3	3	
Carcass ID Number	4 5 1	4 5 2 1	4 5 6 1	4 5 8 1	9	4 6 1 1	4	6 5	6	6 8	7 0	7 2	3	7 4	4 7 5 1	6	7	8	9		4 8 4 1	_	4 8 8 1	9	-	Total Tissues, Tumors
General Body System None																						_				
Genital System		_																			_	_				
Ovary Cystadenoma Granulosa cell tumor benign Hemangiosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X		+	50 1 1 1
Uterus Hemangiosarcoma Polyp stromal	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 2
Hematopoietic System							_																			
Blood Bone marrow	_										,			,												1
Hemangiosarcoma		7	•	•	+	+	+	+	_	+	+	+	+	+	+	+	+	+	+	+	+	•	+	+	+	50 1
Lymph node Mediastinal, hepatocellular carcinoma,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	50
metastatic, liver																X										1
Lymph node, mandibular Lymph node, mesenteric	+		· +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	+	+	+	50 46
Spleen	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	46 49
Hemangiosarcoma	•	•	•	•	•		•	•	•	•	•	•	•		•	•	•				,	,	•	•	'	3
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	M	+	+	+	+	+	+	44
Integumentary System			_	_			-			_	_							_		_		_	_			
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· M	(+	+	+	46
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	49
Subcutaneous tissue, fibrosarcoma																										1

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

Number of Days on Study	4 9 0	5 2 8	6	5 8 6	6 6 0	6 7 7	7 1 2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9		7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	
Carcass ID Number	4 5 4 1	4 7 1 1	4 3 5 1	4 6 9 1	4 3 7 1	4 4 7 1			4 2 5 1			8	2	4	4 3 6 1				4 6 2 1		_	4 4 6 1	4 4 8 1	4 4 9 1	-	
Respiratory System																										
Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver	+	+ X		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X		+	+	+	+	
Osteosarcoma, metastatic, bone			X																							
Nose Trachea			+		+		+		+		+		+		+		+							+	+	
Special Senses System Harderian gland Adenoma																										
Urinary System					_									_		_										
Kidney Urinary bladder	+	+	+	+	+	+	+ M		+		-	+	-	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions		-						-	-																	
Multiple organs	+	+	+				+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	
Lymphoma malignant histiocytic				X	X	X			x							х			X	х		х				

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 200 ppm (continued)

Number of Days on Study	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 3	7 3 3	7 3 3									
Carcass ID Number	4 5 1	4 5 2 1	4 5 6 1	4 5 8 1	4 5 9 1	4 6 1	4 6 4 1	4 6 5 1	4 6 6 1	4 6 8 1	4 7 0 1	4 7 2 1	4 7 3 1	4 7 4 1	4 7 5 1	4 7 6 1	4 7 7 1	4 7 8 1	4 7 9 1	4 8 2 1	4 8 4 1	4 8 5 1	4 8 8 1		4 9 0 1	Total Tissues/ Tumors
Respiratory System																						_				
Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 2
liver																X										1
Osteosarcoma, metastatic, bone																										. 1
Nose Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
Special Senses System		_				_		_			_	_	_		_					_		_	_			
Harderian gland						+				+						+										3
Adenoma										X						X										2
Urinary System						_						_				_		_	_				_	_		
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Systemic Lesions			_					_	_				_	_			_			_	_	_	_		_	
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymphoma malignant histiocytic																										4
Lymphoma malignant mixed																X			X				Х			9

TABLE D2a Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: First Study: 400 ppm

2	2	2	2	5	5	-						6	7	7	7	7	7	7	7	7	7	7	7	7		
																1 2	9	9	9	9	9	9		-		
5.	5	5	5	4	5	5	5	5	4	4	5	5	5	5	- <u> </u>	5	4	4	4	4	4	5	5	5		
1	0	4	4	-	-																					
_																										
		_																_								
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Α	+	+	+																				+	+		
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
+	+	+	+	+	+														+	+	+	+	+	+		
+	+	+	+	+	+	+	+	+	+										+	+	+	+	+	+		
+	+	_																	+	+	+	+	+	+		
+	+	_																	+	+	+	+	+	+		
+	+																			+	+	+	+	+		
+	+	+																	+	+	+	+	+	+		
Á	+	+																	+	+	+	+	+	+		
+																										
·	٠	•	·		•	·		·	·	٠	·	٠	•	•		•		·	•					•		
																		x		•		x				
					x					x					x											
																	x		x	x	x	-				
																	7.		•	-	1.			71		
																		'								
																		Y								
	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_		_	_	_			_		
T				T	+		1					T	T	+	T											
-	<u> </u>	-	T	T					1	+	<u> </u>		<u> </u>	4					1							
	÷	4	Ţ	<u>,</u>	Ţ	<u> </u>	÷			÷	<u>.</u>	, +	1	÷	1	÷	1		1		Ţ			1		
'	'	1	'	•	•	•	٠	•	•	٠	•	٠	•	•	'	•	•	•	٠	'	'	•	•	1		
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
									_										-						***	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
						_					_							_								
4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
·	+	+	+	+	+	+	+	+	+	+																
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•	•	•	•				
4	4	+	+	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	+	+	+					
T 		T	T		1	1	4	Δ.								4.	<u>.</u>	Ţ	1	4.	1					
· · ·	+	→	- -	Ψ ±	-	1	M				-		•		1	+	1	_	1	+	M	T]				
	→	, <u> </u>	T																			. T				
т.	~	7	~	Τ'	141	т	т-		Τ'	141	т-	т	т	Т	τ.	-			Τ.	~	7	~	-	т		
																	Λ									
1	4		_				_	_	.1			_	_	_	_	_	_		_	_	_	ــــــــــــــــــــــــــــــــــــــ		_		
—	┰			~	т.	т	т	т.	~	7	т		+	т		т	T		т.	~	т-		7			
	8 0 5 1 5 1 + A A + + + + + + + + + + + + + + + +	8 8 8 0 3 5 5 5 1 0 5 2 1 1 + + + + + + + + + + + + + + + + +	8 8 8 0 3 4 5 5 5 5 1 0 4 5 2 2 1 1 1 +	8 8 8 8 8 0 3 4 5 5 5 5 5 1 0 4 4 4 5 2 2 0 1 1 1 1 1 + + + + + + + + + + + + + +	8 8 8 8 2 0 3 4 5 2 5 5 5 5 4 1 0 4 4 9 5 2 2 0 1 1 1 1 1 1 + + + + + + + + + + + + + + + +	8 8 8 8 2 7 0 3 4 5 2 9 5 5 5 5 4 5 1 0 4 4 9 4 5 2 2 0 1 1 1 1 1 1 1 1 +	8 8 8 8 2 7 8 0 3 4 5 2 9 5 5 5 5 5 4 5 5 1 0 4 4 9 4 3 5 2 2 0 1 1 9 1 1 1 1 1 1 1 + + + + + + + + + + + +	8 8 8 8 2 7 8 0 0 3 4 5 2 9 5 0 5 5 5 5 4 5 5 5 1 0 4 4 9 4 3 5 5 2 2 0 1 1 9 7 1 1 1 1 1 1 1 1 + + + + + + + + + + +	8 8 8 8 2 7 8 0 1 0 3 4 5 2 9 5 0 3 5 5 5 5 4 5 5 5 5 1 0 4 4 9 4 3 5 2 5 2 2 0 1 1 9 7 1 1 1 1 1 1 1 1 1 1 + + + + + + + + +	8 8 8 8 2 7 8 0 1 2 0 3 4 5 2 9 5 0 3 3 5 5 5 5 4 5 5 5 5 4 1 0 4 4 9 4 3 5 2 9 5 2 2 0 1 1 9 7 1 4 1 1 1 1 1 1 1 1 1 1 1 + + + + + + + + + + + + + + + + + + +	8 8 8 8 2 7 8 0 1 2 2 2 0 3 4 5 2 9 5 0 3 3 9 9 5 5 5 5 4 4 1 0 4 4 9 4 3 5 2 9 9 5 2 2 0 1 1 9 7 1 4 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 0 3 4 5 2 9 5 0 3 3 9 5 5 5 5 5 4 5 5 5 5 4 4 5 1 0 4 4 9 4 3 5 2 9 9 3 5 2 2 0 1 1 9 7 1 4 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 9 0 3 4 5 2 9 5 0 3 3 9 5 0 5 5 5 5 4 5 5 5 5 4 4 5 5 5 1 0 4 4 9 4 3 5 2 2 9 9 3 4 5 2 2 0 1 1 9 7 1 4 3 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 3 4 5 2 9 5 0 3 3 9 5 0 3 5 5 5 5 4 5 5 5 5 4 4 5 5 5 5 4 4 5 5 5 1 0 4 4 9 4 3 5 2 9 9 3 4 3 5 2 2 0 1 1 9 7 1 4 3 4 4 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 5 5 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 0 0 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 5 5 5 5 4 5 5 5 5 4 4 5 5 5 5 5 5	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 1 0 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 2 2	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 9 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 2 9 5 0 3 4 5 2 9 5 0 3 4 5 2 9 5 0 3 4 5 2 9 5 0 3 4 5 2 9 5 0 3 4 5 5 5 5 5 5 4 1 0 4 4 9 4 3 5 2 9 9 3 4 3 5 6 1 9 5 2 2 0 1 1 1 9 7 1 4 3 4 4 3 0 0 7 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 0 3 4 5 2 9 9 5 5 5 5 4 5 5 5 5 4 4 5 5 5 5 5 5 5 4 4 1 0 4 4 9 4 3 5 2 9 9 3 4 3 5 6 1 9 9 5 2 2 0 1 1 9 7 1 4 3 4 4 3 0 0 7 2 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 0 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 2 9 9 9 9 9 5 0 3 4 5 2 9 9 9 9 5 0 3 4 5 2 9 9 9 9 5 0 3 4 5 2 9 9 9 9 5 0 3 4 5 2 9 9 9 9 5 0 3 4 3 5 6 1 9 9 9 9 5 2 2 2 0 1 1 9 7 1 4 3 4 4 3 0 0 7 2 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 0 3 4 5 2 9 5 0 3 3 3 9 5 0 3 4 5 2 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 2 2 0 3 4 5 2 9 5 0 3 3 3 9 5 0 3 4 5 2 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 2 2 2 0 3 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 2 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 3 0 3 4 5 2 9 5 0 3 3 9 5 0 3 4 5 2 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	8 8 8 8 2 7 8 0 1 2 2 4 9 0 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

Table D2a	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triam	terene:
First Study: 400 ppm (continued)	

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2 9	9	9	3 0	3 0			3 0			3 0		3 0		2			3 2	2	3 2		2	2	2	2	
	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
Carcass ID Number	0			0											2											
	5 1														9 1											
limentary System												_							-							
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	+	+	+	+	+	+	+	+						+	+	+	+		+	+	+	+	+	+	
Intestine small, jejunum	+	+	+	+	+	-	+	+	+			-	+		+	+	+	+	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+			+	
Hepatocellular carcinoma								X															X			
Hepatocellular carcinoma, multiple																										
Hepatocellular adenoma			X			Х							X	Х	X				X				X	X		
Hepatocellular adenoma, multiple				X			X			Х	X					Х		X			X				X	
Mesentery					+														+			+				
Osteosarcoma, metastatic, uncertain primary site																										
Pancreas		,					,																			
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	
Stomach	T	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach		+		+		+			+	+	+	+		+	+	+	+	+	+	+	+	+	+		+	
Papilloma squamous	•		X		т	т	~	т	т	_	т	+	Ŧ	т	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System				_							_	_		_		_			_	_				_		
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Indocrine System			_									_		_	_		_	_		_					_	
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Spindle cell, adenoma										X		-			-	-	-	-	-	•	•	-	•		•	
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland	+	+	+	+	+	+	+	M	+	+	+	+	+	+	M	+	+	+	+	+	+	+	M	+	+	
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pars distalis, adenoma					X									Х					X							
Pars intermedia, adenoma										X																
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Follicular cell, adenoma																										

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 400 ppm (continued)

	7 7 7 7 7 7 7 7 7 7	
Number of Days on Study	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
	5 5 5 5 5 5 5 5 5 5	
Carcass ID Number	4 4 5 5 5 5 5 5 5 5	Total
	8 9 1 2 3 4 5 6 8 9	Tissues
	1 1 1 1 1 1 1 1 1	Tumor
Alimentary System		
Esophagus	+ + + + + + + + +	60
Gallbladder	+ + + M + + + + + +	55
Intestine large	+ + + + + + + + +	60
Intestine large, cecum	+ + + + + + + + +	60
Intestine large, colon	+ + + + + + + + +	59
Intestine large, rectum	+ + + + + + + + +	58
Intestine small	+ + + + + + + + +	60
Intestine small, duodenum	+ + + + + + + + +	59
Intestine small, ileum	+ + + + + + M + + +	57
Intestine small, jejunum	+ + + + + + + + +	59
Liver	+ + + + + + + + +	60
Hepatocellular carcinoma	$\mathbf{X} \cdot \mathbf{X} \qquad \mathbf{X}$	6
Hepatocellular carcinoma, multiple		2
Hepatocellular adenoma	X X X X X X	22
Hepatocellular adenoma, multiple	X	14
Mesentery Osteosarcoma, metastatic, uncertain	+	5
primary site		1
Pancreas	+ + + + + + + + +	60
Salivary glands	+ + + + + + + + +	60
Stomach	+ + + + + + + + +	60
Stomach, forestomach	+ + + + + + + + +	60
Papilloma squamous Stomach, glandular	+ + + + + + + + +	1 60
Cardiovascular System Heart	+ + + + + + + + +	60
Endocrine System		20
Adrenal gland	+ + + + + + + + +	60 60
Adrenal gland, cortex	T T T T T T T T T	2
Spindle cell, adenoma		59
Adrenal gland, medulla	+ + + + + + + + + + + + + + + + + + +	59 59
Islets, pancreatic Parathyroid gland	+ + + + + + + + + + + + + + + + + + +	53
Parathyroid gland Pituitary gland	+ + + M + + + + + + + + + + + + + + + +	58
Pars distalis, adenoma	X	5
Pars intermedia, adenoma	Λ	1
Thyroid gland	+ + + + + + + + +	60
Follicular cell, adenoma	,	1

Nervous System Brain

							5																	7	7	
Number of Days on Study	0	3	4	5	2	9	8 5	0	3	3	9	5	0	3	4	5	2	9	9	9	9	9	9	9		
							5																			
Carcass ID Number							9																			
							í																			
General Body System None										-						_						•				
Genital System	***		-																							
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cystadenoma																										
Mixed tumor benign Uterus							+								1											
Polyp stromal	т	т	7	т	т	т	т	Т	т	т	т	_	т	T-	7	т	т	т	т	т	т	T		т	_	
Hematopoietic System								_		_																
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hemangiosarcoma										X																
Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Inguinal, squamous cell carcinoma, metastatic, skin																	x									
Lymph node, mandibular	+	+					+																			
Lymph node, mesenteric Spleen	+	+ 					++																			
Hemangiosarcoma	-	+	+	Τ.	_	+	т	Τ"	7	X	+	Τ.	т	T	_	T	_	т	т	T	т	т	Т	т	~	
Thymus	+	+	+	+	+	I	+	+	+		+	+	+	+	M	+	M	+	M	+	+	+	M	+	+	
Integumentary System						_														_	_					
Mammary gland	+	M	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Basal cell carcinoma																										
Squamous cell carcinoma																	X									
Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, hemangiosarcoma					х						Х		Х													
Musculoskeletal System															<u> </u>											
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	

TABLE D2a

Individual Animal Tumor Pathology o First Study: 400 ppm (continued)	ı ren	141	C IV	110	C I	11 (.iic	~-	10	aı	rc	-u	50	uu,	, •												,	٠.
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7			
Number of Days on Study	,	2	2												3									-	•			
Number of Days on Study	9	9													2													
	5														5												_	
Carcass ID Number	0		0												2													•
	5														9													
	1	1	1	1	1	1	1	1	1	1	1	1	1	1 -	1	1	1	1	1	1	1	1	1	1	1			
General Body System None																												
Genital System	"																						_					
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Cystadenoma																							•		X			
Mixed tumor benign										Х																		
Uterus	+	+	+	+	+	+	+	+	+	+.			+	+	+	+	+	+	+	+	+	+	+	+	+			
Polyp stromal											Х	X																
Hematopoietic System	10 4.														•													
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Hemangiosarcoma	*																											
Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	+	+	+	+	+	+	+	+			
Inguinal, squamous cell carcinoma, metastatic, skin		•																										
Lymph node, mandibular	M	[+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Lymph node, mesenteric	+	M	(+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	[
Spleen	+	+	+	+	+	+	+.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Hemangiosarcoma																												
Thymus	+	+	+	+	+	. +	+	+	+	+	+	+,	+	+	M	+	M	+	+	M	+	+	+	M	(+			
Integumentary System	. "			-				,																				
Mammary gland	+	+	+	M	M	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	[+	+	+			
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Basal cell carcinoma																									Х			
Squamous cell carcinoma																												
Subcutaneous tissue, fibrosarcoma																					. ,							
Subcutaneous tissue, hemangiosarcoma										X											٠						٠,	
Musculoskeletal System	,							•				_						-										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Nervous System																												
		,			.1	.1	.1.	.1	.1.	ட	.1	.1.	.نـ	_1_		.د	Д.		.1	.1.	_1	J.						
Brain	+	+	-	+	_	+	_	Τ.	· •	_	-	_	7	7	~	-	_		-	_	-	-	- +		+			

TABLE D2a												
Individual Animal	Tumor	Pathology	of	Female	Mice	im	the	2-Year	Feed	Study	Oľ	Triamterene:
First Study: 400 p	pm (cont	tinued)										

Number of Days on Study	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 3 3 3 3	
Carcass ID Number	5 5 5 5 5 5 5 5 5 5 5 5 5 4 4 5 5 5 5 5	Total Tissues/ Tumors
General Body System None		
Genital System Ovary Cystadenoma Mixed tumor benign Uterus Polyp stromal	+ + + + + + M + + + + + + + + + +	59 1 1 60 2
Hematopoietic System Bone marrow Hemangiosarcoma Lymph node Inguinal, squamous cell carcinoma, metastatic, skin Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus	+ + + + + + + + + + + + + + + + + + +	60 1 60 1 58 54 60 1 50
Integumentary System Mammary gland Skin Basal cell carcinoma Squamous cell carcinoma Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, hemangiosarcoma	+ M M + + + + + + + + + + + + + + +	51 60 1 1 3
Musculoskeletal System Bone	+ + + + + + + + +	60
Nervous System Brain	+ + + + + + + +	60

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 400 ppm (continued)

Number of Days on Study	2 8 0	2 8 3	2 8 4	_	5 2 2	5 7 9	5 8 5	6 0 0	_	6 2 3	6 2 9	6 4 5	6 9 0	7 0 3	7 0 4	7 0 5	7 1 2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	
Carcass ID Number	5 1 5 1	5 0 2 1	5 4 2 1	5 4 0 1		5 4 1 1				4 9 4 1	4 9 3 1	5 3 4 1	5 4 4 1	3	5 5 0 1			4 9 2 1	4 9 5 1	6	4 9 8 1	9				
Respiratory System																										
Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Osteosarcoma, metastatic, uncertain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
primary site Nose																			X +							
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System Harderian gland																						+				
Urinary System																			•				_		_	
Kidney Urinary bladder	+	+	+	+	+	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions									_			_														
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+ X		+			+	+	+	+	+	+	+	+	+	
Lymphoma malignant histiocytic Lymphoma malignant lymphocytic											x			х	X											
Lymphoma malignant mixed									х							х			х							

TABLE D2a	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:	
First Study: 400 ppm (continued)	

		_																								
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 3 0	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2											
Carcass ID Number	0		0 8		1 0	1 2	1	1 8	1	2	2	2 5	2	2	5 2 9 1				3	3 7	5 3 8 1	4		4		
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Osteosarcoma, metastatic, uncertain	+	+	+	+ X X		+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	
primary site Nose Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	
Special Senses System Harderian gland																				+						
Urinary System Kidney Urinary bladder	+	+	+	++	++	++	+	+	++	++	++	+	++	+++	+	+	+	+	+	++	++	+	+	+	+	
Systemic Lesions Multiple organs Lymphoma malignant histocytic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymphoma malignant lymphocytic Lymphoma malignant mixed		X		x								x														

TABLE D2a
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
First Study: 400 ppm (continued)

Number of Days on Study	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 3	
Carcass ID Number	5 5 5 5 5 5 5 5 5 5 5 5 4 4 5 5 5 5 5 5	Total Tissues/ Tumors
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Osteosarcoma, metastatic, uncertain	+ + + + + + + + + + + + *	60 1 3
primary site Nose Trachea	+ + + + + + + + + + + + + + + + + + + +	1 60 60
Special Senses System Harderian gland		2
Urinary System		
Kidney Urinary bladder	+ + + + + + + + + + + + + + + + + + + +	60 60
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed	+ + + + + + + + + + X	60 3 2 6

TABLE D2b	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Stu	dy of Triamterene:
Second Study: 0 ppm	

Number of Days on Study	8 8	3	3	5	1	4	8	0	1	2		3	3		7 3 0				3	3		3	3	7 3 0	3	
Carcass ID Number	7 6 8 1	7		2 0	1 7		6 1		2 1	4 8		1 2	1 3	1	7 1 5 1	1 8	1 9	2	2						3	
Alimentary System						-															-					
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	<u>.</u>	+	+	·	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+	+	·	
Intestine large		·	·	÷	+	·	<u>.</u>	+	+		+	+	+	+	+	÷	<u>.</u>	+	<u>.</u>	<u>.</u>	<u>.</u>	<u>.</u>	·	<u>.</u>	÷	
Intestine large, cecum	+	+	+	+	À	+	+	+	+		+	+			+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	·	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	. +	+	+	+	+	+		+	+			+	+	+	+	+	+	+	÷	+	+	+	
Intestine small	·	+	+	+	À				+			+			+		+	+	+	+	+	<u>.</u>	+	<u>.</u>	+	
Intestine small, duodenum	+	+	+		A		+	+	+		+	+	+	+		+	+	+	+	+	+	+	+	+	+	
Intestine small, ileum		+	+			+			+				•		+		-	+	+	+	+	+	+	+	+	
Intestine small, jejunum	·	+	+		A										+					+	+	÷	+	+	4	
Liver		+				+						+			+							+				
Hepatocellular carcinoma	•	•	•	,	x		•	•	•	•	•	•	•	•		•	•	x		x	•	•		•	1	
Hepatocellular adenoma													X													
Hepatocellular adenoma, multiple											X		•-					x								
Mesentery		+									•															
Pancreas	+	+		+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Cardiovascular System		_																		_						
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System					_																	•				
Adrenal gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	
Adrenal gland, cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Spindle cell, adenoma																										
Adrenal gland, medulla	+	+	+		M		+	+	+	+	+	+	+	+	+	+			+		+	+	+	+	+	
Islets, pancreatic	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	
Adenoma																			X							
Parathyroid gland															+											
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																										
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

None

^{+:} Tissue examined microscopically A: Autolysis precludes examination

None

TABLE D2b Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: Second Study: 0 ppm (continued)

Number of Days on Study	7 3 0	3	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0								3	7 3 0	3	
Carcass ID Number	7 3 8 1	3 9	7 4 0		7 4 3 1	7 4 4 1		7 4 7 1	7 4 9 1		7 5 1				7 5 6 1	7	8	9	0	2		4	5		6 7	Total Tissue Tumoi
Alimentary System	· · · · ·																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder			. 4	•	+	·	+	+	+	+	÷	+	+	+	+	<u>.</u>	+	+	+	+	+	+	÷	+	+	50
Intestine large	4	. +	. +	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	<u>.</u>	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, colon	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	+	<u>.</u>	<u>.</u>	+	<u>.</u>	50
Intestine large, rectum	, +	. +			+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+	+	+	+	+	50
Intestine small	-4	. 4		. +	+	+	+	+	+	+	+	+	+	÷	÷	+	+	+	+	+	+	+	+	+	+	49
Intestine small, duodenum	+		. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, ileum	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	+	+	<u>.</u>	+	+	+	+	+	49
Intestine small, jejunum	4	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Liver	+	. 4		+	+	+	+			+	+	+	+	+		+	+	+	+		+	+	+	+	-	50
Hepatocellular carcinoma			•		•		•	•	•	X		•	•	•	•	•	$\dot{\mathbf{x}}$	•	•	•	•	•	•	٠	•	5
Hepatocellular adenoma				Х					X														X			4
Hepatocellular adenoma, multiple										X																3
Mesentery																								+		2
Pancreas	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Salivary glands	+	. 4	. 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach	+		. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Cardiovascular System	···				_	_																				
Heart	+	. 4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																					_					
Adrenal gland	+	. 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal gland, cortex	+	+	- 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Spindle cell, adenoma																Х									X	2
Adrenal gland, medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Islets, pancreatic Adenoma	+	. 4	. 4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1
Parathyroid gland	4	· N	1 +	. +	+	+	+	+	+	+	+	+	+	+	M	M	+	+	+	+	+	+	+	+	+	47
Pituitary gland															+											49
Adenoma																						X				1
Thyroid gland	4	. +	. +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	50

TABLE D2b	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of	Triamterene:
Second Study: 0 ppm (continued)	

											_	_	_							_			_				
Number of Days on Study	1	4 8 8	5 3 4	5 3 9	5 5 5	6 1 6	6 4 2	6 8 3	7 0 1				7 3 0	7 3 0	7 3 0		7 3 0										
		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		7	7	7	_	7	7	7	7	7	
Carcass ID Number	r :	6 8	7 0 1	3 0 1	0	1 7 1	3 5 1	6 1 1	5 2 1	2 1 1	4 8 1	1 1 1	1 2 1	1 3 1	4	5	1 8 1	1 9 1	2 2 1			2 8 1	2 9 1	3 1 1	3 3 1	3	
Genital System	- 1		-			_			-			·	<u> </u>	_			_		_					_		_	
Clitoral gland Hemangiosarcoma											+										+ X		+				
Ovary Uterus		+	+	+	+	+ +	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	
Adenocarcinoma		_	_	_	~	_	_	_	т	т-	_	Τ	_	Т	т	т	_	*	T	-	~	+	_	_	+	+	
Hemangiosarcoma					Х																						
Leiomyosarcoma					-																						
Sarcoma stromal																							X				•
Hematopoietic System																•										-	
Blood					+																						٠
Bone marrow		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node Lymph node, mandibular		+	1	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	*	+	+	+	+	A	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	м	+	
Spieen	٠.	+	+	+	+	M	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	
Hemangiosarcoma					X								X								X						
Thymus	,	+	+	÷		+	+	+	M	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, bone								-					,							X							
Integumentary System													_								•						
Mammary gland	٠	+	+	+	+	+	+	M	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Skin		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Subcutaneous tissue, myxosarcoma Subcutaneous tissue, neurofibrosarcoma										x	х																
Musculoskeletal System						<u> </u>		_																			
Bone Fibrosarcoma		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	
Nervous System													-														
Brain		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System			_					_									_		_						_		
Lung		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma																X											
Alveolar/bronchiolar carcinoma Hepatocellular carcinoma, metastatic, liver																									X		
Nose		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
1.000		•	•	•	•	•	•		•	•	•	-	•		•	•	•	•	•	•	•	•	•	•	•	•	

TABLE D2b Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: Second Study: 0 ppm (continued)

									_	_												_	_			
Number of Days on Study	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	3	7 3 0	3	7 3 0	7 3 0	7 3 0		7 3 0	7 3 0	7 3 0			7 3 0		3	7 3 0	7 3 0		7 3 0	
Carcass ID Number	3 8	7 3 9 1	4 0	7 4 1 1	7 4 3 1	7 4 4 1	4	4 7		5 0	5 1		5		5 6		7 5 8 1				7 6 3 1		-	6	7	Total Tissues/ Tumors
Genital System Clitoral gland Hemangiosarcoma Ovary Uterus Adenocarcinoma Hemangiosarcoma Leiomyosarcoma Sarcoma stromal	++	+ + +	++	++	++	+ + X	+++	+++	+ +	+++	++	++	++	++	++	++	++	++	+ + X	+ ++	++	+ ++	++	+ ++	++	7 1 50 50 1 1 1
Hematopoietic System Blood Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma Thymus Fibrosarcoma, metastatic, bone	+ + + + + +	+ + + + + +	+++++++	+++++++++++++++++++++++++++++++++++++++	+++++++	+++++++	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	++++++	++++++	++++++	+ + + + + +	+++++++	++++++	+++++++	+++++++	++++++	+++++++	++++++++	+ + + + + +	+ + + + +	1 50 50 50 47 49 3 47
Integumentary System Mammary gland Skin Subcutaneous tissue, myxosarcoma Subcutaneous tissue, neurofibrosarcoma	+	+	++	++	+	+	++	+	++	++	++	+	+	++	+	+	+ +	++	++	++	++	+	++	+	+	49 50 1
Musculoskeletal System Bone Fibrosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X		+	+	50 2
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Hepatocellular carcinoma, metastatic, liver	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	50 2 1
Nose Trachea	+	+	+	+	+	+ +	+	++	+	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	50 50

TABLE D2b
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
Second Study: 0 ppm (continued)

		1 4	5 4	5	5	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	9	3 3		3	5	1	4	g.	'n	1	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
number of Days on Study		3 4			_	-	•	3	1	2	4	0	0	0	0	0	0	0	0	0	0	-	0	0	0	0	
			_	,	<i></i>	_	۷	ر	1		*		_	·			_					_					
		7 7	, ,	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Carcass ID Number	. (5 7	7 :	3	2	1	3	6	5	2	4	1	1	1	1	1	1	1	2	2	2	2	2	3	3	3	
	8	3 () (0	0	7	5	1	2	1	8	1	2	3	4	5	8	9	2	3	5	8	9	1	3	7	
	:	1 1	1 :	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Special Senses System Harderian gland												+										+		+	-		
Urinary System																											
Kidney		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Urinary bladder	•	+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	
Systemic Lesions					_					•																	
Multiple organs		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	+ +	
Lymphoma malignant lymphocytic																											

Table D2b Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: Second Study: 0 ppm (continued)

Number of Days on Study	7 3 0	•		7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	_	_	7 3 0	7 3 0	7 3 0	7 3 0		
Carcass ID Number	7 3 8 1		9	7 4 0 1	7 4 1	7 4 3 1	7 4 4 1	7 4 6 1	7 4 7 1	7 4 9 1	7 5 0 1	7 5 1	7 5 3 1	7 5 4 1	7 5 5	7 5 6 1	7 5 7 1	7 5 8 1	7 5 9 1	7 6 0 1	7 6 2 1	•		-	-	7 6 6 1	7	T	otal issues/ umors
Special Senses System Harderian gland												-		-							•					+			4
Urinary System Kidney Urinary bladder	4	- -	+	+	+	+	+	+	- +	- + - +	· +	. +	. +	+	+	+	+	+	+	+	+	- +	⊢ ·	+	++	++	+		50
Systemic Lesions Multiple organs Lymphoma malignant lymphocytic Lymphoma malignant mixed	4	+	+	+ X	·	+	+	+	- +	- +	- +	- +	- +	. +	+	. +	. +	+ X		. +	+	- 4	۲		+ X	+	+ X		50 1 8

TABLE D2b
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
Second Study: 400 ppm

Number of Days on Study		1 2	l	3	3	7	0	3	6 6 3	7	6 7 6	8	8	8	9	3	7 3 0	3			7 3 0					7 3 0			
Carcass ID Number		3) }	0	2	•	1 4	9	8	2 4	5	1 5	1 9	1	2					7 7		7 9	8 0	8 1	8 2	7 8 3 1	8 4		
Alimentary System				_															-	_									
Esophagus			٠	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder			+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large			+	+	+	+	+	+			+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum		٠.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, uterus					x	•	•	•	•	•	•	•	•	•	•		•	•	•	•	•	, •	•	•	Ċ.	•	. •	٠.	
Intestine large, rectum		_	+	+		+	+	+	+	м	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	
Intestine small		٠.	, +	<u>.</u>	+	+	+	+	+	+	÷	+	+	+	+	+	<u>.</u>	+	+	+	÷	÷	4	+	<u>,</u>	+	+	+	
Intestine small, duodenum			+	+	<u>.</u>	÷	+	+	+	<u>.</u>	+	+	+	+	+	+	+	+	÷	٠,	+	+	+	+	+	+	+	+	
Intestine small, ileum			+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	4	+	+	+	+	+	+	+	<u>.</u>	
Intestine small, jejunum			L	<u>.</u>	+	+	+	+	<u>.</u>	÷	+	+	÷	+	+	+	÷	+	<u>.</u>	+	·	+		+	+	·	+	·	
Liver			+	<u>.</u>	+	<u>.</u>	+	·	÷	÷	+	<u>.</u>	+	+	+	+	+	+	÷	+	+	·	+	·	+	+	·	+	
Hepatocellular carcinoma			•	•	•	•	•	•	•	•	•	•	٠	•	•	•	x	•	•	x	-	•		٠	x		•	•	
Hepatocellular carcinoma, multiple											х						•			1.									
Hepatocellular adenoma											71					x									х		v	x	
Hepatocellular adenoma, multiple		•												Y	х			x	х	Y	Y	Y			1	x		- /1	
Mesentery						+									1.		"	11		+	7.	7.		4	+	. ^-			
Pancreas			ı.	+	+	+	A	+	+	4	+	+	4	+	+	+	+	+			+	+	+		+	+	+	+	
Salivary glands			Ļ	<u>.</u>	<u>.</u>	<u>.</u>	1.	·	÷	<u>,</u>	<u>.</u>	<u>.</u>	Ļ	<u>.</u>	÷	÷	<u>.</u>	<u>.</u>	+	÷	÷	+	÷		+	÷	<u>,</u>		
Stomach			Ļ	+	<u>.</u>	Ļ	<u> </u>	+	Ţ	<u>,</u>	·	Ţ	Ţ	, +	Ţ	+	+	+	+	+	+	+	Ţ	Ţ	_	•	i	+	
Stomach, forestomach			· •	÷	÷	÷	, +	<u>.</u>	+	<u>.</u>	+	·	+	+	÷	+			+				+	4	+			+	
Papilloma squamous			•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	x		•	•	•	•	•	•	•	•	
Stomach, glandular			_	_	_	+	_	_	_	_	+	_	_	_	_	_	_	_			_	_	_		_	+	_	_	
Stomach, giandulai			_	T		_		_		_									_							_			
Cardiovascular System																													
Heart	•	. •	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System																													
Adrenal gland			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal gland, cortex		,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Spindle cell, adenoma																													
Adrenal gland, medulla			+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Islets, pancreatic			+	+	+	+	Α	+	Α	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	
Parathyroid gland			+	+	+	+									+											+	+	+	
Pituitary gland			+	+	+	+									+											+	M	1 +	
Adenoma								-																					
Pars distalis, adenoma																										X			
Pars distalis, carcinoma																			Х										
																			+								-	.+	

TABLE D2b Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: Second Study: 400 ppm (continued)

		_		_				_	_	_	_					_		_	_	_	_	_	_		
7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
7	7	7	7	7	7	7	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
8	9	9	9	9	9	9		0	0	_					_	_						2	2	-	Total
9	1	2	4	5	6	8		1	3													7	8	0	Tissue
1	1	1	1	-																					Tumor
	_			_				_	_		_							_	_	_	_				
4	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_		51
		T	T	T	Ĭ	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	50
	<u> </u>	<u> </u>		<u> </u>	<u> </u>	<u> </u>	1	Ï	1	T	<u> </u>	<u> </u>		T	<u> </u>	T	<u>_</u>	T		<u> </u>	<u> </u>			T	51
4	+	+	+	+	+	+	+	+	+	1	4	4	+	+	+	+	+	+	+	+	+	1	_	+	51
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
	•	•	•	•	•	•	•	•	•	•	•	,	,		•	•	٠.	•		•	•	•	'	•	1
_	_	_	_	_	+	_	4	+	4	4	_	_	_	_	_	_	+	+	+	+	4	1	_	+	50
4	+	+	+	+	+	4	+	+	+	+	+	1	1	+	+	4	+	+	+	+	+	+	4	+	51
<u>.</u>	+	+	+	+	<u>.</u>	<u>.</u>	+	+	<u>.</u>	, +	+	+	+	+	<u>.</u>	+	<u>.</u>	÷	+	+	+	+	+	<u>.</u>	51
<u>.</u>	+	+	<u>,</u>	<u>.</u>	<u>,</u>	<u> </u>	÷	+	<u> </u>	<u>'</u>	<u>'</u>	<u>_</u>	+	<u>'</u>	+	<u>,</u>	<u>.</u>	+	<u>,</u>	<u>.</u>	+	<u>+</u>	+	4	51
<u>,</u>	<u>.</u>	+	<u>.</u>	<u>.</u>	<u>.</u>	<u>.</u>	÷	÷	÷	<u>.</u>	Ţ	÷	÷	÷	<u>,</u>	÷	<u>,</u>	+	÷	Ţ	<u> </u>	<u>.</u>	4	÷	51
<u>,</u>	+	<u> </u>	+	<u>,</u>	<u> </u>	+	+	+	<u>.</u>	+	<u> </u>	<u> </u>	i	<u>'</u>	+	+	<u>.</u>	+	<u>.</u>	<u> </u>	+	, +	+	1	51
-	•	•	•	'		,	•	•			•	•	•	т	•			•			-	7	т	т	9
					^			x	^	^						^	Α,		^						2
						x		*			¥			Y	x					¥					9
		x			x			x	x		^		x		^	x			x				x		19
		•					7.	*	1			"	71			•			,,				+		7
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+	+	+	+	+	+	+	+	+	+	·	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	51
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>.</u>	51
·	+	+	+	+	+	+	+	+	+	+	<u>.</u>	+	+	+	+	+	+	+	+	+	+	+	+	<u>,</u>	51
	•	•	•	Ċ	•	•	•	٠.	•	•		,	•	•	•	•	•	•	•	•	•	•		'	1
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
	_			_	_	_	_	_	_	_	_		_	-	_	_		_	-	_		_	_		
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
		-		_	_		_	_	_	_	_		_	_	_		<u>-</u> -			_	_			<u> </u>	
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
						.4																			2
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
1	+	+	P.4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 45
	T	T	IM				T 32	+	+	+		,±		+			+		+	+	+	+	+	+	45 47
+	+	+	+	+	M	+	+	+	+	+	+	+		+	+	+	+	IVI	+	+	+	+	+	+	1
													^												2
		×																							
		X																							1
	3 0 7 8 9 1 1 + + + + + + + + + + + + + + + + + +	3 3 0 0 0 7 7 7 8 9 9 1 1 1 1 + + + + + + + + + + + + + +	3 3 3 3 0 0 0 0 7 7 7 7 8 9 9 9 1 2 1 1 1 1 + + + + + + + + + + + + + + +	3 3 3 3 3 0 0 0 0 0 7 7 7 7 7 8 9 9 9 9 1 2 4 1 1 1 1 1 + + + + + + + + + + + + + +	3 3 3 3 3 3 3 0 0 0 0 0 0 0 0 0 0 0 0 0	3 3 3 3 3 3 3 3 3 0 0 0 0 0 0 0 0 0 0 0	3 3 3 3 3 3 3 3 3 3 3 0 0 0 0 0 0 0 0 0	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3

TABLE D2b	
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Tri	amterene:
Second Study: 400 ppm (continued)	•

Number of Days on Study	4 1 2	3	3	7	0	6 3 9	6	7	7	8	8	8	9	3	3	3	3	3	3	3	3	3	3	3	3	3	
·	7	7	8	7	8	7	8	8	7	8	8	8	8	7	7	7	7	7	7	7	7	7	7	7	7	7	
Carcass ID Number	9 3 1	0	3	4	4	9 9 1	8	4	5	5	9	1	0	2	3	5	6	7	8	9	0	1	2	3	4	8	
General Body System None									-										_								
Genital System																	-						_				
Clitoral gland																				+		+					
Ovary Granulosa cell tumor benign	+	• •		- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	
Teratoma benign																		^		x							
Uterus	+	. 4	- +	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	
Fibrosarcoma			>																								
Hematopoietic System													_														
Bone marrow	+	. +	- 4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node	+	. +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mandibular	+	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Mast cell tumor malignant																											
Lymph node, mesenteric	+					(+ · +																					
Spleen Thymus	+					M																					
Integumentary System					_					_																	
Mammary gland	+		- 4	- +	. +	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Skin						+																					
Subcutaneous tissue, mast cell tumor malignant									,																		
Musculoskeletal System					_												_			_				_			
Bone		_	_	- +	• +	+	_	+	_	+	+	+		_		+	<u>+</u>	+		+		_ +	+	<u>+</u>	_	+	
Nervous System									.1		+		+	,	+	J.		_1	.1.	.1	.1	.1	1	+		1	
Brain		_		- 1	- +			+		_		_	+	_	_	_	_	_	_			<u> </u>		-	_		
Respiratory System																											
Lung	+		+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar carcinoma Hepatocellular carcinoma, metastatic,																											
liver									X														X				
Nose	+		+ +	+ +	• +	+	+	+									+	+	+	+	+	+	+	+	+	+	
Trachea	+	•	-	r 1	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

Table D2b												
Individual Animal	Tumor	Pathology	of	Female	Mice	im	the	2-Year	Feed	Study	of	Triamterene:
Second Study: 400	ppm (c	ontinued)										

				_		_						_				_					_					
	7	7	7	7	7	7	7	7	7	7	7	7	7	7		7			7			7	7	7	7	
Number of Days on Study	3	3	3 0	3 0	3	3 0	3 0	3 0		3 0	3 0	3 0	3 0		3 0	3 0			3 0			3	3 0	3 0	3 0	
		_	_			_									-		_									
		7	7	7		7	7		-	_	-	_	_	_	8	_	-					8		_	8	770 4 B
Carcass ID Number	8		9	9	9		9								1											Total
	9	1	2												0											Tissues
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Tumors
General Body System None			•																			•	-			
Genital System																		_				_				
Clitoral gland															+										+	4
Ovary	+	4	4	+	+	+	+	+	+	+	+	м	+	+		+	+	+	+	М	+	+	+	+		49
Granulosa cell tumor benign	ŗ	'	•	•	•	•	•	'	٠	•	•	.71	•	•	•	•	•	•	•		•	•	•	•	•	1
Teratoma benign																										1
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Fibrosarcoma	·	·	•	٠	·	·	•	•		·	·	·		·					·			·		·	·	1
Hematopoietic System														_	_	_	_		_		-			_		
Bone marrow	+	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Lymph node	·	+		. +	+	+	+	+		+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Lymph node, mandibular		. +	. +	. +	+		+					+	+	+	-	•	+	+	+	+	+	+	+		+	51
Mast cell tumor malignant	•	·	•	•	•	•	•	x		•	•	•		•	,		•	•	•	•	•	•	•	•	•	1
Lymph node, mesenteric	+		. 4	+	+	+	4			+	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Spleen				+	· +	+			+				+	+		+	+	·	+	·	+	+	+		+	51
Thymus	÷	+	+	M	· +	+					-				•		-	+	+	+	+	+	+		+	43
Integumentary System									_								_		_			-	_	_		
Mammary gland	+		. 4		4	+	+	4	4	+	_	4	4	+	4	_	4	4	4	_	4	_	4	4	_	50
Skin					·	<u>.</u>	<u>,</u>	+	+	+	<u>.</u>	÷	+	<u>.</u>	Ţ	<u>.</u>	·	+	+	÷	·	+		·	+	51
Subcutaneous tissue, mast cell tumor				•	,	•	•	•	•	•	'	,	•	•	•	•	•	•	•	•	•		•	•	•	51
malignant								X																		1
Musculoskeletal System							_	-		_	_	1		_												
Bone	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Nervous System																										
Brain	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Respiratory System																										
Lung	+	- 4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	51
Alveolar/bronchiolar carcinoma																								Х		1
Hepatocellular carcinoma, metastatic,																										
liver						Х											X									4
Nose	+	. +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Trachea	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51

TABLE D2b
Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene:
Second Study: 400 ppm (continued)

		_												_		_		_		_				_			
N. J. C.D. and Glad	4	5	5	5	6	6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	4	3 4	8	5	9	3	3	6	2	7	7	5	0	0	0	0	0	0	0	0	0	0	0	0	0	
	7	7	8	7	8	7	8	8	7	8	8	8	8	7	7	7	7	7	7	7	7	7	7	7	7	7	
Carcass ID Number	9	9	2	7	1	9	1	2	8	1	1	2	2	7	7	7	7	7	7	7	8	8	8	8	8	8	
	3	-	3	4	4	9	8	4	5	5	9	1	0	2	3	5	6	7	8	9	0	1	2	3	4	8	
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Special Senses System																											
Harderian gland											+		+														
Adenoma											X		*														
Urinary System																											
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Urinary bladder	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	
Fibrosarcoma, metastatic, uterus			Х																								
Systemic Lesions	*	=																									
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymphoma malignant histiocytic Lymphoma malignant lymphocytic								X		X X	X																
Lymphoma malignant mixed Lymphoma malignant undifferentiated cell type				X	X	X	X															X			X		

TABLE D2b Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of Triamterene: Second Study: 400 ppm (continued)

Number of Days on Study	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	
Carcass ID Number	7 8 9 1	_	7 9 2 1	7 9 4 1	7 9 5 1	7 9 6 1	7 9 8 1	8 0 0 1	8 0 1 1	8 0 3 1	8 0 4 1	8 0 6 1	8 0 8 1	8 0 9 1	8 1 0 1	8 1 1 1	8 1 2 1	8 1 6 1	8 1 7 1	8 2 2 1	8 2 5 1	8 2 6 1	8 2 7 1	8 2 8 1	8 3 0 1	Total Tissues/ Tumors
Special Senses System Harderian gland Adenoma					+ X												+									4 3
Urinary System Kidney Urinary bladder Fibrosarcoma, metastatic, uterus	+	+	+	+	++	+	+	++	++	+	++	+	+	+	++	+	+	+	+	+	+	+	+	+	+	51 50 1
Systemic Lesions Multiple organs Lymphoma malignant histiocytic Lymphoma malignant lymphocytic Lymphoma malignant mixed Lymphoma malignant undifferentiated cell type	+	+	+	+	+ x	+	+ x	+	+	+	+ X	+ X	+	+	+	+	+	+	+	+ X	+	+	+ x	+	+	51 3 2 10

TABLE D3a Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study

				
	0 ppm	100 ppm	200 ppm	400 ppm
Adrenal Cortex: Adenoma				- M 4 <u></u>
Overall rates ^a	3/50 (6%)	0/50 (0%)	3/50 (6%)	2/60 (3%)
Adjusted rates ^b	7.6%	0.0%	7.0%	4.7%
Terminal rates ^c	2/38 (5%)	0/43 (0%)	3/43 (7%)	2/43 (5%)
First incidence (days)	723	_e ` ´	729 (T)	729 (T)
Life table tests ^d	P = 0.559N	P = 0.105N	P = 0.608N	$P \approx 0.449N$
Logistic regression tests ^d	P = 0.557N	P = 0.107N	P = 0.628N	P = 0.449N
Cochran-Armitage test ^a	P = 0.514N			
Fisher exact test ^d		P = 0.121N	P = 0.661N	P = 0.414N
Harderian Gland: Adenoma				
Overall rates	1/50 (2%)	3/50 (6%)	2/50 (4%)	0/60 (0%)
Adjusted rates	2.6%	7.0%	4.7%	0.0%
Terminal rates	1/38 (3%)	3/43 (7%)	2/43 (5%)	0/43 (0%)
First incidence (days)	729 (T)	729 (T)	729 (T)	- , ,
Life table tests	P = 0.214N	P = 0.350	P = 0.543	P = 0.475N
ogistic regression tests	P = 0.214N	P = 0.350	P = 0.543	P = 0.475N
Cochran-Armitage test	P = 0.196N			
Fisher exact test		P=0.309	P = 0.500	P = 0.455N
Liver: Hepatocellular Adenoma				
Overall rates	10/50 (20%)	22/50 (44%)	23/50 (46%)	36/60 (60%)
Adjusted rates	25.6%	51.2%	52.3%	78.1%
Terminal rates	9/38 (24%)	22/43 (51%)	22/43 (51%)	33/43 (77%)
First incidence (days)	723	729 (T)	712	579
Life table tests	P<0.001	P=0.022	P = 0.015	P<0.001
ogistic regression tests	P<0.001	P = 0.014	P = 0.008	P<0.001
Cochran-Armitage test	P<0.001	D 0000	D 0007	
Fisher exact test		P=0.009	P = 0.005	P<0.001
Liver: Hepatocellular Carcinoma				
Overall rates	4/50 (8%)	4/50 (8%)	3/50 (6%)	8/60 (13%)
Adjusted rates	10.0%	9.3%	7.0%	18.6%
Terminal rates	3/38 (8%)	4/43 (9%)	3/43 (7%)	8/43 (19%)
First incidence (days)	589	729 (T)	729 (T)	729 (T)
ife table tests	P=0.136	P=0.575N	P≈0.438N	P=0.248
ogistic regression tests	P=0.159	P = 0.614N	P=0.472N	P = 0.272
Cochran-Armitage test	P = 0.183	D 0 (40)	D 0.500M	D 0.004
Fisher exact test		P=0.643N	P = 0.500N	P = 0.281
Liver: Hepatocellular Adenoma or Carcinoma	10/50 (0/5)	0.000 (500)	25.50 (505)	ABI/A //A
Overall rates	13/50 (26%)	26/50 (52%)	25/50 (50%)	37/60 (62%)
Adjusted rates	32.3%	60.5%	56.8%	80.3%
Terminal rates	11/38 (29%)	26/43 (60%)	24/43 (56%)	34/43 (79%)
First incidence (days)	589	729 (T)	712	579
Life table tests	P<0.001	P=0.021	P=0.035	P<0.001
Logistic regression tests	P<0.001	P = 0.014	P = 0.022	P<0.001
Cochran-Armitage test	P<0.001	D 0.005	D 0011	D +0.004
Fisher exact test		P = 0.007	P = 0.011	P<0.001

TABLE D3a
Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ppm	160 ppm	200 ppm	400 ppm
Lung: Alveolar/bronchiolar Adenoma				
Overall rates	4/50 (8%)	5/50 (10%)	2/50 (4%)	1/60 (2%)
Adjusted rates	10.5%	11.6%	4.3%	2.3%
Terminal rates	4/38 (11%)	5/43 (12%)	1/43 (2%)	1/43 (2%)
First incidence (days)	729 (T)	729 (T)	528	729 (T)
Life table tests	P = 0.060N	P=0.578	P=0.285N	P = 0.144N
Logistic regression tests	P=0.053N	P=0.578	P=0.330N	P=0.144N
Cochran-Armitage test	P=0.053N	1 -0.570	1 -0.55014	1 0.14414
Fisher exact test	1 - 0.03311	P = 0.500	P = 0.339N	P = 0.130N
Lung: Alveolar/bronchiolar Carcinoma				•
Overall rates	0/50 (0%)	1/50 (2%)	0/50 (0%)	3/60 (5%)
Adjusted rates	0.0%	2.3%	0.0%	7.0%
Terminal rates	0/38 (0%)	1/43 (2%)	0/43 (0%)	3/43 (7%)
First incidence (days)	- ` ′	729 (T)	- ` ′	729 (T)
Life table tests	P = 0.050	P = 0.525	_	P = 0.144
Logistic regression tests	P = 0.050	P = 0.525	_	P = 0.144
Cochran-Armitage test	P = 0.065			
Fisher exact test		P = 0.500	_	P = 0.159
Lung: Alveolar/bronchiolar Adenoma or Carci	noma			
Overall rates	4/50 (8%)	6/50 (12%)	2/50 (4%)	3/60 (5%)
Adjusted rates	10.5%	14.0%	4.3%	7.0%
Terminal rates	4/38 (11%)	6/43 (14%)	1/43 (2%)	3/43 (7%)
First incidence (days)	729 (T)	729 (T)	528	729 (T)
Life table tests	P = 0.228N	P = 0.449	P = 0.285N	P = 0.432N
Logistic regression tests	P = 0.202N	P = 0.449	P = 0.330N	P = 0.432N
Cochran-Armitage test	P = 0.196N			
Fisher exact test		P = 0.370	P = 0.339N	P = 0.399N
Pituitary Gland (Pars Distalis or Unspecified	•		aa. (car)	# /# a .a .a .
Overall rates	7/49 (14%)	5/47 (11%)	3/48 (6%)	5/58 (9%)
Adjusted rates	18.4%	12.2%	7.1%	11.6%
Terminal rates	7/38 (18%)	5/41 (12%)	3/42 (7%)	5/43 (12%)
First incidence (days)	729 (T)	729 (T)	729 (T)	729 (T)
Life table tests	P=0.249N	P=0.325N	P=0.120N	P=0.294N
Logistic regression tests	P=0.249N	P = 0.325N	P = 0.120N	P = 0.294N
Cochran-Armitage test	P=0.214N	D 0.410N	D 016Th	D 0000
Fisher exact test		P = 0.410N	P = 0.167N	P=0.268N
Skin (Subcutaneous Tissue): Fibrosarcoma	2150 //015	0.60 (0.01)	1/50 (0%)	0100 (5%)
Overall rates	3/50 (6%)	0/50 (0%)	1/50 (2%)	3/60 (5%)
Adjusted rates	7.1%	0.0%	2.3%	5.8%
Terminal rates	1/38 (3%)	0/43 (0%)	1/43 (2%)	0/43 (0%)
First incidence (days)	530 D 0 400	- D 0.10037	729 (T)	522 B. 0.501N
Life table tests	P=0.480	P=0.109N	P=0.275N	P=0.581N
Logistic regression tests	P=0.492	P = 0.133N	P = 0.324N	P = 0.592N
Cochran-Armitage test	P = 0.500	D 0.101N	D 0.30001	D 0.5505
Fisher exact test		P = 0.121N	P = 0.309N	P = 0.570N

TABLE D3a
Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
Spleen: Hemangiosarcoma	-			·
Overall rates	1/49 (2%)	0/50 (0%)	3/49 (6%)	1/60 (2%)
Adjusted rates	2.6%	0.0%	7.1%	2.0%
Terminal rates	1/38 (3%)	0/43 (0%)	3/42 (7%)	0/43 (0%)
First incidence (days)	729 (T)	-	729 (T)	623
ife table tests	P=0.505	P = 0.475N	P=0.342	P=0.725N
ogistic regression tests	P = 0.533	P = 0.475N	P = 0.342	P = 0.717N
Cochran-Armitage test	P = 0.539			
isher exact test		P = 0.495N	P = 0.309	P = 0.699N
All Organs: Hemangiosarcoma				
Overall rates	2/50 (4%)	1/50 (2%)	5/50 (10%)	2/60 (3%)
Adjusted rates	5.0%	2.3%	11.6%	4.2%
Terminal rates	1/38 (3%)	1/43 (2%)	5/43 (12%)	1/43 (2%)
First incidence (days)	711	729 (T)	729 (T)	623
Life table tests	P = 0.504	P = 0.466N	P = 0.267	P = 0.646N
ogistic regression tests	P = 0.537	P = 0.471N	P = 0.248	P = 0.626N
Cochran-Armitage test	P = 0.548			
Fisher exact test		P = 0.500N	P = 0.218	P = 0.619N
All Organs: Malignant Lymphoma or Histic	ocytic Sarcoma			
Overall rates	12/50 (24%)	9/50 (18%)	13/50 (26%)	11/60 (18%)
Adjusted rates	28.4%	19.8%	28.2%	22.1%
Cerminal rates	8/38 (21%)	7/43 (16%)	10/43 (23%)	5/43 (12%)
First incidence (days)	530	629	586	613
ife table tests	P=0.441N	P=0.229N	P = 0.553N	P=0.372N
ogistic regression tests	P=0.353N	P = 0.265N	P = 0.558	P = 0.306N
Cochran-Armitage test	P = 0.346N	D 004007	D 0.500	D 0 0 1 0 D 7
Fisher exact test		P=0.312N	P=0.500	P=0.310N
All Organs: Benign Neoplasms	22/10 (110)	0.00	00/50 /5/04	0440440
Overall rates	22/50 (44%)	31/50 (62%)	28/50 (56%)	36/60 (60%)
Adjusted rates	54.8%	70.4%	62.2%	78.1%
Terminal rates	20/38 (53%)	30/43 (70%)	26/43 (60%)	33/43 (77%)
First incidence (days)	114 P-0.020	664 B-0.154	528 B-0 241	579 B-0.027
Life table tests	P=0.029	P=0.154	P=0.341	P=0.027
Logistic regression tests	P=0.081	P = 0.100	P = 0.238	P = 0.061
Cochran-Armitage test Fisher exact test	P=0.123	P = 0.054	P = 0.159	P = 0.069
All Organs: Malignant Neoplasms				
Overall rates	20/50 (40%)	17/50 (34%)	21/50 (42%)	25/60 (42%)
Adjusted rates	45.5%	36.0%	44.6%	47.1%
Ferminal rates	14/38 (37%)	13/43 (30%)	17/43 (40%)	15/43 (35%)
First incidence (days)	530	250	560	522
Life table tests	P=0.252	P=0.223N	P=0.477N	P=0.430
ogistic regression tests	P=0.354	P = 0.304N	P = 0.579N	P=0.517
		1 0100711	1 0.57711	
Cochran-Armitage test	P = 0.360			

TABLE D3a Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
All Organs: Benign or Malignant Neoplasms				
Overall rates	34/50 (68%)	40/50 (80%)	40/50 (80%)	46/60 (77%)
Adjusted rates	75.5%	83.3%	81.6%	85.2%
Terminal rates	27/38 (71%)	35/43 (81%)	34/43 (79%)	35/43 (81%)
First incidence (days)	114	250	528	522
Life table tests	P = 0.109	P = 0.443	P = 0.446	P = 0.155
ogistic regression tests	P = 0.243	P = 0.199	P = 0.217	P = 0.218
Cochran-Armitage test	P = 0.266			
Fisher exact test		P = 0.127	P = 0.127	P = 0.211

(T)Terminal sacrifice

Observed incidence at terminal kill

Not applicable; no neoplasms in animal group

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, bone marrow, brain, clitoral gland, gallbladder, heart, kidney, larynx, liver, lung, nose, ovary, pancreas, parathyroid gland, pituitary gland, salivary gland, spleen, thyroid gland, and urinary bladder; for other tissues, denominator is number of animals necropsied.

Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

TABLE D3b Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study

	0 ppm	400 ppm	
Harderian Gland: Adenoma			
Overall rates ^a	0/50 (0%)	3/51 (6%)	
Adjusted rates ^b	0.0%	7.4%	
Terminal rates ^c	0/40 (0%)	1/38 (3%)	
First incidence (days)	_е	687	
Life table tests ^d		P = 0.113	
Logistic regression tests ^d		P = 0.124	
Fisher exact test ^d		P = 0.125	
Liver: Hepatocellular Adenoma			
Overall rates	7/50 (14%)	28/51 (55%)	
Adjusted rates	17.5%	70.0%	
Terminal rates	7/40 (18%)	26/38 (68%)	
First incidence (days)	730 (T)	687	
Life table tests		P<0.001	
Logistic regression tests		P<0.001	
Fisher exact test		P<0.001	
Liver: Hepatocellular Carcinoma			
Overall rates	5/50 (10%)	11/51 (22%)	
Adjusted rates	12.0%	28.0%	
Terminal rates	4/40 (10%)	10/38 (26%)	
First incidence (days)	616	676	
Life table tests		P=0.073	
Logistic regression tests		P=0.082	
Fisher exact test		P = 0.093	
Liver: Hepatoblastoma or Hepatocellular Carci		44/54 (000)	
Overall rates	5/50 (10%)	11/51 (22%)	
Adjusted rates	12.0%	28.0%	
Terminal rates	4/40 (10%)	10/38 (26%)	
First incidence (days)	616	676 P-0.072	
Life table tests		P=0.073	
Logistic regression tests		P=0.082 P=0.093	
Fisher exact test		r = 0.093	
Liver: Hepatocellular Adenoma or Carcinoma	10/50 /2001	21/51 (610%)	
Overall rates	10/50 (20%)	31/51 (61%) 75.6%	
Adjusted rates	24.2%	28/38 (74%)	
Terminal rates	9/40 (23%) 616	676	
First incidence (days)	010	P<0.001	
Life table tests	•	P<0.001	
Logistic regression tests Fisher exact test		P<0.001	
Lung: Alveolar/bronchiolar Adenoma or Carcin	noma		
Overall rates	3/50 (6%)	1/51 (2%)	
Adjusted rates	. 7.5%	2.6%	
Terminal rates	3/40 (8%)	1/38 (3%)	
First incidence (days)	730 (T)	730 (T)	
Life table tests	,50 (1)	P=0.324N	
Logistic regression tests		P=0.324N	
Politic refression rese			

TABLE D3b Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ррт	400 ppm	
Pituitary Gland (Pars Distalis or Unspec	cified Site): Adenoma		
Overall rates	1/49 (2%)	3/47 (6%)	
Adjusted rates	2.6%	8.6%	
Terminal rates	1/39 (3%)	3/35 (9%)	
First incidence (days)	730 (T)	730 (T)	
Life table tests		P = 0.267	
Logistic regression tests		P = 0.267	
Fisher exact test		P=0.293	
Pituitary Gland (Pars Distalis or Unspec			
Overall rates	1/49 (2%)	4/47 (9%)	
Adjusted rates	2.6%	11.4%	
Terminal rates	1/39 (3%)	4/35 (11%)	
First incidence (days)	730 (T)	730 (T)	
Life table tests		P=0.148	
Logistic regression tests		P=0.148	
Fisher exact test		P=0.168	
Spleen: Hemangiosarcoma	2140 (201)	0/51 (00/2)	
Overall rates	3/49 (6%)	0/51 (0%)	
Adjusted rates	7.0%	0.0%	
Terminal rates	2/40 (5%) 555	0/38 (0%)	
First incidence (days) Life table tests		P=0.128N	
Logistic regression tests	•	P=0.101N	
Fisher exact test		P=0.114N	
All Organs: Hemangiosarcoma	0/50 ((0))	0.61 (0.64)	
Overall rates	3/50 (6%)	0/51 (0%)	
Adjusted rates	7.0%	0.0%	
Terminal rates	2/40 (5%)	0/38 (0%)	
First incidence (days)	555	P=0.129N	
Life table tests		P=0.128N P=0.107N	
Logistic regression tests Fisher exact test		P=0.118N	
		1 -0.11614	
All Organs: Hemangioma or Hemangisa Overall rates	rcoma 3/50 (6%)	0/51 (0%)	
Adjusted rates	7.0%	0.0%	
Terminal rates	2/40 (5%)	0/38 (0%)	
First incidence (days)	555	• (0 <i>70)</i>	
Life table tests	333	P=0.128N	
Logistic regression tests		P=0.107N	
Fisher exact test		P = 0.118N	
All Organs: Malignant Lymphoma or H	istiocytic Sarcoma		
Overall rates	9/50 (18%)	15/51 (29%)	
Adjusted rates	19.9%	32.6%	
Terminal rates	5/40 (13%)	8/38 (21%)	
First incidence (days)	534	578	
Life table tests		P=0.124	
Logistic regression tests		P = 0.146	
Fisher exact test		P = 0.133	

TABLE D3b
Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm
All Organs: Benign Neoplasms	· · · · · · · · · · · · · · · · · · ·	
Overall rates	12/50 (24%)	31/51 (61%)
Adjusted rates	30.0%	75.6%
Terminal rates	12/40 (30%)	28/38 (74%)
First incidence (days)	730 (T)	687
Life table tests		P<0.001
Logistic regression tests		P<0.001
Fisher exact test		P<0.001
All Organs: Malignant Neoplasms		·
Overall rates	23/50 (46%)	28/51 (55%)
Adjusted rates	47.8%	59.2%
Terminal rates	15/40 (38%)	19/38 (50%)
First incidence (days)	534	534
Life table tests		P=0.202
Logistic regression tests		P=0.259
Fisher exact test		P=0.243
All Organs: Benign or Malignant Neoplasms		
Overall rates	29/50 (58%)	43/51 (84%)
Adjusted rates	60.3%	87.8%
Terminal rates	21/40 (53%)	32/38 (84%)
First incidence (days)	534	534
Life table tests		P = 0.008
Logistic regression tests		P = 0.003
Fisher exact test		P = 0.003

⁽T)Terminal sacrifice

Not applicable; no neoplasms in animal group

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, bone marrow, brain, clitoral gland, gallbladder, heart, kidney, larynx, liver, lung, nose, ovary, pancreas, parathyroid gland, pituitary gland, salivary gland, spleen, thyroid gland, and urinary bladder; for other tissues, denominator is number of animals necropsied.

b Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

Observed incidence at terminal kill

Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and the exposed group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Fisher exact test compares directly the overall incidence rates. For all tests, a lower incidence in the exposure group is indicated by N.

Table D4 Historical Incidence of Liver Neoplasms in Untreated Female $B6C3F_1$ Mice^a

		Incidence in Controls				
Study	Hepatocellular Adenoma	Hepatocellular Carcinoma	Hepatocellular Adenoma or Carcinoma	Hepatoblastoma		
Historical Incidence at Battell	e Columbus Laboratory					
2.4-Dichlorophenol	0/50	2/50	2/50	0/50		
5,5-Diphenylhydantoin	5/48	0/48	5/48	0/48		
Dowicide EC-7 pentachlorophenol	l 1/34	0/34	1/34	0/34		
Ethylene thiourea	2/50	2/50	4/50	0/50		
Polybrominated biphenyls (Firema	ster FF-1®) 4/50	1/50	5/50	0/50		
Technical grade pentachloropheno		0/33	3/33	0/33		
Overall Historical Incidence						
Total	74/863 (8.6%)	28/863 (3.2%)	98/863 (11.4%)	1/863 (0.1%)		
Standard deviation	6.5%	2.9%	7.6%	0.5%		
Range	0%-28%	0%-10%	3%-34%	0%-2%		

^a Data as of 3 April 1991

 $\begin{array}{c} \text{TABLE D5a} \\ \text{Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene:} \\ \text{First Study}^a \end{array}$

	0 ppm	100 ppm	200 ppm	400 ppm
Disposition Summary				
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
15-Month interim evaluation	10	10	10	
2-Year study				
Early deaths Moribund	8	5	1	10
Natural deaths	4	2	6	7
Survivors	•	•	v	,
Died last week of study	1	2	1	
Terminal sacrifice	37	41	42	43
Animals examined microscopically	70	70	70	70
3-Month Interim Evaluation				-
Alimentary System				
Stomach, forestomach	(7)			(8)
Mucosa, hyperplasia, papillary, diffuse	í (14%)			• •
Cardiovascular System None	,			
Endocrine System None	,			
General Body System None				
Genital System			****	
Ovary Cyst	(7)	(1) 1 (100%)		(8)
Hematopoietic System None		- <u> </u>		
Integumentary System None				
Musculoskeletal System None				
Nervous System None	1.7		· · · · · · · · · · · · · · · · · · ·	

TABLE D5a Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
B-Month Interim Evaluation (continued) Respiratory System None				
Special Senses System None				
Urinary System None				
15-Month Interim Evaluation				
Alimentary System Liver	(10)	(2)	(10)	
Basophilic focus	2 (20%)	(-)	(**)	
Eosinophilic focus	· ·		1 (10%)	
Infiltration cellular, lymphocyte Inflammation, necrotizing, acute			1 (10%) 4 (40%)	
Vacuolization cytoplasmic		1 (50%)	4 (40%) 2 (20%)	
Pancreas	(10)	- (5070)	(10)	
Acinus, cytoplasmic alteration	2 (20%)			
Stomach, glandular	(10)		(10)	
Inflammation, subacute			1 (10%)	
Cardiovascular System None				
Endocrine System None				
General Body System None				
Genital System				
Ovary	(10)	(3)	(10)	
Angiectasis	£ (500t)		1 (10%)	
Cyst Uterus	5 (50%) (10)	3 (100%) (4)	1 (10%) (10)	
Dilatation	3 (30%)	4 (100%)	5 (50%)	
Hematopoietic System None				
Integumentary System None				

TABLE D5a
Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ppm	100 ppm	200 ppm	400 ppm
5-Month Interim Evaluation (continued) Musculoskeletal System None				
Nervous System None				
despiratory System				
Special Senses System Rone		ur v		
Jrinary System				
Cidney Nephropathy	(10) 7 (70%)	(10) 2 (20%)	(10) 4 (40%)	
-Year Study		to the second se		
limentary System				
Gallbladder	(48)	(47)	(49)	(55)
Inflammation, chronic active		1 (2%)		
ntestine large, colon	(48)	(50)	(49)	(59)
Inflammation, acute		4 4 0)	(50)	1 (2%)
ntestine small, duodenum	(47)	(50)	(50)	(59)
Inflammation, acute Ulcer		1 (2%)		1 (2%)
ntestine small, jejunum	(47)	(48)	(48)	(59)
Diverticulum, single	(**)	(40)	(10)	1 (2%)
iver	(50)	(50)	(50)	(60)
Basophilic focus	1 (2%)	6 (12%)	6 (12%)	` 10 (17%)
Basophilic focus, multiple				1 (2%)
Clear cell focus		1 (2%)	4 (8%)	3 (5%)
Eosinophilic focus	7 (14%)	11 (22%)	17 (34%)	7 (12%)
Eosinophilic focus, multiple	1 (201)		2 (4%)	
Inflammation, chronic active Mixed cell focus	1 (2%)		1 (2%)	1 (2%)
Necrosis, acute	1 (2%)		1 (270)	1 (2%)
Regeneration	- (-/-)		2 (4%)	- (=/-/
Thrombus		1 (2%)	` '	1 (2%)
Mesentery	(8)	(10)	(8)	(5) ` ´
Angiectasis			1 (13%)	
Ectopic tissue	1 (13%)		1 (400)	
Inflammation, chronic active	2 (25%)	9 (90%)	1 (13%)	2 (600)
Fat, necrosis Pancreas	2 (25%) (49)	(50)	6 (75%) (50)	3 (60%) (60)
Inflammation, chronic active	(17)	1 (2%)	(50)	(00)
Vacuolization cytoplasmic	1 (2%)	- //		
Acinus, atrophy	2 (4%)	3 (6%)	1 (2%)	1 (2%)
Duct, ectasia	• •	2 (4%)	, ,	` ,

TABLE D5a
Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ррт	100 ppm	200 ppm	400 ppm
2-Year Study (continued)				
Alimentary System (continued)				
Stomach, forestomach	(49)	(50)	(50)	(60)
Acanthosis	2 (4%)	2 (4%)	2 (4%)	7 (12%)
Inflammation, acute	` ,	1 (2%)	` ,	3 (5%)
Inflammation, chronic active		` ,	1 (2%)	` ,
Stomach, glandular	(49)	(50)	(50)	(60)
Inflammation, acute		1 (2%)	1 (2%)	
Cardiovascular System				
Heart	(50)	(50)	(50)	(60)
Inflammation, chronic active	()	V- ·/	1 (2%)	()
Mineralization			1 (2%)	
Endocrine System				
Adrenal gland, cortex	(50)	(50)	(50)	(60)
Angiectasis	1 (2%)	(50)	(50)	(00)
Cyst	1 (2%)		1 (2%)	
Hyperplasia	- (=/~)	2 (4%)	- (=/0)	
Hypertrophy	3 (6%)	3 (6%)	1 (2%)	4 (7%)
Mineralization	(/		//	1 (2%)
Adrenal gland, medulla	(47)	(50)	(50)	(59)
Angiectasis	1 (2%)	` '	` /	` '
Mineralization				1 (2%)
slets, pancreatic	(49)	(49)	(50)	(59)
Hyperplasia	1 (2%)	2 (4%)		
Pituitary gland	(49)	(47)	(48)	(58)
Pars distalis, cyst	1 (2%)		1 (2%)	3 (5%)
Pars distalis, hyperplasia	7 (14%)	3 (6%)	6 (13%)	9 (16%)
Pars intermedia, cyst		1 (2%)		
Pars intermedia, hyperplasia		2 (4%)	1 (2%)	1 (2%)
Pars intermedia, hypertrophy	(40)	(10)	(50)	2 (3%)
Thyroid gland	(49)	(49)	(50)	(60)
Inflammation, chronic active		1 (2%)	40.000	1 (2%)
Follicular cell, hyperplasia	4 (8%)	17 (35%)	18 (36%)	28 (47%)
General Body System None	-			
Genital System				
Ovary	(48)	(50)	(50)	(59)
Angiectasis	1 (2%)	1 (2%)	4 (8%)	1 (2%)
Cyst	13 (27%)	17 (34%)	18 (36%)	26 (44%)
Hemorrhage	1 (2%)	=- ()	()	2- ()
Thrombus	1 (2%)			
Uterus	(48)	(50)	(50)	(60)
Angiectasis	` '	` '	1 (2%)	1 (2%)
Dilatation			` '	4 (7%)
Hyperplasia, glandular, cystic	38 (79%)	44 (88%)	47 (94%)	53 (88%)
Thrombus	` ,	1 (2%)	• •	` ,

TABLE D5a
Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene:
First Study (continued)

	0 ррт	100 ppm	200 ppm	400 ppm
2-Year Study (continued)			- A2	
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(60)
Myelofibrosis	20 (40%)	19 (38%)	19 (38%)	17 (28%)
Lymph node, mandibular	(46)	(49) ` ´	(50) ` ´	(58) ` ´
Infiltration cellular, histiocyte		1 (2%)	` ,	` '
Necrosis		• •		1 (2%)
Lymphatic, ectasia			1 (2%)	
ymph node, mesenteric	(43)	(45)	(46)	(54)
Cyst	,	• •	1 (2%)	, ,
Necrosis				1 (2%)
Thrombus		1 (2%)		` '
Spleen	(49)	(50)	(49)	(60)
Hematopoietic cell proliferation	2 (4%)	¥ (8%)	5 (10%)	1 (2%)
Necrosis	` /	` /	` '	2 (3%)
Гhymus	(38)	(44)	(44)	(50)
Necrosis	2 (5%)	• •	, ,	4 (8%)
Integumentary System				
Mammary gland	(36)	(43)	(46)	(51)
Hyperplasia	(55)	(.5)	(13)	1 (2%)
Skin	(50)	(49)	(49)	(60)
Alopecia	3 (6%)	1 (2%)	1 (2%)	5 (8%)
Hemorrhage	1 (2%)	- ()	- ()	- ()
Inflammation, chronic active	1 (2%)			
Ulcer	2 (4%)	1 (2%)		1 (2%)
	2 (1,%)			
Musculoskeletal System				
Bone	(50)	(50)	(50)	(60)
Bilateral, tarsal, hyperostosis		1 (2%)		
Femur, cyst			1 (2%)	
Nervous System				
Peripheral nerve		(1)		
Degeneration		1 (100%)		
Spinal cord		(1)		
Degeneration		1 (100%)		
				· · · · · · · · · · · · · · · · · · ·
Respiratory System	(50)	(50)	(50)	icm
Lung	(50)	(50)	(50)	(60)
Alveolar epithelium, hyperplasia	2 (4%)	1 (2%)	(50)	4 (7%)
Vose	(50)	(50)	(50)	(60)
Inflammation, acute	2 (4%)	2 (4%)	(50)	7 (12%)
Trachea	(50)	(50)	(50)	(60)
Inflammation, acute	<u></u> .		1 (2%)	
Special Senses System				
Special Senses System Harderian gland	(1)	(3)	(3) 1 (33%)	(2)

TABLE D5a Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene: First Study (continued)

	Ф ррт	100 ppm	200 ppm	400 ppm
2-Year Study (continued)				
Urinary System				
Kidney	(50)	(50)	(50)	(60)
Atrophy	1 (2%)			
Cyst				1 (2%)
Infarct			1 (2%)	40 (000)
Nephropathy	28 (56%)	36 (72%)	43 (86%)	49 (82%)
Pigmentation		1 (2%)		

^a Number of animals examined microscopically at site and number of animals with lesion

TABLE D5b Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene: Second Study^a

	0 ррт	400 ppm	
Disposition Summary			
Animals initially in study	60	60	
15-Month interim evaluation	10	9	
2-Year study			
Early deaths	_	_	
Moribund	7	4	
Natural deaths	3	9	
Survivors Terminal sacrifice	40	38	
Terminar sacrifice	40	36	
Animals examined microscopically	60	60	
15-Month Interim Evaluation			
Alimentary System			
Liver	(10)	(9)	
Basophilic focus	1 (10%)	1 (11%)	
Eosinophilic focus	1 (10%)		
Pancreas	(10)	(9)	
Inflammation, chronic active	•	1 (11%)	
Cardiovascular System None			
Endocrine System			
Pituitary gland	(10)	(9)	
Pars distalis, hyperplasia	3 (30%)	2 (22%)	
Thyroid gland	(10)	(9)	
Cyst	1 (10%)	1 (11%)	
Follicular cell, hyperplasia		1 (11%)	· · · · · · · · · · · · · · · · · · ·
General Body System None			
Genital System			
Ovary	(10)	(9)	
Cyst	1 (10%)	2 (22%)	
Uterus	(10)	(9)	
Hyperplasia, cystic, glandular	10 (100%)	7 (78%)	
Hematopoietic System	40:	(0)	
Bone marrow	(10)	(8)	
Myelofibrosis		1 (13%)	
Integumentary System	40	(0)	
Skin	(10)	(9)	
Alopecia	1 (10%)		

TABLE D5b
Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene:
Second Study (continued)

	0 p	pm	400	pm	
15-Month Interim Evaluation (continued) Musculoskeletal System None					
Nervous System None					
Respiratory System None					
Special Senses System None			·		
Urinary System Kidney	(10)		(9)		
Nephropathy	(10)	(30%)	3	(33%)	
2-Year Study					
Alimentary System					
Esophagus	(50)		(51)		
Ulcer		(2%)	()		
Muscularis, degeneration		(2%)			
Gallbladder	(50)		(50)		
Mucosa, hyperplasia	` '			(2%)	
Intestine small, ileum	(49)		(51)	`	
Peyer's patch, inflammation, granulomatous	` '			(2%)	
Liver	(50)		(51)		
Angiectasis			1	(2%)	
Basophilic focus				(10%)	
Clear cell focus				(8%)	
Eosinophilic focus	9	(18%)	16	(31%)	
Infarct	_	(201)	1	(2%)	
Infiltration cellular, lymphocyte	1	(2%)		(00)	
Inflammation, acute	2	(40%)		(2%)	
Inflammation, chronic active Mixed cell focus		(4%)	1	(2%)	
Necrosis, acute	1	(2%)	1	(2%)	
Vacuolization cytoplasmic				(2%)	
Mesentery	(2)		(7)	()	
Ectopic tissue	1	(50%)	(,)		
Artery, inflammation, chronic active		, ,	1	(14%)	
Fat, necrosis	1	(50%)		(86%)	
Pancreas	(49)	•	(50)		
Cyst				(2%)	
Acinus, atrophy		(6%)		(2%)	
Duct, ectasia	2	(4%)	1	(2%)	

TABLE D5b
Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
2-Year Study (continued)			· · · · · · · · · · · · · · · · · · ·
Alimentary System (continued)			
Stomach, forestomach	(50)	(51)	
Acanthosis	1 (2%)	1 (2%)	
Stomach, glandular	(50)	(51)	
Dysplasia		1 (2%)	
Cardiovascular System			
Heart	(50)	(51)	
Degeneration	2 (4%)		
Mineralization	1 (2%)	1 (2%)	
Endocrine System			
Adrenal gland, cortex	(50)	(51)	•
Hypertrophy	3 (6%)	2 (4%)	
Adrenal gland, medulla	(49)	(51)	
Hyperplasia		1 (2%)	
Islets, pancreatic	(49)	(48)	
Hyperplasia		1 (2%)	
Pituitary gland	(49)	(47)	
Pars distalis, cyst	1 (2%)	-	
Pars distalis, hyperplasia	22 (45%)	16 (34%)	
Thyroid gland	(50)	(51)	
Follicular cell, hyperplasia	9 (18%)	32 (63%)	
General Body System None			
Genital System			
Clitoral gland	(7)	(4)	
Dilatation	5 (71%)	4 (100%)	
Inflammation	1 (14%)	` ,	
Ovary	(50)	(49)	
Cyst	14 (28%)	14 (29%)	
Cyst, multiple	•	1 (2%)	*
Uterus	(50)	(51)	
Hemorrhage	1 (2%)		•
Hyperplasia, cystic, glandular	42 (84%)	40 (78%)	
			•
Hematopoietic System	(50)	(51)	
Hematopoietic System Bone marrow	(50) 19 (38%)	(51) 18 (35%)	
Hematopoietic System Bone marrow Myelofibrosis	19 (38%)	18 (35%)	
Hematopoietic System Bone marrow Myelofibrosis	19 (38%) (50)		
Hematopoietic System Bone marrow Myelofibrosis Lymph node Lumbar, cyst	19 (38%)	18 (35%)	
Hematopoietic System Bone marrow Myelofibrosis Lymph node Lumbar, cyst Mediastinal, inflammation, granulomatous	19 (38%) (50)	18 (35%) (51)	
Hematopoietic System Bone marrow Myelofibrosis Lymph node Lumbar, cyst	19 (38%) (50) 1 (2%)	18 (35%) (51) 1 (2%)	

TABLE D5b Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of Triamterene: Second Study (continued)

	0 ppm	400 ppm	
2-Year Study (continued)			
Hematopoietic System (continued)			
Lymph node, mesenteric	(47)	(47)	
Congestion	1 (2%)	,	
Cyst	- ()	1 (2%)	
Infiltration cellular, histiocyte	2 (4%)	1 (2%)	
Spleen	(49)	(51)	
Hematopoietic cell proliferation	1 (2%)	5 (10%)	
Hemorrhage	1 (370)	1 (2%)	
Hyperplasia, lymphoid	1 (2%)	2 (4%)	
Lymphoid follicle, hyperplasia	1 (2%)	2 (177)	
Integumentary System			
Mammary gland	(49)	(50)	
Ectasia	()	1 (2%)	
Hyperplasia	2 (4%)	2 (4%)	
Skin	(50)	(51)	
Cyst epithelial inclusion	1 (2%)	(44)	•
Inflammation, chronic active	1 (2%)		
Musculoskeletal System None			
Nervous System			
Brain	(50)	(51)	
Compression		1 (2%)	
Cyst epithelial inclusion	1 (2%)		
Arteriole, infiltration cellular, lymphocyte	1 (2%)		
Respiratory System			
Lung	(50)	(51)	
Hemorrhage	1 (2%)	()	
Alveolar epithelium, hyperplasia	1 (2%)	1 (2%)	
Pleura, infiltration cellular, lymphocyte	1 (2%)	. (270)	
Nose	(50)	(51)	
Inflammation, acute	2 (4%)	3 (6%)	
Special Senses System			
Harderian gland	(4)	(4)	
Hyperplasia	(4) 4 (100%)	(4) 1 (25%)	
Aberkinger		1 (23/0)	
Urinary System			
	(50)	(51)	
Urinary System Kidney Nephropathy	(50) 17 (34%)	(51) 21 (41%)	

Number of animals examined microscopically at site and number of animals with lesion

APPENDIX E GENETIC TOXICOLOGY

SALMONELL	A Protocol	300
CHINESE H.	AMSTER OVARY CELL CYTOGENETICS ASSAYS	30X
\mathbb{R} ESULTS.		301
TABLE E1	Mutagenicity of Triamterene in Salmonella typhimurium	302
TABLE E2	Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells	
	by Triamterene	304
Table E3	Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells	
	by Triamterene	300

GENETIC TOXICOLOGY

SALMONELLA PROTOCOL

Testing was performed as reported by Mortelmans et al. (1986). Triamterene was sent to the laboratory as a coded aliquot from Radian Corporation (Austin, TX). Triamterene was incubated with the Salmonella typhimurium tester strains (TA98, TA100, TA1535, TA1537) either in buffer or S9 mix (metabolic activation enzymes and cofactors from Aroclor 1254-induced male Sprague-Dawley rat or Syrian hamster liver) for 20 minutes at 37° C prior to the addition of soft agar supplemented with *l*-histidine and *d*-biotin, and subsequent plating on minimal glucose agar plates. Incubation continued for an additional 48 hours.

Each trial consisted of triplicate plates of concurrent positive and solvent (dimethylsulfoxide) controls and of at least five doses of triamterene. High dose was limited by solubility and did not exceed $10,000~\mu g/p$ late. All assays were repeated.

In this assay, a positive response is defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal response is defined as an increase in revertants which was not dose-related, not reproducible, or of insufficient magnitude to support a determination of mutagenicity. A negative response was obtained when no increase in revertant colonies was observed following chemical treatment.

CHINESE HAMSTER OVARY CELL CYTOGENETICS ASSAYS

Testing was performed as reported by Galloway et al. (1985, 1987). Triamterene was sent to the laboratory as a coded aliquot from Radian Corporation (Austin, TX). It was tested in cultured Chinese hamster ovary (CHO) cells for induction of sister chromatid exchanges (SCEs) and chromosomal aberrations (Abs) both in the presence and absence of Aroclor 1254-induced male Sprague-Dawley rat liver S9 and cofactor mix. Cultures were handled under gold lights to prevent photolysis of bromodeoxyuridine-substituted DNA. Each test consisted of concurrent solvent and positive controls and of at least three doses of triamterene; the high dose was limited by toxicity.

In the SCE test without S9, CHO cells were incubated for 26 hours with triamterene in McCoy's 5A medium supplemented with 10% fetal bovine serum, *l*-glutamine (2mM), and antibiotics. Bromodeoxyuridine (BrdU) was added 2 hours after culture initiation. After 26 hours, the medium containing triamterene was removed and replaced with fresh medium plus BrdU and Colcemid, and incubation was continued for 2 hours. Cells were then harvested by mitotic shake-off, fixed, and stained with Hoechst 33258 and Giemsa. In the SCE test with S9, cells were incubated with triamterene, serum-free medium, and S9 for 2 hours. The medium was then removed and replaced with medium containing BrdU and no triamterene and incubation proceeded for an additional 26 hours, with Colcemid present for the final 2 hours. Harvesting and staining was the same as for cells treated without S9.

In the chromosomal aberration test without S9, cells were incubated in McCoy's 5A medium with triamterene for 8.5 hours; Colcemid was added and incubation continued for 2 hours. The cells were then harvested by mitotic shake-off, fixed, and stained with Giemsa. For the Abs test with S9, cells were treated with triamterene and S9 for 2 hours, after which the treatment medium was removed and the cells incubated for 10 to 12 hours in fresh medium, with Colcemid present for the final 2 hours. Cells were harvested in the same manner as for the treatment without S9.

Cells were selected for scoring on the basis of good morphology and completeness of karyotype $(21 \pm 2 \text{ chromosomes})$. All slides were scored blind and those from a single test were read by the same

person. For the SCE test, 50 second-division metaphase cells were scored for frequency of SCEs per cell from each dose level; 100 first-division metaphase cells were scored at each dose level for the Abs test. Classes of aberrations included simple (breaks and terminal deletions), complex (rearrangements and translocations), and other (pulverized cells, despiralized chromosomes, and cells containing 10 or more aberrations).

Statistical analyses were conducted on both the slopes of the dose-response curves and the individual dose points. An SCE frequency 20% above the concurrent solvent control value was chosen as a statistically conservative positive response. The probability of this level of difference occurring by chance at one dose point is less than 0.01; the probability for such a chance occurrence at two dose points is less than 0.001. A single increased dose was considered weak evidence of a positive response two increased doses were sufficient to evaluate the trial as positive. Chromosomal aberration data are presented as percentage of cells with aberrations. As with SCE, both the dose-response curve and individual dose points were statistically analyzed. For a single trial, a statistically significant (P<0.05) difference for one dose point and a significant trend (P<0.015) were considered weak evidence for a positive response; significant differences for two or more doses indicated the trial was positive (Galloway et al., 1987).

RESULTS

Triamterene (10 to 10,000 μ g/plate) was tested in two laboratories for induction of gene mutations in Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 with a preincubation protocol in the presence and the absence of Aroclor 1254-induced male Sprague-Dawley rat or Syrian hamster liver S9; no induction of mutations was observed in either laboratory (Table E1; Mortelmans et al., 1986). In cytogenetic tests with Chinese hamster ovary cells, triamterene induced sister chromatid exchanges with and without Aroclor 1254-induced male Sprague-Dawley rat liver S9 (Table E2). Without S9, doses tested ranged from 0.5 to 40 μ g/mL; 10 μ g/mL was the lowest dose at which a positive response occurred. With S9, doses of 5 to 500 μ g/mL were tested and the lowest effective dose was 160 μ g/mL. Tests for induction of chromosomal aberrations in CHO cells were negative, with and without S9 activation. With S9, the first trial showed a significant increase in aberrations at 50 μ g/mL, but this response was not repeated in a subsequent trial (Table E3).

TABLE E1
Mutagenicity of Triamterene in Salmonella typhimurium^a

				Revertant	s/plate ^b			
Strain	Dose	-S9		+10% han	ister S9	+10% rat S9		
	(μg/plate)	Trial 1	Trial 2	Trial 1	Trial 2	Trial 1	Trial 2	
Study	performed :	at EG&G Mas	on Research Ins	titute	,			
A100								
	0	102 ± 0.9	103 ± 2.0	120 ± 9.0	94 ± 5.2	122 ± 8.1	83 ± 7.5	
	10	93 ± 3.4						
	33	97 ± 4.0	85 ± 1.5	123 ± 8.6	83 ± 4.6	114 ± 6.7	92 ± 11.6	
	100	114 ± 9.0	97 ± 1.2	136 ± 4.6	97 ± 6.7	131 ± 12.5	89 ± 4.3	
	333	96 ± 4.0	102 ± 7.3	134 ± 5.5	102 ± 4.6	113 ± 3.2	90 ± 7.0	
	1,000	101 ± 10.4	48 ± 0.7	106 ± 16.3	68 ± 7.4	107 ± 8.1	74 ± 7.6	
	2,000	101 ± 10.4	70 ± 0.7	$25 \pm 2.6^{\circ}$	12 ± 1.9^{c}	$67 \pm 9.5^{\circ}$	74 ± 7.6 25 ± 9.6	
	3,333		$9 \pm 2.5^{\circ}$	23 ± 2.0	12 ± 1.9	07 ± 9.5	23 ± 9.0	
rial su ositive	mmary control ^d	Negative 2,140 ± 29.7	Negative 1,338 ± 99.7	Negative 1,443 ± 42.4	Negative 946 ± 33.3	Negative 2,051 ± 101.1	Negative 1,234 ± 16.4	
A153	5		•					
	0	14 ± 2.6	28 ± 5.0	9 ± 1.8	7 ± 2.0	9 ± 1.9	8 ± 1.7	
	10	9 ± 1.7						
	33	12 ± 2.7	17 ± 3.3	11 ± 1.2	9 ± 1.9	10 ± 1.2	9 ± 1.5	
	100	12 ± 2.7 12 ± 1.8	17 ± 3.3 19 ± 1.0	8 ± 2.5	9 ± 1.9	9 ± 0.3	8 ± 0.6	
	333	12 ± 1.8 13 ± 2.3		9 ± 1.2		9 ± 0.5 13 ± 2.5		
			14 ± 1.8				8 ± 1.7	
	1,000	5 ± 1.5	3 ± 1.0	8 ± 0.9	7 ± 1.5	8 ± 0.7	5 ± 0.6	
	2,000		4	6 ± 0.7^{c}	0 . 0 . 0	6 ± 1.2^{c}	a ^=4	
	3,333		1 ± 0.0^{c}		0 ± 0.0^{c}		$1 \pm 0.7^{\circ}$	
	mmary control	Negative 1,537 ± 42.2	Negative 978 ± 131.0	Negative 107 ± 6.4	Negative 115 ± 7.4	Negative 128 ± 3.5	Negative 111 ± 9.6	
Γ A153 '	7							
	. 0	7 ± 1.5	4 ± 1.2	9 ± 1.5	6 ± 0.3	9 ± 1.2	5 ± 1.5	
	10	8 ± 1.5	7 = 1.2) <u> </u>	0 1 0.5	/ _ 1. <u>u</u>	3 - 1.5	
	33	4 ± 1.8	7 ± 0.3	10 ± 0.9	7 ± 0.7	13 ± 3.5	5 ± 0.9	
	100	10 ± 1.5	3 ± 1.2	12 ± 0.7	7 ± 0.7	8 ± 1.5	5 ± 1.9	
	333	6 ± 1.2	6 ± 1.8	7 ± 1.9	7 ± 0.7	10 ± 0.3	4 ± 0.3	
	1,000	5 ± 0.9	2 ± 1.5	6 ± 1.3	3 ± 1.2	9 ± 2.0	4 ± 1.7	
	2,000			4 ± 1.2^{c}		7 ± 2.3^{c}	<u>.</u>	
	3,333		0 ± 0.0^{c}		0 ± 0.3^{c}		2 ± 0.9	
	mmary control	Negative 461 ± 51.1	Negative 105 ± 9.8	Negative 166 ± 9.7	Negative 85 ± 2.3	Negative 209 ± 10.7	Negative 142 ± 3.2	
ΓA98								
	0	19 ± 2.3	17 ± 1.5	32 ± 2.0	27 ± 2.1	31 ± 1.0	29 ± 1.2	
	10	16 ± 2.8		: •				
	33	16 ± 1.5	15 ± 0.9	29 ± 1.8	26 ± 3.0	34 ± 2.5	30 ± 2.0	
	100	18 ± 1.2	13 ± 0.9 13 ± 1.5	22 ± 3.2	28 ± 2.5	39 ± 4.1	25 ± 2.7	
	333	16 ± 1.2 14 ± 1.8	15 ± 1.5 15 ± 1.5	30 ± 2.6	28 ± 2.3 27 ± 5.3	40 ± 0.9	$\frac{23 \pm 2.7}{27 \pm 2.7}$	
					$\frac{27 \pm 3.5}{18 \pm 1.5}$	28 ± 5.4	27 ± 2.7 21 ± 1.2	
	1,000	17 ± 2.6	15 ± 0.9	20 ± 2.3	10 ± 1.3			
	2,000		kc	19 ± 3.0^{c}	44 . 450	24 ± 3.4^{c}	0 : 22	
	3,333		$9 \pm 2.3^{\circ}$		14 ± 1.0^{c}		9 ± 3.0	
Trial su	ımmary	Negative	Negative	Negative	Negative	Negative	Negative	
	control	$2,805 \pm 16.7$	$1,166 \pm 54.5$	954 ± 24.8	520 ± 12.7	$1,277 \pm 21.8$	730 ± 54.0	

TABLE E1
Mutagenicity of Triamterene in Salmonella typhimurium (continued)

			Revertants/plate							
Strain	Dose	-89)	+10% har	nster S9	+10%	rat S9			
	(μg/plate)	Trial 1	Trial 2	Trial 1	Trial 2	Trial 1	Trial 2			
Study	performed	at Case Wester	n Reserve Univ	ersity						
TA100										
111100	0	134 ± 7.3	104 ± 6.8	178 ± 9.0	125 ± 24.8	176 ± 4.3	117 ± 18.0			
	100	106 ± 5.2	111 ± 7.4	167 ± 10.9	107 ± 9.6	126 ± 16.8	132 ± 11.2			
	333	116 ± 6.0	94 ± 1.5	167 ± 7.9	133 ± 7.2	151 ± 15.6	160 ± 6.8			
	1,000	108 ± 2.3	107 ± 6.0^{c}	157 ± 5.0	133 ± 5.2^{c}	122 ± 19.4	$130 \pm 4.7^{\circ}$			
	3,333	$91 \pm 5.4^{\circ}$	93 ± 5.9^{c}	104 ± 3.7^{c}	142 ± 5.2^{c}	77 ± 3.8^{c}	$94 \pm 14.0^{\circ}$			
:	10,000	63 ± 12.3^{c}	55 ± 4.2^{c}	104 ± 7.0^{c}	108 ± 9.8^{c}	99 ± 6.5^{c}	$63 \pm 12.7^{\circ}$			
	mmary control	Negative 1,058 ± 172.1	Negative 1,533 ± 44.4	Negative 1,740 ± 159.2	Negative 1,936 ± 152.5	Negative 1,468 ± 152.6	Negative 2,471 ± 176.8			
TA153	5									
	0	26 ± 0.9	28 ± 5.4	19 ± 2.0	23 ± 4.0	21 ± 0.9	26 ± 1.5			
	100	27 ± 1.7	25 ± 5.2	12 ± 2.3	18 ± 0.9	20 ± 2.6	23 ± 3.2			
	333	29 ± 1.5	29 ± 2.8	16 ± 1.5	29 ± 2.6	17 ± 1.2	27 ± 3.2			
	1,000	26 ± 3.2	31 ± 4.1^{c}	20 ± 1.2	17 ± 4.0^{c}	10 ± 0.3	17 ± 0.6			
	3,333	10 ± 1.2^{c}	22 ± 3.6^{c}	8 ± 0.6^{c}	16 ± 0.9^{c}	4 ± 2.1^{c}	18 ± 0.9			
	10,000	8 ± 1.2^{c}	15 ± 1.5^{c}	$5 \pm 0.6^{\circ}$	13 ± 1.8^{c}	8 ± 0.6^{c}	12 ± 0.9			
	immary control	Negative 1,264 ± 245.1	Negative 1,837 ± 143.4	Negative 418 ± 24.6	Negative 439 ± 14.4	Negative 222 ± 15.7	Negative 418 ± 35.9			
TA153	7									
	0	15 ± 3.1	14 ± 1.2	30 ± 1.2	23 ± 2.1	22 ± 1.9	19 ± 2.6			
	100	10 ± 3.3	13 ± 0.9	28 ± 1.3	19 ± 2.5	27 ± 4.3	15 ± 1.2			
	333	10 ± 1.8	10 ± 0.9	14 ± 2.0	17 ± 1.8	18 ± 5.2	16 ± 2.0			
	1,000	11 ± 2.6	10 ± 1.5^{c}	$15 \pm 2.1^{\circ}$	18 ± 2.0^{c}	15 ± 1.0^{c}	12 ± 0.6			
	3,333	$6 \pm 2.0^{\circ}$	9 ± 0.7^{c}	$9 \pm 2.2^{\circ}$	10 ± 1.2^{c}	6 ± 1.5^{c}	9 ± 0.7			
	10,000	4 ± 0.0^{c}	7 ± 0.9^{c}	6 ± 1.5^{c}	5 ± 1.2^{c}	7 ± 2.4^{c}	4 ± 0.9			
	ummary e control	Negative 984 ± 55.2	Negative 1,000 ± 124.5	Negative 209 ± 28.6	Negative 486 ± 16.1	Negative 393 ± 45.5	Negative 800 ± 40.5			
TA98										
	0	37 ± 3.4	42 ± 3.4	47 ± 2.3	46 ± 2.7	37 ± 2.7	38 ± 3.2			
	100	34 ± 3.5	40 ± 2.2	37 ± 3.3	39 ± 2.1	38 ± 3.7	45 ± 6.4			
	333	32 ± 1.8	42 ± 2.3	43 ± 3.5	46 ± 7.5	37 ± 3.7	46 ± 2.6			
	1,000	28 ± 6.0	37 ± 5.7^{c}	$18 \pm 4.5^{\circ}$	$34 \pm 1.5^{\circ}$	33 ± 3.1^{c}	31 ± 5.3			
	3,333	16 ± 1.7^{c}	31 ± 5.2^{c}	18 ± 1.3^{c}	$23 \pm 2.6^{\circ}$	22 ± 2.4^{c}	22 ± 4.7			
	10,000	13 ± 0.9^{c}	26 ± 0.6^{c}	10 ± 0.3^{c}	17 ± 2.0^{c}	$13 \pm 3.5^{\circ}$	14 ± 0.9			
	ummary e control	Negative 171 ± 11.0	Negative 444 ± 30.5	Negative 692 ± 85.2	Negative 1,681 ± 148.0	Negative 636 ± 59.0	Negative 1,997 ± 90.0			

The detailed protocol and these data are presented in Mortelmans et al. (1986). 0 μ g/plate dose is the solvent control.

Precipitate on plate

Revertants are presented as mean \pm the standard error from three plates.

^d 2-Aminoanthracene was used on all strains in the presence of S9. In the absence of metabolic activation, 4-nitro-o-phenylenediamine was tested on TA98, sodium azide was tested on TA100 and TA1535, and 9-aminoacridine was tested on TA1537.

TABLE E2
Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by Triamterene^a

Compound	Dose μg/mL	Total Cells	No. of Chromo- somes	No. of SCEs	SCEs/ Chromo- some	SCEs/ Cell	Hrs in BrdU	Relative SCEs Chromosome (%) ^b
9								,
Trial 1 Summary: Weak positive								
Dimethylsulfoxide		50	1,039	451	0.43	9.0	26.0	
Mitomycin-C	0.005	50	1,039	1,581	1.52	31.6	26.0	250.55
Triamterene							•	
	0.5	50	1,046	414	0.39	8.3	26.0	-8.82
	1.6	50	1,034	520	0.50	10.4	26.0	15.86
	5.0	50	1,038	503	0.48	10.1	26.0	11.64
	16.0	50	1,019	738	0.72	14.8	26.0	66.85*
	-							P<0.001 ^c
Trial 2 Summary: Positive								¥
Dimethylsulfoxide		50	1,033	411	0.39	8.2	26.0	
Mitomycin-C								
	0.005	50	1,050	1,393	1.32	27.9	26.0	233.44
	0.010	50	1,045	2,049	1.96	41.0	26.0	392.81
Triamterene								
	5.0	50	1,046	497	0.47	9.9	26.0	19.42
	10.0	50	1,039	641	0.61	12.8	26.0	55.06*
	20.0 40.0	50 0	1,037	1,017	0.98	20.3	26.0	146.49*
								P<0.001

TABLE E2
Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by Triamterene (continued)

Compound	Dose μg/mL	Total Cells	No. of Chromo- somes	No. of SCEs	SCEs/ Chromo- some	SCEs/ Cell	Hrs in BrdU	Relative SCEs Chromosome (%)
9								
Trial 1 Summary: Negative								
Dimethylsulfoxide .		50	1,034	573	0.55	11.5	26.0	
Cyclophosphamide	• •	5 0	1.000	2.005	2.00	(0.1	. 260	421.02
	2.0	50	1,039	3,005	2.89	60.1	26.0	421.92
Triamterene								
	5.0	50	1,034	522	0.50	10.4	26.0	-8.90
	16.0	50	1,017	437	0.42	8.7	26.0	-22.46
	50.0	50	1,028	661	0.64	13.2	26.0	16.03
	160.0	50	1,025	590	0.57	11.8	26.0	3.87
	500.0	0					26.0	
								P = 0.007
Trial 2 Summary: Positive								
Dimethylsulfoxide		50	1.046	424	0.41	0.7	2(0	
		50	1,046	434	0.41	8.7	26.0	
Cyclophosphamide								
	1.5	50	1,044	1,894	1.81	37.9	26.0	337.24
	2.0	50	1,049	3,083	2.93	61.7	26.0	608.34
Triamterene								
•	5.0	50	1,048	424	0.40	8.5	26.0	-2.49
	16.0	50	1,051	437	0.41	8.7	26.0	0.21
	50.0	50	1,044	485	0.46	9.7	26.0	11.96
	160.0	50	1,047	696	0.66	13.9	26.0	60.22*
	500.0	50	1,036	909	0.87	18.2	26.0	111.47*
								P<0.001

^{*} Significant increase (P<0.01)

Study performed at Environmental Health Research & Testing, Inc. SCE=sister chromatid exchange;
BrdU=bromodeoxyuridine. A detailed description of the SCE protocol is presented by Galloway et al. (1985, 1987).

b SCEs/chromosome of culture exposed to triamterene relative to those of culture exposed to solvent.

Significance of relative SCEs/chromosome tested by the linear regression trend test vs. log of the dose

TABLE E3 Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells by Triamterene^a

			S9_					+ <u>S</u> 9		
Dose μg/mL	Tot Cel		No. of Abs	Abs/ Cell	Percent Cells w/Abs	Dose μg/mL	Total Cells	No. of Abs	Abs/ Cell	Percent Cells w/Abs
rial 1 - Harves immary: Negativ		10.5	hours			Trial 1 - Harvest Summary: Question		0 hours		
Dimethylsulfoxid						Dimethylsulfoxide				
	10	0	1	0.01	1.0		100	0	0.00	0.0
Aitomycin-C						Cyclophosphamide		•		
0.2	50 10	0	23	0.23	18.0	50.0	100	117	1.17	67.0
riamterene						Triamterene				
1.6	10	0	1	0.01	1.0	5.0	100	1	0.01	1.0
5.0	10	0	0	0.00	0.0	16.0	100	4	0.04	3.0
16.0	10	0	0	0.00	0.0	50.0	100	8	0.08	7.0*
50.0	10	0	0	0.00	0.0	160.0	100	1	0.01	1.0
						500.0	100	2	0.02	2.0
					$P = 0.933^{b}$					P=0.13
						Trial 2 - Harvest Summary: Negative		0 hours	•	
						Dimethylsulfoxide				
						•	100	0	0.00	0.0
						Cyclophosphamide 50.0	100	133	1.33	61.0
						Triamterene				
						25.0	100	0	0.00	0.0
						50.0	100	2	0.02	2.0
						100.0	100	ī	0.02	1.0
						200.0	100	ō	0.00	0.0
						600.0	100	0	0.00	0.0
										P=0.58

Significant increase (P<0.05)
Study performed at Environmental Health Research & Testing, Inc. Abs=aberrations. A detailed presentation of the technique for detecting chromosomal aberrations is found in Galloway et al. (1985, 1987).

Significance of percent cells with aberrations tested by the linear regression trend test vs. log of the dose

APPENDIX F ORGAN WEIGHTS AND ORGAN-WEIGHT-TO-BODY-WEIGHT RATIOS

Table F1	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats	
	in the 15-Day Feed Study of Triamterene	308
Table F2	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats	
	in the 13-Week Feed Study of Triamterene	310
Table F3	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats	
	at the 3-Month Interim Evaluation in the 2-Year Feed Study	
	of Triamterene	312
Table F4	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study	
	of Triamterene	313
Table F5	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
	in the 15-Day Feed Study of Triamterene	314
Table F6	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
	in the 13-Week Feed Study of Triamterene	310
Table F7	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
	at the 3-Month Interim Evaluation in the 2-Year Feed Study	
	of Triamterene	318
Table F8	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study	
m ===	of Triamterene: First Study	319
Table F9	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study	
	of Triamterene: Second Study	320

TABLE F1
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 15-Day Feed Study of Triamterene^a

Organ	0 ppm	1,000 ppm	3,000 ррт	•
Male				
n	5	5	4	
Necropsy body wt	243 ± 4	244 ± 6	125 ± 4**	
Brain				
Absolute	1.764 ± 0.018	1.758 ± 0.015	$1.625 \pm 0.025**$	
Relative	7.26 ± 0.14	7.24 ± 0.24	$13.03 \pm 0.63**$	
Heart				
Absolute	0.863 ± 0.005	0.812 ± 0.015 *	$0.451 \pm 0.020**$	
Relative	3.55 ± 0.07	3.33 ± 0.06	3.60 ± 0.12	
R. Kidney				
Absolute	1.053 ± 0.019	1.063 ± 0.040	$0.666 \pm 0.026**$	
Relative	4.33 ± 0.11	4.36 ± 0.06	$5.35 \pm 0.38**$	•
Liver				
Absolute	12.839 ± 0.269	13.972 ± 0.508	$5.744 \pm 0.278**$	
Relative	52.85 ± 1.47	57.25 ± 0.73	46.11 ± 3.17	
Lungs				•
Absolute	1.579 ± 0.155	1.386 ± 0.151	$0.755 \pm 0.119**$	
Relative	6.50 ± 0.66	5.64 ± 0.49	6.09 ± 1.05	
R. Testis				
Absolute	1.273 ± 0.031	1.280 ± 0.040	$0.963 \pm 0.026**$	
Relative	5.23 ± 0.08	5.25 ± 0.03	7.70 ± 0.05 **	
Thymus			L	
Absolute	0.418 ± 0.017	0.367 ± 0.016 *	$0.038 \pm 0.004^{**b}$	
Relative	1.72 ± 0.09	1.51 ± 0.06	$0.30 \pm 0.03**^{b}$	

TABLE F1
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 15-Day Feed Study of Triamterene (continued)

Organ	0 ppm	1,000 ppm	3,000 ppm
Female			
n	5	5	3
Necropsy body wt	163 ± 8	161 ± 3	106 ± 12**
Brain			
Absolute	1.735 ± 0.030	1.664 ± 0.027	1.580 ± 0.040 **
Relative	10.63 ± 0.20	10.34 ± 0.13	15.27 ± 1.62**
Heart			
Absolute	0.657 ± 0.027	0.600 ± 0.021	0.408 ± 0.031 **
Relative	4.02 ± 0.16	3.72 ± 0.06	3.89 ± 0.23
R. Kidney			
Absolute	0.759 ± 0.015	0.738 ± 0.036	0.563 ± 0.033 **
Relative	4.65 ± 0.08	4.58 ± 0.16	5.39 ± 0.38 *
Liver			
Absolute	8.196 ± 0.180	8.330 ± 0.457	7.530 ± 0.703
Relative	50.17 ± 0.51	51.64 ± 2.27	71.57 ± 4.15**
Lungs			
Absolute	1.152 ± 0.052	1.070 ± 0.044	$0.796 \pm 0.089**$
Relative	7.04 ± 0.21	6.63 ± 0.16	7.52 ± 0.19
Thymus			
Absolute	0.349 ± 0.014	0.340 ± 0.014	$0.036 \pm 0.003**$
Relative	2.13 ± 0.07	2.11 ± 0.08	0.34 ± 0.02 **

Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

^{*} P≤0.01

a Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error). No data calculated for the 10,000, 30,000, and 60,000 ppm groups due to 100% mortality.

n=2

TABLE F2
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 13-Week Feed Study of Triamterene^a

ergan	0 ppm	150 ppm	600 ppm	1,200 ppm
fale		······································		
	10	10	10	10
lecropsy body weight	364 ± 7	356 ± 10	351 ± 7	$332 \pm 16*$
rain				
Absolute	2.05 ± 0.03	2.01 ± 0.04	2.07 ± 0.03	$1.90 \pm 0.03**$
Relative	5.65 ± 0.10	5.69 ± 0.17	5.89 ± 0.10	5.82 ± 0.24
eart	_	4		
Absolute	1.34 ± 0.07^{b}	1.34 ± 0.04^{b}	1.31 ± 0.06	1.22 ± 0.04
Relative	3.73 ± 0.18^{b}	3.72 ± 0.14^{b}	3.73 ± 0.13	3.75 ± 0.19
Kidney				
Absolute	1.43 ± 0.04	1.37 ± 0.04	1.34 ± 0.04	1.19 ± 0.03**
Relative	3.93 ± 0.11	3.85 ± 0.09	3.83 ± 0.06	3.64 ± 0.18
er				
Absolute	12.55 ± 0.45	12.08 ± 0.50	12.44 ± 0.35	11.95 ± 0.44
Relative	34.5 ± 1.0	34.0 ± 1.1	35.4 ± 0.7	36.5 ± 1.6
ngs				
Absolute	1.47 ± 0.06	1.48 ± 0.04	1.47 ± 0.05	1.38 ± 0.05
Relative	4.05 ± 0.14	4.17 ± 0.06	4.17 ± 0.09	4.24 ± 0.22
Testis				
Absolute	1.49 ± 0.02	1.45 ± 0.03	1.44 ± 0.03	1.48 ± 0.02
Relative	4.10 ± 0.07	4.09 ± 0.06	4.12 ± 0.09	$4.52 \pm 0.16**$
mus ^c				
Absolute -	270.0 ± 13.0	280.0 ± 14.6	300.1 ± 16.2	237.9 ± 10.4
Relative	0.74 ± 0.03	0.79 ± 0.04	0.85 ± 0.04	0.73 ± 0.04

TABLE F2
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 13-Week Feed Study of Triamterene (continued)

Organ	0 ppm	150 ppm	600 ppm	1,200 ppm	
Female		· · · · · · · · · · · · · · · · · · ·			
n	10	10	10	10	
Necropsy body weight	197 ± 2	196 ± 2	191 ± 3	183 ± 11	
Brain					
Absolute	1.89 ± 0.03	1.78 ± 0.03 *	1.90 ± 0.03	$1.78 \pm 0.03^{*}$	
Relative	9.58 ± 0.16	9.06 ± 0.19	9.97 ± 0.17	9.93 ± 0.44	•
Heart	_				
Absolute	$0.86 \pm 0.02^{\rm b}$	0.79 ± 0.02	0.81 ± 0.02	0.73 ± 0.03 **	
Relative	4.36 ± 0.13^{b}	4.03 ± 0.09	4.27 ± 0.08	4.09 ± 0.24	•
R. Kidney					
Absolute	0.78 ± 0.02	0.76 ± 0.01	0.75 ± 0.02	0.66 ± 0.01 **	
Relative	3.95 ± 0.11	3.85 ± 0.03	3.92 ± 0.06	3.70 ± 0.16	
Liver					
Absolute	6.78 ± 0.15	6.81 ± 0.13	6.88 ± 0.16	6.26 ± 0.23	
Relative	34.5 ± 1.0	34.8 ± 0.9	36.0 ± 0.6	35.0 ± 1.8	•
Lungs					
Absolute	1.11 ± 0.04	1.11 ± 0.03	1.05 ± 0.04	0.98 ± 0.03 *	
Relative	5.66 ± 0.19	5.65 ± 0.13	5.52 ± 0.24	5.46 ± 0.19	
Thymus ^c					
Absolute	254.9 ± 15.1	242.7 ± 15.4	228.0 ± 9.6	$209.2 \pm 3.3^{*}$	
Relative	1.30 ± 0.08	1.23 ± 0.07	1.20 ± 0.05	1.17 ± 0.06	

^{*} Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

^{**} P≤0.0

Organ and body weights are given in grams unless otherwise specified; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error). No data calculated for the 2,400 ppm group due to 100% mortality.

Weights are given in milligrams.

TABLE F3
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene^a

Organ	0 ppm	150 ppm	300 ppm	600 ppm
Male				
n Gg	10	10	10	10
Necropsy body wt	350 ± 8	331 ± 5	336 ± 7	349 ± 5
Brain				
Absolute	1.98 ± 0.02	1.93 ± 0.02	1.96 ± 0.02	1.99 ± 0.02
Relative	5.67 ± 0.11	5.83 ± 0.11	5.84 ± 0.12	5.73 ± 0.07
L. Kidney				
Absolute	1.20 ± 0.03	$1.08 \pm 0.02**$	1.13 ± 0.02	1.14 ± 0.03
Relative	3.43 ± 0.06	3.25 ± 0.06 *	3.35 ± 0.04	3.26 ± 0.06 *
R. Kidney				
Absolute	1.17 ± 0.03	$1.08 \pm 0.02*$	1.10 ± 0.02	1.15 ± 0.02
Relative	3.35 ± 0.08	3.28 ± 0.06	3.27 ± 0.02	3.29 ± 0.04
Liver				
Absolute	10.77 ± 0.37	10.17 ± 0.19	10.67 ± 0.29	11.48 ± 0.36
Relative	30.8 ± 0.7	30.7 ± 0.4	31.7 ± 0.5	32.9 ± 0.8*
Female				
n	10	10	10	10
Necropsy body wt	194 ± 3	186 ± 3	183 ± 3*	182 ± 4*
Brain				
Absolute	1.83 ± 0.02	1.80 ± 0.07	1.80 ± 0.01	1.82 ± 0.02
Relative	9.47 ± 0.15	9.70 ± 0.32	9.85 ± 0.14	10.05 ± 0.18
L. Kidney				•
Absolute	0.67 ± 0.01	0.64 ± 0.01	0.62 ± 0.01 *	0.63 ± 0.01 *
Relative	3.48 ± 0.07	3.44 ± 0.04	3.38 ± 0.07	3.46 ± 0.05
R. Kidney				
Absolute	0.67 ± 0.02	0.65 ± 0.02	0.62 ± 0.01 *	0.63 ± 0.02 *
Relative	3.47 ± 0.08	3.50 ± 0.06	3.36 ± 0.06	3.48 ± 0.07
Liver				
Absolute	5.32 ± 0.12	5.08 ± 0.20	5.14 ± 0.11	5.21 ± 0.15
Relative	27.5 ± 0.5	27.4 ± 0.8	28.0 ± 0.5	28.7 ± 0.6

^{*} Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

^{**} P<0.01

Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

TABLE F4
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene^a

Organ	0 ppm	150 ppm	300 ppm	600 ppm
MISIG				
n	10	10	10	10
Necropsy body weight	471 ± 8	493 ± 10	462 ± 10	471 ± 6
Brain				
Absolute	2.06 ± 0.02	2.07 ± 0.02	2.11 ± 0.02	2.11 ± 0.02
Relative	4.38 ± 0.10	4.20 ± 0.08	4.58 ± 0.08	4.49 ± 0.05
L. Kidney				
Absolute	1.49 ± 0.03	1.56 ± 0.04^{b}	1.51 ± 0.04	1.51 ± 0.03
Relative	3.16 ± 0.04	3.14 ± 0.08^{b}	3.27 ± 0.05	3.22 ± 0.05
R. Kidney				
Absolute	1.45 ± 0.03	1.56 ± 0.04	1.52 ± 0.05	1.50 ± 0.03
Relative	3.09 ± 0.06	3.18 ± 0.08	3.28 ± 0.06	3.19 ± 0.05
Liver				
Absolute	14.80 ± 0.45	16.22 ± 0.34 *	15.78 ± 0.36	15.71 ± 0.42
Relative	31.4 ± 0.6	32.9 ± 0.6	34.2 ± 0.4**	33.3 ± 0.6**
Female				
n	10	. 10	10	10
Necropsy body weight	295 ± 5	287 ± 6	295 ± 3	281 ± 10
Brain				
Absolute	1.91 ± 0.02	1.89 ± 0.02	1.89 ± 0.03	1.93 ± 0.02
Relative	6.48 ± 0.12	6.61 ± 0.14	6.40 ± 0.09	6.95 ± 0.25
L. Kidney				
Absolute	0.93 ± 0.02	0.90 ± 0.02	0.88 ± 0.02	0.91 ± 0.03
Relative	3.15 ± 0.05	3.16 ± 0.06	2.98 ± 0.07	3.27 ± 0.09
R. Kidney				
Absolute	0.94 ± 0.02	0.90 ± 0.02	0.87 ± 0.01	0.93 ± 0.03
Relative	3.18 ± 0.05	3.14 ± 0.07	2.96 ± 0.04 *	3.32 ± 0.07
Liver				
Absolute	8.94 ± 0.21	8.43 ± 0.21	8.59 ± 0.19	9.12 ± 0.29
Relative	30.3 ± 0.4	29.4 ± 0.6	29.1 ± 0.7	32.7 ± 1.1

^a Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

** P≤0.01

n=9

Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

TABLE F5
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 15-Day Feed Study of Triamterene^a

Organ		0 ppm	300 ppm	1,000 ppm	
Male				· · · · · · · · · · · · · · · · · · ·	
n		5	5	5	
Necropsy body wt		25.3 ± 0.7	24.6 ± 0.5	25.8 ± 0.8	
Brain					
Absolute		0.440 ± 0.016	0.422 ± 0.008	0.440 ± 0.013	
Relative		17.44 ± 0.82	17.16 ± 0.33	17.09 ± 0.29	
Heart	•			•	
Absolute		0.160 ± 0.006	0.165 ± 0.007	0.133 ± 0.013	
Relative		6.31 ± 0.20	6.71 ± 0.27	$5.14 \pm 0.39*$	
R. Kidney		•			
Absolute		0.277 ± 0.007	0.259 ± 0.008	0.251 ± 0.013	
Relative		10.96 ± 0.45	10.53 ± 0.19	9.71 ± 0.24 *	
Liver					
Absolute		1.499 ± 0.054	1.562 ± 0.065	1.660 ± 0.091	
Relative		59.15 ± 0.93	63.33 ± 1.41	64.31 ± 1.86 *	
Lungs					
Absolute		0.197 ± 0.008	0.190 ± 0.001	0.199 ± 0.008	
Relative		7.77 ± 0.30	7.72 ± 0.16	7.71 ± 0.19	
R. Testis			•	•	
Absolute		0.102 ± 0.002	0.106 ± 0.006	0.099 ± 0.004	
Relative		4.06 ± 0.17	4.30 ± 0.23	3.85 ± 0.14	
Thymus					
Absolute		0.041 ± 0.005	0.040 ± 0.002	0.031 ± 0.005	
Relative		1.63 ± 0.21	1.65 ± 0.10	1.23 ± 0.19	

TABLE F5
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 15-Day Feed Study of Triamterene (continued)

Organ	0 ppm	300 ppm	1,000 ppm	
Female				
n	5	5	5	
Necropsy body wt	20.7 ± 0.3	19.6 ± 0.6	21.3 ± 0.3	
Brain				
Absolute	0.452 ± 0.007	0.432 ± 0.014	0.445 ± 0.004	
Relative	21.84 ± 0.31	22.08 ± 0.25	20.89 ± 0.42	
Heart				
Absolute	0.151 ± 0.014	0.133 ± 0.009	0.109 ± 0.007 *	
Relative	7.30 ± 0.75	6.79 ± 0.35	$5.13 \pm 0.37^{\circ}$	
R. Kidney				
Absolute	0.194 ± 0.008	0.174 ± 0.007	0.177 ± 0.007	
Relative	9.34 ± 0.26	8.86 ± 0.20	$8.30 \pm 0.27^{\circ}$	
Liver				
Absolute	1.317 ± 0.024	1.213 ± 0.047	1.238 ± 0.020	
Relative	63.57 ± 0.99	61.91 ± 1.41	58.09 ± 0.73°°	
Lungs				
Absolute	0.190 ± 0.008	0.196 ± 0.008	0.195 ± 0.004	
Relative	9.16 ± 0.25	10.02 ± 0.39	9.16 ± 0.15	
Thymus				
Absolute	0.054 ± 0.004	0.051 ± 0.004	0.049 ± 0.003	
Relative	2.58 ± 0.17	2.64 ± 0.24	2.32 ± 0.15	

F Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

^{**} P≤0.01

a Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error). No data calculated for the 3,000, 10,000, and 30,000 ppm groups due to 100% mortality.

TABLE F6
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 13-Week Feed Study of Triamterene^a

Organ	0 ppm	100 ppm	400 ppm	800 ppm	
Male			· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
n	10	6	10	10	
Necropsy body weight	26.8 ± 0.9	25.3 ± 0.9	25.5 ± 0.8	$24.4 \pm 0.6^{\circ}$:
Brain					
Absolute	0.44 ± 0.01	0.46 ± 0.03	0.43 ± 0.01	0.41 ± 0.01	
Relative	16.5 ± 0.6	18.2 ± 0.8	16.9 ± 0.5	17.0 ± 0.5	
Heart					
Absolute	0.16 ± 0.01	0.15 ± 0.01	0.15 ± 0.01	0.14 ± 0.01	
Relative	5.82 ± 0.12	6.04 ± 0.20	5.84 ± 0.23	5.90 ± 0.23	:
R. Kidney					
Absolute	0.23 ± 0.01	0.22 ± 0.01	0.24 ± 0.01	0.20 ± 0.01	
Relative	8.71 ± 0.41	8.87 ± 0.23	9.36 ± 0.20	8.09 ± 0.19	· · · · · · · · · · · · · · · · · · ·
Liver					*
Absolute	1.16 ± 0.03	1.15 ± 0.04	1.13 ± 0.04	1.07 ± 0.04	
Relative	43.5 ± 1.0	45.4 ± 0.8	44.5 ± 1.2	43.6 ± 1.1	
Lungs					•
Absolute	0.17 ± 0.01	0.17 ± 0.01^{b}	0.15 ± 0.00	0.16 ± 0.01	••
Relative	6.52 ± 0.25	6.64 ± 0.14^{b}	6.05 ± 0.15	6.65 ± 0.17	
R. Testis					
Absolute	0.12 ± 0.00	0.10 ± 0.01	0.11 ± 0.00	0.11 ± 0.00	
Relative	4.34 ± 0.14	3.95 ± 0.47	4.38 ± 0.24	4.71 ± 0.15	n
Thymus ^c		•			
Absolute	33.60 ± 3.25	23.50 ± 5.19	34.00 ± 4.20	$19.30 \pm 2.13**$	
Relative	1.26 ± 0.13	0.94 ± 0.22	1.32 ± 0.13	0.79 ± 0.09 *	

TABLE F6
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 13-Week Feed Study of Triamterene (continued)

Dryan	0 ppm	100 ppm	400 ppm	800 ppm
remale				
1	10	10	10	8
Necropsy body weight	20.0 ± 0.4	19.3 ± 0.5	19.1 ± 0.3	19.6 ± 0.4
Brain				
Absolute	0.45 ± 0.02	0.46 ± 0.01	0.47 ± 0.02	0.47 ± 0.01
Relative	22.6 ± 0.9	23.9 ± 1.1	24.6 ± 0.9	24.2 ± 0.5
Heart				
Absolute	0.15 ± 0.02	0.13 ± 0.01	0.13 ± 0.00	0.12 ± 0.00
Relative	7.27 ± 0.96	6.86 ± 0.60	6.68 ± 0.12	5.87 ± 0.16
. Kidney				
Absolute	0.18 ± 0.01	0.17 ± 0.01	0.17 ± 0.00^{d}	0.15 ± 0.01
Relative	8.94 ± 0.47	8.75 ± 0.49	8.67 ± 0.13^{d}	$7.60 \pm 0.41^{\circ}$
iver				
Absolute	0.97 ± 0.03	0.94 ± 0.04	0.90 ± 0.02	0.93 ± 0.03
Relative	48.6 ± 1.2	48.5 ± 1.2	46.9 ± 0.7	47.6 ± 0.5
ungs				
Absolute	0.16 ± 0.01	0.14 ± 0.00^{d}	0.15 ± 0.00	0.16 ± 0.01
Relative	7.83 ± 0.38	7.41 ± 0.25^{d}	7.68 ± 0.13	8.13 ± 0.34
hymus ^c				
Absolute	35.40 ± 5.86	32.90 ± 3.44	29.50 ± 2.14	28.63 ± 3.82
Relative	1.75 ± 0.27	1.71 ± 0.18	1.55 ± 0.12	1.44 ± 0.17

Georgia Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

°° P≤0.01

n=9

Organ and body weights are given in grams unless otherwise specified; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error). No data calculated for the 1,600 ppm group due to 100% mortality.

Weights are given in milligrams.

TABLE F7 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene^a

Organ	0 ppm	100 ppm	200 ppm	400 ppm
Male				
n	10	10	10	10
Necropsy body wt	28.3 ± 0.5	27.9 ± 0.9	28.4 ± 0.6	26.2 ± 0.8
Brain				
Absolute	0.45 ± 0.00	0.46 ± 0.01	0.46 ± 0.01	0.45 ± 0.00
Relative	16.1 ± 0.3	16.5 ± 0.6	16.3 ± 0.4	17.2 ± 0.5
L. Kidney	•			
Absolute	0.23 ± 0.00	0.22 ± 0.01	0.23 ± 0.01	0.21 ± 0.00 **
Relative	8.16 ± 0.13	7.96 ± 0.29	8.19 ± 0.22	8.05 ± 0.26
R. Kidney				
Absolute	0.24 ± 0.00	0.24 ± 0.00	0.25 ± 0.01	0.22 ± 0.01
Relative	8.35 ± 0.10	8.52 ± 0.24	8.66 ± 0.22	8.57 ± 0.27
Liver	•			
Absolute	1.10 ± 0.02	1.07 ± 0.01	1.10 ± 0.02	$1.02 \pm 0.02**$
Relative	38.7 ± 0.5	38.5 ± 1.0	38.7 ± 0.6	39.0 ± 0.7
Female				
n	10	10	10	10
Necropsy body wt	22.5 ± 0.5	23.1 ± 0.5	23.2 ± 0.5	22.6 ± 0.6
Brain				
Absolute	0.47 ± 0.00	0.47 ± 0.00	0.47 ± 0.01	0.46 ± 0.00
Relative	20.8 ± 0.5	20.2 ± 0.5	20.5 ± 0.3	20.7 ± 0.5
L. Kidney				
Absolute	0.16 ± 0.00	0.15 ± 0.00	0.16 ± 0.01	0.16 ± 0.00
Relative	6.97 ± 0.19	6.54 ± 0.13	7.10 ± 0.17	7.09 ± 0.15
R. Kidney		•		
Absolute	0.17 ± 0.00	0.16 ± 0.00	0.17 ± 0.00	0.17 ± 0.00
Relative	7.36 ± 0.17	6.89 ± 0.15	7.31 ± 0.16	7.56 ± 0.14
Liver				
Absolute	0.97 ± 0.02	0.95 ± 0.01	0.99 ± 0.03	0.98 ± 0.02
Relative	43.1 ± 0.4	41.3 ± 0.8	42.6 ± 0.8	43.7 ± 0.5

^{**} Significantly different (P≤0.01) from the control group by Williams' or Dunnett's test

Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

TABLE F8
Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene: First Study^a

Organ	0 ppm	100 ppm	200 ppm	
Male				
n	10	10	10	
Necropsy body wt	40.8 ± 1.1	37.5 ± 1.1	38.7 ± 1.0	
Brain				
Absolute	0.47 ± 0.00	0.46 ± 0.00	0.47 ± 0.01	
Relative	11.7 ± 0.4	12.5 ± 0.4	12.3 ± 0.4	
L. Kidney				
Absolute	0.320 ± 0.007	0.310 ± 0.006	0.305 ± 0.007	
Relative	7.89 ± 0.19	8.31 ± 0.18	7.93 ± 0.28	
R. Kidney				
Absolute	0.34 ± 0.01	0.33 ± 0.01	0.32 ± 0.01	
Relative	8.43 ± 0.17	8.81 ± 0.16	8.38 ± 0.25	
Liver				
Absolute	1.46 ± 0.06	1.40 ± 0.09	1.34 ± 0.03	
Relative	35.8 ± 1.0	37.2 ± 1.8	34.6 ± 0.7	
Female				
n	10	10	10	
Necropsy body wt	46.8 ± 1.5	45.1 ± 1.7	47.0 ± 2.1	
Brain				
Absolute	0.48 ± 0.00	0.48 ± 0.00	0.48 ± 0.01	
Relative	10.4 ± 0.3	10.7 ± 0.4	10.5 ± 0.6	
L. Kidney				
Absolute	0.233 ± 0.004	0.226 ± 0.009	0.225 ± 0.006	
Relative	5.02 ± 0.10	5.03 ± 0.14	4.85 ± 0.15	
R. Kidney				
Absolute	0.24 ± 0.00	0.24 ± 0.01	0.25 ± 0.01	
Relative	5.22 ± 0.15	5.25 ± 0.11	5.42 ± 0.16	<i>'</i>
Liver				
Absolute	1.52 ± 0.06	1.43 ± 0.06	1.50 ± 0.06	
Relative	32.6 ± 0.9	31.7 ± 0.6	32.1 ± 0.8	

Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

TABLE F9 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene: Second Study^a

Organ	0 ррт	400 ppm	
Male		,	
n	10	10	
Necropsy body weight	45.3 ± 1.2	46.2 ± 1.0	
Brain	•		
Absolute	0.46 ± 0.01	$0.48 \pm 0.00**$	e e e
Relative	10.2 ± 0.3	10.4 ± 0.2	
L. Kidney			·
Absolute	0.34 ± 0.01	0.33 ± 0.01	
Relative	7.41 ± 0.16	7.10 ± 0.16	
R. Kidney			
Absolute	0.35 ± 0.01	0.35 ± 0.01	
Relative	7.81 ± 0.16	7.60 ± 0.16	•
Liver			
Absolute	2.01 ± 0.09	2.02 ± 0.09	
Relative	44.3 ± 1.1	43.5 ± 1.0	
Female			
	40	^	• "
n	10	9	
Necropsy body weight	48.1 ± 1.2	48.2 ± 2.1	•
Brain			
Absolute	0.48 ± 0.01	0.49 ± 0.01	
Relative	10.0 ± 0.3	10.3 ± 0.4	
L. Kidney			
Absolute	0.23 ± 0.01	0.27 ± 0.06	
Relative	4.71 ± 0.18	5.71 ± 1.24	
R. Kidney			
Absolute	0.23 ± 0.01	0.24 ± 0.01	
Relative	4.86 ± 0.14	5.07 ± 0.24	
Liver			
Absolute	1.73 ± 0.04	1.79 ± 0.07	
Relative	36.0 ± 0.6	37.3 ± 1.0	

^{**} Significantly different (P<0.01) from the control group by Williams' or Dunnett's test

Organ and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

APPENDIX G HEMATOLOGY, CLINICAL CHEMISTRY, AND URINALYSIS

Table G1	Hematology, Clinical Chemistry, and Urinalysis Data for Rats	
•	in the 13-Week Feed Study of Triamterene	322
Table G2	Hematology, Clinical Chemistry, and Urinalysis Data for Rats	
	at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene	324
TABLE G3	Hematology, Clinical Chemistry, and Urinalysis Data for Rats	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene	326
Table G4	Hematology, Clinical Chemistry, and Urinalysis Data for Mice	
	in the 13-Week Feed Study of Triamterene	328
Table G5	Hematology, Clinical Chemistry, and Urinalysis Data for Mice	
	at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene	330
Table G6	Hematology, Clinical Chemistry, and Urinalysis Data for Mice	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene:	
	First Study	332
Table G7	Hematology, Clinical Chemistry, and Urinalysis Data for Mice	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene:	
	Second Study	334

TABLE G1 Hematology, Clinical Chemistry, and Urinalysis Data for Rats in the 13-Week Feed Study of Triamterene^a

Analysis	0 ppm	150 ppm	600 ppm	1,200 ppm
Male				
n	10	10	9	10
Hematology				
Hematocrit (%)	45.2 ± 0.4	45.9 ± 0.4	45.1 ± 0.9	47.3 ± 0.6*
Hemoglobin (g/dL)	17.8 ± 0.2	17.8 ± 0.1	17.5 ± 0.4	18.5 ± 0.2*
Erythrocytes (10 ⁶ /μL)	8.99 ± 0.05	9.07 ± 0.06	8.91 ± 0.16	9.20 ± 0.11
Mean cell volume (fL)	50.1 ± 0.3	50.6 ± 0.2	50.4 ± 0.3	$51.3 \pm 0.2**$
Mean cell hemoglobin (pg)	19.8 ± 0.1	19.7 ± 0.1	19.6 ± 0.1	20.1 ± 0.1
Mean cell hemoglobin concentration (g/dL)	39.4 ± 0.3	38.9 ± 0.3	38.8 ± 0.3	39.0 ± 0.2
Leukocytes (10 ³ /µL)	8.70 ± 0.72	7.48 ± 0.64	$6.36 \pm 0.38*$	7.22 ± 0.43
Segmented neutrophils (10 ³ /µL)	2.03 ± 0.24	1.65 ± 0.16	1.51 ± 0.15	$1.39 \pm 0.13*$
Lymphocytes ($10^3/\mu$ L)	6.31 ± 0.48	5.47 ± 0.53	$4.59 \pm 0.26*$	5.62 ± 0.34
Monocytes $(10^3/\mu L)$	0.20 ± 0.02^{b}	0.23 ± 0.03	0.16 ± 0.03^{c}	0.18 ± 0.03^{c}
Eosinophils (10 ³ /µL)	0.17 ± 0.04^{d}	0.14 ± 0.04^{b}	$0.20 \pm 0.08^{\rm e}$	0.12 ± 0.02^{b}
1	10	10	10	10
Clinical chemistry				
Creatinine (mg/dL)	0.63 ± 0.03	0.63 ± 0.04	0.64 ± 0.03	0.67 ± 0.03
Sodium (mEq/L)	151 ± 1	152 ± 1	150 ± 1	149 ± 1
Potassium (mEq/L)	6.7 ± 0.1	$7.4 \pm 0.1*$	6.8 ± 0.2	7.0 ± 0.2
Chloride (mEq/L)	106 ± 1	107 ± 0	106 ± 0	$105 \pm 0*$
Calcium (mg/dL)	11.92 ± 0.12	11.93 ± 0.17	11.58 ± 0.19	11.84 ± 0.20
Phosphorus (mg/dL)	8.4 ± 0.4	8.4 ± 0.3	8.1 ± 0.4	$7.7~\pm~0.2$
1	10	10	10	10
Urinalysis				
Urine volume (mL/24 hr)	7 ± 1	7 ± 1	9 ± 2	11 ± 1*
Specific gravity	1.038 ± 0.004	1.038 ± 0.002	1.035 ± 0.004	$1.026 \pm 0.003*$

TABLE G1
Hematology, Clinical Chemistry, and Urinalysis Data for Rats in the 13-Week Feed Study of Triamterene (continued)

Analysis	0 ppm	150 ppm	600 ppm	1,200 ppm
Female				
n	10	10	9	9
Hematology				
Hematocrit (%)	43.8 ± 0.4	44.9 ± 0.5	43.9 ± 0.4	44.7 ± 0.9
Hemoglobin (g/dL)	16.9 ± 0.2	17.5 ± 0.2	16.9 ± 0.2	17.2 ± 0.3
Erythrocytes (10 ⁶ /µL)	8.04 ± 0.07	8.24 ± 0.09	8.00 ± 0.09	8.07 ± 0.17
Mean cell volume (fL)	54.5 ± 0.2	54.7 ± 0.2	54.8 ± 0.2	$55.6 \pm 0.2**$
Mean cell hemoglobin (pg)	21.0 ± 0.1	21.2 ± 0.1	21.1 ± 0.1	21.2 ± 0.1
Mean cell hemoglobin concentration (g/dL)		39.0 ± 0.3	38.5 ± 0.2	38.4 ± 0.2
Leukocytes (10 ³ /μL)	4.54 ± 0.26	5.39 ± 0.54	4.86 ± 0.41	4.84 ± 0.26
Segmented neutrophils (10 ³ /µL)	1.08 ± 0.13	1.11 ± 0.19	1.23 ± 0.22	1.02 ± 0.10
Lymphocytes (103/µL)	3.28 ± 0.19	4.12 ± 0.39	3.48 ± 0.24	3.64 ± 0.30
Monocytes (10 ³ /μL)	0.13 ± 0.02^{c}	0.14 ± 0.02^{d}	0.14 ± 0.02^{c}	0.13 ± 0.03
Eosinophils $(10^3/\mu L)$	0.11 ± 0.01^{d}	0.13 ± 0.03^{d}	0.10 ± 0.00^{f}	$0.10 \pm 0.03^{\rm e}$
n	10	10	10	10
Clinical chemistry				
Creatinine (mg/dL)	0.62 ± 0.02	0.66 ± 0.02	0.61 ± 0.02	0.59 ± 0.02
Sodium (mEq/L)	149 ± 1	150 ± 1	149 ± 1	149 ± 1
Potassium (mEq/L)	6.5 ± 0.1	6.7 ± 0.2	6.6 ± 0.2	6.9 ± 0.2
Chloride (mEq/L)	108 ± 1	108 ± 0	108 ± 1	108 ± 0
Calcium (mg/dL)	11.73 ± 0.17	12.00 ± 0.13	11.57 ± 0.20	11.38 ± 0.16
Phosphorus (mg/dL)	7.1 ± 0.3	7.1 ± 0.4	6.7 ± 0.3	7.4 ± 0.3
n	10	10	10	10
Urinalysis				
Urine volume (mL/24 hr)	10 ± 1	10 ± 1	11 ± 1	6 ± 1*
Specific gravity	1.021 ± 0.003	1.019 ± 0.003	1.018 ± 0.003	1.030 ± 0.004

Significantly different (P<0.05) from the control group by Dunn's or Shirley's test

^{**} P≤0.01

Mean ± standard error

b n≈9

n=8

n=7

e n=5 f n=6

TABLE G2
Hematology, Clinical Chemistry, and Urinalysis Data for Rats at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene^a

Analysis	0 ppm	150 ppm	300 ppm	600 ppm
Male				
1	10	10	10	10
Hematology				
Hematocrit (%)	43.6 ± 0.7	43.8 ± 0.4	44.1 ± 0.4	44.4 ± 0.5
Hemoglobin (g/dL)	15.4 ± 0.2	15.4 ± 0.1	15.5 ± 0.1	15.7 ± 0.1
Erythrocytes (10 ⁶ /μL)	9.33 ± 0.09	9.23 ± 0.09	9.36 ± 0.07	9.39 ± 0.09
Mean cell volume (fL)	46.9 ± 0.6	47.7 ± 0.4	47.2 ± 0.3	47.3 ± 0.2
Mean cell hemoglobin (pg)	16.5 ± 0.1	16.7 ± 0.1	16.6 ± 0.1	16.7 ± 0.1
Mean cell hemoglobin concentration (g/dL)		35.0 ± 0.2	35.1 ± 0.2	35.4 ± 0.2
Platelets (10 ³ /µL)	689.5 ± 27.4	710.2 ± 16.2	708.7 ± 13.9	686.1 ± 50.0
Reticulocytes (106/µL)	1.44 ± 0.18	1.61 ± 0.13	1.30 ± 0.13	1.56 ± 0.11
Leukocytes (10 ³ /µL)	5.93 ± 0.31	5.40 ± 0.13	5.30 ± 0.17	5.78 ± 0.19
Segmented neutrophils (10 ³ /µL)	1.77 ± 0.16	1.36 ± 0.08	1.59 ± 0.12	1.59 ± 0.14
Lymphocytes $(10^3/\mu L)$	4.14 ± 0.31	3.90 ± 0.15	3.57 ± 0.18	4.11 ± 0.19
Monocytes $(10^3/\mu L)$	0.01 ± 0.01	0.07 ± 0.02	0.05 ± 0.02	0.03 ± 0.02
Eosinophils (10 ³ /µL)	0.04 ± 0.02	0.10 ± 0.03	$0.13 \pm 0.02*$	0.05 ± 0.02
Nucleated erythrocytes (10 ³ /μL)	0.30 ± 0.15	0.10 ± 0.10	0.00 ± 0.00	0.00 ± 0.00 *
1	10	10	10	10
Clinical chemistry				
Urea nitrogen (mg/dL)	14.9 ± 0.4	14.8 ± 0.5	14.8 ± 0.6	15.6 ± 0.3
Creatinine (IU/L)	0.47 ± 0.03	0.43 ± 0.03	0.44 ± 0.05	0.51 ± 0.06
Sodium (mEq/L)	144 ± 1	144 ± 1	144 ± 1	145 ± 1
Potassium (mEq/L)	4.0 ± 0.2	4.1 ± 0.1	4.1 ± 0.2	4.2 ± 0.3
Chloride (mEq/L)	102 ± 0	102 ± 1	103 ± 1	102 ± 0
Calcium (mg/dL)	5.20 ± 0.18	5.10 ± 0.08	5.16 ± 0.17	4.98 ± 0.05
Phosphorus (mg/dL)	5.8 ± 0.2	6.1 ± 0.2	6.2 ± 0.1	6.6 ± 0.2 *
Bicarbonate (mEq/L)	29.75 ± 0.29	29.75 ± 0.22	28.83 ± 0.58	28.84 ± 0.28
Total bilirubin (mg/dL)	0.3 ± 0.0	0.4 ± 0.0	0.3 ± 0.1	0.3 ± 0.0
pH	7.39 ± 0.00	7.38 ± 0.01	7.39 ± 0.01	7.36 ± 0.01 *
n Urinalysis	10	10	10	10
Urine volume (mL/16 hr)	7 ± 0	8 ± 1	8 ± 1	10 ± 1
Specific gravity	1.031 ± 0.004	1.031 ± 0.005	1.029 ± 0.004	1.026 ± 0.003

TABLE G2
Hematology, Clinical Chemistry, and Urinalysis Data for Rats at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene (continued)

Analysis	0 ppm	150 ppm	300 ppm	600 ppm
Female				
n	10	10	10	10
Hematology				
Hematocrit (%)	43.9 ± 0.5	44.3 ± 0.7	44.9 ± 0.5	42.9 ± 0.8
Hemoglobin (g/dL)	15.4 ± 0.1	15.4 ± 0.1	15.7 ± 0.1	15.0 ± 0.3
Erythrocytes (10 ⁶ /μL)	8.69 ± 0.08	8.72 ± 0.07	8.81 ± 0.10	8.46 ± 0.10
Mean cell volume (fL)	50.5 ± 0.4	50.9 ± 0.6	51.1 ± 0.4	50.8 ± 0.7
Mean cell hemoglobin (pg)	17.8 ± 0.2	17.7 ± 0.2	17.8 ± 0.1	17.7 ± 0.2
Mean cell hemoglobin concentration (g/dL)		34.9 ± 0.6	34.9 ± 0.4	35.0 ± 0.4
Platelets (10 ³ /µL)	697.3 ± 19.8^{b}	730.9 ± 25.4^{b}	742.2 ± 15.2	689.8 ± 31.8
Reticulocytes (10 ⁶ /µL)	1.51 ± 0.15	1.43 ± 0.11	1.45 ± 0.13	1.50 ± 0.11
Leukocytes (10 ³ /µL)	4.47 ± 0.18	4.46 ± 0.22	4.51 ± 0.23	5.04 ± 0.35
Segmented neutrophils (10 ³ /µL)	0.96 ± 0.07	0.94 ± 0.07	1.01 ± 0.12	1.07 ± 0.07
Lymphocytes (10 ³ /μL)	3.46 ± 0.17	3.44 ± 0.18	3.40 ± 0.17	3.90 ± 0.34
Monocytes (10 ³ /μL)	0.00 ± 0.00	0.01 ± 0.01	0.00 ± 0.00	0.01 ± 0.01
Eosinophils (10 ³ /µL)	0.06 ± 0.02	0.05 ± 0.03	0.06 ± 0.02	0.06 ± 0.02
Nucleated erythrocytes (10 ³ /µL)	0.10 ± 0.10	0.30 ± 0.15	0.20 ± 0.13	0.00 ± 0.00
n Clinical chemistry	10	10	9	10
emical elementy				
Urea nitrogen (mg/dL)	16.1 ± 0.7	14.4 ± 0.5	15.2 ± 0.3	14.8 ± 0.7
Creatinine (IU/L)	0.38 ± 0.02	0.44 ± 0.03	0.44 ± 0.03	0.54 ± 0.04**
Sodium (mEq/L)	143 ± 1	145 ± 1	145 ± 1	144 ± 1
Potassium (mEq/L)	3.7 ± 0.1	3.7 ± 0.2	3.8 ± 0.1	4.3 ± 0.3
Chloride (mEq/L)	105 ± 1	106 ± 1	106 ± 1	105 ± 1
Calcium (mg/dL)	4.78 ± 0.08	4.75 ± 0.06	4.62 ± 0.16	4.88 ± 0.13
Phosphorus (mg/dL)	6.3 ± 0.2	5.9 ± 0.3	6.3 ± 0.3	6.2 ± 0.4
Bicarbonate (mEq/L)	27.89 ± 0.31	27.19 ± 0.29	27.87 ± 0.49	27.80 ± 0.36
Total bilirubin (mg/dL)	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.1
pH	7.37 ± 0.01	7.36 ± 0.02	7.38 ± 0.01	7.35 ± 0.02
n	10	10	10	10
Urinalysis				
Urine volume (mL/16 hr)	7 ± 1	10 ± 1	11 ± 1°	8 ± 1
Specific gravity	1.019 ± 0.003	1.012 ± 0.001	$1.011 \pm 0.002^{\circ}$	1.014 ± 0.002

^{&#}x27; Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

n=9

^{**} P≤0.01

a Mean ± standard error

TABLE G3
Hematology, Clinical Chemistry, and Urinalysis Data for Rats at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene^a

Analysis	0 ppm	150 ppm	300 ppm	600 ppm
Male			 	
1	9	8	9	9
Hematology				
Hematocrit (%)	50.7 ± 2.3	51.5 ± 0.9	53.3 ± 1.1	55.8 ± 1.5
Hemoglobin (g/dL)	14.3 ± 0.6	14.6 ± 0.1	15.2 ± 0.3	15.6 ± 0.3
Erythrocytes (10 ⁶ /µL)	9.53 ± 0.40	9.57 ± 0.12	9.95 ± 0.18	10.24 ± 0.22
Mean cell volume (fL)	53.3 ± 0.4	53.8 ± 0.8	53.9 ± 0.6	54.6 ± 0.4
Mean cell hemoglobin (pg)	15.1 ± 0.1	15.3 ± 0.2	15.3 ± 0.2	15.2 ± 0.1
Mean cell hemoglobin concentration (g/dl.		28.4 ± 0.3	28.4 ± 0.3	27.9 ± 0.3
Platelets $(10^3/\mu L)$	836.3 ± 86.7	766.8 ± 41.7	798.6 ± 24.3	824.9 ± 66.1
Reticulocytes (%)	1.55 ± 0.17^{b}	1.20 ± 0.12	1.33 ± 0.15	1.19 ± 0.12
Leukocytes (10 ³ /µL)	5.48 ± 0.45	5.45 ± 0.38	5.36 ± 0.55	5.72 ± 0.33
Segmented neutrophils (%)	2.01 ± 0.34	1.75 ± 0.29	2.01 ± 0.37	2.06 ± 0.24
Lymphocytes $(\frac{1}{2}0^3/\mu L)$	3.36 ± 0.23	3.58 ± 0.21	3.21 ± 0.29	3.52 ± 0.36
Monocytes $(10^3/\mu L)$	0.05 ± 0.03	0.03 ± 0.01	0.04 ± 0.02	0.01 ± 0.01
Eosinophils $(10^3/\mu L)$	0.06 ± 0.02	0.09 ± 0.02	0.09 ± 0.03	$0.13 \pm 0.02**$
Nucleated erythrocytes (/100 leukocytes)	0.778 ± 0.278	0.000 ± 0.000	0.778 ± 0.662	0.556 ± 0.294
ı	10	10	10	10
Clinical chemistry				
Urea nitrogen (mg/dL)	17.1 ± 1.4	17.7 ± 1.6^{c}	18.3 ± 1.2	15.9 ± 1.3
Creatinine (mg/dL)	0.40 ± 0.03	0.38 ± 0.03^{c}	0.43 ± 0.04	0.40 ± 0.04
Sodium (mEq/L)	148 ± 2	149 ± 4	147 ± 2	152 ± 2
Potassium (mEq/L)	4.9 ± 0.3	5.1 ± 0.5	4.9 ± 0.3	5.2 ± 0.3
Chloride (mEq/L)	104 ± 2	112 ± 2*	109 ± 2	109 ± 2
Calcium (mg/dL)	4.35 ± 0.11	4.82 ± 0.47	4.48 ± 0.18	4.48 ± 0.09
Phosphorus (mg/dL)	5.5 ± 0.5	5.6 ± 0.2	6.1 ± 0.3	5.8 ± 0.3
Bicarbonate (mEq/L)	31 ± 0	29 ± 1	30 ± 0	31 ± 0
Total bilirubin (mg/dL)	0.3 ± 0.0	0.5 ± 0.1	0.5 ± 0.1	0.4 ± 0.0
pH	7.26 ± 0.03	7.31 ± 0.02	7.27 ± 0.03	7.23 ± 0.03
1	10	10	10	10
Jrinalysis				
Urine volume (mL/16 hr)	7 ± 1	6 ± 1	6 ± 0	9 ± 1 ^c
Specific gravity	1.042 ± 0.004	1.044 ± 0.005	1.041 ± 0.003	1.034 ± 0.003

TABLE G3
Hematology, Clinical Chemistry, and Urinalysis Data for Rats at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene (continued)

Analysis	0 ppm	150 ppm	300 ppm	600 ppm
remale				
ı	9	10	10	9
Hematology				
Hematocrit (%)	49.3 ± 0.9	50.7 ± 0.9	51.8 ± 0.4	50.1 ± 1.0
Hemoglobin (g/dL)	14.4 ± 0.2	14.6 ± 0.2	14.8 ± 0.1	14.4 ± 0.2
Erythrocytes (10 ⁶ /µL)	8.58 ± 0.11	8.89 ± 0.08	8.97 ± 0.06*	8.73 ± 0.16
Mean cell volume (fL)	57.4 ± 0.5	56.9 ± 0.8	57.5 ± 0.4	57.1 ± 0.5
Mean cell hemoglobin (pg)	16.8 ± 0.1	16.4 ± 0.1	16.5 ± 0.1	16.5 ± 0.1
Mean cell hemoglobin concentration (g/dL)		28.9 ± 0.5	28.6 ± 0.3	28.8 ± 0.3
Platelets (10 ³ /µL)	605.3 ± 24.9	$669.6 \pm 14.6^{\circ}$	659.6 ± 11.5	628.6 ± 33.9
Reticulocytes (%)	1.60 ± 0.17	1.53 ± 0.10	1.59 ± 0.12	1.56 ± 0.20
Leukocytes (10 ³ /μL)	3.08 ± 0.22	2.53 ± 0.17	2.61 ± 0.14	3.52 ± 0.25
Segmented neutrophils (10 ³ /µL)	0.90 ± 0.09	0.87 ± 0.08	0.84 ± 0.06	1.13 ± 0.17
Lymphocytes (10 ³ /μL)	2.12 ± 0.20	1.62 ± 0.14	1.72 ± 0.15	2.32 ± 0.20
Monocytes $(10^3/\mu L)$	0.01 ± 0.01	0.01 ± 0.00	0.00 ± 0.00	0.01 ± 0.01
Eosinophils $(10^3/\mu L)$	0.05 ± 0.01	0.03 ± 0.01	0.04 ± 0.01	0.07 ± 0.02
Nucleated erythrocytes (/100 leukocytes)	1.56 ± 0.50	0.80 ± 0.42	0.80 ± 0.42	1.89 ± 1.11
n Clinical chemistry	10	10	10	10
Chinear Chemistry				
Urea nitrogen (mg/dL)	19.7 ± 0.9	17.5 ± 1.5	14.8 ± 1.5	18.4 ± 1.2
Creatinine (mg/dL)	0.47 ± 0.05	0.42 ± 0.02	0.42 ± 0.02	0.46 ± 0.03
Sodium (mEq/L)	144 ± 1	147 ± 3	147 ± 3	144 ± 2
Potassium (mEq/L)	5.2 ± 0.3	5.1 ± 0.3	5.0 ± 0.2	5.7 ± 0.3
Chloride (mEq/L)	109 ± 2	109 ± 2	111 ± 1	108 ± 2
Calcium (mg/dL)	4.56 ± 0.10	4.40 ± 0.13	4.36 ± 0.12	4.77 ± 0.11
Phosphorus (mg/dL)	6.1 ± 0.7	5.8 ± 0.3	6.2 ± 0.2	7.3 ± 0.6
Bicarbonate (mEq/L)	28 ± 1^{c}	29 ± 0	29 ± 0^{c}	29 ± 1
Total bilirubin (mg/dL)	0.6 ± 0.1	0.4 ± 0.0	0.4 ± 0.0	0.5 ± 0.1
pH	7.20 ± 0.03^{c}	7.22 ± 0.03	7.27 ± 0.02^{c}	7.17 ± 0.05
n	10	10	10	10
Urinalysis				
Urina voluma (ml /16 hr)	6 ± 1^{b}	$6 \pm 1^{\mathbf{b}}$	6 . 1	
Urine volume (mL/16 hr) Specific gravity	$6 \pm 1^{\circ}$ 1.025 ± 0.004	$6 \pm 1^{\circ}$ 1.026 ± 0.003	6 ± 1	6 ± 1
Specific gravity	1.043 ± 0.004	1.020 ± 0.003	1.026 ± 0.002	1.029 ± 0.002

P Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

^{**} P≤0.01

Mean ± standard error

n=8

n=9

TABLE G4
Hematology, Clinical Chemistry, and Urinalysis Data for Mice in the 13-Week Feed Study of Triamterene^a

Analysis	0 ppm	100 ppm	400 ppm	800 ppm
Male			· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
	10	6	10	10
Tematology				¥
Hematocrit (%)	37.2 ± 1.0	35.9 ± 1.2	38.0 ± 0.4	36.2 ± 1.0
Hemoglobin (g/dL)	15.1 ± 0.4	14.7 ± 0.5	15.6 ± 0.2	14.8 ± 0.4
Erythrocytes (10 ⁶ /μL)	7.40 ± 0.19	7.15 ± 0.24	7.63 ± 0.09	7.15 ± 0.24
Mean cell volume (fL)	50.1 ± 0.3	50.2 ± 0.5	49.9 ± 0.2	50.6 ± 0.4
Mean cell hemoglobin (pg)	20.4 ± 0.1	20.6 ± 0.2	20.5 ± 0.1	20.7 ± 0.1
Mean cell hemoglobin concentration (g/dL)	40.7 ± 0.2	41.0 ± 0.2	41.1 ± 0.3	40.9 ± 0.1
Leukocytes (10 ³ /µL)	4.05 ± 0.40	3.35 ± 0.49	3.38 ± 0.29	$2.78 \pm 0.33^{*b}$
Segmented neutrophils (10 ³ /µL)	0.70 ± 0.07	0.50 ± 0.07	0.65 ± 0.09	0.63 ± 0.17^{b}
Lymphocytes (10 ³ /µL)	3.25 ± 0.33	2.77 ± 0.42	2.71 ± 0.25	$2.07 \pm 0.25^{\circ b}$
Monocytes (10 ³ /μL)	0.14 ± 0.02^{c}	$0.10 \pm 0.00^{\mathbf{d}}$	0.10 ± 0.00^{d}	0.12 ± 0.02^{c}
r	10	6	10	9
Clinical chemistry		•		
Sodium (mEq/L)	158 ± 2	159 ± 1	157 ± 3	162 ± 3
Potassium (mEq/L)	8.5 ± 0.4	8.4 ± 0.5	8.2 ± 0.4	8.7 ± 0.4
Chloride (mEq/L)	123 ± 1	123 ± 1	123 ± 2	124 ± 1
Calcium (mg/dL)	11.61 ± 0.27^{e}	11.48 ± 0.49^{f}	11.08 ± 0.25^g	11.57 ± 0.58^{h}
Phosphorus (mg/dL)	10.2 ± 1.2^{e}	13.6 ± 2.4^{f}	13.1 ± 1.1	10.1 ± 2.2^{g}
1	10	6	10	9 .
Jrinalysis				
Urine volume (mL/24 hr)	2 ± 0	2 ± 0	2 ± 0^e	1 ± 0
Specific gravity	1.031 ± 0.005	1.032 ± 0.004	1.016 ± 0.003	1.028 ± 0.005

TABLE G4 Hematology, Clinical Chemistry, and Urinalysis Data for Mice in the 13-Week Feed Study of Triamterene (continued)

Analysis	0 ppm	1 00 ppm	400 ppm	800 ppm
Female				
n	10	9	9	8
Hematology			• •	
Hematocrit (%)	38.7 ± 0.7	38.8 ± 0.5	39.2 ± 0.5	39.0 ± 0.5
Hemoglobin (g/dL)	15.8 ± 0.3	15.7 ± 0.2	15.8 ± 0.2	15.7 ± 0.2
Erythrocytes (10 ⁶ /μL)	7.64 ± 0.12	7.67 ± 0.10	7.67 ± 0.08	7.58 ± 0.10
Mean cell volume (fL)	50.7 ± 0.2	50.7 ± 0.2	51.1 ± 0.3	51.4 ± 0.3
Mean cell hemoglobin (pg)	20.6 ± 0.1	20.4 ± 0.1	20.6 ± 0.2	20.7 ± 0.1
Mean cell hemoglobin concentration (g/dL)	40.8 ± 0.2	40.4 ± 0.2	40.3 ± 0.2	40.4 ± 0.2
Leukocytes (10 ³ /μL)	3.76 ± 0.39	$2.46 \pm 0.45^{\circ}$	2.08 ± 0.19 **	$2.21 \pm 0.41**$
Segmented neutrophils (10 ³ /µL)	0.66 ± 0.05	0.44 ± 0.06	0.61 ± 0.08	0.51 ± 0.11
Lymphocytes (10 ³ /μL)	3.01 ± 0.35	1.91 ± 0.39 *	1.46 ± 0.20 **	$1.66 \pm 0.36**$
Monocytes (10 ³ /μL)	0.13 ± 0.02^{g}	0.10 ± 0.03^{g}	0.07 ± 0.03^{h}	0.13 ± 0.03^{h}
n	9	10	10	8
Clinical chemistry				
Sodium (mEq/L)	152 ± 2	156 ± 1	157 ± 2	154 ± 1
Potassium (mEq/L)	7.5 ± 0.3	7.3 ± 0.3	7.7 ± 0.4	8.0 ± 0.4
Chloride (mEq/L)	120 ± 2	121 ± 1	122 ± 2	119 ± 1
Calcium (mg/dL)	11.66 ± 0.38^{i}	11.13 ± 0.32^{i}	10.78 ± 0.43^{b}	12.66 ± 0.57^{c}
Phosphorus (mg/dL)	11.5 ± 0.6	$11.1 \pm 0.8^{\mathbf{b}}$	13.1 ± 1.1	14.4 ± 1.0 *
1	7	. 9	9	6
Jrinalysis				
Urine volume (mL/24 hr)	0 ± 0^g	3 ± 1^e	0 ± 0^{e}	1 ± 1
Specific gravity	1.008 ± 0.003	1.012 ± 0.006	1.020 ± 0.007	1.013 ± 0.005

Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

^{°°} P≤0.01

Mean ± standard error

n=9 n=5

n=2

n=7

n=6

n=3

n=8

TABLE G5
Hematology, Clinical Chemistry, and Urinalysis Data for Mice at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene^a

Analysis	0 ppm	100 ppm	200 ppm	400 ppm
Male		 		
n Homotology	9	10	10	10
Hematology				
Hematocrit (%)	44.2 ± 0.9	44.4 ± 0.9	44.5 ± 0.5	44.2 ± 0.6^{b}
Hemoglobin (g/dL)	17.7 ± 0.3	17.5 ± 0.4	17.4 ± 0.2	17.2 ± 0.3^{b}
Erythrocytes (10 ⁶ /μL)	11.19 ± 0.23	11.31 ± 0.20	11.27 ± 0.14	11.25 ± 0.16^{b}
Mean cell volume (fL)	39.3 ± 0.3	39.2 ± 0.3	39.4 ± 0.2	39.4 ± 0.2^{b}
Mean cell hemoglobin (pg)	15.8 ± 0.1	$15.5 \pm 0.1^{*}$	15.5 ± 0.2	$15.3 \pm 0.2*^{b}$
Mean cell hemoglobin concentration (g/dl	± 0.3	39.5 ± 0.4	39.2 ± 0.4	$38.8 \pm 0.4^{*b}$
Platelets (10 ³ /μL)	1.014.4 ± 108	$1.043.8 \pm 102$	$1.114.4 \pm 59.4$	863.6 ± 111 ^b
Reticulocytes (10 ⁶ /μL)	2.23 ± 0.23	1.91 ± 0.15	1.86 ± 0.11	1.83 ± 0.16
Leukocytes (10 ³ /µL)	2.47 ± 0.26	$1.60 \pm 0.20*$	1.76 ± 0.26	1.71 ± 0.16
Segmented neutrophils (10 ³ /µL)	0.46 ± 0.08	0.30 ± 0.04	0.36 ± 0.08	$0.27 \pm 0.06*$
Lymphocytes (10 ³ /µL)	1.98 ± 0.23	$1.30 \pm 0.18*$	1.41 ± 0.22	1.44 ± 0.14
Monocytes $(10^3/\mu L)$	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Eosinophils (10 ³ /µL)	0.01 ± 0.01	0.01 ± 0.01	0.00 ± 0.00	0.00 ± 0.00
Nucleated erythrocytes (10 ³ /µL)	0.22 ± 0.15	0.00 ± 0.00	0.00 ± 0.00	0.10 ± 0.10
n	9	10	10	10
Clinical chemistry				
Urea nitrogen (mg/dL)	23.6 ± 0.7	24.1 ± 0.7	22.6 ± 0.7	23.1 ± 1.1
Creatinine (mg/dL)	0.63 ± 0.06	0.60 ± 0.07	0.70 ± 0.07	0.66 ± 0.08
Sodium (mEq/L)	156 ± 1^{c}	156 ± 2	157 ± 1	159 ± 1
Potassium (mEq/L)	10.1 ± 1.3^{c}	$7.3 \pm 0.6^*$	8.1 ± 1.2*	7.5 ± 0.8 *
Chloride (mEq/L)	121 ± 1°	120 ± 2	121 ± 1	120 ± 1
Calcium (mg/dL)	4.68 ± 0.14	4.61 ± 0.13	4.64 ± 0.10	4.52 ± 0.13
Phosphorus (mg/dL)	14.6 ± 1.5	14.1 ± 1.3	15.3 ± 2.0	19.9 ± 2.9
Bicarbonate (mEq/L)	8.97 ± 1.27	9.78 ± 1.32	9.31 ± 1.09	8.54 ± 1.28
Total bilirubin (mg/dL)	0.5 ± 0.1	0.3 ± 0.0	0.4 ± 0.1^{b}	0.4 ± 0.1
pH	6.89 ± 0.04	6.96 ± 0.06	6.96 ± 0.05	6.93 ± 0.08
n	9	10	10	10
Urinalysis	-			
Urine volume (mL/16 hr)	1 ± 0	1 ± 0	0 ± 0	1 ± 0
Specific gravity	1.045 ± 0.003	1.048 ± 0.004	1.041 ± 0.003	1.051 ± 0.013

TABLE G5 Hematology, Clinical Chemistry, and Urinalysis Data for Mice at the 3-Month Interim Evaluation in the 2-Year Feed Study of Triamterene (continued)

Analysis	0 ppm	100 ppm	200 ppm	400 ppm
Female				
n Hematology	10	10	10	10
Hematology				
Hematocrit (%)	46.1 ± 0.8	45.5 ± 0.7	45.4 ± 0.8	45.9 ± 0.7
Hemoglobin (g/dL)	18.0 ± 0.2	17.6 ± 0.3	17.7 ± 0.3	17.6 ± 0.3
Erythrocytes (10 ⁶ /µL)	11.50 ± 0.20	11.26 ± 0.15	11.28 ± 0.13	11.35 ± 0.14
Mean cell volume (fL)	40.1 ± 0.4	40.1 ± 0.2	40.1 ± 0.3	40.4 ± 0.3
Mean cell hemoglobin (pg)	15.7 ± 0.2	15.7 ± 0.2	15.7 ± 0.2	15.5 ± 0.1
Mean cell hemoglobin concentration (g/dL	39.1 ± 0.6	38.9 ± 0.4	39.1 ± 0.4	38.4 ± 0.4
Platelets (10 ³ /μL)	1,103 ± 47	$1,098 \pm 37$	$1,084 \pm 85$	$1,098 \pm 74^{b}$
Reticulocytes (10 ⁶ /μL)	1.70 ± 0.12	1.62 ± 0.18	1.50 ± 0.10	1.71 ± 0.12
Leukocytes $(10^3/\mu L)$	3.14 ± 0.40	3.54 ± 0.40	2.82 ± 0.40	2.89 ± 0.36
Segmented neutrophils (10 ³ /µL)	0.43 ± 0.09	0.61 ± 0.13	0.43 ± 0.07	0.52 ± 0.09
Lymphocytes (10 ³ /μL)	2.66 ± 0.34	2.87 ± 0.32	2.38 ± 0.36	2.34 ± 0.29
Monocytes $(10^3/\mu L)$	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Eosinophils $(10^3/\mu L)$	0.02 ± 0.01	0.06 ± 0.02	0.02 ± 0.01	0.03 ± 0.02
Nucleated erythrocytes (10 ³ /µL)	0.00 ± 0.00	0.10 ± 0.10	0.10 ± 0.10	0.00 ± 0.00
1	10	10	10	10
Clinical chemistry				
Urea nitrogen (mg/dL)	21.8 ± 0.7	21.5 ± 1.6	19.2 ± 0.9°	100 + 0500
Creatinine (mg/dL)	0.62 ± 0.04	0.61 ± 0.06	1.04 ± 0.44	18.0 ± 0.5 °° 0.68 ± 0.13
Sodium (mEq/L)	0.02 ± 0.04 153 ± 1	0.01 ± 0.00 154 ± 1	1.04 ± 0.44 156 ± 0	
Potassium (mEq/L)	7.6 ± 0.7	6.6 ± 0.3	6.7 ± 0.5	156 ± 1 $6.1 \pm 0.4^{\circ}$
Chloride (mEq/L)	120 ± 1	120 ± 1	122 ± 1	
Calcium (mg/dL)	4.65 ± 0.10	4.60 ± 0.09	4.55 ± 0.07	121 ± 1 4.47 ± 0.05
Phosphorus (mg/dL)	15.3 ± 1.9	12.5 ± 1.3	4.33 ± 0.07 14.7 ± 1.5	13.0 ± 1.6
Bicarbonate (mEq/L)	8.45 ± 0.93	10.21 ± 1.35	8.47 ± 1.05	
Total bilirubin (mg/dL)	0.43 ± 0.93 0.4 ± 0.0	0.21 ± 1.33 0.3 ± 0.0	0.47 ± 1.05 0.4 ± 0.1	9.80 ± 1.04 0.3 ± 0.0
pH	6.98 ± 0.04	7.06 ± 0.05	0.4 ± 0.1 7.04 ± 0.04	7.06 ± 0.04
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	7.00 = 0.04
า	10 .	10	10	10
Urinalysis				
Urine volume (mL/16 hr)	1 ± 0	1 ± 0	1 ± 0	1 ± 0
Specific gravity	1.042 ± 0.004	1.059 ± 0.012	1.041 ± 0.004	1.058 ± 0.003 *

Significantly different (P \leq 0.05) from the control group by Dunn's or Shirley's test P \leq 0.01

Mean ± standard error

n=9

n=10

TABLE G6
Hematology, Clinical Chemistry, and Urinalysis Data for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene: First Study^a

Analysis	0 ppm	100 ppm	200 ppm	
Male	· · · · · · · · · · · · · · · · · · ·		·	<u></u>
1	10	10	9	
Hematology				¥ - 4
Hematocrit (%)	58.1 ± 0.5	56.2 ± 0.7	53.4 ± 0.8**	• •
Hemoglobin (g/dL)	16.9 ± 0.2	16.5 ± 0.2	15.8 ± 0.3 **	
Erythrocytes (10 ⁶ /µL)	11.90 ± 0.12	11.78 ± 0.15	11.21 ± 0.21 °	
Mean cell volume (fL)	48.7 ± 0.4	$47.7 \pm 0.3^{\circ}$	47.9 ± 0.5	
Mean cell hemoglobin (pg)	14.2 ± 0.1	14.0 ± 0.1	14.1 ± 0.1	
Mean cell hemoglobin concentration (g/dL)	29.2 ± 0.3	29.3 ± 0.2	29.4 ± 0.3	
Platelets (10 ³ /µL)	1.471 ± 23	1.479 ± 36	1.415 ± 25	****
Reticulocytes (106/µL)	1.33 ± 0.12	1.11 ± 0.13	1.24 ± 0.37	the made of
Leukocytes (10 ³ /µL)	3.28 ± 0.35	2.78 ± 0.20	2.76 ± 0.26	The same of
Segmented neutrophils (10 ³ /µL)	1.10 ± 0.12	0.71 ± 0.07 *	0.86 ± 0.08	2.47
Lymphocytes (10 ³ /µL)	2.13 ± 0.28	2.04 ± 0.19	1.86 ± 0.24	• • •
Monocytes (10 ³ /µL)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	
Eosinophils (10 ³ /μĹ)	0.06 ± 0.01	0.04 ± 0.01	0.04 ± 0.01	• •
	10	10	10	
Clinical chemistry	•			
Urea nitrogen (mg/dL)	32.0 ± 1.3	$28.0 \pm 0.8^{*}$	26.5 ± 1.1**	
Creatinine (mg/dL)	0.18 ± 0.02^{b}	0.22 ± 0.03	0.17 ± 0.02	N
Sodium (mEq/L)	155 ± 1	157 ± 1	156 ± 1	÷ t
Potassium (mEq/L)	4.4 ± 0.1	4.1 ± 0.1	$4.1 \pm 0.3^*$. "
Chloride (mEq/L)	122 ± 1	120 ± 1	121 ± 1	•
Calcium (mg/dL)	3.96 ± 0.05	3.97 ± 0.05	3.92 ± 0.09	
Phosphorus (mg/dL)	7.9 ± 0.4	7.4 ± 0.4	7.9 ± 0.5	
Bicarbonate (mEq/L)	13.95 ± 0.77	15.00 ± 0.74	15.73 ± 0.58	12 -
Total bilirubin (mg/dL)	0.2 ± 0.1	0.4 ± 0.1	0.3 ± 0.1	
рН	7.18 ± 0.01	7.16 ± 0.02	7.18 ± 0.02	
	10	10	10	
Jrinalysis	•			
Urine volume (mL/16 hr)	1 ± 0	2 ± 0	1 ± 0	4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 - 4 -
Specific gravity	1.031 ± 0.002	1.030 ± 0.003	1.039 ± 0.004 *	

TABLE G6
Hematology, Clinical Chemistry, and Urinalysis Data for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene: First Study (continued)

Analysis	0 ppm	1CO ppm	200 ppm	
Female				
1	10	10	10	
Hematology				
Hematocrit (%)	57.4 ± 0.8	57.1 ± 0.8	57.9 ± 0.8	
Hemoglobin (g/dL)	16.4 ± 0.2	16.5 ± 0.1	16.6 ± 0.2	
Erythrocytes (10 ⁶ /µL)	11.62 ± 0.09	11.85 ± 0.10	11.78 ± 0.17	
Mean cell volume (fL)	49.4 ± 0.4	48.1 ± 0.5	49.0 ± 0.4	
Mean cell hemoglobin (pg)	14.1 ± 0.1	13.9 ± 0.1	14.1 ± 0.1	
Mean cell hemoglobin concentration (g/dL)	28.7 ± 0.2	28.9 ± 0.2	28.7 ± 0.2	
Platelets (10 ³ /µL)	1.149 ± 40	$1,186 \pm 18$	$1,168 \pm 46$	
Reticulocytes (10 ⁶ /μL)	1.41 ± 0.18	1.04 ± 0.13	1.40 ± 0.16	
Leukocytes (10 ³ /μL)	2.48 ± 0.12	2.44 ± 0.20	2.58 ± 0.19	
Segmented neutrophils (10 ³ /µL)	0.75 ± 0.10	0.89 ± 0.15	0.88 ± 0.14	
Lymphocytes (103/µL)	1.68 ± 0.15	1.60 ± 0.14	1.67 ± 0.16	
Monocytes (10 ³ /μL)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	
Eosinophils $(10^3/\mu L)$	0.04 ± 0.01	0.03 ± 0.01	0.04 ± 0.01	
n	10	10	· 10	
Clinical chemistry				
Urea nitrogen (mg/dL)	27.2 ± 1.6	23.6 ± 1.3	22.7 ± 1.4	
Creatinine (mg/dL)	0.17 ± 0.03	0.18 ± 0.02	0.17 ± 0.03	
Sodium (mEq/L)	152 ± 1	155 ± 1	154 ± 1	
Potassium (mEq/L)	4.8 ± 0.4	4.5 ± 0.3	$4.2 \pm 0.4^{\circ}$	
Chloride (mEq/L)	116 ± 1	115 ± 1	118 ± 2	
Calcium (mg/dL)	3.96 ± 0.08	4.11 ± 0.09	4.20 ± 0.22	
Phosphorus (mg/dL)	8.84 ± 0.83	7.68 ± 0.56	7.93 ± 0.58	
Bicarbonate (mEq/L)	16.29 ± 0.73	16.54 ± 0.30	16.24 ± 1.10	
Total bilirubin (mg/dL)	$0.2 \pm 0.0^{\mathrm{b}}$	$0.2 \pm 0.0^{\circ}$	$0.4 \pm 0.2^{\circ}$	
рН	7.16 ± 0.02	7.20 ± 0.02	7.20 ± 0.02	
1 .	10	10	10	
Urinalysis				
Urine volume (mL/16 hr)	1 ± 0	1 ± 0	1 ± 0	
Specific gravity	1.025 ± 0.002	1.029 ± 0.004	1.028 ± 0.003	

O Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

^{°°} P≤0.01

Mean ± standard error

n=9

TABLE G7
Hematology, Clinical Chemistry, and Urinalysis Data for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene: Second Study^a

Analysis	0 ppm	400 ppm	
Male			
n	10	10	
Hematology			
Hematocrit (%)	50.9 ± 0.7	49.7 ± 1.1	
Hemoglobin (g/dL)	14.3 ± 0.1	13.7 ± 0.4	
Erythrocytes (10 ⁶ /µL)	9.37 ± 0.12	9.08 ± 0.24	
Mean cell volume (fL)	54.3 ± 0.2	54.9 ± 0.5	
Mean cell hemoglobin (pg)	15.3 ± 0.1	15.1 ± 0.1	
Mean cell hemoglobin concentration (g/dL)	28.1 ± 0.2	27.6 ± 0.3	
Platelets (10 ³ /µL)	$1,132.0 \pm 25.0$	$1,090.0 \pm 36.0$	
Reticulocytes (10 ⁶ /μL)	1.57 ± 0.09	1.67 ± 0.16	
Leukocytes (10 ³ /µL)	4.44 ± 0.40	3.66 ± 0.38	
Segmented neutrophils (10 ³ /µL)	1.03 ± 0.12	0.85 ± 0.16	
Lymphocytes (10 ³ /µL)	3.27 ± 0.32	2.65 ± 0.26	
Monocytes $(10^3/\mu L)$	0.01 ± 0.01	0.01 ± 0.01	
Eosinophils $(10^3/\mu L)$	0.13 ± 0.03	0.14 ± 0.03	
Nucleated erythrocytes (/100 leukocytes)	0.00 ± 0.00	0.00 ± 0.00	
n	10	10	
Clinical chemistry			
Urea nitrogen (mg/dL)	37.5 ± 1.8	37.1 ± 2.1	
Creatinine (IU/L)	0.34 ± 0.03	0.29 ± 0.04	
Sodium (mEq/L)	160 ± 1	159 ± 1	
Potassium (mEq/L)	5.0 ± 0.2	4.6 ± 0.2	
Chloride (mEq/L)	· 113 ± 1	114 ± 1	
Calcium (mg/dL)	4.98 ± 0.15	4.97 ± 0.11	
Phosphorus (mg/dL)	7.6 ± 0.3	7.9 ± 0.4	
Bicarbonate (mEq/L)	16.80 ± 1.26	17.30 ± 1.01	
Total bilirubin (mg/dL)	0.5 ± 0.1	0.4 ± 0.0	
pH	7.15 ± 0.03	7.14 ± 0.04	
n	10	9	
Urinalysis			
Urine volume (mL/16 hr)	1 ± 0	1 ± 0	
Specific gravity	1.039 ± 0.003	1.037 ± 0.003	

TABLE G7

Hematology, Clinical Chemistry, and Urinalysis Data for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of Triamterene: Second Study (continued)

Analysis	0 ppm	400 ppm	
Female			
n Hematology	10	9	
Tellatology			
Hematocrit (%)	52.4 ± 0.4	52.6 ± 0.4	
Hemoglobin (g/dL)	14.6 ± 0.1	14.6 ± 0.2	
Erythrocytes (10 ⁶ /μL)	9.44 ± 0.11	9.62 ± 0.09	
Mean cell volume (fL)	55.5 ± 0.3	54.7 ± 0.5	
Mean cell hemoglobin (pg)	15.5 ± 0.1	15.2 ± 0.1	
Mean cell hemoglobin concentration (g/dL)	27.9 ± 0.1	27.7 ± 0.1	
Platelets (10 ³ /µL)	878.6 ± 41.8	925.6 ± 31.9	
Reticulocytes $(10^6/\mu L)$	1.75 ± 0.13	1.58 ± 0.16	
Leukocytes $(10^3/\mu L)$	2.76 ± 0.13	3.04 ± 0.29	
Segmented neutrophils (10 ³ /µL)	0.73 ± 0.07	0.82 ± 0.08	
Lymphocytes (10 ³ /µL)	1.93 ± 0.25	2.12 ± 0.24	
Monocytes (10 ³ /μL)	0.01 ± 0.01	0.01 ± 0.01	
Eosinophils $(10^3/\mu\text{L})$	0.01 ± 0.01 0.09 ± 0.02	0.01 ± 0.01 0.10 ± 0.03	
Nucleated erythrocytes (/100 leukocytes)	0.09 ± 0.02 0.20 ± 0.13	0.10 ± 0.03 0.00 ± 0.00	
redicated crythrocytes (7100 leukocytes)	0.20 ± 0.15	0.00 ± 0.00	
n	10	9	
Clinical chemistry		,	
Urea nitrogen (mg/dL)	31.5 ± 0.7	33.0 ± 1.3	
Creatinine (IU/L)	0.28 ± 0.03	0.19 ± 0.03*	
Sodium (mEq/L)	157 ± 1	155 ± 1	
Potassium (mEq/L)	4.9 ± 0.3	4.8 ± 0.3	
Chloride (mEq/L)	114 ± 1	113 ± 1	
Calcium (mg/dL)	4.91 ± 0.13	4.94 ± 0.09	
Phosphorus (mg/dL)	7.1 ± 0.3	7.0 ± 0.4	
Bicarbonate (mEq/L)	15.36 ± 0.78	14.87 ± 0.69	
Total bilirubin (mg/dL)	$0.4 \pm 0.0^{\mathbf{b}}$	0.4 ± 0.1	
pH	7.15 ± 0.03	7.24 ± 0.03*	
	= 0.05	7.07 = 0.05	
n	10	9	
Urinalysis		•	
Urine volume (mL/16 hr)	1 ± 0	$2 \pm 0^{\circ *^{c}}$	
Specific gravity	1.032 ± 0.003	$1.022 \pm 0.003*$	

F Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

^{**} P≤0.01

Mean ± standard error

n=9

n=8

APPENDIX H CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

Procuremen	t and Characterization of Triamterene	338
PREPARATION	AND ANALYSIS OF DOSE FORMULATIONS	339
	Imfrared Absorption Spectrum of Triamterene	340
Figure H2		341
Table H1	Preparation and Storage of Dose Formulations in the Feed Studies	- 11
	of Triamterene	342
	Results of Analysis of Dose Formulations for Rats and Mice	•
	in the 15-Day Feed Studies of Triamterene	343
Table H3	Results of Analysis of Dose Formulations for Rats and Mice	0.40
	in the 13-Week Feed Studies of Triamterene	32121
	Results of Analysis of Dose Formulations for Rats and Mice	277
	in the 2-Year Feed Studies of Triamterene	346
	Results of Referee Analysis of Dose Formulations for Rats and Mice	J-\W
	in the 13-Week and 2-Year Feed Studies of Triamterene	32⊿(0)

CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

PROCUREMENT AND CHARACTERIZATION OF TRIAMTERENE

Triamterene, manufactured by Secifarma (Milan, Italy), was obtained from Gyma Laboratories of America (Garden City, NJ) in one lot (84/1). Lot 84/1 was used during the 15-day, 13-week, and 2-year studies. Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (MRI; Kansas City, MO). MRI reports on analyses performed in support of the triamterene studies are on file at the National Institutes of Environmental Health Sciences.

The study chemical, a yellow microcrystalline solid, was identified as triamterene by infrared, ultraviolet/visible, and nuclear magnetic resonance spectroscopy. All spectra (Figures H1 and H2) were consistent with those expected for the structure and with the literature description for the spectra of triamterene (Sadtler Standard Spectra).

Initially, lot 84/1 was broken into two subbatches. The relative purity of the two subbatches of lot 84/1 was determined by high-performance liquid chromatography (HPLC) using a Waters μ Bondapak C₁₈ column with an isocratic solvent system of: A) 0.005 M sodium hepanesulfonate in water containing 1% glacial acetic acid and B) 0.005 M sodium hepanesulfonate in methanol containing 1% glacial acetic acid at a ratio of 40:60 A:B, and a flow rate of 1 mL/minute. Acetanilide was added as an internal standard. Ultraviolet detection was at 254 nm. The two subbatches of the bulk chemical were identical within the limits of experimental error.

The purity was determined by elemental analyses, Karl Fischer water analysis, potentiometric titration, thin-layer chromatography (TLC), and HPLC. Titration was performed by dissolving triamterene in a mixture of formic acid:acetic anhydride:glacial acetic acid (1:1:2). After cooling, the mixture was titrated with 0.1 N perchloric acid in glacial acetic acid using a combination pH/mV electrode. TLC was performed on Silica Gel 60F-254 plates with two solvent systems: A) chloroform:methanol:concentrated ammonium hydroxide (66:33:1) and B) 2-butoxyethanol:diethanolamine (99:1). Visualization of the dried plates was by visible light, ultraviolet light at 254 nm and 366 nm, and by spraying with a solution of hexachloroplatinic acid in aqueous potassium iodide. HPLC was performed using the system described, for the relative purity analyses, but with a 50:50 ratio of the solvent system.

Elemental analyses for carbon, hydrogen, and nitrogen were in agreement with the theoretical values for triamterene. Karl Fischer water analysis indicated $0.087 \pm 0.008\%$ water. Potentiometric titration of the functional amine group with perchloric acid indicated the purity to be $101.1 \pm 0.9\%$. TLC with either solvent system A or B indicated a major spot, a strong trace, a trace, and a slight trace impurity. Two-dimensional development using solvent system B indicated that the impurities were due in part to decomposition of the solvent system. HPLC indicated no impurities with a peak area greater than or equal to 0.1% of the major peak area. The overall purity was determined to be at least 99%.

The United States Pharmacopeia (USP XX) requirement for purity of triamterene is 98% to 102%. Comparison of the major peaks of lot 84/1 and the USP XX standard using the HPLC system described for relative purity analyses indicated a purity of $101.1 \pm 2.2\%$ of lot 84/1 relative to the standard. Thus, lot 84/1 met the USP requirement for purity.

Stability studies were performed by the analytical chemistry laboratory using HPLC with the 2:3 isocratic solvent system described above. Lot 84/1 was found to be stable in bulk form when stored for 2 weeks protected from light at temperatures up to 60° C. The stability of the bulk chemical was monitored

periodically at the study laboratory using titration and HPLC; no degradation of the study chemical was detected.

Preparation and Analysis of Dose Formulations

The dose formulations were prepared by mixing appropriate amounts of triamterene and feed in a Patterson-Kelley twin-shell blender with an intensifier bar (Table H1). Homogeneity and stability studies were conducted by the analytical chemistry laboratory on the dosed feed preparations. Feed samples for the homogeneity studies, collected from the bottom, top right, and top left areas of the blender, were analyzed by ultraviolet spectroscopy using a dimethylsulfoxide extract of the feed sample in methanol for comparison of ultraviolet absorbance at 370 nm to a standard curve for dose formulations of 1,000 ppm or greater. For dose formulations of 100 to 500 ppm, dosed feed extracts were analyzed by HPLC using a solvent system of: A) 0.06M aqueous sodium bromide and B) 0.06M sodium bromide in methanol 60:40 (A:B) with ultraviolet detection at 370 nm. Stability studies were performed using the same HPLC system described for the homogeneity analyses. Dose formulations in feed were stable for up to 2 weeks when stored protected from light at 5° C.

The dose formulations were analyzed at the beginning of the 15-day studies by the study laboratory and were within 10% of the target concentrations (Table H2). During the 13-week studies, the dose formulations were analyzed twice; all dose formulations for rats and 15 of 17 dose formulations for mice were within 10% of the target concentrations (Table H3). During the 2-year studies, the dose formulations were analyzed at least once every 8 weeks (Table H4). All dose formulations were within 10% of the target concentrations, except for dose formulations prepared 12 June 1985 for rats receiving 600 ppm and for mice receiving 400 ppm. Rats in the 600 ppm group received 0 ppm; this dosing period was approximately 1% of the 103-week dosing duration and was considered to have no effect on the results. Mice in the 400 ppm group received approximately 1,600 ppm, which caused 16 deaths. Survivors of the dosing accident were returned to the appropriate dose formulation (first study), but the 2-year study was restarted for the 0 and 400 ppm groups (second study). During the second mouse study, the 400 ppm dose formulations were all within 10% of the target concentration.

Periodic analyses of the dose formulations of triamterene were performed by the study laboratory and the analytical chemistry laboratory with either an HPLC or ultraviolet spectroscopic method. Results of the analyses performed by the analytical chemistry laboratory indicated good agreement with the results of the study laboratory (Table H5).




FIGURE H1
Infrared Absorption Spectrum of Triamterene




FIGURE H2 Nuclear Magnetic Resonance Spectrum of Triamterene

TABLE H1
Preparation and Storage of Dose Formulations in the Feed Studies of Triamterene

15-Day Studies	13-Week Studies	2-Year Studies
Preparation Dose formulations were prepared by mixing triamterene with a small amount of the feed to form a premix. The premix and additional feed were layered into a Patterson-	Same as the 15-day studies, but prepared every 2 weeks	Same as the 15-day studies, but the formulations were mixed for 15 minutes with the intensifier bar on for the first 5 minutes. Dose formulations were prepared weekly.
Kelley twin shell blender and mixed for 10 minutes with the intensifier bar on. Dose formulations were prepared weekly.		
Chemical Lot Number 84/1	84/1	84/1
Maximum Storage Time 2 weeks	2 weeks	2 weeks
Storage Conditions In the dark, refrigerated	In the dark, below 5° C	In the dark, at or below 5° C
Study Laboratory International Research and Development Corporation, Mattawan, MI	International Research and Development Corporation, Mattawan, MI	Battelle, Columbus Division, Columbus, OH
Referee Laboratory Midwest Research Institute, Kansas City, MO	Midwest Research Institute, Kansas City, MO	Midwest Research Institute, Kansas City, MO

TABLE H2
Results of Analysis of Dose Formulations for Rats and Mice in the 15-Day Feed Studies of Triamterene

Date Prepared	Date Analyzed	Target Concentration (ppm)	Determined Concentration ^a (ppm)	Difference from Target (%)
Rats				
29 April 1982	6 May 1982	10,000 30,000	9,990 29,800	0 -1
	10 May 1982	1,000 3,000	1,000 2,970	0 -1
	11 May 1982	60,000	60,900	+2
Alice				
29 April 1982	6 May 1982	10,000 30,000	10,100 31,600	+1 +5
	10 May 1982	1,000 3,000	1,040 2,930	+4 -2
	12 May 1982	300	296	-1

a Results of duplicate analyses

TABLE H3
Results of Analysis of Dose Formulations for Rats and Mice in the 13-Week Feed Studies of Triamterene

Date Prepared	Date Analyzed	Target Concentration (ppm)	Determined Concentration ^a (ppm)	Difference from Target (%)
				
5 September 1982b	10 September 1982	2,400°	2,400	0
•	•	2,400 ^d	2,340	-2
		2,400 ^e	2,420	+1
	16 December 1982 ^f	150 ^c	147	-2
	To December 1902	150 ^d	155	+3
		150 ^e	155	+3
13 September 1982	16 September 1982	300	281	-6
	10 Depression 1302	600	576	-4
		1,200	1,210	+1
		2,400 ^c	2,470	+3
		2,400 ^d	2,460	+3
		2,400 ^e	2,420	+1
	10 December 1982 ^f	150	144	-4
		150	148	-1
•		150	148	-1
15 September 1982	10 December 1982 ^f	200	198	-1
25 October 1982	28 October 1982	300	274	-9
		600	593	-1
		1,200	1,250	+4
	10 December 1982 ^f	150	148	-1

TABLE H3 Results of Analysis of Dose Formulations for Rats and Mice in the 13-Week Feed Studies of Triamterene (continued)

Date Prepared	Date Analyzed	Target Concentration (ppm)	Determined Concentration ^a (ppm)	Difference from Target (%)
Mice				
5 September 1982	10 September 1982	1.600 ^c	1,470	-8
		1,600 ^c 1,600 ^d	1,410	-12
		1,600 ^e	1,430	-11
	16 December 1982 ^f	100°	108	+8
	10 2000111001 1702	100 ^d	104	+4
		100 ^e	103	+3
15 September 1982	17 September 1982	400	385	-4
		800	813	+2
		1,600	1,620	+1
	10 December 1982 ^f	100°	105	+5
		$100^{\mathbf{d}}$	96	
		100 ^e	98	-4 -2
		200	198	-1
27 October 1982	28 October 1982	400	378	-5
	_:	800 · · ·	782	-2
	10 December 1982 ^f	100	101	+1
	10 2000111001 1702	200	202	+1
			202	· •

Results of duplicate analyses

Prestart dose formulations used for homogeneity evaluation but not for dosing

Sample selection from top of twin-shell blender

Sample selection from middle of twin-shell blender

Sample selection from bottom of twin-shell blender Analyzed late due to difficulty in developing analysis procedures

TABLE H4
Results of Analysis of Dose Formulations for Rats and Mice in the 2-Year Feed Studies of Triamterene

Date Prepared	Date Analyzed	Target Concentration (ppm)	Determined Concentration ^a (ppm)	Difference from Target (%)
Rats				
4 September 1984	5 September 1984	150	149.4	0
·	•	300	296.9	-1
		600	586.6	-2
13 November 1984	15 November 1984	300	277.4	-8
		600	588.6	-2
	16 November 1984	150	148.7	-1
2 January 1985	2 January 1985	150	137.0	~9
•	•	300	276.0	-8
		600	562.6	-6
25 February 1985	28 February 1985	150	145.0	-3
•	•	300	299.5	0
		600	595.5	-1
26 April 1985	2 May 1985	150	145.4	-3
		300	294.4	-2
	·	600	601.0	0
12 June 1985	3, 5 July 1985	150	163,4	+9
12 0 41.00	0, 0 0 1.9 1 200	300	317.9	+6
·		600	0.0	
20 June 1985	26 June 1985	150	146.5	-2
20 04.10 2505	20 02.10 1700	300	292.3	-3
		600	595.9	-1
15 August 1985	16 August 1985	150	138,9	-7
6	g	300	291.6	-3
		600	589.8	-2
10 October 1985	15 October 1985	150	155.3	+4
**		300	307.1	+2
		600	595.9	-1
5 December 1985	10 December 1985	150	150.8	- +1
		300	301.9	+1
		600	590.3	-2
6 February 1986	10 February 1986	150	147.2	-2
•	•	300	304.5	+2
		600	595.5	-1
27 March 1986	28 March 1986	150	163.5	+9
		300	310.3	+3
		600	594.2	-1

TABLE H4

Results of Analysis of Dose Formulations for Rats and Mice in the 2-Year Feed Studies of Triamterene (continued)

Date Prepared	Date Analyzed	Target Concentration (ppm)	Determined Concentration (ppm)	Difference from Target (%)
Rats (continued)				
22 May 1986	23 May 1986	150	156.0	+4
		300	298.8	0
		600	605.6	+1
17 July 1986	21 July 1986	150	143.6	-4
•	•	300	284.7	- 5
		600	579.4	-3
Mice: First Study				
10 September 1984	12 September 1984	100	99.1	-1
		200	209.1	+5
		400	404.6	+1
13 November 1984	15 November 1984	200	185.4	-7
		400	372.7	-7
	16 November 1984	100	99.6	0
2 January 1985	2 January 1985	100	91.7	-8
•	•	200	184.8	-8
		400	366.6	-8
25 February 1985	28 February 1985	100	100.5	+1
	-	200	197.0	-1
		400	391.5	-2
26 April 1985	2 May 1985	100	98.2	-2
•	•	200	195.8	-2
		400	401.1	0
12 June 1985	3, 5 July 1985	100	107.9	+8
	•	200	205.1	+3
		400	1,616.0	+404 ^b
	5 July 1985 ^c	400	1,589.8	+397
20 June 1985	26 June 1985	100	97.8	-2
		200	200.3	0
		400	399.2	0

TABLE H4 Results of Analysis of Dose Formulations for Rats and Mice in the 2-Year Feed Studies of Triamterene (continued)

Date Prepared	Date Analyzed	Target Concentration (ppm)	Determined Concentration (ppm)	Difference from Target (%)
Mice: First and Secon	nd Study			
15 August 1985	16 August 1985	100	101.1	+1
		200	197.9	-1
		400	412.3	+3
10 October 1985	15 October 1985	100	98.9	-1
	10 000001 1700	200	205.3	+3
		400	410.4	+3
				_
5 December 1985	10 December 1985	100	101.5	+2
		200 400	197.6 397.0	-1 -1
		400	397.0	-1
6 February 1986	10 February 1986	100	100.4	0
, , , , , , , , , , , , , , , , , , , ,		200	203.2	+2
		400	403.2	+1
27 March 1986	28 March 1986	100	99.5	0
27 Match 1900	20 Watch 1900	200	205.7	+3
		400	362.9	-9
20.34 1007	02 Mari 1007	100	98	-2
22 May 1986	23 May 1986	100 200	98 192	-2 -4
		400	398	0
		100	2,0	· ·
17 July 1986	21 July 1986	100	95	-5
		200	194	-3
		400	390	-3
Mice: Second Study 11 September 1986	11 Contombor 1006	400	400	0
11 September 1986	11 September 1986	400	400	· ·
7 November 1986	7 November 1986	400	392	-2
		,	400	. 4
9 January 1987	12 January 1987	400	403	+1
6 March 1987	6 March 1987	400	403	+1
1 May 1987	4 May 1987	400	385	-4
26 June 1987	27 June 1987	400	398	0
14 August 1987	17 August 1987	400	396	-1

Results of duplicate analyses

Analyzed dose preparation room samples after the formulation had been used for dosing of animals

Analyzed dose formulations taken from the animal room

TABLE H5 Results of Referee Analysis of Dose Formulations for Rats and Mice in the 13-Week and 2-Year Feed Studies of Triamterene

		Determined Conce		
Date Prepared	Target Concentration (ppm)	Study Laboratory ^a	Refer ee Laboratory ^b	
13-Week Studies Mice				
15 September 1982	200	198	194 ± 8	
2-Year Studies Rats				
4 September 1984	150	149	151 ± 3	
15 August 1985	600	590	596 ± 6	
27 March 1986	300	310	301 ± 6	
Mice				
25 February 1985	100	101	99 ± 0.7	
12 June 1985	400	1,616	$1,590 \pm 10$	
11 September 1986	400	400	409 ± 7	
6 March 1987	400	403	404 ± 4	
14 August 1987	400	396	403 ± 3	

Results of duplicate analyses Results of triplicate analyses; mean \pm standard error

APPENDIX I FEED AND COMPOUND CONSUMPTION

TABLE II	Feed and Compound Consumption by Male Rats in the 2-Year Feed Study	
	of Triamterene	352
TABLE I2	Feed and Compound Consumption by Female Rats in the 2-Year Feed Study	
	of Triamterene	353
Table 13	Feed and Compound Consumption by Male Mice in the 2-Year Feed Study	
	of Triamterene: First Study	354
Table 14	Feed and Compound Consumption by Female Mice in the 2-Year Feed Study	
	of Triamterene: First Study	355
TABLE IS	Feed and Compound Consumption by Male Mice in the 2-Year Feed Study	
	of Triamterene: Second Study	356
TABLE I6	Feed and Compound Consumption by Female Mice in the 2-Year Feed Study	
	of Triamterene: Second Study	357

TABLE I1 Feed and Compound Consumption by Male Rats in the 2-Year Feed Study of Triamterene

	0р	pm		150 ppn	n		300 ppn	1	600 ppm			
Week	Feed (g/day) ^a	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight (g)	Dose/	
4	16.6	241	15.9	237	10.0	17.3	234	22.2	15.8	231	41.0	
5	17.4	263	17.4	263	9.9	18.0	254	21.2	17.4	255	40.8	
9	14.6	316	15.4	317	7.3	14.4	308	14.0	14.1	305	27.7	
12	15.8	350	15.6	349	6.7	17.0	347	14.7	15.8	347	27.3	
13	17.9	356	18.0	358	7.5	17.9	355	15.1	17.9	355	30.2	
17	16.1	379	15.4	384	6.0	15.4	378	12.3	15.9	374	25.6	
21	16.9	396	17.3	399	6.5	18.0	391	13.8	17.7	390	27.2	
25	15.8	414	15.8	415	5.7	16.1	409	11.8	16.0	408	23.5	
29	15.8	425	16.9	426	5.9	15.8	417	11.3	16.4	418	23.5	
33	16.7	444	17.5	445	5.9	16.7	441	11.4	16.5	434	22.9	
37	16.8	451	16.4	457	5.4	17.0	448	11.4	16.0	439	21.8	
42	17.1	455	16.7	458	5.5	16.5	453	10.9	16.2	447	21.8	
45	17.4	465	18.0	467	5.8	17.4	460	11.4	16.5	449	22.0	
49	17.2	479	17.1	483	5.3	17.6	470	11.2	17.2	458	22.5	
53	17.3	482	16.1	481	5.0	16.9	472	10.7	16.8	459	21.9	
57	8.3	481	16.2	488	5.0	16.8	478	10.5	17.4	466	22.5	
61	15.4	485	15.8	488	4.9	15.7	476	9.9	16.4	467	21.0	
65	14.8	484	15.1	491	4.6	14.9	477	9.4	14.3	466	18.4	
73	17.3	490	16.4	489	5.0	16.7	480	10.4	15.6	463	20.1	
77	15.9	488	15.3	486	4.7	15.7	473	9.9	15.7	466	20.2	
81	16.5	487	16.7	489	5.1	16.8	477	10.5	16.2	466	20.9	
85	15.8	482	15.1	482	4.7	15.8	473	10.0	14.8	459	19.3	
89	15.3	471	15.2	467	4.9	15.8	462	10.3	14.8	455	19.5	
93	14.6	454	13.7	449	4.6	14.9	447	10.0	15.4	446	20.8	
97	14.8	435	13.9	439	4.8	13.7	421	9.7	14.7	426	20.6	
101	14.7	420	14.7	415	5.3	14.7	405	10.9	15.6	401	23.4	
104	10.8	382	14.5	418	5.2	11.4	391	8.8	14.0	393	21.4	
Mean fo												
1-13	16.4	305	16.4	305	8.3	16.9	300	17.4	16.2	299	33.4	
14-52	16.6	434	16.8	437	5.8	16.7	430	11.7	16.5	424	23.4	
53-104	14.7	465	15.3	468	4.9	15.4	456	10.1	15.5	449	20.8	

Grams of feed consumed per animal per day
Milligrams of triamterene consumed per day per kilogram body weight

TABLE I2 Feed and Compound Consumption by Female Rats in the 2-Year Feed Study of Triamterene

	0 p	om		150 ppn	1		300 ppn	n.	600 ppm			
Week	Feed (g/day) ^a	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day	
5	11.5	164	11.2	162	10.4	11.3	160	21.2	11.1	159	41.8	
9	10.9	188	10.6	186	8.6	10.9	183	17.8	10.7	184	35.0	
13	10.3	200	10.2	199	7.7	10.5	199	15.8	9.7	192	30.3	
17	10.7	206	10.1	204	7.4	10.7	207	15.5	10.8	203	31.7	
21	10.9	211	11.3	210	8.0	11.0	211	15.7	10.9	208	31.5	
25	9.9	214	9.4	212	6.6	9.7	214	13.6	9.7	212	27.6	
29	10.4	221	11.0	219	7.6	11.0	221	14.9	10.6	217	29.3	
33	11.0	229	10.9	227	7.2	11.0	230	14.3	10.8	224	29.0	
37	11.4	241	11.3	237	7.1	11.5	240	14.4	11.5	235	29.4	
41	11.5	246	11.5	244	7.1	11.2	241	14.0	11.2	241	28.0	
45	11.8	252	11.7	248	7.1	12.1	250	14.5	11.4	245	27.9	
49	12.5	262	12.5	258	7.3	12.5	262	14.3	12.1	252	28.9	
53	12.7	276	12.6	273	6.9	12.8	272	14.1	12.4	264	28.0	
57	11.5	284	11.9	283	6.3	11.7	286	12.3	12.2	274	26.8	
61	11.1	290	11.2	287	5.9	11.5	290	11.9	11.6	279	24.9	
65	11.2	298	11.5	295	5.8	11.4	297	11.5	11.3	284	23.9	
69	11.6	304	11.7	301	5.8	11.8	303	11.7	11.5	290	23.8	
73	12.5	314	11.8	310	5.7	12.2	313	11.7	11.7	297	23.7	
77	12.7	319	12.6	316	6.0	12.5	315	11.9	12.7	301	25.4	
81	12.6	327	12.8	324	5.9	12.9	321	12.1	12.7	307	24.9	
85	12.7	335	12.0	327	5.5	12.6	326	11.6	11.8	309	22.9	
89	13.0	344	12.8	333	5.8	12.4	323	11.5	11.9	305	23.5	
93	13.3	343	12.5	331	5.7	12.9	331	11.7	12.3	312	23.6	
97	11.9	339	12.1	332	5.5	11.7	324	10.8	11.8	309	23.0	
101	11.4	337	12.1	336	5.4	13.3	332	12.1	12.7	318	23.9	
104	10.4	333	11.8	337	5.2	12.2	332	11.0	10.2	317	19.3	
Mean fo	or weeks											
1-13	10.9	184	10.7	182	8.9	10.9	181	18.3	10.5	178	35.7	
14-52	11.1	231	11.1	229	7.3	11.2	231	14.6	11.0	226	29.3	
53-104	12.0	317	12.1	313	5.8	12.3	312	11.8	11.9	298	24.1	

Grams of feed consumed per animal per day Milligrams of triamterene consumed per day per kilogram body weight

TABLE I3 Feed and Compound Consumption by Male Mice in the 2-Year Feed Study of Triamterene: First Study

	0 р	pm		100 ppn	1 ·		200 ppn	1		400 ppn	1
Week	Feed (g/day) ^a	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight	Dose/
. 7	4.8	26.6	5.4	26.9	20 .	4.9	26.8	36	5.0	. 26.7	75
9	5.3	28.7	5.9	28.8	20	4.9	28.2	35	4.9	28.3	69
13	4.5	31.5	4.6	31.3	15	4.6	31.4	29	4.8	30.7	63
18	4.5	34.0	4.6	33.9	. 14	4.6	33.7	27	4.7	33.6	57
21	4.8	34.4	4.5	34.8	13	4.8	34.3	28	4.7	34.0	55
25	4.9	34.5	4.8	35.2	14	5.2	34.6	30	5.1	34.7	59
29	4.6	36.0	4.5	36.7	12	4.8	35.9	27	4.8	35.6	54
33	4.7	37.9	4.9	38.4	13	5.1	37.6	27	4.9	37.3	52
37	4.8	38.3	5.3	39.0	14	5.6	38.6	29	5.3	38.5	55
41	5.5	39.4	5.6	40.5	14	5.7	39.4	29	3.8	32.9	47
45	4.6	40.7	5.1	41.0	12	5.2	40.5	25	5.5	38.0	58
49	4.8	41.6	4.9	41.9	12	5.0	41.1	24 .	5.4	39.3	55 [°]
53	5.2	42.3	5.4	43.3	12	5.6	42.3	27	5.7	40.9	55
57	5.0	43.1	5.4	43.8	12	5.4	42.8	25	5.5	41.9	
61	5.0	43.8	5.2	44.1	12	5.3	42.9	25	5.6	42.5	52
65	5.0	44.8	5.0	44.9	11	5.3	43.6	25	5.1	43.1	48
69	4.6	44.8	4.4	45.8	10	4.3	44.4	19	4.3	44.2	39
73	5.0	45.2	5.2	46.2	11	5.4	45.2	24	5.6	44.8	50
77	5.0	45.5	5.1	46.6	11	5.0	45.7	22	5.3	45.5	47
81	5.0	45.5	5.0	46.1	11	5.2	45.2	23	5.1	44.5	46
85	5.0	45.7	4.6	46.2	10	5.0	45.2	22	5.1	44.7	46
89	5.2	44.9	5.1	46.0	11	5.4	44.6	24	5.7	44.3	52
93	4.9	47.1	5.0	46.9	11	5.1	45.5	22	5.1	44.9	45
97	5.1	46.6	5.1	48.3	11	5.5	45.8	24	5.5	45.3	49
101	4.8	46.0	4.8	46.6	10	5.1	45.2	23	5.2	45.0	46
104	4.7	44.4	4.6	45.1	10	4.6	43.8	21	4.7	43.0	44
Mean fo											
1-13	4.9	28.9	5.3	29.0	18	4.8	28.8	34	4.9	28.6	69
14-52	4.8	37.4	4.9	37.9	13	5.1	37.3	27	4.9	36.0	
53-104	5.0	45.0	5.0	45.7	11	5.2	44.4	23	5.3	43.9	48

Grams of feed consumed per animal per day Milligrams of triamterene consumed per day per kilogram body weight

TABLE 14 Feed and Compound Consumption by Female Mice in the 2-Year Feed Study of Triamterene: First Study

	0 p	DIM .		100 ppn	1		200 ppm	·		400 ppn	1
Week	Feed (g/day) ^a	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day) ^b	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day)	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day
7	4.9	22.9	5.0	22.9	22	5.1	22.9	45	4.8	22.7	85
9	5.3	25.0	5.1	24.8	20	5.3	24.6	43	5.3	24.8	85
13	5.2	26.8	6.0	26.7	22	6.3	26.8	47	6.1	26.3	93
18	5.2	30.3	6.3	30.1	21	6.2	30.0	41	6.1	29.7	82
21	6.0	31.6	6.0	31.0	19	6.9	31.1	44	6.7	30.4	89
25	6.2	33.5	6.3	33.2	19	6.5	33.4	39	6.4	32.9	78
29	6.1	36.2	4.5	35.6	13	6.3	35.4	35	5.9	35.2	
33	6.1	37.5	6.3	36.9	17	6.3	37.1	34	6.5	36.4	
37	7.0	39.7	6.9	39.1	18	7.2	38.5	38	7.0	37.6	
41	6.6	40.6	6.3	40.3	16	6.6	39.6	33	3.9	30.3	-
45	5.5	42.3	5.8	41.9	14	6.2	41.2	30	6.3	38.2	
49	5.3	43.9	5.4	43.6	12	5.7	42.7	27	5.9	40.9	
53	5.9	45.5	6.1	45.3	13	6.2	44.4	28	6.2	42.1	59
57	5.4	46.2	5.7	46.4	12	5.4	45.3	24	5.6	43.3	51
61	5.5	46.8	5.5	47.0	12	5.4	46.1	23	5.7	44.1	52
65	5.2	48.0	5.2	48.7	11	5.3	47.5	23	5.3	45.8	46
69	6.1	48.7	4.9	49.8	10	5.2	48.3	21	5.1	46.8	44
73	5.1	49.8	5.4	51.3	11	5.2	49.6	21	5.6	48.0	47
77	5.0	50.2	5.1	52.6	10	5.0	51.0	19	5.2	49.2	42
81	5.3	50.6	5.1	52.1	10	5.0	50.7	20	5.0	48.7	41
85	5.1	50.9	4.9	52.6	9	4.9	50.7	20	5.1	49.0	42
89	4.9	50.3	5.1	52.1	10	5.2	50.6	20	5.4	48.1	45
93	5.5	51.2	5.7	53.8	11	5.4	51.2	21	5.9	49.5	48
97	5.3	51.6	5.2	54.2	10	5.0	50.2	20	5.1	49.1	42
101	4.9	49.4	4.8	52.8	9	4.9	49.3		4.9	46.6	42
104	4.9	47.0	5.1	49.9	10	5.0	47.4	21	5.0	44.4	45
Mean fe	or weeks										
1-13	5.1	24.9	5.4	24.8		5.6	24.8	45	5.4	24.6	
14-52	6.0	37.3	6.0	36.9	17	6.4	36.6		6.1	34,6	
53-104	5.3	49.0	5.3	50.6	10	5.2	48.7	22	5.4	46.8	46

Grams of feed consumed per animal per day Milligrams of triamterene consumed per day per kilogram body weight

TABLE I5 Feed and Compound Consumption by Male Mice in the 2-Year Feed Study of Triamterene: Second Study

	0 ppm					
Week	Feed (g/day) ^a	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day) ^b	
4	4.3	23.8	4.8	24.0	79	
8	4.3	27.6	4.4	27.9	63	
12	4.9	31.5	4.9	31.4	62	
17	4.5	34.4	4.4	34.3	51	
21	3.8	36.9	3.8	36.9	41	
25	4.6	38.9	4.6	39.3	46	
29	4.1	40.8	4.1	40.9	40	
33	4.1	42.1	4.2	42.8	39	
37	4.0	43.2	2.6	43.6	24	
41	4.0	44.0	4.1	44.3	37	
45	4.0	44.6	4.1	45.0	36	
49	4.2	45.8	4.3	46.1	37	
53	4.2	45.8	4.1	46.0	36	
57	4.2	45.2	4.3	45.8	38	
61	4.1	46.4	4.3	46.9	37	
65	4.0	46.2	4.4	46.1	38	
69	4.3	46.7	4.3	47.0	36	
73	4.6	47.2	4.4	48.1	37	
77	5.0	46.7	4.7	47.7	39	
81	4.5	46.5	4.4	46.9	38	
85	4.6	47.4	4.5	47.5	38	
89	4.5	45.9	4.4	46.0	38	
93	4.4	45.6	4.2	44.4	38	
97	4.3	45.4	4.1	42.9	38	
101	4.7	43.4	4.8	41.4	46	
lean for weeks						
-13	4.5	27.6	4.7	27.8	68	
4-52	4.1	41.2	4.0	41.5	39	
3-101	4.4	46.0	4.4	45.9	38	

Grams of feed consumed per animal per day
Milligrams of triamterene consumed per day per kilogram body weight

TABLE I6 Feed and Compound Consumption by Female Mice in the 2-Year Feed Study of Triamterene: Second Study

	O K	pm		400 ppm		
Week	Feed (g/day) ^a	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dosc/ Day (mg/kg/day) ^b	
				· · · · · · · · · · · · · · · · · · ·		
4	4.8	20.1	5.2	20.0	105	
8	5.7	23.4	5.6	23.7	94.	
12	6.6	26.6	6.6	26.4	100	
17	6.2	30.4	6.0	30.2	79	
21	6.0	32.9	5.9	32.5	72	
25	6.3	35.5	6.8	35.0	78	
29	5.5	37.5	5.8	37.2	63	
33	5.4	39.5	5.9	39.2	60	
37	5.5	40.0	5.5	39.8	55	
41	5.3	42.1	5.7	41.4	55	
45	6.0	43.3	6.5	42.9	60	
49	6.1	45.0	6.1	44.5	55	
53	5.5	45.6	5.7	44.8	51	
57	5.4	45.8	5.8	45.1	52	
61	4.9	47.7	5.2	46.9	45	
65	5.9	47.7	5.5	47.0	47	
69	5.8	48.6	5.5	47.7	46	
73	5.6	49.3	5.6	48.8	45	
77	6.1	49.5	5.9	48.7	49	
81	5.7	49.2	5.3	48.8	43	
85	5.7	49.9	5.6	48.8	46	
89	5.5	49.5	5.6	47.8	47	
93	5.5	49.6	5.9	47.7	50	
97	5.2	48.7	5.2	44.2	47	
101	6.0	45.9	6.2	43.3	57	
ean for week	s					
-13	5.7	23.4	5.8	23.4	99	
4-52	5.8	38.5	6.0	38.1	64	
3-101	5.6	48.2	5.6	46.9	48	

Grams of feed consumed per animal per day Milligrams of triamterene consumed per day per kilogram body weight

APPENDIX J INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NIH-07 RAT AND MOUSE RATION

	Ingredients of NIH-07 Rat and Mouse Ration	360
	The same of the completion will and Rough Mouse Ration	500
	District of Composition of NITI of Rat and Mouse Ration	TANK.
Table J3 Table J4	Contaminant Levels in NIH-07 Rat and Mouse Ration	362

TABLE J1 Ingredients of NIH-07 Rat and Mouse Ration^a

Ingredients ^b	Percent by Weight		
Ground #2 yellow shelled corn	24.50		
Ground hard winter wheat	23.00		
Soybean meal (49% protein)	12.00		
Fish meal (60% protein)	10.00		
Wheat middlings	10.00		
Dried skim milk	5.00		
Alfalfa meal (dehydrated, 17% protein)	4.00		
Corn gluten meal (60% protein)	3.00		
Soy oil	2.50		
Dried brewer's yeast	2.00		
Dry molasses	1.50		
Dicalcium phosphate	1.25		
Ground limestone	0.50		
Salt	0.50		
Premixes (vitamin and mineral)	0.25		
•		4 1	

TABLE J2 Vitamins and Minerals in NIH-07 Rat and Mouse Ration^a

	Amount	Source	
Vitamins			
A	5,500,000 IU	Stabilized vitamin A palmitate or acetate	
	4,600,000 IU	D-activated animal sterol	•
D ₃ K ₃	2.8 g	Menadione	
d - α -Tocopheryl acetate	20,000 IU		
Choline	560.0 g	Choline chloride	
Folic acid	2.2 g		
Niacin	30.0 g		
d-Pantothenic acid	18.0 g	d-Calcium pantothenate	• •
Riboflavin	3.4 g	w Calcium pantomenato	
Thiamine	10.0 g	Thiamine mononitrate	. 1.11
	4,000 μg		·
B ₁₂ Pyridoxine	1.7 g	Pyridoxine hydrochloride	
Biotin	140.0 mg	d-Biotin	
Minerals			
Iron	120.0 g	Iron sulfate	
Manganese	60.0 g	Manganous oxide	
Zinc	16.0 g	Zinc oxide	
Copper	4.0 g	Copper sulfate	
Iodine	1.4 g	Calcium iodate	
Cobait	0.4 g	Cobalt carbonate	

^a Per ton (2,000 lb) of finished product

a NCI, 1976; NIH, 1978
 b Ingredients were ground to pass through a U.S. Standard Screen No. 16 before being mixed.

TABLE J3
Nutrient Composition of NIH-07 Rat and Mouse Ration

	Mean 🛨 Standard			
Nutrient	Deviation	Range	Number of Sa	mples
Protein (% by weight)	22.21 ± 0.55	21.0-23.2	27	
Crude fat (% by weight)	5.59 ± 0.41	4.6-6.3	27.	
Crude fiber (% by weight)	3.50 ± 0.37	2.8-4.7	27	
Ash (% by weight)	6.65 ± 0.43	6.0–7.9	27	
Amino Acids (% of total diet)				
Arginine	1.308 ± 0.606	1.210-1.390	8	
Cystine	0.306 ± 0.084	0.1810.400	8	
Glycine	1.150 ± 0.047	1.060~1.210	8	
Histidine	0.576 ± 0.024	0.5310.607	8	
Isoleucine	0.917 ± 0.029	0.881-0.944	8	
Leucine	1.946 ± 0.055	1.850-2.040	8	
Lysine	1.270 ± 0.058	1.200-1.370	8	
Methionine	0.448 ± 0.128	0.306-0.699	8	
Phenylalanine	0.987 ± 0.140	0.665-1.110	8	
Threonine	0.877 ± 0.042	0.824-0.940	8	
Tryptophan	0.236 ± 0.176	0.107-0.671	8	
Tyrosine	0.676 ± 0.105	0.564-0.794	8	
Valine	1.103 ± 0.040	1.050-1.170	8	
Essential Fatty Acids (% of total	diet)			
Linoleic	2.393 ± 0.258	1.830-2.570	7	
Linolenic	0.280 ± 0.040	0.210-0.320	ŕ	
Vitamins				
Vitamin A (IU/kg)	$8,694 \pm 3,836$	4,500-19,000	27	
Vitamin D (IU/kg)	$4,450 \pm 1,382$	3,000-6,300	4	
α-Tocopherol (ppm)	37.95 ± 9.406	22.50-48.90	8	
Thiamine (ppm)	21.67 ± 3.52	18.0-37.0	27	
Riboflavin (ppm)	7.92 ± 0.87	6.10-9.00	8	
Niacin (ppm)	103.38 ± 26.59			
Pantothenic acid (ppm)		65.0-150.0	8	
	29.54 ± 3.60	23.0-34.0	8	
Pyridoxine (ppm)	9.55 ± 3.48	5.60-14.0	8	,, ·
Folic acid (ppm)	2.25 ± 0.73	1.80-3.70	8	
Biotin (ppm)	0.254 ± 0.042	0.19-0.32	8	
Vitamin B ₁₂ (ppb)	38.45 ± 22.01	10.6-65.0	8	
Choline (ppm)	$3,089 \pm 328.69$	2,400–3,430	8	:
Minerals Coloium (%)	1.10 - 0.40	0.00 - 10		
Calcium (%)	1.13 ± 0.12	0.90-1.40	26	
Phosphorus (%)	0.92 ± 0.06	0.81-1.10	27	
Potassium (%)	0.883 ± 0.078	0.772-0.971	6	
Chloride (%)	0.526 ± 0.092	0.380-0.635	8	
Sodium (%)	0.313 ± 0.390	0.258-0.371	8	
Magnesium (%)	0.168 ± 0.010	0.151-0.181	8	,
Sulfur (%)	0.280 ± 0.064	0.208-0.420	8	
Iron (ppm)	360.54 ± 100	255.0-523.0	8	
Manganese (ppm)	91.97 ± 6.01	81.70-99.40	8	
Zinc (ppm)	54.72 ± 5.67	46.10-64.50	8	
Copper (ppm)	11.06 ± 2.50	8.090-15.39	8	
Iodine (ppm)	3.37 ± 0.92	1.52-4.13	6	
Chromium (ppm)	1.79 ± 0.36	1.04-2.09	8	
Cobalt (ppm)	0.681 ± 0.14	0.490-0.780	4	

TABLE J4 Contaminant Levels in NIH-07 Rat and Mouse Ration

ΓABLE J4 Contaminant Levels in NIH-07	Rat and Mouse Ration	•	en e
	Mean ± Standard		
,	Deviation ^a	Range	Number of Samples
		<u> </u>	
Contaminants		. · · · · · · · · · · · · · · · · · · ·	
Arsenic (ppm)	0.64 ± 0.23	0.17-0.98	27
Cadmium (ppm) ^b	0.10 ± 0.02	<0.10-0.20	27
Lead (ppm)	0.42 ± 0.20	0.05-0.87	27
Mercury (ppm) ^c	0.05 ± 0.01	<0.05-0.08	27
Selenium (ppm)	0.36 ± 0.07	0.25-0.48	27
Aflatoxins (ppb)	<5.0	='	27
Nitrate nitrogen (ppm)	18.25 ± 8.38	2.9-34.0	27
Nitrite nitrogen (ppm)	0.16 ± 0.18	<0.10-1.00	27
BHA (ppm)	2.30 ± 0.78	<2.00-5.00	27
BHT (ppm) ^d	1.67 ± 1.04	<1.00-4.00	27
Aerobic plate count (CFU/g) ^e	$140,329 \pm 151,668$	39,000-570,000	27
Coliform (MPN/g) ^f	266 ± 491	<3.00-2,400	27
E. coli (MPN/g)g	4.92 ± 7.86	<3.00-43.0	26
E. coli (MPN/g)h	10.30 ± 28.96	<3.00-150	27
Total nitrosoamines (ppb) ⁱ	7.02 ± 2.67	3.30-13.30	27
N-Nitrosodimethylamine (ppb) ⁱ	6.16 ± 2.47	3.00-13.00	27
N-Nitrosopyrrolidine (ppb)	0.87 ± 0.94	0.30-4.30	27
Pesticides Pesticides			
α-BHC ^j	< 0.01		27
B-BHC	<0.02		27
7-BHC	<0.01		27
δ-BHC	< 0.01		27
Heptachlor	< 0.01		27
Aldrin	< 0.01		27
Heptachlor epoxide	< 0.01		27
DDE	< 0.01		27
DDD	< 0.01		27
DDT	< 0.01		27
НСВ	< 0.01		27
Mirex	< 0.01		27
Methoxychlor	< 0.05		27
Dieldrin	< 0.01		27
Endrin	< 0.01		27
Telodrin	< 0.01		27
Chlordane	< 0.05		27
Toxaphene	< 0.1		27
Estimated PCBs	<0.2		27
Ronnel	< 0.01		27
Ethion	< 0.02		27
Trithion	< 0.05		27
Diazinon	<0.1		27
Methyl parathion	< 0.02		27
Ethyl parathion	< 0.02		27
Malathion ^k	0.15 ± 0.19	0.05-0.85	27
Endosulfan I	< 0.01		27
Endosulfan II	< 0.01		27
Endosulfan sulfate	< 0.03		27

TABLE J4
Contaminant Levels in NIH-07 Rat and Mouse Ration (continued)

For values less than the limit of detection, the detection limit is given for the mean.

- Mean, standard deviation, and range include one value of 0.20 ppm obtained from the lot milled 8 October 1985; all other values are less than or equal to the detecton limit.
- Mean, standard deviation, and range include one value of 0.08 ppm obtained from the lot milled 3 September 1986; all other values were less than or equal to the detection limit.

Sources of contamination: soy oil and fish meal

CFU = colony forming unit.

MPN = most probable number.

Mean, standard deviation, and range exclude 1 large value of 150 MPN/g obtained in lot 17 October 1984.

Mean, standard deviation, and range include value given in g.

All values were corrected for percent recovery.

BHC = hexachlorocyclohexane or benzene hexachloride

Fourteen lots contained more than 0.05 ppm.

APPENDIX K SENTINEL ANIMAL PROGRAM

METHODS .		366 368
RESULTS		
Table K1	Murine Virus Antibody Determinations for Rats and Mice	369

SENTINEL ANIMAL PROGRAM

METHODS

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals are untreated, and are subject to identical environmental conditions as the study animals. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Rats

13 Weeks

At the end of the 13-week study, samples for viral screening were collected from five sentinel rats of each sex. In the 2-year study, five rats of each sex were sampled during quarantine and at the beginning of the 2-year study. During the 2-year study, five animals of each designated sentinel group were killed at 6, 12, and 18 months on study. Five rats of each sex assigned to the 600 ppm group in the 2-year studies were killed at 24 months. One female rat in the sentinel animal group was sampled at moribund sacrifice on 13 February 1986. Blood from each animal sampled was collected and allowed to clot. Serum for the viral screening was separated, cooled on ice, and shipped to Microbiological Associates, Incorporated (Bethesda, MD) for determination of the antibody titers. The following tests were performed:

15 Weeks			
Method of Analysis	Time of Analysis		
Complement Fixation			
RCV (rat coronavirus)	End of study		
Hemagglutination Inhibition			
H-1 (Toolan's H-1 virus)	End of study		
KRV (Kilham rat virus)	End of study		
PVM (pneumonia virus of mice)	End of study		
Sendai	End of study		
ELISA			
RCV/SDA	End of study		
(rat coronavirus/sialodacryoadenitis)	· · · · · · · · · · · · · · · · · · ·		
2 Years			
Method of Analysis	Time of Analysis		
ELISA			
CARB (cilia associated-respiratory bacillus)	24 months		
Mycoplasma arthritidis	6, 12, 18, and 24 months		
Mycoplasma pulmonis	6, 12, 18, and 24 months		
PVM	6, 12, 18, and 24 months		
RCV/SDA	6, 12, 18, and 24 months		
Sendai	6, 12, 18, and 24 months		
Hemagglutination Inhibition			
H-1	6, 12, 18, and 24 months		
KRV	6, 12, 18, and 24 months		
IXIX	5, 12, 15, and 27 months		

Mice

13 Weeks

At the end of the 13-week study, samples for viral screening were collected from five sentinel mice of each sex. In the 2-year study, five mice of each sex were sampled in quarantine. During the initial 2-year study (first study) and the restarted 2-year study (second study), five mice of each sex from the sentinel animal group were sampled at the beginning of the studies and at approximately 6, 12, and 18 months. At the end of the 2-year studies, samples were also collected from five mice of each sex in the 400 ppm groups of the first study and from five mice of each sex from 0 and 400 ppm groups of the second study. On 22 May 1985, five mice of each sex from the first study sentinel animals were sampled for MHV screening. Seven male mice in the first study, which were sacrificed moribund, were sampled. Blood from each animal sampled was collected and allowed to clot. Serum for the viral screenings was separated, cooled on ice, and shipped to Microbiological Associates, Incorporated (Bethesda, MD) for determination of the antibody titers. The following tests were performed:

Method of Analysis	Time of Analysis
Complement Fixation	
MHV	End of study
RCV	End of study
Hemagglutination Inhibition	
Ectromelia virus	End of study
	End of study
GDVII (mouse encephalomyelitis virus)	End of study
MVM (minute virus of mice)	End of study
PVM	End of study
Polyoma virus	End of study
Reovirus 3	End of study
Sendai	End of study
2 Years	
First Study	
Method of Analysis	Time of Analysis
Complement Fixation	Time of Analysis
LCM (lymphocytic choriomeningitis virus)	6, 12, 18, and 24 months
2011 (Isimphocytic choriomeningths virus)	0, 12, 10, and 24 months
ELISA	
CARB	24 months
Ectromelia virus	6, 12, 18, and 24 months
GDVII	6, 12, 18, and 24 months
Mouse adenoma virus	6, 12, 18, and 24 months
MHV (mouse hepatitis virus)	6, 12, 18, and 24 months
M. arthritidis	6, 12, 18, and 24 months
M. pulmonis	6, 12, 18, and 24 months
PVM	6, 12, 18, and 24 months
Reo 3	
Sendai	6, 12, 18, and 24 months
Scridar	6, 12, 18, and 24 months
Hemagglutination Inhibition	
K (papovavirus)	6, 12, 18, and 24 months
MVM	6, 12, 18, and 24 months
Polyoma virus	6, 12, 18, and 24 months
•	, -,,
Immunofluorescence Assay	
Immunofluorescence Assay EDIM (epizootic diarrhea of infant mice)	6, 12, 18, and 24 months

Second Study	
Method of Analysis	Time of Analysis
Complement Fixation	
LCM	6 and 12 months
ELISA	
CARB	12 and 24 months
Ectromelia virus	6, 12, 18, and 24 months
GDVII	6, 12, 18, and 24 months
Mouse adenoma virus	6, 12, 18, and 24 months
MHV	6, 12, 18, and 24 months
M. arthritidis	6, 12, and 24 months (males only)
M. pulmonis	6, 12, and 24 months (males only)
PVM	6, 12, 18, and 24 months
Reovirus 3	6, 12, 18, and 24 months
Sendai	6, 12, 18, and 24 months
Hemagglutination Inhibition	
K	6, 12, 18, and 24 months
MVM	6, 12, and 18 months
Polyoma virus	6, 12, 18, and 24 months
Immunofluorescence Assay	
EDIM	6, 12, 18, and 24 months

The serology results for sentinel animals are presented in Table K1.

Table K1
Murine Virus Antibody Determinations for Rats and Mice in the 13-Week and 2-Year Feed Studies of Triamterene

	Interval	Incidence of Antibody in Sentinel Animals	Positive Serologic Reaction for
	Studies		
Rats	13 weeks	0/10	None positive
2-Year S	tudies		
Rats	6 months	1/10	M. arthritidis ^a
	12 months	1/10	M. arthritidis
	18 months	1/9	M. arthritidis
	24 months	2/10	CARB
First Stud	i y		
Mice	6 months	0/10	None positive
	12 months	0/10	None positive
	18 months	0/10	None positive
	24 months	1/10	M. arthritidis
Second Si	udv		
Mice	6 months	0/10	None positive
	12 months	1/10	M. arthritidis
	18 months	0/10	None positive
	24 months	1/10	M. arthritidis

a Possible Mycoplasma arthritidis

NATIONAL TOXICOLOGY PROGRAM TECHNICAL REPORTS PRINTED AS OF NOVEMBER 1993

TR No. CHEMICAL

201 2,3,7,8-Tetrachlorodibenzo-p-dioxin (Dermal)

- 206 1,2-Dibromo-3-chloropropane
- 207 Cytembena
- 208 FD & C Yellow No. 6
- 209 2,3,7,8-Tetrachlorodibenzo-p-dioxin (Gavage)
- 210 1.2-Dibromoethane
- 211 C.I. Acid Orange 10
- 212 Di(2-ethylhexyl)adipate
- 213 Butyl Benzyl Phthalate
- 214 Caprolactam
- 215 Bisphenol A
- 216 11-Aminoundecanoic Acid
- 217 Di(2-Ethylhexyl)phthalate
- 219 2,6-Dichloro-p-phenylenediamine
- 220 C.I. Acid Red 14
- 221 Locust Bean Gum
- 222 C.I. Disperse Yellow 3
- 223 Eugenol
- 224 Tara Gum
- 225 D & C Red No. 9
- 226 C.I. Solvent Yellow 14
- 227 Gum Arabic
- 228 Vinylidene Chloride
- 229 Guar Gum
- 230 Agar
- 231 Stannous Chloride
- 232 Pentachloroethane
- 233 2-Biphenylamine Hydrochloride
- 234 Allyl Isothiocyanate
- 235 Zearalenone
- 236 D-Mannitol
- 237 1,1,1,2-Tetrachloroethane
- 238 Ziram
- 239 Bis(2-chloro-1-Methylethyl)ether
- 240 Propyl Gallate
- 242 Diallyl Phthalate (Mice)
- 243 Trichlorethylene (Rats and Mice)
- 244 Polybrominated Biphenyl Mixture
- 245 Melamine
- 246 Chrysotile Asbestos (Hamsters)
- 247 L-Ascorbic Acid
- 248 4,4'-Methylenedianiline Dihydrochloride
- 249 Amosite Asbestos (Hamsters)
- 250 Benzyl Acetate
- 251 2,4- & 2,6-Toluene Diisocyanate
- 252 Geranyl Acetate
- 253 Allyl Isovalerate
- 254 Dichloromethane (Methylene Chloride)
- 255 1,2-Dichlorobenzene
- 257 Diglycidyl Resorcinol Ether
- 259 Ethyl Acrylate
- 261 Chlorobenzene
- 263 1,2-Dichloropropane
- 266 Monuron
- 267 1,2-Propylene Oxide
- 269 Telone II® (1,3-Dichloropropene)
- 271 HC Blue No. 1
- 272 Propylene

TR No. CHEMICAL

- 273 Trichloroethylene (Four Rat Strains)
- 274 Tris(2-ethylhexyl)phosphate
- 275 2-Chloroethanol
- 276 8-Hydroxyquinoline
- 277 Tremolite
- 278 2,6-Xylidine
- 279 Amosite Asbestos
- 280 Crocidolite Asbestos
- 281 HC Red No. 3
- 282 Chlorodibromomethane
- 284 Diallylphthalate (Rats)
- 285 C.I. Basic Red 9 Monohydrochloride
- 287 Dimethyl Hydrogen Phosphite
- 288 1,3-Butadiene
- 289 Benzene
- 291 Isophorone
- 293 HC Blue No. 2
- 294 Chlorinated Trisodium Phosphate
- 295 Chrysotile Asbestos (Rats)
- 296 Tetrakis(hydroxymethyl) phosphonium Sulfate & Tetrakis(hydroxymethyl) phosponium Chloride
 - 98 Dimethyl Morpholinophosphoramidate
- 298 Dimethyl Morpholine299 C.I. Disperse Blue 1
- 300 3-Chloro-2-methylpropene
- 301 o-Phenylphenol
- 303 4-Vinylcyclohexene
- 304 Chlorendic Acid
- 305 Chlorinated Paraffins (C₂₃, 43% chlorine)
- 306 Dichloromethane (Methylene Chloride)
- 307 Ephedrine Sulfate
- 308 Chlorinated Pariffins (C12, 60% chlorine)
- 309 Decabromodiphenyl Oxide
- 310 Marine Diesel Fuel and JP-5 Navy Fuel
- 311 Tetrachloroethylene (Inhalation)
- 312 n-Butyl Chloride
- 313 Mirex
- 314 Methyl Methacrylate
- 315 Oxytetracycline Hydrochloride
- 316 1-Chloro-2-methylpropene
- 317 Chlorpheniramine Maleate
- 318 Ampicillin Trihydrate
- 319 1,4-Dichlorobenzene
- 320 Rotenone
- 321 Bromodichloromethane
- 322 Phenylephrine Hydrochloride
- 323 Dimethyl Methylphosphonate
- 324 Boric Acid
- 325 Pentachloronitrobenzene
- 326 Ethylene Oxide
- 327 Xylenes (Mixed)328 Methyl Carbamate
- 329 1,2-Epoxybutane
- 330 4-Hexylresorcinol
- 331 Malonaldehyde, Sodium Salt
- 332 2-Mercaptobenzothiazole
- 333 N-Phenyl-2-naphthylamine
- 334 2-Amino-5-nitrophenol
- 335 C.I. Acid Orange 3

NATIONAL TOXICOLOGY PROGRAM TECHNICAL REPORTS PRINTED AS OF NOVEMBER 1993 (CONT.)

TR No.	CHEMICAL	TR No.	CHEMICAL
226	Penicillin VK	380	Epinephrine Hydrochloride
	Nitrofurazone	381	d-Carvone
	Erythromycin Stearate	382	Furfural
	2-Amino-4-nitrophenol	385	Methyl Bromide
340	Indinated Glycerol	386	Tetranitromethane
341	Nitrofurantoin	387	Amphetamine Sulfate
	Dichlorvos	. 388	Ethylene Thiourea
	Benzyl Alcohol	389	Sodium Azide
344	Tetracycline Hydrochloride	390	3,3'-Dimethylbenzidine Dihydrochloride
345	Roxarsone	391	Tris(2-chloroethyl) Phosphate
346	Chloroethane	392	Chlorinated Water and Chloraminated Water
	D-Limonene	393	Sodium Fluoride
348	@-Methyldopa Sesquihydrate	394	Acetaminophen
	Pentachlorophenol	395	Probenecid
	Tribromomethane	396	Monochloroacetic Acid
351	p-Chloroaniline Hydrochloride	397	C.I. Direct Blue 15
352	N-Methylolacrylamide	398	Polybrominated Biphenyls
353	2,4-Dichlorophenol	399	Titanocene Dichloride
	Dimethoxane	401	2,4-Diaminophenol Dihydrochloride
355	Diphenhydramine Hydrochloride	402	Furan
356	Furosemide	403	Resorcinol
357	Hydrochlorothiazide	404	5,5-Diphenylhydantoin
358	Ochratoxin A	405	C.I. Acid Red 114
359	8-Methoxypsoralen	406	γ-Butyrolactone
360	N,N-Dimethylaniline	407	C.I. Pigment Red 3
361	Hexachloroethane	408	Mercuric Chloride
	4-Vinyl-1-Cyclohexene Diepoxide	409	Quercetin
	Bromoethane (Ethyl Bromide)	410	Naphthalene
364	Rhodamine 6G (C.I. Basic Red 1)	411	C.I. Pigment Red 23
365	Pentaerythritol Tetranitrate	412	4,4-Diamino-2,2-Stilbenedisulfonic Acid
	Hydroquinone		Ethylene Glycol
	Phenylbutazone		Pentachloroanisole
	Nalidixic Acid		Polysorbate 80
369	Alpha-Methylbenzyl Alcohol	· - -	o-Nitroanisole
	Benzofuran	417	p-Nitrophenol
371	Toluene	418	p-Nitroaniline
372	, , , , , , , , , , , , , , , , , , , ,	419	
373		421	Talc
374	Glycidol	422	Coumarin
	Vinyl Toluene	423	•
	Allyl Glycidyl Ether	427	
377		431	Benzyl Acetate
378	Benzaldehyde	434	1,3-Butadiene
379	2-Chloroacetophenone	443	Oxazepam

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Central Data Management, NIEHS, P.O. Box 12233, MD A0-01, Research Triangle Park, NC 27709.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
National Toxicology Program
Central Data Management
P.O. Box 12233, MD A0-01
Research Triangle Park, NC 27709

Official Business
Penalty for Private Use - \$300

SPECIAL FOURTH-CLASS RATE POSTAGE AND FEES PAID DHHS/NIH Permit No. G-763

> NIH Publication No. 94-3151 December 1993